

AUTHOR INDEX*

Volume 53

A

Aaltonen, L. A., 5849, 5853
 Abbi, R., 2758
 Abboud, C. N., 5274
 Abe, S., 1982
 Abecassis, J., 165
 Abe-Hashimoto, J., 2534
 Abel, G., 2581
 Abel, P., 5365
 Abonyi, M., 5982
 Abraham, G. N., 5274
 Abraham, I., 1354
 Abraham, R. T., 1862
 Abrahamsson, P.-A., 1724, 1967
 Abrams, J. T., 5501
 Acetoso, M., 5429
 Adachi, E., 2884
 Adachi, S., 4153
 Adachi, Y., 1706
 Adams, E. G., 1354
 Adams, G. P., 94, 3217, 4026
 Adamson, P. C., 472
 Adkins, D. A., 4243
 Adolf, G. R., 4754
 Afshari, C. A., 1777
 Agarwal, M. L., 5897
 Agarwal, R., 5409
 Agrawal, A., 1348
 Ahern, J., 266
 Aherne, G. W., 3321
 Ahluwalia, G., 5714
 Ahmad, I., 1484
 Ahmann, G. J., 5320
 Ahmed, F. E., 2249
 Ahn, M.-C., 3362
 Aida, Y., 429
 Aiello, A., 6036
 Akazawa, K., 5000
 Akerkar, S., 721
 Akeson, W., 4890
 Akimoto, H., 4658
 Akita, R., 4960
 Akiyama, M., 2940
 Akiyama, S.-I., 5680
 Akman, S. A., 1269
 Alaoui-Jamali, M. A., 4900, 5370
 Alavaikko, M., 4486
 Al-Baker, S., 4567, 4913
 Albeck, M., 1838, 5962
 Albertini, M., 1286
 Alberto, R., 5727
 Alberts, D. S., 550
 Albin, N., 3541, 4608
 Albino, A. P., 3327
 Albright, K. D., 1571
 Aldaz, C. M., 5339
 Alder, H., 5624
 Alexander, D. B., 1808, 1816
 Alexander, J. P., 1380
 Alexander, R. B., 2358
 Alfieri, A. A., 3518
 Alimena, G., 3800
 Ali-Osman, F., 4143, 5663
 Allalunis-Turner, M. J., 3674
 Allan, L. A., 2128
 Allegra, C. J., 4828
 Allen, B. J., 1770

Allen, H. J., 2667
 Allen, T. M., 1484
 Allred, D. C., 3369
 Almquist, K. C., 4866
 Alosco, T. R., 3964
 Alpert, E., 2803
 Alt, E., 2020
 Altas, I., 4322
 Altavilla, G., 5569
 Altomonte, M., 3343
 Alvord, W. G., 2204
 Amadori, D., 2614
 Amann, E., 5475
 Amanuma, H., 429
 Ames, M. M., 1032
 Amiel, D., 4890
 Amin, S., 4182
 Amlot, P., 3015
 Amox, D., 1098
 Amstad, P. A., 38
 Ananthaswamy, H. N., 2961
 Andersen, T. I., 5849
 Anderson, L. M., 3874
 Anderson, M. S., 806
 Anderson, M. W., 410
 Anderson, P., 2300
 Anderson, P., 5610
 Anderson, R., 318
 Andersson, B. S., 3603
 Andl, T., 4189
 Andrade, S. P., 3000
 Andreassen, A., 468
 Andreeff, M., 2100
 Andreola, S., 5864
 Angeletti, C. A., 2846
 Anglard, P., 3092
 Angstworm, M., 1027
 Angus, B., 2697
 Ankrapp, D. P., 3399
 Annino, L., 3800
 Antignac, C., 2888
 Anttila, S., 5643
 Anver, M. R., 4329
 Anzano, M. A., 1480, 4461
 Aoiike, A., 1328
 Aoki, D., 3643
 Aoki, M., 5038
 Aragaki, C. C., 212
 Arai, H., 4466, 5127
 Arakawa, H., 490
 Arand, G., 1416
 Araujo, D., 6011
 Arbuck, S. G., 4828
 Arceci, R. J., 310
 Archer, G. E., 2338
 Ardelt, B., 3186, 4613
 Ardouin, P., 1550
 Ariazi, E. A., 3849
 Ariyoshi, K., 5475
 Arkel, Y. S., 221
 Arlett, C. F., 609
 Armour, E. P., 2740
 Armstrong, B., 4337
 Armstrong, E., 2603
 Arnsmeier, S. L., 6058
 Asano, Y., 3638
 Aschele, C., 3677
 Ask, A., 5262

Asplund, T., 388
 Aston, C., 2858
 Atchison, L., 3118
 Atkinson, E. N., 5188
 Atsumi, S., 4896
 Attal, M., 4850
 Au, J. L.-S., 3314
 Audette, M., 826
 Audrézet, M. P., 5745
 Aukerman, S. L., 4273
 Austin, C. A., 3591
 Austin, E. A., 4619
 Austin, V. N., 1929
 Austruy, E., 2888
 Auzannet, V., 523
 Avila, M. A., 4474
 Azhari, R., 5841

B

Baak, J. P. A., 5413
 Baas, F., 310, 1747
 Baba, K., 1706
 Baba, T., 1871
 Bachelot, T., 4715
 Bäckström, T., 2309, 4550
 Bacus, S. S., 5251
 Badalament, R. A., 3314
 Bader, S., 2410
 Baeckström, D., 755
 Baek, J.-H., 4811
 Bagaglio, D. M., 2260
 Baggs, R. B., 2522
 Baglioni, C., 348
 Bail, J. P., 5745
 Bailey, D., 3574
 Bailey, M. Q., 3308
 Baiocchi, G., 1297
 Baird, S., 1122
 Baker, M. A., 3052
 Balcerzak, S. P., 4843
 Baldus, S. E., 4367
 Baldwin, R. L., 2704
 Balis, F. M., 472, 725, 1032, 1596, 2587, 4828
 Balkwill, F. R., 2087, 5365
 Balla, G., 5308
 Balla, J., 5308
 Balmain, A., 6022
 Balosso, J., 2105
 Bamberger, U., 1974
 Banerjee, S., 717
 Bankert, R. B., 3964
 Banks, S., 810
 Bannasch, P., 4204, 5447
 Bara, J., 4367
 Barbanti-Brodano, G., 5569
 Barbany, G., 2044
 Barber, J. L., 5071
 Barcellos-Hoff, M. H., 3880
 Bardi, G., 1895
 Bargetzi, M. J., 4010
 Barker, E., 362
 Barnard, G. F., 4048
 Barnathan, E. S., 3109
 Barnea, G., 3118
 Barnes, L., 5654
 Barnett, T., 27
 Barra, Y., 5121
 Barrett, J. C., 1777, 3098, 3475
 Barrios, E., 5750
 Barry, M. A., 2349
 Barth, R. F., 3308
 Bartke, I., 4424
 Bartolucci, M., 5429
 Bartram, C. R., 4053
 Bartram, H.-P., 3283
 Barzan, L., 5775
 Barzi, A., 19
 Baselga, J., 2379, 4637
 Baserga, R., 1102
 Basler, J. W., 5597
 Basolo, F., 2957
 Basrur, V. S., 1091
 Basset, P., 165, 4096
 Bassioulas, P., 2374
 Bast, A., 4603
 Bast, R. C., Jr., 1218, 1939, 3839
 Bastian, N. R., 5507
 Bastin, A. M., 1286
 Basu, H. S., 3948
 Basu-Modak, S., 4505
 Batist, G., 4900
 Baudoin, C., 1175
 Bauer, K. D., 681
 Baumgartner, K. J., 46
 Baxter, L. T., 2466
 Baylin, S. B., 1684, 2715, 2719
 Beamer, W. G., 1059, 3741
 Beaney, R. P., 2300
 Bear, H. D., 833
 Beaucage, S. L., 868
 Beauchemin, N., 4938
 Bechhofer, R., 1286
 Beck, W. T., 1373, 5946
 Becker, M., 1602
 Becker, M., 5439
 Beckett, M. A., 1978, 3667, 5542
 Beelen, R. H. J., 4399
 Beems, D. B., 4603
 Beere, H. M., 3034
 Beger, H. G., 2704, 5289
 Bei, M., 3229
 Bei, R., 2154
 Beijnen, J. H., 2061
 Beittenmiller, H., 2272
 Belaguli, N. S., 4432
 Belanger, A. J., 4803
 Belardelli, F., 569, 1107
 Belehradek, J., Jr., 5462
 Belinsky, S. A., 410
 Bell, C., 1788
 Bell, D. A., 1489
 Bell, R. H., Jr., 3925
 Bell, W. N., 500
 Bellocq, J.-P., 4096
 Belotti, D., 3812
 Benabid, A. L., 4715
 Ben-Baruch, N., 5251
 Bendig, M. M., 851
 Benedetti, P., 1297
 Benedetti, P., 4343
 Bengoufa, D., 5872
 Benjamin, W. H., Jr., 2810
 Bennett, E. P., 5494

* For title of article and coauthors, see listing in Contents of Volume 53 beginning on page i at the end of this index issue.

- Bennett, J. A., 3149
 Bennett, W. P., 2035, 4817
 Benning, C. M., 1724
 Beran, M., 3603
 Berchuck, A., 1218, 1906, 1939, 5100
 Berdel, W. E., 3747
 Berezin, F., 1293, 2304
 Berg, R. J. W., 1642, 4212
 Berg, S. L., 2587
 Berger, F. R., 4715
 Berger, M. S., 3416, 5663
 Bergeron, R. J., 581, 2071
 Berggren, M. I., 4297
 Berggren, M. M., 1862
 Bergstraesser, L. M., 2644
 Bergstresser, P. R., 4014
 Berhane, K., 4257
 Berkow, R. L., 2810
 Berkowitz, R. S., 1489
 Berlin, O., 4890
 Bernacki, R. J., 581, 2667
 Bernerd, F., 1175
 Bernstein, M., 5269
 Bérout, C., 2888
 Berse, B., 4727
 Berthold, F., 4053
 Bertino, J. R., 3677
 Bertola, G., 3343
 Bertoni, G., 1456
 Berzofsky, J. A., 3257
 Best, L. L., 2265
 Bettelheim, P., 3638
 Bevan, D. R., 3399
 Beyaert, R., 2623
 Bhachech, N., 3294
 Bhardwaj, G., 3221
 Bhat, H. K., 5447
 Bhatia, K., 4776
 Bhimani, R. S., 1255, 4528
 Bhuyan, B. K., 1354
 Bi, N., 884
 Bicher, A., 3694
 Bickers, D. R., 3439
 Bicknell, R., 4161
 Bièche, I., 1990
 Biedermann, K. A., 1244, 6011
 Biedler, J. L., 4978
 Biersack, A., 4268
 Biesma, B., 5915
 Biggar, S., 2112
 Bigger, C. A. H., 1273
 Bignami, M., 1149
 Bigner, D. D., 120, 2338, 3217
 Bignozzi, F., 5569
 Billingham, M. E., 4658
 Billström, A., 4573
 Binder, B. R., 1788
 Binelli, G., 209
 Björklund, A., 2140
 Birchmeier, W., 1690
 Bird, R. P., 4499
 Birrer, M. J., 3103
 Birt, D. F., 27
 Bisagni, E., 5987
 Bishop, J. E., 3935
 Bissery, M.-C., 2823, 5987
 Bissett, D., 523
 Bistocchi, M., 2846, 4665
 Biswas, C., 3154
 Bivins, H. M., 1777
 Bizanek, R., 5127
 Bizzi, B., 1297
 Bjarnason, G., 4837
 Bjerkvig, R., 5158
 Black, P. M., 1312
 Blaese, R. M., 83
 Blaeuenstein, P., 5727
 Blair, A., 2421
 Blair, D. G., 2976
 Blake, N. J., 2976
 Blanckaert, V. D., 4075
 Blanco, G., 4486
 Blaney, S. M., 725, 1032
 Blank, M., 4082
 Blankenstein, M. A., 4563
 Blankenstein, T., 714, 4134
 Blanz, J., 5135
 Blättler, W. A., 1360
 Blazar, B. R., 4273
 Bleehen, N. M., 4680
 Blichert-Toft, M., 2513
 Blick, M., 1630
 Blickensderfer, D. B., 5401
 Bliss, D. P., Jr., 67
 Block, N. L., 4493, 4855
 Bloemen, E., 456
 Bloemers, H. P. J., 6061
 Blommaert, F. A., 5669
 Blood, C. H., 2661
 Bloom, L. B., 4582
 Bloomfield, C. D., 1670
 Blot, W. J., 795, 1317
 Blumberg, P. M., 2507
 Boccardo, F., 4769
 Boddy, A. V., 3758
 Bode, P., 4860
 Bodley, A., 1332
 Bodner, E., 260
 Boghosian-Sell, L., 3118
 Bognel, C., 1550
 Bohlén, H., 4310
 Böhm, J., 5797
 Bohr, V. A., 5377
 Boicocchi, M., 5775
 Boku, N., 5022
 Boland, I., 1534
 Boldt, D. H., 3930
 Bols, B. L. M. C., 4797
 Bolton, E. S., 2358
 Bolton, M. G., 3499
 Boman, B. M., 1630
 Bomme, L., 1895
 Bonaiti-Pellié, C., 452
 Bonardi, M. A., 3015
 Bonavida, B., 2591
 Bonin, G., 3655
 Bonkhoff, H., 4035
 Bonsing, B. A., 3804
 Boobis, A. R., 6076
 Bookman, M. A., 4026
 Bookstein, R., 3369
 Boone, E., 2623
 Borchard, F., 4791
 Borchert, A. A., 1286
 Borden, E. C., 4109, 5176
 Borg, A., 5882
 Borgatti, P., 4481
 Borisch, B., 921
 Borkowski, A., 4817
 Børresen, A.-L., 468, 1637, 5849, 5853
 Borst, P., 1747
 Bortell, R., 2399
 Borup-Christensen, P., 5920
 Bos, E., 456
 Bosch, F. X., 4189
 Bosl, G. J., 3730
 Bossenmaier, B., 4424
 Bostick, R. M., 4230
 Bostick-Bruton, F., 242, 3694
 Bottero, F., 5791
 Botti, G., 3198
 Boucher, Y., 2466, 4764
 Bouillon, M., 826
 Bouiziar, Z., 5076
 Boulay, V., 283
 Bourguignat, A., 3536
 Bourret, L. A., 1360
 Bova, G. S., 3869
 Bowden, G. T., 417
 Bowen, K. J., 5929
 Bowen, P. E., 3723
 Bowman, E. D., 3486
 Bowman, W. P., 2954
 Boyd, D., 3109, 4143
 Boyd, J., 1906, 5100
 Boyd, M. R., 1794
 Boyer, C. M., 1939
 Boyer, J. C., 3270
 Boylan, J. F., 472
 Boyle, J. O., 4477
 Boynton, R. F., 1889
 Brabant, G., 4987
 Brach, M. A., 3638
 Brachman, D. G., 3667
 Bradley, L. M., 3149
 Bradner, R. C., 2460
 Brakkee, J. H., 544
 Bramson, J., 3237, 5370
 Branda, R. F., 5401
 Bras, J., 310
 Brattain, M. G., 4041
 Braun, D. P., 3362
 Braun, S., 1027
 Braunbeck, T. A., 3700
 Braunschweiler, P. G., 1091
 Breccia, M., 3800
 Brechbiel, M. W., 2834, 5683
 Bréchet, C., 235
 Bredehorst, R., 592, 2368
 Breier, G., 5822
 Breikreuz, T., 4035
 Breitman, M. L., 615
 Brem, H., 329
 Brennan, J., 67
 Brennan, M. F., 5483
 Brenner, D. A., 2279
 Brenner, D. E., 2796
 Brent, T. P., 1731
 Bressac, B., 5872
 Bridges, A. J., 2553
 Brigati, D. J., 937
 Briggs, S. L., 3956
 Bright, R. K., 5734
 Brightman, B. K., 3433
 Bringuier, P. P., 3241
 Brisson, L., 5269
 Brocklehurst, C., 2840
 Brockmüller, J., 1004
 Broder, S., 477
 Brodeur, G. M., 2715, 5269
 Brodie, C., 3968
 Broek, D., 1867
 Broekhoven, M. G., 4399
 Brøgger, A., 5849, 5853
 Brondyk, W. H., 2162
 Bronner, G., 165
 Brooks, J., 2719
 Brossard, J., 5269
 Brown, G. A., 5885
 Brown, J., 2803
 Brown, J. M., 1244, 4633, 6011
 Brown, J. P., 334
 Brown, L. F., 4727
 Brown, L. M., 2421
 Brown, P. D., 2087
 Brown, R. R., 1286
 Brown, T. J., 1304
 Brown, T. R., 1751
 Brownell, A. L., 5867
 Brownell, G. L., 5867
 Broxterman, H. J., 1475, 1747
 Bruce, J. L., 12
 Brugières, L., 452, 2888
 Bruland, O. S., 468
 Brunet, J.-F. M., 4715
 Brünner, N., 283, 1911, 2513, 3229
 Bruno, N. A., 4658
 Bruno, R., 1037
 Bruno, S., 401
 Brunson, K. W., 1921
 Bryant, J., 5654
 Brylawski, B. P., 3865
 Bu, D., 5386
 Bucana, C. D., 937
 Buchanan, J., 3574
 Buchberg, A. M., 1498
 Buchhagen, D. L., 1098, 2410
 Büchler, M., 2704, 5289
 Budach, W., 5012, 5018
 Budding, M., 977
 Budillon, A., 868
 Buettner, G. R., 711, 3670
 Bugat, R., 4850
 Bugg, B. Y., 1373
 Bühring, H.-J., 4424
 Buist, M. R., 5413
 Bukowski, R. M., 1380, 5613
 Bulbul, M., 3574
 Bult, A., 2061
 Bunch, R. T., 3547
 Bunting, P., 4837
 Buras, R. R., 3712
 Burger, C. W., 5413
 Burkart, W., 1507
 Burke, T. G., 1583
 Burmeister, L. F., 2421
 Burns, C. P., 711, 3670
 Burns, L. A., 1862
 Burrell, M., 2231
 Burris, H. A., 5929
 Burt, M., 2858, 5483
 Busch, F. W., 4424
 Busquets, X., 5554
 Bussemakers, M. J. G., 3869
 Butcher, R. D., 3405
 Butel, J. S., 1646, 3374
 Butler, R. N., 3455
 Buttitta, F., 2846, 4665
 Byers, S. W., 1233
 Byrd, J. C., 1437

* For title of article and coauthors, see listing in Contents of Volume 53 beginning on page i at the end of this index issue.

C

- Cabanillas, F., 2118
 Cabral, F., 4573
 Cai, D. W., 4129
 Caillou, B., 5314
 Cairns, P., 1230
 Calcagnile, A., 1149
 Calderwood, S. K., 12, 2212
 Califano, D., 5523
 Callahan, R., 1990, 2846, 4665, 5617
 Calle, E. E., 1322
 Callery, P. S., 766
 Calorini, L., 1952, 3349
 Calvo, S., 2957
 Camera, L., 2834
 Cameron, M. J., 1043
 Campagnoni, A. T., 170
 Campani, D., 4665
 Campbell, C., 2697
 Canaani, E., 2147, 3800, 4489, 5624
 Canaani, O., 9044
 Canal, P., 4850
 Candreva, E. C., 5750
 Canevari, S., 5791
 Canman, C. E., 5219
 Cannistra, S. A., 3830
 Cannizzaro, L. A., 3118
 Cansado, J., 4474
 Cantor, K. P., 2421
 Cantoreggi, S., 3505
 Canzian, F., 209
 Cao, X. R., 6051
 Capeau, J., 2762
 Capitani, S., 4481
 Capuani, L., 4343
 Carbone, A., 3343
 Carbone, D. P., 3257
 Carboni, J. M., 4041
 Carcelain, G., 3569
 Cardiff, R. D., 3233
 Cardona, H., 3536
 Carlsen, S. A., 2906
 Carlson, P., 4337
 Carmeli, S., 1343
 Carmella, S. G., 721
 Carmichael, J., 5649
 CarMichael, M. J., 744
 Carmichael, P. L., 944
 Caron de Fromental, C., 5872
 Carr, I., 4499
 Carrasquillo, J. A., 2834
 Carriero, M. V., 3198
 Carroll, P., 2199
 Carroll, R. S., 1312
 Carson, D. A., 1098
 Carter, B. S., 3869
 Cascinu, S., 5429
 Casero, R. A., Jr., 2071
 Casey, G., 2712
 Casey, L., 3362
 Cassidy, J., 523
 Casson, A., 1676
 Castagnetta, L., 741
 Castello, M. A., 2044
 Castles, C. G., 5934
 Castonguay, A., 2498
 Catalano, G., 5429
 Catchpoole, D. R., 4287
 Catlett, J., 4337
 Catsafados, E., 4769
 Cattaneo, M. G., 5566
 Cavalletti, E., 544
 Cavallo, F., 5067
 Cavanaugh, P. G., 4418
 Cavenee, W. K., 957, 2386, 2715, 4486
 Cazals-Hatem, D., 4978
 Cecchetti, D., 4665
 Celli, G., 2287
 Center, M. S., 3658
 Cermak, J., 5308
 Cerra, M., 3198
 Cerutti, P. A., 38
 Cesnjaj, M., 5214
 Cetin, Y., 4987
 Cha, C., 16
 Chabot, G. G., 1550, 3541, 4608
 Chace, D., 334
 Chadwick, G. A., 523
 Chae, H. P., 447
 Chae, Y.-H., 2028, 3719
 Chaganti, R. S. K., 2732
 Challine, D., 1534
 Chamberlin, H., 1142
 Chambers, A. F., 701
 Chambon, P., 165, 4096
 Champême, M.-H., 1990, 5617
 Chandan-Langlie, M., 1431
 Chaney, S. G., 799
 Chang, A. E., 1043, 4315
 Chang, C., 1244
 Chang, C., 4648
 Chang, E. H., 1889, 4452
 Chang, H.-C., 1653
 Chang, H.-L., 1990, 5617
 Chang, H. R., 1122
 Chang, K.-S., 4449
 Chang, K.-T., 1079
 Chang, P.-L., 2217
 Chang, R. L., 3294
 Chang, S., 1122
 Chang, T. K. H., 2490, 5629
 Chang, Y.-M., 3677
 Chang, Y.-s., 1317
 Chang, Z.-F., 3253
 Charles, J. F., 5745
 Chasin, M., 329
 Chastre, E., 2762
 Chatelut, E., 4850
 Chazin, V. R., 2715, 4960
 Chella, A., 2846
 Chen, A., 5339
 Chen, A. P., 4828
 Chen, A. Y., 1332
 Chen, B.-X., 1388
 Chen, C. H., 1511
 Chen, C.-J., 790
 Chen, C.-S., 3853
 Chen, D.-S., 1653
 Chen, G., 2544
 Chen, H.-C., 717
 Chen, H.-x., 1974
 Chen, J., 6028
 Chen, K., 221
 Chen, L. B., 1916, 4048, 5808
 Chen, M., 5946
 Chen, P.-J., 1653
 Chen, R., 3394
 Chen, R. S., 3233
 Chen, S.-H., 4648
 Chen, T.-H., 4720
 Chen, T.-M., 1167
 Chen, W.-T., 3159
 Chen, Y. Q., 2723
 Chen, Z. J., 112
 Chen, Z. Y., 9
 Chenard, M.-P., 4096
 Cheng, E. H. C., 2260
 Cheng, J. Q., 4761
 Cheng, L. Z., 2527
 Cheng, S.-M., 3253
 Cheng, X., 5592
 Cheng, Y.-c., 1974
 Cheong, N., 1213, 5592
 Cherian, M. G., 922, 1829
 Cherkui, G., 2762
 Cherrick, H. M., 4811
 Chervitz, D. L., 641
 Cheshire, P. J., 2823
 Chew, K., 2199
 Chiang, Y., 6017
 Chiappetta, G., 5523
 Chin, D., 5251
 Chin, J. L., 1829
 Chioce, E. A., 3125
 Chirivi, R. G. S., 5051
 Chisena, T., 4828
 Chiu, M. L., 977
 Cho-Chung, Y. S., 868
 Chokshi, S., 3028
 Chompret, A., 452
 Choudhury, S., 3394
 Chowdary, D., 5127
 Christen, R. D., 1571
 Christensen, I. J., 2513
 Christian, M. C., 1794
 Christman, J. K., 5033
 Christou, M., 968
 Chu, E., 3362
 Chung, K. Y., 1676
 Chung, L. W. K., 2852, 5300
 Chung, Y.-s., 884
 Ciardiello, F., 5548
 Cimino, G., 3800
 Cincotta, A. H., 2571
 Cincotta, L., 2571
 Cines, D. B., 3109
 Cirafo, A. M., 5548
 Clark, G. M., 3736, 5929
 Clark, S. H., 6058
 Clarke, C. L., 5940
 Clarke, R., 283, 3229
 Clarkson, B., 401
 Clausen, H., 5494
 Clavel, M., 1037
 Cleary, K. R., 937
 Clément, F., 1182
 Clementi, F., 5566
 Clerget, M., 1421
 Cleris, L., 5374
 Cleton-Jansen, A.-M., 3804
 Clezardin, P., 1421, 4695
 Cliby, W., 2393
 Cliby, W. A., 4456
 Clift, S., 2221
 Cline, J. M., 101
 Cockett, A. T. K., 1724, 1967
 Coderre, J. A., 3308
 Codignola, A., 5566
 Coffey, D. S., 744, 1995, 4720
 Coffey, R. J., 1630
 Coggin, D. L., 1403
 Cohen, L. K., 2221
 Cohen, R. J., 1899
 Cohen-Salmon, M., 2888
 Colby, T. V., 4817
 Cole, C., 53
 Cole, D. E., 725, 1032
 Cole, J., 609
 Cole, M., 4881
 Cole, S. P. C., 3221, 4156, 4866
 Coleman, C. N., 12, 2212
 Coleman, K., 4041
 Coletta, K. A., 777
 Colletta, G., 5548
 Collins, D. C., 533
 Collins, V. P., 2475, 2736, 3674
 Colnaghi, M. I., 5791, 5864
 Colofiore, J. R., 3518
 Colombo, E., 681
 Colvin, O. M., 2338
 Comeau, L. D., 3865
 Comstock, G. W., 795
 Conaldi, P. G., 2957
 Conney, A. H., 1255, 3294
 Connolly, J. M., 4686
 Conrad, F., 260
 Cook, J. A., 2066
 Cooke, T. G., 4161
 Cooney, D. A., 5714
 Coons, S. W., 5605
 Coppes, M. J., 2712
 Corallini, A., 5569
 Cordeiro-Stone, M., 3865
 Cordon-Cardo, C., 2379, 5780
 Cork, A., 3603, 4449
 Cornelisse, C. J., 3804
 Correa, P., 1317
 Correo, R., 4477
 Corry, P. M., 2740
 Cortessis, V. K., 212, 5083
 Cosand, W. L., 2560
 Cossman, J., 4251
 Costa, A., 4769, 6036
 Costa, M., 460
 Cotelingam, J. D., 5181
 Couderc, B., 1182
 Cowan, J. M., 5542
 Cowan, K. H., 2587
 Cowens, J. W., 2796
 Cowser, L. M., 2330
 Cragoe, E. J., Jr., 1599
 Craig, C., 1032
 Craig, F. E., 3930
 Creaven, P. J., 2796, 5970
 Crechet, F., 3246
 Creek, K. E., 905
 Crespi, C. L., 5629
 Cressman, D. E., 3789
 Crimmin, M. J., 2087
 Croce, C. M., 2954, 3118, 3800, 4489, 5624
 Crompton, N. E. A., 1507
 Crone, T. M., 4750
 Croop, J. M., 310, 977
 Cropp, C. S., 1990, 5617
 Cruz, P. D., Jr., 4014
 Cui, X. X., 3294
 Culver, K. W., 83
 Cummings, K. K., 2961
 Curti, B. D., 2204
 Cushing, M., 477

* For title of article and coauthors, see listing in Contents of Volume 53 beginning on page i at the end of this index issue.

Cutler, D. S., 3149
Cysyk, R., 4828

D

- Da, D., 3765
Dabelsteen, E., 5494
Dabholkar, M., 3694
Daburon, F., 3246
Dahiya, R., 641, 1437
Dahlöf, B., 4573
D'Aiuto, G., 3198
D'Alessio, A., 5523
Dalla-Favera, R., 2732
Dalton, W. S., 1475
Damani, M. T., 271
Dämmrich, J., 4197
Dandona, P., 5104
Danforth, D. N., Jr., 1538
Danks, M. K., 1373
Danø, K., 1911, 2513
Danyluk, J., 4960
Darwiche, N., 2287
Darzynkiewicz, R. J., 4613
Darzynkiewicz, Z., 401, 1945, 3186, 4613, 5096
Das Gupta, T. K., 5740
Dashner, K., 1312
Daurès, J-P., 61
Daver, A., 61
David, L., 5494, 5853
Davidson, N. E., 291, 2071, 3976, 5424
Davies, B., 2087, 5365
Davies, D. S., 6076
Davies, R. E., 53
Davies, S. M., 4781
Davis, J., 5424
Davis, R. L., 2386
Davoodi, F., 3712
Dawson, B. V., 550
Dawson, G., 170
Day, M. L., 5597
Day, N. K., 1188
Day, R. S., III, 3674
Daya-Grosjean, L., 1625
Dean, P. A., 4652
DeAngelis, C., 4837
Debinski, W., 4588
de Boer, C. J., 4148
Debruyne, F. M. J., 3241, 5512
DeCarvalho, M., 4828
DeCastro, R., 3154
Decensi, A., 4769
De Clerck, Y. A., 693
deConinck, E. C., 3472
Dedrick, R. L., 2092, 3752
Deeley, R. G., 3221, 4156
Deen, D. F., 3948
Defendi, V., 1167
de Francis, V., 5523
de Frankrijker, E., 4563
DeFranzo, B., 3830
DeFreitas, E., 5501
Deftos, L. J., 1724
DeGraff, W., 5845
de Gruilj, F. R., 53, 4212
Deguchi, T., 5350
Deguchi, Y., 373
de Haas, M., 1747
Deisseroth, A., 4772
Dejana, E., 3812
de Jong, B., 5707
de Jong, J., 4603
de Jong, S., 1064
Dekkers, J. A. J. M., 1642
DeLacey, K. A., 4456
de la Chapelle, A., 5849, 5853
Delage, S., 2762
de la Monte, S. M., 3823
De Leo, A. B., 1602
Del Ferro, E., 5429
Delia, D., 6036
Della Porta, G., 209
Delmas, P. D., 1421, 4695
Delsite, R., 1416
De Luca, L. M., 2287
Del Vecchio, S., 3198
Demarchez, M., 1175
Demple, B., 3250
den Engelse, L., 5669
den Hollander, W., 5413
Denial, T. M., 1665
Denicoff, A. M., 2587
Dennert, G., 6001
Dennis, I., 5649
Den Otter, W., 5754
Denyn, M-M., 5512
Derbyshire, E. J., 3000
de Rijk, D., 3611
Deroussent, A., 1534
Derynck, R., 4391
Desai, D., 4182
Desgrandchamps, F., 5872
Desnoyers, S., 3976, 5370
de Tribolet, N., 957, 5345
Deutsch, T. F., 5954
Dev, I. K., 810
De Valck, D., 2623
de Vernejoul, M-C., 5076
Devilee, P., 3804
Devine, P. L., 4082
Devitt, M. L., 3518
de Vos, S., 3638
de Vries, E. G. E., 248, 1064, 1475, 1747, 5707, 5915
De Vries, H. T., 248, 784
Dew, S. E., 2965
Dewey, W. C., 1239
Dewhirst, M. W., 3765
Deytieu, S., 5076
Diamantstein, T., 714, 4134
Diamond, E. L., 795
Diasio, R. B., 2816, 5433
Diaz, M. O., 2410
Dickerson, S. H., 810
Dickson, R. B., 873, 1409, 2168, 2178
DiCunto, F., 5517
Diehl, V., 4310
Diella, F., 2846, 4665
Diep, A., 5083
Dietel, M., 2683
Dietrich, D. R., 3505
Dietzfelbinger, H. F., 3747
Diffey, B. L., 609
Di Gregorio, C., 3726
Di Lorenzo, T. P., 910
DiMassimo, B. I., 1195
Dimitroff, K., 27
Dinnen, R. D., 1877
Di Pierro, F., 5067
Dipple, A., 1273
di Sant'Agnese, P. A., 1724, 1967
Discher, H., 4189
Diserens, A-C., 5345
Ditzel, H., 5920
Dive, C., 1735, 2133, 3321
Diwan, B. A., 3874
Dixit, V. M., 378
Dizdaroglu, M., 1269
Djakiew, D., 1416
Dmitrovsky, E., 2379
Doan, V. T., 3486
Dobbs, D., 5683
Dobrovic, A., 3455
Dodson, M. K., 2393, 4456
Dodson, R., 2810
Dogliotti, E., 1149
Dohi, K., 2940
Doi, T., 5350
Doki, Y., 3421
Dolan, M. E., 4281
Doll, M. A., 509
Dominici, C., 2044
Donehower, R. C., 1794
Dong, L., 4542, 5554
Donis-Keller, H. R., 2947
Donker, T. H., 4563
Donohue, J. H., 4652
Donthineni-Rao, R., 4890
Dorant, E., 75, 4860
Dorie, M. J., 4633
Dörken, B., 4310
Doroshov, J. H., 1269
Dorr, R. T., 550
Dorsch, M., 714
Dosesu, J., 2618
Dos Santos, B., 3386
Dotto, G. P., 5517
Dou, Q-P., 1493
Downing, J. R., 5108
Dowsett, M., 266
Drach, J., 2100
Dragani, T. A., 209
Drake, J., 4828
Drakoulis, N., 1004
Dralle, H., 4987
Dranoff, G., 2221
Drechsler, K., 4082
Drees, M., 3058
Dressler, L. A., 4297
Dreyfus, F., 235
Dritschilo, A., 4474
Droller, M. J., 4971
Drougard, C., 1625
Drouin, J., 4695
Druck, T., 1498, 3118
Drucker, D. J., 2980
Dube, D. K., 6067
Dube, S., 6067
Dubeau, L., 4138
Duch, D. S., 810
Duffy, F. A., 5915
Duh, F-M., 861
Dumenco, L. L., 997
Duncan, L., 298
Dunne, A. D., 176
Durand, R. E., 733
Durr, F. E., 3336
Durrani, F. A., 1560
Dusel, G., 3283
Dutcher, J. P., 3509
Du Vignaud, P., 4595
Dvorak, H. F., 2631, 2912, 4727
Dvorak, J. M., 2631

E

- Early, J. A., 1577
East, N., 2087
Eastman, A., 2349
Eaton, D. L., 9, 2313
Eber, M., 165
Ebert, E. C., 1608
Ebina, M., 3103
Ebisuzaki, K., 1877
Eby, Y. J., 4477
Eccles, D. M., 2128
Eccles, M. R., 5166
Eckardt, J. R., 5929
Eckhardt, J. N., 5071
Edinger, M. G., 1380
Edwards, C. C., 1731
Edwards, C. L., 5188
Eggensperger, D., 600
Egorin, M. J., 766
Egyházi, S., 4257
Ehara, H., 5350
Ehninger, G., 5135
Eijdens, E. W. H. M., 1747
Eisenberg, S. P., 4010
Eisenbrand, G., 3058
Eklöv, S., 3193
El-Bayoumy, K., 2028, 3719
El-Beltagi, H. M., 3008
Eliaison, J. F., 2319
Eliyah, S., 5
el Kouni, M. H., 3687
el Kouni, M. M., 3687
Elledge, S. J., 1986
Ellis, L. M., 937
Elmore, E., 3475
Elmore, L. W., 254
Elstad, C. A., 4075
Emmerman, J. T., 4224
Emi, M., 857, 1172, 3869
Emons, G., 5439
Empereur, S., 2762
Enders, C., 4189
Endlich, B., 1511
Endo, Y., 1397
Endo, Y., 5419
Engelman, R. W., 1188
Engelmann, A., 165
Enomoto, M., 5079
Enomoto, T., 1883
Enright, H., 5308
Epner, D. E., 1995
Epstein, J. I., 329, 744, 3869
Erb, K., 5920
Erdos, G. W., 1899
Erickson, L. C., 4281
Ericson, L. E., 4987
Erlander, B. F., 1388
Erlichman, C., 4837
Ermler, D., 1788
Escot, C., 2901
Esherrick, J. S., 5517
Esposito, G., 3198
Esselman, W. J., 2272
Esteban, E. F., 3233
Estival, A., 1182
Estrov, Z., 3289
Esumi, H., 2786

* For title of article and coauthors, see listing in Contents of Volume 53 beginning on page i at the end of this index issue.

- Ethier, S. P., 627
 Eto, S., 4643
 Ettinger, D. S., 1794
 Evans, C. A., 1735
 Evans, C. D., 4866
 Evans, D. L., 2133
 Evans, M. K., 5377
 Evans, S. R. T., 3712
 Everett, G., 2421
 Ewers, T. G., 3416
 Ewing, C. M., 3585
 Extra, J.-M., 1037
 Eyfjörð, J. E., 1637
- F**
- Fabbro, D., 4542
 Fagarasan, M., 5214
 Fahl, W. E., 2162, 4900
 Fair, K., 2947
 Fair, W. R., 227, 5780
 Falcone, V., 2957
 Falvella, F. S., 209
 Fan, H., 3433
 Fan, Z., 4322, 4637
 Fand, I., 4026
 Fante, R., 3726
 Farbstein, H., 5251
 Fardel, O., 231
 Farmer, B., 3455
 Farr, P. M., 2697
 Faure, F., 3569
 Favaudon, V., 2105
 Fecarotta, E., 741
 Fedeli, A., 5429
 Federici, F., 19
 Fedida, D., 4156
 Fee, F., 6022
 Feist, H., 1956
 Feix, J. B., 806
 Felgner, J., 1956
 Felix, C. A., 2954, 4489
 Fell, H. P., 2123
 Fenaux, P., 5872
 Fenger, C., 1895, 5920
 Fenton, W., 4701
 Fêrec, C., 5745
 Ferguson, R. J., 509
 Ferguson-Smith, M., 861
 Fernig, D. G., 4627
 Ferone, R., 810
 Ferradini, L., 3569
 Ferrantini, M., 1107
 Ferrara, G. B., 5581
 Ferraro, T., 1255
 Ferris, C. A., 1360
 Ferrone, S., 112, 2830, 3343, 3349, 4303, 4927
 Fessler, B., 5797
 Feuerstein, B. G., 3948
 Feunteun, J., 452
 Fey, M. F., 921
 Fidler, A. E., 5166
 Fidler, I. J., 937
 Fields, S. M., 5929
 Fiers, W., 2623
 Figari, I., 4391
 Finch, M. D., 3355
 Fingert, H. J., 3028
 Finke, J. H., 1380, 5613
 Finley, G. G., 2919
 Finn, O. J., 5386
- Fiorani, P., 4343
 Fiore, L., 2957
 Firestone, G. L., 1808, 1816
 Fischer, L., 1956
 Fish, E. N., 5148
 Fishbaugh, P. M., 1489
 Fisher, C. J., 515
 Fisher, H., 5458
 Fisher, L. M., 3591
 Fisher, P. B., 1929
 Fisher, T. C., 3321
 Fishman, E. K., 1794
 FitzGerald, D. J. P., 340, 819, 4588
 Flam, F., 2927
 Flamant, F., 452
 Flanders, K. C., 5517
 Flanders, W. D., 1322
 Fleischer, D., 4938
 Fletcher, R. G., 2279
 Fleuren, G. J., 3804
 Flôrenes, V. A., 468
 Flotte, T. J., 5954
 Foddai, M. L., 1297
 Fodde, R., 2614
 Fodstad, Ø., 468, 3784
 Foglietti, G., 5429
 Fojo, A., 283
 Foley, J. W., 2571
 Folkman, J., 5297
 Folsom, A. R., 536, 4230
 Fontana, J. A., 3226
 Fontenot, J. D., 5386
 Fonti, R., 3198
 Forbes, P. D., 53
 Ford, H., Jr., 5714
 Ford, J., 3262
 Formelli, F., 5374, 6036
 Fornari, F. A., 3547
 Forni, G., 5067
 Forni, M., 5067
 Fortini, P., 1149
 Fossâ, S. D., 5849
 Fosse, P., 5987
 Foster, T. H., 1249
 Fournier, G., 5872
 Fowler, J. F., 4413
 Fox, S. B., 4161
 Fox, T. R., 2265
 Franchetti, P., 19
 Frandsen, T. L., 3229
 Frank, T. S., 627
 Frappart, L., 1421
 Frati, L., 2457
 Fraumeni, J. F., Jr., 1317
 Fredman, P., 120
 Freeman, J., 5012, 5018
 Freeman, S. M., 5274
 Freireich, E. J., 4449
 Frelinger, J. G., 2112
 French, J. E., 2750
 French, R. R., 3015
 Frenkel, K., 1255, 4528
 Frestedt, J., 3853
 Freter, C. E., 283
 Frey, C. M., 1079
 Friche, E., 1373
 Friedman, H. S., 120, 2338
 Friedman, P. N., 334
 Friess, H., 2704, 4741, 5289
 Frisoli, J. K., 5954
- Frixen, U. H., 3618
 From, L., 2235
 Frostesjö, L., 5262
 Fry, M., 2895
 Fu, X., 1204
 Fuchs, H. E., 2338
 Fudge, K., 3073
 Fujihira, S., 5350
 Fujii, D. K., 158
 Fujii, N., 4466
 Fujii, T., 1136
 Fujiki, H., 239, 992, 1012, 1777, 1982, 3462
 Fujimoto, K., 1136
 Fujita, H., 1156
 Fujita, J., 3795
 Fujita, K., 2566
 Fujita, M., 1883
 Fujita, N., 5022
 Fujita, S., 464
 Fujita, T., 4262, 5233
 Fujita, Y., 4823
 Fujita-Yamaguchi, Y., 3736
 Fujiwara, T., 4129
 Fujiwara, Y., 857, 1172, 3869
 Fujiwara, Y., 3302
 Fuks, A., 3817
 Fuks, Z., 2987
 Fukuda, Y., 368
 Fukumura, D., 2676
 Fukushima, K., 2970
 Fukushima, M., 4004
 Fukushima, S., 32, 4218
 Fuller, G. N., 120
 Funa, K., 3193, 4550
 Funke, I., 1690
 Fuqua, S. A. W., 4443, 5882, 5934
 Furihata, M., 4823
 Furlitu, T., 675
 Furlanetto, R. W., 2522
 Furmanski, P., 5055
 Furukawa, H., 3632
 Furukawa, K., 5395
 Furukawa, K., 5395
 Furukawa, T., 1204, 3070
 Furukawa, T., 5680
 Furusato, M., 1906
 Fusamoto, H., 3899
 Futakuchi, M., 32
 Futreal, P. A., 1218
 Futscher, B. W., 1373
- G**
- Gabbianelli, M., 569
 Gabriele, L., 569, 1107
 Gagliardi, A., 533
 Gale, R. P., 5624
 Galivan, J., 2227
 Gall, H., 456
 Gallagher, H. S., 5188
 Gallegos, A., 4297
 Gallick, G. E., 1630
 Gallie, B. L., 3574
 Gallinger, S., 271
 Gallion, H. H., 3839
 Gamarra, F., 1590
 Gamson, J., 5845
 Ganapathi, R., 3262
 Ganesan, T., 5649
 Gansbacher, B., 4020
- Gansow, O. A., 2834, 5683
 Gao, H., 1783
 Gao, X., 2723
 Garcia de Palazzo, I. E., 94, 3217
 Gardes, M., 452
 Gardner, G. R., 2976
 Garewal, H., 1469
 Gariboldi, M., 209
 Garin-Chesa, P., 3327
 Garmestani, K., 2834
 Garofalo, A., 5051
 Gasa, S., 2484, 5638
 Gasdaska, P. Y., 1338, 5458
 Gasparollo, A., 3343
 Gasparotto, D., 5775
 Gatter, K. C., 4161
 Gatti, R. A., 438, 5083
 Gattioni-Celli, S., 1952, 3349
 Gaut, Z. N., 6074
 Gawlak, S. L., 334
 Gazdar, A. F., 1079, 2410, 5181
 Gazitt, Y., 1899
 Gebhardt, R., 5135
 Gehani, S. K., 3394
 Gehring, U., 3513
 Ceil, L., 861
 Gelfand, E., 3968
 Gelman, I. H., 915
 Gelos, U., 5750
 Georges, E., 5994
 Georges, R. N., 1743
 Gerdes, H., 279
 Gerretsen, M., 3524
 Gerson, S. L., 997
 Gerwin, B. I., 985, 2035
 Gespach, C., 2762
 Getzenberg, R. H., 744
 Gewirtz, D. A., 3547
 Gharehbaghi, K., 2344
 Ghatti, C. A., 2457
 Ghislain, J., 5148
 Ghosh, B. C., 5181
 Ghosh, L., 717
 Ghosh, R., 38
 Ghosh, S. K., 5501
 Giavazzi, R., 3812, 5051
 Gibbs, C. J., Jr., 6067
 Gibellini, D., 4481
 Gibson, D. F. C., 4413
 Gierthy, J. F., 3149
 Gilissen, M. J., 2548
 Gill, I., 3694
 Gill, N. S., 2700
 Gill, T. J., III, 4089
 Gillett, N., 4391
 Gillin, J. S., 279
 Gillis, K. C. P. M., 4797
 Gilmore, K. S., 231
 Ginsberg, R., 2796
 Ginya, H., 5559
 Giocanti, N., 2105
 Gioioso, D., 5012, 5018
 Giovanella, B. C., 1577
 Giovarelli, M., 5067
 Gismondi, V., 5581
 Gispén, W. H., 544
 Gleave, M. E., 2852, 5300
 Glennie, M. J., 3015
 Glick, A. B., 4803
 Gliozzo, B., 3736

- Gloghini, A., 3343
 Gloudemans, T., 5754
 Glover, M. T., 5328
 Glowacka, D., 1312
 Gnarra, J. R., 861, 2719, 3092
 Godal, A., 3784
 Goddard, P. M., 2581
 Godolphin, W., 4960
 Godwin, A. K., 3662, 3771, 5225
 Godwin, K. A., 472, 725
 Godwin, T. A., 762
 Goepfert, H., 1676
 Goetz, A. E., 1590
 Going, J. J., 4161
 Goldbohm, R. A., 75, 4860
 Goldenberg, D. M., 819
 Goldenberg, G. J., 3530, 5885
 Goldfine, I. D., 3736
 Goldin, E., 2374
 Goldmacher, V. S., 1360
 Goldspiel, B., 4828
 Goldstein, A. L., 5214
 Goldstein, L., 4828
 Goldstein, S. M., 762
 Goldsworthy, S. M., 2265
 Goldsworthy, T. L., 2265
 Gollahon, L. S., 5339
 Golumbek, P. T., 5841
 Gomella, L., 1102
 Gong, J., 1945, 3186, 4613, 5096
 Gonzalez-Zulueta, M., 4066, 5620
 Good, R. A., 1188
 Good, S. S., 4619
 Gooderham, N., 6076
 Goodgame, R., 2803
 Goodin, S., 5382
 Goodman, M. F., 4582
 Goodman, P., 4837
 Goonetilleke, R., 3919
 Gorczyca, W., 1945, 3186
 Gordon, J. N., 4971
 Gorelick, F. S., 2260
 Goris, M. L., 3022
 Goshorn, S. C., 2123
 Gosland, M., 5382
 Goss, P. E., 3574
 Gottesman, M. M., 747
 Gouérou, H., 5745
 Gould, M. N., 2272, 3849, 5766
 Gouyette, A., 1534, 1550, 3541, 4608
 Goya, L., 1808, 1816
 Grabowski, D., 3262
 Graem, N., 1911
 Graham, M. A., 523
 Gramacho, C., 1222
 Grandis, J. R., 3579
 Grand-Perret, T., 4595
 Grant, T. D., 2700
 Granzen, B., 1373
 Graves, D., 3667
 Gray, G. D., 577
 Gray, K., 509
 Gray, R., 4108
 Gray, R. D., 1998
 Greaves, P., 3919
 Greco, G., 569
 Greco, W. R., 2796
 Green, M. H. L., 609
 Greenall, M., 3597
 Greenfield, L., 3752
 Greenhalgh, D. A., 5071
 Gregory, C. D., 3321
 Greiner, J. W., 600
 Greipp, P. R., 5320
 Grekin, R. C., 762
 Grem, J. L., 4828
 Grenier, J., 61
 Gresser, I., 1107
 Grianti, C., 5429
 Griffin, R. J., 1599
 Griffith, O. W., 3207
 Grignani, F., 6036
 Grignani, F., 6036
 Grignon, D., 2723
 Grimm, E. A., 2597, 4129
 Grisham, J. W., 500
 Grizzle, W. E., 4555
 Grobholz, R., 4204
 Groce, A., 2479, 5676
 Groden, J., 5581
 Groff, J. M., 1761
 Grogan, T. M., 417
 Gromo, G., 3015
 Grond, M. P., 2279
 Grøndahl-Hansen, J., 2513
 Grondard, L., 5987
 Groopman, J. D., 3499
 Gros, P., 1657, 5269
 Gross, A. J., 67
 Grossberg, S. E., 5176
 Grover, P. L., 944
 Grunberger, D., 1255, 4528
 Grune, T., 5143
 Grunenwald, D., 4608
 Gruss, H.-J., 3638
 Gu, J., 3899
 Gu, J. R., 4817
 Gu, X., 3046
 Gu, Y., 5624
 Gualandi, F., 5569
 Gudas, L. J., 472
 Gudat, F., 2199
 Gudkov, A. V., 5251
 Guengerich, F. P., 2028
 Guglielmi, C., 3800
 Guichard, S., 4850
 Guillaudeau, J., 3536
 Guillaume, T., 3139
 Guillouzo, A., 231
 Gulati, S. C., 3730
 Gulino, A., 5067
 Gullick, W. J., 627
 Gum, E. T., 641
 Gunja-Smith, Z., 4493
 Günther, U., 1516
 Guo, H.-Y., 2479, 5676
 Guo, X., 1974
 Guo, Z., 3276
 Gusella, J. F., 3465
 Gustafson, D. L., 5470
 Gustin, T., 4715
 Guthrie, P. D., 5300
 Guzman, R. C., 1816
- H
- Haag, J. D., 3849
 Haber, D. A., 4757
 Habuchi, T., 3795
 Hacker, H.-J., 4204, 5447
 Hadi, A., 5043
 Haegeman, G., 2623
 Hagenbeek, A., 3008
 Haghayegh, S., 1444
 Hagiwara, A., 687
 Hahm, H. A., 291
 Hahn, S. M., 2066
 Haile, R. W., 212, 5083
 Hain, J., 1507
 Hainaut, P., 1739, 4469
 Hait, W. N., 2260
 Haite, N. E., 2128
 Hajek, R. A., 5188
 Hajnal, A., 4670
 Hakim, J., 4477
 Haldorsen, T., 5849
 Hall, E. J., 1368
 Hall, W. A., 2092
 Halling, K. C., 2393
 Hallman, J. C., 2823
 Halloran, P. M., 1360
 Halpin, J., 6006
 Hamada, H., 2538
 Hamada, J.-i., 4418
 Hamaguchi, K., 3771, 5225
 Hamann, P. R., 3336
 Hamanoue, M., 1281
 Hamazaki, S., 3795
 Hamburger, A. W., 557
 Hamdan, O., 3139
 Hamers, F. P. T., 544
 Hamilton, J. M., 4828
 Hamilton, T. A., 1380
 Hamilton, T. C., 3662, 3771, 5225
 Hamlin, H. A., Jr., 3172
 Hammond, D., 1032
 Hamou, M.-F., 5345
 Han, H.-J., 5087
 Han, I., 4913
 Han, Z.-x., 1317
 Hanada, M., 4978
 Hanada, R., 5284
 Hanafusa, H., 915
 Hanauske, A. R., 3747
 Hanby, A., 5365
 Hancock, S. L., 3857
 Handel, L. M., 3771
 Hanisch, F.-G., 4082, 4367, 4791
 Hank, J., 1286
 Hanna, M. G., Jr., 456, 2368
 Hansen, H. J., 819
 Hanski, C., 4082
 Hanski, M.-L., 4082
 Hanss, M., 4695
 Hansson, G. C., 755, 4987
 Hansson, J., 4257
 Hao, W., 1921
 Hao, X.-Y., 4257
 Hao, Z.-M., 4452
 Hara, A., 772, 3903
 Harada, M., 106
 Haraf, D., 3667
 Haraguchi, M., 5680
 Haraguchi, T., 1808
 Haran-Ghera, N., 2147, 3433
 Harcourt, S. A., 609
 Hard, G. C., 4534
 Hardingham, J. E., 3455
 Hardy, E., 5745
 Harel, W., 1113
 Harker, W. G., 1373
 Härkönen, P. L., 5199
 Harlow, S. P., 681
 Harmon, J. M., 4059
 Harms, D., 4053
 Haroun, E. A., 3008
 Harpalani, A. D., 766
 Harrap, K. R., 2581
 Harrington, A. M., 3486
 Harrington, T., 1218
 Harris, A. L., 3597, 4161, 5649
 Harris, C. C., 985, 1684, 2035, 4817, 5377
 Harris, J. E., 3362
 Harris, L. C., 1731
 Hart, A. A. M., 5669
 Hart, I. R., 962, 3860
 Hartley, D. F., 1249
 Hartley, J. A., 3321
 Hartley-Asp, B., 1833, 4573
 Hartmann, L. C., 2393, 4456
 Hartmann, O., 1534
 Harwell, L., 5721
 Harwell, S. E., 2522
 Hasan, T., 153, 5954
 Hasegawa, A., 354
 Hasegawa, T., 1555
 Hashimoto, H., 4823
 Hassan, F., 3314
 Hata, H., 495
 Hata, Y., 5982
 Hatala, M. A., 4686
 Hatano, T., 4238
 Hattori, Y., 1136
 Hauda, K. M., 2221
 Haugen, A., 5853
 Hauser, S. H., 1952
 Hawkins, G. A., 2368
 Hay, K., 271
 Hayashi, H., 1871
 Hayashi, K., 5284
 Hayashi, N., 3899
 Hayashi, S.-i., 2994
 Hayashi, T., 2940
 Hayashi, Y., 4218
 Hayashi, Y., 5284
 Hayashido, Y., 147
 Hayes, J. D., 3887, 5643
 He, J., 3674
 Healey, J. H., 16, 3327
 Heath, C. W., Jr., 1322
 Heath, L. S., 810
 Heaton, K. M., 2597
 Hebel, D., 577
 Heby, O., 5262
 Hecht, S. S., 721, 2189, 2780, 3719
 Heckel, A., 1974
 Hefta, L. J. F., 1612
 Hei, T. K., 1368
 Heider, K.-H., 1262, 4197, 4754
 Heidorn, K., 1956
 Heike, Y., 5022
 Heim, S., 1895, 2140
 Heimbüchel, G., 4367
 Heimdal, K., 5849
 Hein, D. W., 509
 Hein, G., 4134
 Heiss, M. M., 1690
 Heitjan, D. F., 6042
 Heldin, P., 388

* For title of article and coauthors, see listing in Contents of Volume 53 beginning on page i at the end of this index issue.

- Helmerhorst, T. J. M., 5413
 Hemler, M., 2192
 Hendrix, M. J. C., 550, 3411
 Hennequin, C., 2105
 Hennes, T., 1456
 Hennig, E., 3294
 Hennings, H., 4803
 Henriksen, R., 4550
 Henry, D. L., 4041
 Henry, I., 2888
 Henry, J. L., 1403
 Henry, M., 3103
 Henttu, P., 1051
 Heraït, P., 1550
 Herberman, R. B., 1461, 5654
 Herbst, R., 4424
 Hercbergs, A., 3262
 Hercend, T., 3569
 Herget, T., 5208
 Herlyn, M., 1450
 Herman, C. J., 5055
 Hermann, G. G., 1162, 5620
 Hermus, R. J. J., 75, 4860
 Hernandez, O. M., 577
 Herold-Mende, C., 4189
 Herrera, H., 2479, 5676
 Herrlich, P., 1262, 1516, 4197, 4754
 Herrmann, F., 3638
 Hertel, L. W., 4582
 Herzberg, K. T., 2631
 Heston, W. D. W., 227
 Heyninck, K., 2623
 Hiasa, Y., 4408
 Hibbs, J. B., Jr., 5507
 Hibi, K., 1
 Hickman, J. A., 3034, 3321
 Hida, T., 1709
 Hidaka, H., 2051
 Hiipakka, R. A., 1967
 Hilden, J. M., 3853
 Hilf, R., 1249
 Hill, D. E., 2231, 2728
 Hill, S. M., 5934
 Hillig, M., 2587
 Hillmann, A. G., 4059
 Hilsenbeck, S. G., 3369, 4443
 Hinman, L. M., 3336
 Hino, O., 5856
 Hinton, D. E., 1761, 3700
 Hintz, R., 2858
 Hinz, H. R., 1577
 Hirabayashi, H., 1461, 5654
 Hirai, H., 5419
 Hirai, K., 4175
 Hirai, S., 112
 Hiramatsu, K., 4175
 Hirano, H., 3643
 Hirano, S., 1696
 Hirata, T., 1833
 Hirohashi, S., 2005, 5903
 Hirohata, S., 4175
 Hirose, M., 32
 Hirsch, A., 5872
 Hirvonen, A., 5643
 Hitomi, Y., 5759
 Hittelman, W. N., 2874
 Ho, C., 5386
 Ho, J. J. L., 884
 Ho, J. P., 3221
 Ho, S. B., 641, 1437
 Ho, S.-m., 528
 Hoang-Vu, C., 4987
 Hock, H., 714
 Hockenbery, D., 1853
 Hoda, S., 2379
 Hodgson, C. P., 1630
 Hodnick, W. F., 4907
 Hoerl, B. J., 1338
 Hoffman, R. M., 1204, 2479, 3070, 5676
 Hoffman, T., 5382
 Hoffmann, D., 2758
 Hoffmann, J.-S., 2895
 Höfler, H., 5797
 Hofmann, A., 3283
 Hofmann, M., 1262, 1516, 5345
 Hogg, D., 3574
 Høje, J., 468
 Holder, J. W., 3475
 Hollande, E., 1182
 Holm, I., 5853
 Holm, R., 468, 5853
 Holmes, M., 94
 Holmgren, L., 2927
 Holst-Hansen, C., 3229
 Holt, M., 2947
 Holt, P. R., 2745
 Hölzel, F., 5439
 Homann, N., 4189
 Hong, J.-Y., 1783
 Hong, S.-J., 5300
 Hong, W. K., 1676, 2874, 5113
 Hongo, T., 5284
 Honig, S. F., 2168
 Honke, K., 2484, 5638
 Honn, K. V., 2723
 Honoki, K., 5038
 Hoogewerf, A. J., 2912
 Hoon, D. S. B., 949, 5244
 Horak, E., 3597
 Horan, P. K., 2358
 Hori, K., 5528
 Hori, M., 953
 Horie, M., 5350
 Horikoshi, I., 3046
 Horikoshi, T., 2830
 Horio, Y., 1
 Horn, T., 1162, 5620
 Hornung, S. K., 2313
 Hosick, H. L., 2655
 Hosono, M., 4218
 Hota, C., 701
 Houdek, P. V., 1091
 Houghton, J. A., 2823, 4243
 Houghton, P. J., 2823
 Houin, G., 4850
 Houston, L. L., 4026
 Hovig, E., 468
 Howarth, N. M., 298
 Howell, S. B., 1571, 1596
 Høyer-Hansen, G., 1911
 Hrabie, J. A., 564
 Hruban, R. H., 4477
 Hsiao, S.-H., 1079
 Hsieh, J.-T., 2852, 5300
 Hsieh, L.-L., 1278
 Hsieh, T.-T., 1278
 Hsiung, Y., 89
 Hsu, H.-C., 4691
 Hsu, J.-C., 3289
 Hsu, L.-C., 5766
 Hu, C.-p., 4648
 Hu, M.-C., 2865
 Hu, P., 4920
 Hu, X.-z., 4303
 Huang, G.-T., 1653
 Huang, M.-T., 1255
 Huang, P. C., 922
 Huang, Y., 1889
 Huang, Y.-W., 1392
 Huber, B. E., 4619
 Huber, K., 1788
 Hubert, S. L., 3776
 Huebner, K., 1498, 3118, 5624
 Huelskamp, A. M., 5424
 Huff, T., 4337
 Hughes, C. S., 5127
 Huguet, F., 4850
 Hui, F., Jr., 2035
 Hulla, J. E., 9
 Hüls, C., 4134
 Humphreys, J., 810
 Hung, G., 4960
 Hung, M.-C., 891, 5784
 Hurkadli, K. S., 4855
 Hursting, S. D., 2750
 Husgafvel-Pursiainen, K., 5643
 Hussain, A., 3226
 Huston, J. S., 4026
 Hutter, E. K., 2112
 Huvos, A. G., 16
 Huynh, H. T., 1727, 5585
 Hyafil, F., 4595
 Hyman, P., 5458

I

- Iannone, R., 6067
 Iatropoulos, M. J., 4534
 Iavarone, A., 304
 Ichimura, K., 2736
 Ida, N., 737
 Idle, J. R., 3758
 Ihara, Y., 3899
 Ihde, D. C., 67, 5181
 Iihara, K., 3421
 Iinuma, H., 4896
 Ikebe, M., 1706
 Ikeda, H., 675
 Ikeda, H., 3078
 Ikeda, K., 2534
 Ikeda, Y., 1706
 Ikenaga, M., 368, 846
 Ikeyama, S., 4262, 5233
 Iliakis, G., 1213, 5592
 Imai, K., 2994
 Imai, K., 4927
 Imai, S., 5638
 Imam, S. A., 3233
 Imamura, J., 4053
 Imamura, M., 846
 Imaoka, S., 3632, 4071
 Imondi, A. R., 4534
 Imura, H., 368
 Imura, N., 1829, 4767
 Inada, K., 464
 Inaji, H., 4071
 Inazawa, J., 3382
 Inge, T. H., 833
 Ingles, S., 212, 5083
 Inoko, K., 1555
 Inoue, K., 4823
 Inoue, M., 1696, 3421

J

- Jackman, A. L., 3321
 Jackman, J., 4776
 Jackman, R. W., 4727
 Jackson, R. C., 3998
 Jackson, S. M., 733
 Jacob, H. S., 5308
 Jacob, L. S., 3052
 Jacobs, I. J., 1218
 Jacobs, S. C., 3869
 Jacobsen, J., 1755
 Jacobson, L. P., 3499
 Jaffee, E. M., 2221, 5841
 Jagirdar, J., 2858
 Jain, R., 2771
 Jain, R. K., 2466, 4764, 5867
 Jaken, S., 4542
 Jalal, S. M., 5320
 James, C. D., 3674
 Jameson, B. A., 1102
 Janik, J. E., 2204
 Janin, N., 5872
 Janisch, L., 1293, 2304
 Jansson, S., 4987
 Jarvis, L. J., 447
 Jaspers, N. G. J., 438
 Jaszcz, W., 1431
 Jauch, K. W., 1690
 Jaufereally, R., 5345
 Jaussi, R., 1507
 Jayaram, H. N., 2344
 Jeanpierre, C., 2888
 Jefcoate, C. R., 968
 Jeffers, M., 5355
 Jelinek, D. F., 5320
 Jenkins, G. R., 905
 Jenkins, R. B., 2393, 4456
 Jensen, R. T., 3165

- Jensenius, J. C., 5920
 Jerina, D. M., 1273, 3294
 Jerry, D. J., 1646, 3374
 Jessup, M. J., 4048
 Jewett, M., 3574
 Jhanwar, S. C., 16, 4349, 4761, 5780
 Ji, J., 2895
 Jiang, H., 1929
 Jiang, Y., 4224
 Jin, M.-I., 1317
 Jin, Y., 2140
 Jirsch, J., 4156
 Jirtle, R. L., 3849
 Joh, K., 4238
 Johns, D. G., 5714
 Johnson, B. E., 67, 3165, 4169, 5181
 Johnson, J. P., 1690
 Johnson, J. T., 1461, 5654
 Johnson, K. A., 2728
 Johnson, M. D., 873, 2178
 Johnson, P. A., 2092
 Johnson, R. T., 2012
 Jonczyk, P., 3098
 Jondle, D., 4776
 Jones, A. L., 819
 Jones, D., 2118
 Jones, J. A., 1571
 Jones, L. A., 5188
 Jones, M., 2581
 Jones, N. J., 1522
 Jones, P. A., 1162, 4066, 5620
 Jones, R. T., 4817
 Jones-Blackett, S., 5090
 Jordan, E., 4828
 Jordan, K., 4534
 Jordan, V. C., 4413
 Jorgensen, T. J., 4251
 Jorquera, R., 2498
 Joshi, S. S., 1921
 Jothy, S., 957, 4938
 Ju, G., 2597
 Judah, D. J., 3887
 Juell, S., 3784
 Juhlin, C., 5610
 Jullienne, A., 5076
 Junghans, R. P., 5683
 Jungheim, L. N., 3956
 Junien, C., 2888
- K**
- Kaaijk, P., 1475
 Kabuto, T., 3632
 Kaddurah-Daouk, R., 3172
 Kadhim, S. A., 1829
 Kadlec, J. V., 592
 Kadlubar, F. F., 2028
 Kadmon, D., 4461
 Kadomatsu, K., 1281
 Kadomatsu, K., 1480
 Kadowaki, T., 3421
 Kageshita, T., 2830, 3349, 4927
 Kahn, H. J., 2235
 Kaido, T., 1107
 Kaji, H., 5350
 Kajita, S., 1555
 Kakehi, Y., 3795
 Kalbacher, H., 4424
 Kalechman, Y., 1838, 5962
 Kaltenberg, O. P., 4534
 Kalyanaraman, B., 806
 Kamada, T., 3899
 Kamesaki, H., 4251
 Kamesaki, S., 4251
 Kameyama, M., 3632
 Kameyama, S., 5172
 Kaminski, M. J., 4014
 Kamiyama, M., 221
 Kamoshita, S., 5284
 Kanakura, Y., 675
 Kanayama, Y., 675
 Kanda, H., 5244
 Kane, T. D., 6067
 Kaneda, Y., 949
 Kaneko, S., 5000
 Kaneko, T., 2326
 Kaneko, Y., 5284
 Kang, Y., 3040
 Kanjilal, S., 2961
 Kannagi, R., 354, 5559
 Kansas, G. S., 3830
 Kantarjian, H. M., 3289, 3603
 Kantor, J. D., 1971
 Kanzaki, T., 3193
 Kaplan, C., 4695
 Kappler, F., 1751
 Kapuscinski, J., 4613
 Karakousis, C. P., 1670
 Karg, O., 1027
 Kari, F. W., 2750
 Karikó, K., 3109
 Karthaus, H. F. M., 3241, 5512
 Kasai, M., 4466, 5127
 Kashima, T., 170
 Kashmiri, S. V. S., 3355
 Kasper, H., 3283
 Kastan, M. B., 4164
 Kastury, K., 3118
 Kasumi, F., 3382
 Kataoka, H., 3154
 Kataoka, S., 5022
 Katiwalla, M., 2502
 Katiyar, S. K., 5409
 Kato, Y., 953, 1172, 5087
 Katoh, O., 1136
 Katzmann, J. A., 5320
 Kaufman, D. C., 2066
 Kaufman, D. G., 3865
 Kaufmann, S. H., 3976
 Kaupila, A., 5028
 Kaur, G., 2081
 Kawada, Y., 5350
 Kawai, K., 5172
 Kawai, M., 2051
 Kawai, S., 2472
 Kawai, T., 5419
 Kawajiri, K., 2994
 Kawakami, H., 3643
 Kawakami, Y., 5
 Kawamata, H., 5172
 Kawamori, T., 2775, 3903
 Kawamura, K., 4153
 Kawamura, M., 5284
 Kawamura, T., 5350
 Kaye, S. B., 523
 Ke, Y., 985
 Keating, A., 1304
 Keefer, L. K., 564, 5845
 Keeney, G. L., 2393, 4456
 Kehrel, B., 4695
 Kehrl, J. H., 373
 Keith, I. M., 968
 Kelfkens, G., 53
 Kelland, L. R., 2581
 Keller, S. M., 4349
 Kelley, E. E., 3670
 Kelloff, G. J., 2502, 3493
 Kelly, K. F., 2128
 Kelly, R. C., 1354
 Kelly, T., 3159
 Kemp, C. J., 6022
 Kemperman, H., 3611
 Kenemans, P., 5413
 Kennedy, M. J., 5424
 Kennedy, R. C., 5734
 Kensler, T. W., 231, 3499
 Kerb, R., 1004
 Kerbel, R. S., 2708
 Kern, F. G., 1816, 2168, 2178
 Kerr, D. E., 2123
 Kerr, D. J., 523
 Kerr, I. G., 4837
 Kerschmann, R., 2199
 Kersey, J. H., 3853
 Keszenman, D. J., 5750
 Ketterer, B., 231, 5643
 Khan, M. A., 905
 Khan, P. M., 2614
 Khanuja, P. S., 3394
 Khatib, Z. A., 5535
 Khatibi, S., 1596
 Khazaeli, M. B., 4555
 Khokhar, A. R., 4567, 4913
 Kibbey, M. C., 423
 Kido, Y., 4567
 Kieback, D. G., 5188
 Kiefe, C., 2803
 Kiessling, R., 5610
 Kiguchi, K., 5903
 Kikendall, J. W., 3723
 Kikkawa, F., 2051
 Kikuchi, K., 1702, 3078
 Kikuchi, T., 2534
 Kikuchi-Yanoshita, R., 5079
 Kikucki, T., 957
 Killary, A. M., 5043
 Kim, C.-H., 2368
 Kim, J., 1676
 Kim, M. S., 4811
 Kim, S., 1596
 Kim, Y., 3830
 Kim, Y. S., 641, 884, 1437
 Kimel, N., 158
 Kimura, T., 3349, 4927
 King, C. R., 1403
 King, S., 3000
 Kinuya, S., 2834
 Kinzler, K. W., 1986, 2231, 2728
 Kirchgesner, C. U., 6011
 Kirchheimer, J. C., 1788
 Kirkwood, J. M., 4745, 5654
 Kirsh, J. C., 271
 Kishimoto, T., 851
 Kiso, M., 354
 Kitadai, Y., 4102
 Kitagawa, K., 5589
 Kitagawa, T., 953
 Kitahori, Y., 4408
 Kitajima, M., 1204, 3070
 Kitayama, H., 675
 Kitchener, H. C., 2128
 Kittelson, J., 417
 Kittrell, F. S., 663, 668, 1646, 3374
 Kiviniemi, H., 4486
 Klaassen, C. D., 922
 Klaus, M., 2319
 Kleibeuker, J. H., 248
 Klein, E., 1380, 5613
 Klein, E., 2416
 Kleinman, H. K., 423, 3459
 Klemenz, R., 4670
 Klominek, J., 4376
 Kloth, D. M., 1829
 Klotz, D. M., 5934
 Kluin, P. M., 4148
 Kluin-Nelemans, H. C., 4148
 Klusmann, E., 4082
 Knapp, R. C., 1489
 Kneller, R., 1317
 Knick, V. C., 810, 4619
 Knight, R. A., 926
 Knocks, D., 4268
 Knowles, M. A., 133, 1230
 Knowles, P. P., 3000
 Knox, J. D., 417
 Knox, S. J., 3022, 3857
 Knudson, A. G., 5856
 Kobayashi, E., 5038
 Kobayashi, H., 2708
 Kobayashi, K., 1696
 Kobayashi, N., 106
 Kobayashi, T., 1696
 Kobayashi, T., 2484, 5638
 Kobrin, M. S., 2704, 4741, 5289
 Koch, C. J., 3992, 5721
 Koch, K. S., 2279
 Koch, W., 4477
 Koda, K., 1122
 Kodama, S., 1777
 Kodama, S., 2566
 Koeffler, H. P., 4053
 Koeman, J. H., 784
 Koepf, D. S., 5274
 Kogner, P., 2044
 Kohler, M. F., 1906, 5100
 Kohli, V., 3603
 Kohn, K. W., 1853, 4776
 Kohno, K., 1085
 Koi, S., 3382
 Koishihara, Y., 851
 Koji, T., 5419
 Kojima, T., 772, 2775, 3903, 3908
 Kojiri, K., 490
 Kokkinakis, D. M., 2790
 Kokura, S., 2326
 Kokuryu, H., 368
 Kolachana, P., 1023
 Koldovsky, U., 4791
 Komatsu, N., 1156
 Komeda, H., 5350
 Komori, A., 239, 992, 1982, 3462
 Komuro, H., 5284
 Kondo, M., 2326
 Kondo, Y., 4767
 Konishi, F., 5079
 Konishi, M., 5079
 Konishi, N., 4408
 Konishi, Y., 5038
 Kooistra, A. J., 1064

- Korc, M., 636, 2704, 4741, 5289
 Korsmeyer, S. J., 1853
 Kortess, V., 5669
 Koscielny, S., 1534
 Koski, R. A., 2919
 Kostenuik, P. J., 5452
 Koster, J. F., 2548
 Kostka, G., 4424
 Kotasek, D., 3455
 Koutcher, J. A., 3518
 Kovacs, M., 6011
 Kovarik, J. M., 5915
 Koyama, H., 4071
 Koyama, M., 1555
 Kozielski, A. J., 1577
 Kraft, A., 652
 Kraft, A. S., 2810
 Kraiem, Z., 3943
 Krailo, M., 1032
 Krajewski, S., 4701, 4978
 Kramer, B. S., 1079
 Kramer, R., 2950
 Kramer, R. A., 977
 Krausz, T., 5365
 Kraut, E. H., 4843
 Kreipe, H., 1956
 Kreitman, R. J., 340, 819
 Krepinsky, J. J., 2906
 Krett, N. L., 3877
 Krinock, R. A., 4315
 Kripke, M. L., 2961
 Krishan, A., 2544
 Krishna, M. C., 5845
 Krishnamachary, N., 3658
 Krishnan, V., 1802
 Krishnaswamy, G., 1239
 Kristjansen, P. E. G., 4764
 Kroes, R. A., 4281
 Kroin, J. S., 4582
 Kronauge, J. F., 977
 Kronberger, P., 260
 Kronborg, O., 1895, 5920
 Kropshofer, H., 4424
 Krsmanovic, L., 2507
 Krüger-Krasagakes, S., 4134
 Kruthof, E. K. O., 6051
 Krystal, G., 4337
 Ku, C.-K., 1653
 Kubota, T., 1204, 3070, 5676
 Kudo, R., 3382
 Kudoh, S., 1380, 5613
 Kühn, D., 3747
 Kuhn, J. G., 5929
 Kuhnle, G. E. H., 1590
 Kuipers-Dijkshoorn, N., 3804
 Kujoth, G. C., 2162
 Kulkarni, N., 4182
 Kumar, S., 348
 Kumar, S. P., 2745
 Kunitomo, T., 737
 Kunkel, T. A., 3270
 Kunz, H. W., 4089
 Kunzendorf, U., 714
 Kuo, A., 3109
 Kurebayashi, J., 2168, 2178
 Kurie, J., 2379
 Kurimoto, I., 728
 Kuriya, N., 2830, 4927
 Kuriyama, K., 5624
 Kuroishi, T., 1
 Kurosawa, S., 106
 Kurose, I., 2676
 Kurth, L. A., 1546
 Kurz, E. U., 3221
 Kurzman, I. D., 3986
 Kurzrock, R., 2118, 3289, 3603
 Kushi, L. H., 4230
 Kuwano, H., 1706
 Kuwano, M., 1085
 Kuzmin, I., 861, 3118
 Kwak, K.-S., 1437
 Kwon, H., 1017
 Kyle, R. A., 5320
 Kyo, E., 4102
 Kyprianou, N., 3869
- L
- Labrecque, S., 3468
 LaCreta, F., 94
 Ladanyi, M., 16
 Laderoute, K. R., 2700
 Laerum, O. D., 3129
 LaForgia, S., 1498, 3118
 Lahat, N., 3943
 Lai, M.-Y., 1653
 Lai, P.-L., 4691
 Lambek, C., 401
 Lampson, L. A., 176
 Lampson, M. A., 176
 Lan, M. S., 4169
 Lancillotti, F., 2287
 Lane, D. P., 3374, 4817
 Lane, L. B., 2304
 Langdon, S., 1802
 Lange, B. J., 2954, 4489
 Lange-Carter, C. A., 393
 Langenhuisen, M. M. A. C., 4399
 Langley, K. E., 693
 Langmark, F., 5849
 Langmuir, V. K., 3022
 Langouet, S., 231
 Lantz, M., 4010
 La Placa, M., 4481
 Lapré, J. A., 248, 784
 Larkin, H. E., 5897
 Larsen, A. K., 5987
 Larsson, C., 3707, 4356
 Larsson, E., 2927
 Lasic, D. D., 3964
 Lasorella, A., 304
 Lasota, J., 3118
 Lassam, N. J., 2235
 Lassen, E., 5920
 Last, T. J., 2399
 Latif, F., 861, 3118
 Laug, W. E., 6051
 Laun, R., 5439
 Laurent, G., 4850
 Laurent, T. C., 388
 Laurent-Puig, P., 5872
 Lavelle, F., 4784, 5987
 Law, K. L., 3956
 Law, L. W., 1602
 Lawrence, T. S., 5219
 Lawson, S., 4555
 Lazenby, A., 5841
 Lazzareschi, D., 5548
 Le, P. T., 67, 3165
 Leach, F. S., 1986, 2231
 Le Bail, N., 523, 1037
 Lechner, J. F., 985
 Leclerc, J.-M., 5269
 Lecoq, S., 944
 Ledbetter, S. R., 2912
 Le Duc, A., 5872
 Leduy, L., 957
 Lee, A., 2553
 Lee, A., 6001
 Lee, C.-K., 4648
 Lee, I., 2466
 Lee, J. S., 2874
 Lee, M.-S., 4449
 Lee, P.-H., 1653, 4691
 Lee, T. C., 2858
 Leech, V., 1218
 Leek, R., 3597
 Lefaux, J.-L., 3246
 Leffert, H. L., 2279
 Leftwich, J., 4337
 Le Gal, J.-M., 3681
 Lehman, N. L., 5697
 Lehmann, H.-P., 2840
 Lehr, J. E., 224, 3394
 Leigh, B. R., 3857
 Leigh, I. M., 5328
 Leitao, D., 5494
 Leith, J. T., 2188
 Leitel, F., 1690
 LeJeune, S., 3597
 Lelieveld, P., 3008
 Lelievre, E., 3536
 LeMaistre, C. F., 3930
 Lemerle, J., 452, 1534
 Leng, L., 5554
 Leng, Z.-T., 2313
 Leon, J. A., 1929
 Leonard, R. C. F., 2128
 Leong, K., 5841
 Lepage, P., 1657
 Le Paslier, D., 861
 Le Riche, J., 733
 Lerman, M. I., 861, 3118
 Lerner, S. P., 4066
 Lester, S. C., 4676
 Lester, S. M., 3700
 Letessier, E., 5654
 Leu, J.-G., 1388
 Levens, D., 4109
 Lévi, F., 1534
 Levin, A. H., 1493
 Levine, A. J., 929
 Levine, B. A., 1360
 Levitsky, H. I., 5841
 Lewis, R., 16
 Leyshon-Sørland, K., 4874
 Li, B., 5108
 Li, C., 3276
 Li, H., 861
 Li, H., 5345
 Li, H.-C., 5528
 Li, H.-P., 1653
 Li, J.-y., 1317
 Li, P. Y., 3198
 Li, X., 2980
 Lian, J. B., 2399
 Liao, S., 1967
 Lichtner, R. B., 1516
 Lidereau, R., 1990, 5617
 Liebes, L., 3509
 Liebmann, J. E., 2066
 Liefers, G. J., 2712
 Liehr, J. G., 5447
 Lillie, J. W., 3172
 Lin, C.-S., 2950
 Lin, C.-Y., 3159
 Lin, J.-C., 324, 2076
 Lin, J.-C., 4408
 Lin, J.-G., 2865
 Lin, P.-F. M., 4041
 Lin, S., 3730
 Lindblom, A., 3707, 4356
 Lindholm, L., 755
 Lindstrom, M. J., 4413
 Linehan, M., 2719
 Linehan, W. M., 861, 3092
 Ling, C. C., 1511, 2987
 Ling, V., 5994
 Ling, Y.-H., 1583, 1845, 4913
 Lingwood, C. A., 5314
 Linnoila, R. I., 3103, 5181
 Lints, T., 3405
 Liotta, L. A., 2208
 Lipinski, M., 3655
 Lipkin, M., 279, 2745
 Lippman, M. E., 283, 873, 1409, 2168, 2178, 3229
 Lippman, S. M., 5113
 Lips, C. J. M., 5754
 Lipschultz, C., 2066
 Lishko, V. K., 5676
 Little, J. B., 2188
 Littlefield, B. A., 2553
 Liu, A. Y., 2460
 Liu, B. C.-S., 4971
 Liu, C. C., 112
 Liu, L., 2736
 Liu, L. F., 1332, 5908
 Liu, S., 3092
 Liu, T., 2816, 4555
 Liu, W.-d., 1317
 Liu, X.-K., 2780
 Liu, Y.-J., 663
 Liu, Y.-P., 922
 Liu, Y.-X., 89
 Liu, Z., 5994
 Livanos, E. M., 4946
 Livingston, R. B., 5663
 Lloyd, K. O., 5395
 LoBuglio, A. F., 4555
 Lo Coco, F., 3800
 Loeb, L. A., 2895, 4172
 Logan, T. F., 4745
 Lohman, P. H. M., 1642, 4797
 Lohmann, D. R., 5797
 Lokeshwar, B. L., 4493, 4855
 Lokiec, F., 3536
 Lombardi, L., 6036
 Longee, D. C., 120
 Longenecker, M., 1484
 Longfellow, D. G., 922
 Longnecker, D. S., 3925
 Longo, D. L., 2204, 5613
 Look, A. T., 5535
 Lopaczynska, J., 5977
 Lopez, A. R., 4391
 Lopez, M. E., 4741
 Lopez-Berestein, G., 2100
 Lord, E. M., 2112, 5721
 Lorico, A., 5487
 Lotan, R., 4109
 Lote, K., 3129
 Lothe, R. A., 5849, 5853
 Lou, Z., 1498

- Louis, D. N., 3465
 Louvel, D., 1182
 Love, J. L., 6067
 Lowe, J. B., 5559
 Lowe, J. E., 609
 Lowis, S. P., 4881
 Loyson, S., 4148
 Lozac'h, P., 5745
 Lu, C., 2708
 Lu, D., 4089
 Lu, J., 4169
 Lu, L., 1602
 Lu, X. P., 2279
 Lu, Y. Y., 4761
 Lu, Z., 2816, 5433
 Lubejko, B. G., 1794
 Lubin, R., 5872
 Lucas, C., 3536
 Lucas, J., 3968
 Ludwig, W.-D., 3638
 Luk, G. D., 2618, 3723
 Lum, K., 3098
 Lungarotti, F., 5429
 Lupu, R., 2035, 5251
 Lust, J. A., 5320
 Lutz, S., 4035
 Lutz, W. K., 3505
 Lyftogt, C., 641
 Lyn, P., 3730
 Lynch, A. M., 6076
 Lynch, D. H., 1565
 Lynch, H. T., 5100
 Lynch, J., 221
 Lynch, J. H., 1416
 Lynch, M. J., 4041
 Lynch, T. H., 2300
 Lyons, J. C., 324, 1599
 Lysik, R. M., 140, 1195
 Lyubsky, S., 1195
- M**
- Macchiaroni, P., 2846
 MacEwen, E. G., 3986
 MacGrogan, D., 3369
 Machino, S., 4218
 Mackensen, A., 3569
 Mackensen, D. G., 3956
 Mackenzie, P. I., 1529
 MacMillan, D. L., 46
 Madara, K., 2204
 Madhuizen, H. T., 4603
 Maduakor, E. C., 2553
 Maecke, H. R., 5727
 Maeda, O., 2051
 Maestro, R., 5775
 Mafune, K.-I., 1916
 Magnuson, B. A., 4499
 Magnusson, I., 5610
 Magrath, I. T., 127, 4776
 Mahacek, M. L., 627
 Maher, E., 861
 Maher, V. M., 3270
 Mähler, C. G., 2309
 Mahler, M., 2105
 Mai, M., 1397
 Maio, M., 3343
 Makepeace, C. M., 1599
 Makino, S., 4218
 Makita, A., 2484, 5638
 Makos, M., 2715, 2719
 Malapetsa, A., 5370
- Malik, K., 2410
 Malkin, D., 3574
 Malkinson, A. M., 393
 Malm, C., 191
 Maloy, W. L., 3052
 Malspeis, L., 3062
 Mancini, M., 5
 Mancuso, S., 1297, 2457
 Mandahl, N., 2140
 Mandel, U., 5494
 Mandelli, F., 3800
 Manenti, G., 209
 Manfait, M., 3681, 4784
 Mangeney, M., 5314
 Mangin, P., 5872
 Mank, A. R., 2071
 Mannermaa, A., 4486
 Mannervik, B., 4257
 Mannhart, M., 2840
 Manni, A., 6042
 Manning, D. L., 5940
 Manseau, E. J., 4727
 Mansfield, P. J., 378
 Manske, M., 4082
 Mantovani, A., 3812, 5051
 Manzke, O., 4310
 Manzo, G., 5523
 Maragos, C. M., 564
 Marathi, U. K., 4281
 Marchetti, A., 2846, 4665
 Marie, J. P., 235
 Marienhagen, K., 5158
 Marino, P. A., 1719
 Markoe, A. M., 1091
 Markowicz, M., 4960
 Markowitz, S., 1986
 Marks, P. A., 5554
 Marmonti, L., 544
 Marshall, F. F., 2221
 Marshall, G. M., 615, 622
 Marshall, J. D., 1665
 Martell, L. A., 1348
 Martens, A. C. M., 3008
 Martikainen, P. M., 5199
 Martin, A., 452
 Martin, C., 4489
 Martin, D. S., 3518
 Martin, F. J., 3964
 Martin, M., 3246
 Martinez, A., 2740
 Marton, L. J., 3948
 Martucci, R., 1297
 Martuza, R. L., 3125
 Marty, M., 1037
 Marui, N., 1328
 Maruyama, F., 4449
 Masaki, T., 4262
 Masci, A. M., 3355
 Mashal, R. D., 4676
 Massa, O., 3198
 Massaad, L., 3541, 4608
 Masse, E. M., 2912
 Mastrangelo, R., 304
 Masui, H., 4322, 4637
 Matalka, K. Z., 3308
 Mathieu, M.-C., 3541
 Mathieu-Boué, A., 2823
 Matifas, F., 1990
 Matlashewski, G., 3468
 Matsubara, S., 1281
 Matsuda, M., 4238
- Matsuda, M., 5610
 Matsukawa, Y., 1328
 Matsumata, T., 2884
 Matsumoto, K., 1328
 Matsumoto, T., 2534
 Matsumura, T., 4315
 Matsunaga, T., 495
 Matsunaga, T., 3179
 Matsuno, S., 183
 Matsuo, K.-i., 1085
 Matsuo, S., 464
 Matsushime, H., 5535
 Matsushita, Y., 3632
 Matsuura, A., 3078
 Matsuura, S., 5419
 Matsuya, T., 147
 Matsuyoshi, N., 1696
 Matsuzaki, G., 106
 Matsuzawa, Y., 675
 Mattei, M.-G., 4096
 Matthews, J., 6006
 Matushima, T., 1706
 Maudelonde, T., 2901
 Maurel, P., 5121
 Maxuitenko, Y. Y., 3499
 Maxwell, S. A., 5361
 May, W. T., 3865
 Maybaum, J., 5219
 Maydonovitch, C., 3723
 Mayer, B., 1690
 Mayhew, E., 3964, 5877
 Maytin, E. V., 4952
 Mazumdar, M., 3730, 5780
 Mazzoni, M., 4481
 McAdam, A. J., 2112
 McAndrew, S. J., 334
 McAtee, N., 4828
 McAuliffe, T. L., 5176
 McBride, T. J., 4172
 McCabe, R. P., 2368
 McCamant, S. K., 5188
 McCartney, J. E., 4026
 McClain, K. L., 3289
 McClay, E. F., 1571
 McCormick, B., 1971
 McCormick, J. J., 3270
 McCrady, C. W., 833
 McCullers, G. A., 2368
 McCully, C., 1596
 McCutcheon, I., 4143
 McDaniel, T., 1889
 McDonald, T. L., 1921
 McEachern, D., 2740
 McGregor, A. D., 1522
 McGuire, W. L., 3736
 McIntosh, J., 2379
 McKeage, M. J., 2581
 McKenna, W. G., 1128
 McKenzie, D. R., 4230
 McKenzie, I. F. C., 4082
 McLendon, R. E., 120, 2338
 McLeskey, S. W., 2168, 2178
 McMullin, B., 3930
 McPherson, J. P., 5885
 McQueen, T., 2100
 Meadows, G. G., 4075
 Medema, J. P., 728
 Medina, D., 663, 668, 1646, 3374
 Mehta, K., 2100
 Meijer, C. J. L. M., 456, 1475,
- 3524, 4383, 5707
 Meisler, A. I., 2919
 Meissner, S., 868
 Melby, E. L., 1755
 Melder, R. J., 5867
 Melera, P. W., 6031
 Melhem, M. F., 2919, 4089
 Meling, G. I., 5849
 Melino, G., 926
 Melle, J., 235
 Mellstedt, H., 5610
 Melsop, K. A., 1380
 Meltzer, P., 2231
 Meltzer, S. J., 1889
 Ménard, S., 5791, 5864, 6036
 Mendelsohn, J., 4322, 4637
 Mendonca, H. L., 3022
 Mendoza, J. T., 1577
 Meneghetti, C., 3930
 Meneguzzi, G., 1175
 Menendez, A. T., 3336
 Menendez-Botet, C., 3730
 Menichella, G., 1297
 Menrad, A., 1450
 Mentzel, M., 4268
 Mercier, B., 5745
 Meredith, R., 4555
 Meresse, V., 452
 Merkle, K. A., 3294
 Merlino, G., 1719, 4329
 Merlo, G., 2846
 Merrill, J. E., 170
 Merrill, M. A., 4952
 Mertens, F., 2140
 Merwin, J., 4041
 Metcalf, R. A., 4817
 Methlin, G., 165
 Mettler, L., 1956
 Meunier, B., 231
 Mewes, K., 5135
 Meyer, D. J., 231
 Meyer, D. L., 3956
 Meyer, F., 1107
 Meyer, K. B., 1023
 Meyers, S. M., 4518
 Mezzina, M., 1244
 Mi, J.-X., 3455
 Michael, C., 5669
 Michel, F.-B., 61
 Mick, R., 1293, 2304
 Mihatsch, M. J., 2199
 Mihich, E., 2192
 Mii, Y., 5038
 Miki, K., 868
 Miki, K., 4418
 Mikolajczyk, S. D., 3956
 Milani, D., 4481
 Milenic, D. E., 3776
 Millauer, B., 5822
 Miller, J., 581
 Miller, L. A., 2527
 Miller, M. R., 3700
 Miller, R. E., 1565
 Miller, W. R., 1802
 Millikan, R., 212, 5083
 Millon, R., 165
 Mills, G. B., 1304
 Mills, J. J., 2265
 Milner, A. E., 3321
 Milner, B. J., 2128
 Milner, J., 1739, 4469

* For title of article and coauthors, see listing in Contents of Volume 53 beginning on page i at the end of this index issue.

- Milton, J. D., 4627
 Minamoto, T., 2786
 Mincione, G., 5548
 Mineo, A., 5523
 Minna, J. D., 2410, 3257, 5181
 Minnick, D. T., 997
 Miotti, S., 5791
 Mir, L. M., 5462
 Mirkin, B. L., 6058
 Mirski, S. E. L., 4866
 Mirzadeh, S., 5683
 Mishra, S., 557
 Missero, C., 5517
 Mita, M., 4767
 Mitaka, T., 3145
 Mitani, H., 5856
 Mitchell, J. B., 2066, 5845
 Mitchell, K., 5649
 Mitchell, M. A., 5690
 Mitchell, M. S., 1113
 Mitelman, F., 2140
 Mitsui, H., 675
 Mitsui, K.-i., 2260
 Miura, S., 2676
 Miura, S., 5038
 Miyaki, M., 5079
 Miyamoto, K.-i., 1555
 Miyao, N., 4066, 5620
 Miyauchi, Y., 5038
 Miyazaki, T., 2484, 5638
 Miyazaki, Y., 5624
 Miyazawa, M., 183
 Miyazono, K., 183, 3193
 Miyoshi, E., 3899
 Mizoguchi, H., 5613
 Mizoi, T., 183
 Mizuno, K., 2051
 Mizuno, T., 2940
 Moalli, P. A., 3877
 Moch, H., 2199
 Mochizuki, Y., 3145
 Modena, D., 3015
 Modest, E. J., 4297
 Modesti, A., 5067
 Modi, W., 861, 3118
 Moeschberger, M. L., 3308
 Mohanam, S., 2208, 4143
 Mok, S. C.-H., 1489
 Moldenhauer, G., 4310
 Molin, L. F., 4715
 Moll, U., 140
 Möller, P., 5849
 Mölne, J., 4987
 Moltzoff, C. J. M., 5413
 Molyneux, A., 1218
 Monaco, C., 5523
 Monden, M., 857
 Monroe, T. J., 5690
 Monsky, W. L., 3159
 Montelaro, R. C., 5386
 Montgomery, A. M. P., 693
 Moody, T. W., 5214
 Moolten, F. L., 5274
 Moore, D., 2199
 Moore, D., 3736
 Moore, K. H., 1286
 Moore, M., 4837
 Moore, R., 3853
 Moore, R. E., 1343
 Moorehead, R., 4994
 Moran, R. G., 5697
 Morel, F., 231
 Morel-Kopp, M.-C., 4695
 Morgan, J., 4680
 Mori, H., 772, 2775, 3903, 3908
 Mori, M., 1706, 4048
 Mori, N., 4643
 Mori, R., 2884
 Mori, S., 4218
 Mori, S., 5475
 Mori, T., 495, 609
 Mori, T., 857, 1172, 1696, 3421
 Mori, T., 5079
 Morikage, T., 3302
 Morimoto, H., 2591
 Morimoto, R. I., 3034
 Morisaki, T., 949
 Morishita, T., 5038
 Moriyama, K., 737
 Morizet, J., 3541, 4608
 Morjani, H., 3681, 4784
 Mørk, S., 5158
 Mørkrid, L., 4874
 Morris, J. S., 795
 Morrison, S. L., 5244
 Morton, C. L., 4243
 Morton, D. L., 949, 5244
 Morton, R. A., 3585
 Moshier, J. A., 2618
 Mosseri, M., 3028
 Motomura, K., 4071
 Motulsky, A. G., 2313
 Motzer, R. J., 3730
 Mouridsen, H. T., 2513
 Moutou, C., 452
 Moynes, R. A., 1967
 Mrózek, K., 1670
 Mueller, B. A., 3416
 Mueller, B. M., 693
 Mueller, S. C., 3159
 Muggia, F. M., 3694, 5669
 Muindi, J. F., 1226
 Muirhead, K. A., 2358
 Mukhopadhyay, T., 1676, 1743, 4129, 4362
 Mukhtar, H., 3439, 5409, 5897
 Mulcahy, R. T., 4413
 Mulder, N. H., 1064, 1747, 5707, 5915
 Mulholland, G., 1102
 Mullenders, L. H. F., 1642
 Muller, C., 4850
 Müller, C. A., 4424
 Muller, D., 165
 Müller-Hermelink, H.-K., 4197
 Mulligan, L., 957
 Mulligan, R. C., 2221
 Mulshine, J. L., 67, 5181
 Munck, J.-N., 1550
 Mundy, G. R., 737
 Munn, D. H., 2603
 Muñoz, A., 3499
 Murai, T., 4218
 Murakami, H., 1719
 Murakami, M., 2035
 Murakami, S., 4643
 Muramatsu, T., 1281
 Muraoka, M., 5079
 Muraszko, K., 3752
 Muraszko, K. M., 1348
 Murphy, B. J., 2700
 Murphy, J. R., 3723
 Murphy, L. A., 4952
 Murphy, R. F., 472, 4828
 Murphy, S. E., 777
 Murray, J. H., 456
 Murray, S., 6076
 Murrer, B. A., 2581
 Muschel, R. J., 1128
 Muto, M. G., 1489
 Myers, E., 5654
 Myklebust, O., 468
 Myklebust, A. T., 3784
 Myseros, J. S., 329

 N
 Naaktgeboren, J. M., 4797
 Nabiev, I., 4784
 Nachman, J., 1978
 Naeve, C. W., 5108
 Nagafuchi, A., 3585
 Nagai, Y., 5903
 Nagamine, Y., 3618
 Naganuma, A., 1829, 4767
 Nagasawa, H., 2188
 Nagle, R. B., 417
 Naguib, F. N. M., 3687
 Nagura, H., 183
 Nagy, J. A., 2631, 2912
 Nagy, P., 1719
 Nair, M. G., 2227
 Nairn, A. C., 2260
 Naito, M., 5022
 Naito, Y., 1871
 Naito, Y., 2326
 Nakachi, K., 2994
 Nakada, S. Y., 1967
 Nakagawa, I., 4767
 Nakagawara, A., 1281
 Nakagomi, H., 5610
 Nakahashi, K., 4408
 Nakai, M., 737
 Nakajima, M., 5022, 5802
 Nakajima, R., 1883
 Nakajima, T., 1172
 Nakamori, S., 3632
 Nakamura, H., 4053
 Nakamura, N., 2940
 Nakamura, T., 1233
 Nakamura, T., 4489, 5624
 Nakamura, Y., 1, 857, 1172, 3382, 5087
 Nakano, H., 4466
 Nakashima, Y., 464
 Namboodiri, M. M., 1322
 Nandi, S., 1816
 Nangia-Makker, P., 5033
 Naor, N., 3468
 Narayan, S., 2256
 Nash, J. D., 3103
 Nath, K., 5308
 Nau, M. M., 2410
 Nauta, R. J., 3712
 Navre, M., 417
 Nazar-Stewart, V., 2313
 Neal, D., 5365
 Neal, G. E., 3887
 Neckers, L. M., 127
 Nédellec, P., 4938
 Needham, D., 3765
 Nees, M., 4189
 Negrini, M., 2954, 4489, 5569
 Neijt, J. P., 544
 Nelkin, B. D., 2715, 2719
 Nelson, H., 4652
 Nelson, W. G., 4164
 Nepveu, A., 1657
 Nesbitt, J. C., 5181
 Nesland, J. M., 468
 Neufeld, G., 158
 Neuringer, L. J., 5808
 Nevalainen, M. T., 5199
 Newell, D. R., 4881
 Newsham, I., 4486
 Ng, B., 5483
 Nguyen, C. H., 5987
 Nguyen, M., 5297
 Nguyen, N. M., 224
 Nichols, M. G., 1249
 Nichols, P. W., 1162, 4066, 5620
 Nicholson, R. I., 5940
 Nicolson, G. L., 4418, 5802
 Nicotera, T., 5104
 Niehans, G. A., 641
 Niericker, M., 4797
 Nieroda, C., 600
 Nihei, T., 1702
 Niimi, T., 1
 Nikai, H., 4102
 Nikaido, O., 495, 609
 Niloff, J., 3830
 Nilsson, M., 4987
 Nilsson, O., 755
 Nilsson, S., 3193
 Ning, S. M., 3276
 Nisen, P. D., 4757, 6028
 Nishi, S., 2970
 Nishida, K., 1709
 Nishida, N., 368
 Nishigori, C., 2944
 Nishii, H., 1906
 Nishii, Y., 2534
 Nishikawa, A., 3899
 Nishino, H., 1328
 Nishino, Y., 5350
 Nishio, K., 3302
 Nishioka, H., 4408
 Nishioka, K., 2689
 Nitiss, J. L., 89
 Nitz, M., 1004
 Nobori, T., 1098, 2410
 Nocentini, G., 19
 Noda, K., 3382
 Noë, A. J., 5370
 Noe, D. A., 1794
 Noga, S. J., 5424
 Noguchi, K., 2538
 Noguchi, M., 2035
 Noguchi, S., 4071
 Nomizu, M., 3459
 Nomoto, K., 106
 Nomura, K., 464
 Nomura, K., 490
 Nomura, T., 1883
 Nooijen, W. J., 2061
 Nord, L. D., 3518
 Nordenskjöld, M., 3707, 4356
 Nordgren, H., 3193
 Norioka, K.-i., 3145
 Norkus, E. P., 795
 Norman, A. W., 3935
 North, S. M., 1630
 Nortier, H. W. R., 4563

- Norton, L., 2987
 Nosaka, C., 4896
 Notario, V., 4474
 Notkins, A. L., 4169
 Noto, A. C., 3394
 Nounsbaum, J. B., 5745
 Novak-Hofer, I., 5727
 Nowell, P. C., 5624
 Nozawa, S., 3643
 Nozawa, S., 5903
 Numata, M., 495
 Numoto, M., 5815
 Nunes, E., 5750
 Nunn, G., 3919
 Nunoshiba, T., 3250
 Nurmi, M., 5199
 Nurse, P., 1867
 Nuti, M., 2457
 Nyamuswa, G., 5908
 Nyström-Lahti, M., 5849, 5853
- O**
- Oakley, C., 2272
 Öberg, K., 4550
 Oborn, C. J., 668
 O'Brien, S., 3603
 Obuz, V., 1431
 Ochi, Y., 4896
 Ochieng, J., 5033
 Ochoa, A. C., 5613
 O'Connell, S. M., 1608
 O'Connor, P. M., 1853, 4776
 Oda, S., 4643
 Ødum, L., 1823
 O'Dwyer, P. J., 3662, 5225
 Odze, R. D., 271
 Oesch, F., 944
 Oesterreich, S., 4443
 Offerhaus, G. J. A., 4754
 Ogasawara, M., 3561
 Ogata, E., 2534
 Ogawa, M., 464
 Ogawa, O., 3795
 Ogorek, D., 4082
 Oguchi, H., 2051
 Ogura, K., 3795
 O'Hara, C. J., 2840
 Ohara, T., 4218
 Ohashi, K., 953
 Ohata, H., 1172
 Ohi, Y., 1281
 Ohkawa, K., 4238
 Ohkura, T., 2970
 Ohlsson, R., 2927
 Ohly, K., 5424
 Ohmori, K., 354, 5559
 Ohmori, T., 3302
 Ohneseit, P. F., 1162
 Ohnishi, T., 4408
 Ohno, T., 5859
 Ohnuki, Y., 985
 Ohnuma, N., 3179
 Ohsaki, Y., 3165
 Ohshima, M., 4408
 Ohsugi, Y., 851
 Ohta, K., 4175
 Ohta, M., 3118
 Ohta, T., 239, 992
 Ohtake, K., 953
 Ohtani, H., 183
 Ohto, M., 2472
- Ohtoshi, T., 4175
 Ohtsuki, Y., 4823
 Oie, H. K., 5181
 Oikawa, A., 495
 Oikawa, T., 5759
 Oka, H., 1696, 3421
 Okabe, S., 1012, 1982, 3462
 Okada, K., 429
 Okada, S. S., 3109
 Okada, Y., 1397
 Okai, Y., 1612
 Okaichi, K., 4408
 Okamura, W. H., 3935
 Okano, S., 687
 Okayasu, R., 5592
 O'Keefe, M., 3172
 Okihiro, M. S., 1761
 Okochi, E., 5475
 Okuma, M., 5559
 Okura, A., 490
 Old, L. J., 3327
 Oldfield, E. H., 83, 3752
 Olegård, C., 2140
 Oleinick, N. L., 5897
 Oliner, J. D., 2231
 Olinski, R., 1269
 Olive, M., 1630
 Olive, P. L., 733
 Olivieri, Q., 5429
 Olivotto, I. A., 733
 Ollert, M. W., 592
 Olofsson, A., 3193
 Olopade, O. I., 1098, 2410
 Olsnes, S., 1755
 Olsson, I., 4010
 Olumi, A. F., 1162, 4066
 Omata, M., 2472
 Onda, M., 5289
 Ong, D. E., 2965
 Ono, K., 5475
 Ono, T., 2830, 3349, 4927
 Onoda, M., 1416
 Onozaki, K., 1871
 Oosterhuis, J. W., 5707
 Oppenheim, J. J., 564
 Oppermann, H., 4026
 Orazem, J., 2379
 Orcutt, M. L., 861
 Orengo, C. C., 5071
 Orengo, M. A., 4769
 Ormandy, C. J., 5940
 Orr, F. W., 5452
 Orr, M. S., 3547
 Ortmann, O., 5439
 Orton, T., 3919
 Ortonne, J. P., 1175
 Osada, S.-i., 5554
 Osaki, K., 687
 Osborne, C. K., 4443
 Osborne, R. J., 1218
 O'Shaughnessy, J. A., 2587
 O'Shea, J. J., 5613
 Oshima, M., 5589
 Oskarsson, M., 5355
 Ossenkoppele, G. J., 4399
 Ostro, M., 2796
 Otero, G., 4474
 O'Toole, S. M., 3895
 Ottaviano, Y., 3976
 Ottensmeier, C., 3830
 Otter, G. M., 587
- Owen-Lynch, P. J., 1735
 Owen-Schaub, L. B., 4129
 Oyama, F., 2005
 Oyamada, H., 2326
 Oyasu, R., 5172
 Øyjord, T., 468
 Ozbun, M. A., 1646, 3374
 Ozer, H. L., 3327
 Ozols, R. F., 3662, 5225
- P**
- Pääkkö, P., 4817
 Packman, C. H., 5274
 Padarathsingh, M., 5055
 Padura, I. M., 5051
 Paganini-Hill, A., 212, 5083
 Page, R. L., 101
 Pai, L. H., 2834, 4588
 Paik, C. H., 2834
 Pak, A. S., 6006
 Palladino, M. A., 4391
 Paller, A. S., 6058
 Palmer, L. D., 2358
 Pals, S. T., 4754
 Panasci, L. C., 3237, 5370
 Pandis, N., 1895
 Pang, H., 2906
 Panici, P. B., 2457
 Pantazis, P., 1577
 Pantel, K., 1027
 Pantelias, G. E., 5592
 Papa, V., 3736
 Papadopoloulou, L. C., 1072
 Papavassiliou, E. D., 2374
 Pardee, A. B., 1493
 Pardoll, D. M., 2221, 5841
 Parise, O., Jr., 3541, 4608
 Park, J.-G., 5087
 Park, N.-H., 4811
 Park, R. C., 3103
 Park, S., 4757
 Park, S. H., 4461
 Parker, B., 1098
 Parker, K., 3930
 Parker, R. J., 242, 3694
 Parker, S. L., 1906
 Parkin, D. E., 2128
 Partin, A. W., 744, 1995
 Parwaresch, R., 1956
 Pass, H. I., 5181
 Passaniti, A., 1833
 Passlick, B., 1027
 Passos-Coelho, J., 5424
 Pastan, I., 340, 819, 2834, 4588
 Pasternack, G. R., 4720
 Patel, B., 4310
 Patel, U., 717
 Pater, A., 4432
 Pater, M. M., 4432
 Paterlini, P., 235
 Paterson, M. C., 4960
 Patterson, G. M. L., 1343
 Paxton, R. J., 1612
 Payne, C., 3386
 Pearson, A. D. J., 3758, 4881
 Pechoux, C., 1421
 Pecoraro, G., 1167
 Pedersen, P.-H., 5158
 Pedroni, M., 3726
 Pegg, A. E., 3895, 4750
 Pekarek, L. A., 1978
- Peled, A., 2147, 3433
 Peles, E., 5251
 Pelicci, P. G., 6036
 Pellarin, M., 3948
 Pellegata, N. S., 2614
 Pellegrini, S., 2846, 4665
 Pelletier, G., 5872
 Pelletier, J., 5269
 Pelosi, E., 569
 Pelosi, L., 4041
 Peltomäki, P., 5849, 5853
 Pendergast, W., 810
 Pendleton, C. D., 3257
 Pendyala, L., 5970
 Peng, H.-Q., 3574
 Peng, L. F., 1332
 Peng, S.-Y., 4691
 Pensa, F., 4769
 Pepe, S., 2846, 5548
 Peretti, M., 1107
 Peretz, D., 158
 Perez, A., 401
 Perez, R. P., 3771
 Perez-Soler, R., 1583, 1845, 3046, 4913
 Perle, M. A., 2858
 Perng, R.-P., 1079
 Perry, R. R., 3040
 Perry-Lalley, D., 2358
 Pershouse, M. A., 5043
 Persson, H., 2044
 Persson, L., 5262
 Peschle, C., 569, 1297
 Peterhans, E., 1456
 Peter-Katalinic, J., 4367
 Peters, B. P., 101
 Peterson, L. A., 2780
 Petersson, M., 5610
 Peto, R., 4108
 Petrella, E. C., 592
 Petrelli, N., 2796
 Petti, M. C., 3800
 Pettit, G. R., 2810
 Peyrat, J. P., 5872
 Pezzino, V., 3736
 Pezzoni, G., 544
 Pfeffer, U., 741
 Pflug, B. R., 1416
 Pfreundschuh, M., 4367
 Phan, A., 27
 Phang, J. M., 5977
 Pharo, A., 3784
 Phelps, R., 67, 5181
 Philip, P. A., 5649
 Phillips, D. H., 944
 Phillips, R. W., 3723
 Phipps, M., 861
 Pickett, C. B., 3207
 Pienta, K. J., 224, 3394
 Pierceall, W. E., 2961
 Pierelli, L., 1297
 Pierotti, M. A., 209, 6036
 Pietrzkowski, Z., 1102
 Pike, M. C., 4960
 Pilkievicz, F., 2796
 Pillay, S., 3877
 Pimenov, A. M., 5143
 Pinch, H. J., 27
 Pinedo, H. M., 1475
 Ping, W., 5199
 Pinton, P., 3246

* For title of article and coauthors, see listing in Contents of Volume 53 beginning on page i at the end of this index issue.

- Pipas, J. M., 2919
 Pirisi, L., 905
 Pisa, P., 3603
 Pisani, A., 1175
 Pitot, H. C., 3145
 Pittman, S. M., 1222
 Pivik, C., 762
 Piwnica-Worms, D., 977
 Pizzo, S. V., 1998
 Placidi, M., 5121
 Plate, K. H., 5822
 Platko, J. D., 3085
 Platt, K. L., 944
 Plavec, I., 1107
 Plowman, G., 3597
 Plummer, H., III, 4337
 Podratz, K. C., 2393, 4456
 Poiesz, B. J., 6067
 Poirier, G. G., 3976, 5370
 Poisson, N., 452
 Pokorny, R., 5915
 Polihronis, J., 271
 Pollak, M. N., 1727, 5193, 5585
 Pomato, N., 456, 2368
 Pommier, Y., 1583, 4251
 Ponder, B. A. J., 1218
 Ponta, H., 1262, 1516, 4197, 4754
 Ponzani, P., 4769
 Ponz de Leon, M., 3726
 Poole, D. J., 2154
 Poore, C. M., 5977
 Poplack, D. G., 472, 725, 1032, 1596, 2587
 Portella, G., 5523
 Porter, C. W., 581
 Portier, M. M., 1175
 Pospiech, I., 5754
 Potten, C. S., 2057
 Potter, B. V. L., 298
 Potter, J. D., 536, 4230
 Potter, P. M., 1731
 Povirk, L. F., 3547
 Povoski, S. P., 3925
 Powell, C. T., 227
 Powell, W. C., 417
 Powers, J. H., 4059
 Powis, G., 1338, 1862, 4297, 5458
 Pow-Sang, J. M., 577
 Pozzi, L., 5523, 5569
 Prajda, N., 5982
 Prasad, R., 5624
 Prats, H., 1182
 Pratt, S. E., 5193
 Präuer, H., 5797
 Prehn, R. T., 3266
 Press, M. F., 4960, 5188
 Press, N., 3000
 Presti, J. C., Jr., 5780
 Prestigiacomo, L. J., 291, 2071
 Preston, S. R., 5090
 Preudhomme, C., 5872
 Prévost, J., 5370
 Price, B. D., 12, 2212
 Price, J. E., 891
 Price, L., 3758
 Price, M. R., 755
 Priebe, W., 1583, 1845
 Prieto, E., 728
 Primrose, J. N., 5090
 Primus, F. J., 3355
 Prince, C. W., 701, 2217
 Pritsos, C. A., 5470
 Proby, C. M., 5328
 Proietti, E., 569, 1107
 Pron, G., 5462
 Puder, M., 4048
 Puech, C., 2901
 Puistola, U., 5028
 Pujol, H., 61
 Pujol, J.-L., 61
 Pulaski, B. A., 2112
 Pupa, S. M., 5864
 Purdie, K. J., 5328
 Purohit, A., 298
 Pütz, B., 5797
 Pyke, C., 1911
 Pykkänen, L., 5849, 5853
 Pytel, B. A., 348
- Q**
- Qi, C.-F., 600
 Qin, Z., 714
 Qiu, M., 4443
 Qiu, S.-L., 1783
 Quak, J. J., 4383
 Quinn, A. G., 2697
 Quintanilla, M. L., 5071
- R**
- Rackley, R., 2712
 Radda, G. K., 5649
 Rademaker, A., 5172
 Radford, D. M., 2947
 Radi, L., 4534
 Radinsky, R., 937
 Raff, H. V., 2560
 Rahman, A., 4243
 Rahmani, R., 5121
 Raitano, A. B., 636
 Rajagopal, S., 5663
 Rajagopalan, B., 5649
 Rak, J. W., 2708
 Ralfkiaer, E., 1911
 Ralph, R., 3405
 Ram, T. G., 2655
 Ram, Z., 83
 Ramachandran, C., 2544
 Ramirez, L. H., 1550
 Ramsey, P. S., 4652
 Randolph, J. K., 3547
 Ransom, J. H., 456
 Ranzani, G. N., 2614
 Rao, C. V., 2502, 3493, 4182
 Rao, J. S., 2208, 4143
 Rao, P. H., 2732
 Rao, V. N., 215, 3449, 5859
 Rao-Betté, M., 3000
 Rappa, G., 5487
 Raschellá, G., 2044
 Rasmussen, J. W., 5920
 Rasmussen, U. B., 4096
 Rastetter, J. W., 3747
 Ratain, M. J., 1293, 2304
 Raubitschek, A. A., 5683
 Ravichander, P., 1142
 Ravikumar, T. S., 1916
 Rayburn, J., 4686
 Raymond, M., 1657
 Raz, A., 5033
 Rea, D., 5649
 Reaman, G., 1032
 Reddel, R. R., 985
 Reddy, B. S., 2502, 2745, 3493, 3914, 4182
 Reddy, E. S. P., 215, 3449, 5859
 Reding, D., 5176
 Redman, J., 2118
 Reed, E., 242, 3694
 Reed, J. C., 4701, 4978
 Reed, M. J., 298
 Rees, J. L., 2697
 Reeve, A. E., 5166
 Reeve, J. G., 4680
 Reeves, R., 2655
 Rehfeld, J. F., 1823
 Rehm, S., 3874
 Rehnholm, A., 5262
 Reibnegger, G., 260
 Reich, U., 5797
 Reichert, A., 2498
 Reid, J. M., 1032
 Reid, L. M., 652
 Reid, T. M., 4172
 Reifenger, G., 2736
 Reilly, J. G., 67
 Reilly, R. M., 271
 Reinecke, M., 2475
 Reisfeld, R. A., 362, 693, 4933
 Reiss, M., 899
 Reiter, R. E., 2719, 3092
 Reiter, Z., 3555
 Remack, J. S., 1731
 Rempel, S. A., 957, 2386
 Renault, B., 2614
 Renkonen, O., 5600
 Resau, J. H., 5355
 Rettig, W. J., 3327
 Reuben, J., 3930
 Reuter, V. E., 5780
 Reynolds, J. E., 2349
 Rhee, M. S., 2227
 Rhodes, J. M., 4627
 Riccardi, R., 304
 Rice, J. M., 1883, 3874
 Richards, C. A., 4619
 Richards, F., 861
 Richardson, F. C., 4582
 Richardson, J. A., 1392
 Richardson, L., 212, 5083
 Richon, V. M., 5554
 Richter, A., 3283
 Richter, C., 1456
 Richter, F., 3283
 Richter, G., 4134
 Ridderheim, M., 2309, 4550
 Rideout, W. M., III, 1162
 Rieber, M., 2469
 Rieber, M. S., 2469
 Riebow, J., 1338
 Riecken, E.-O., 4082
 Riehmüller, G., 1027
 Rifkind, R. A., 5554
 Rigas, B., 762, 2374
 Riggi, M., 1550
 Rimessi, P., 5569
 Rinaldi, D. A., 5929
 Ringborg, U., 4257
 Rio, M.-C., 165, 4096
 Riou, J.-F., 4784, 5987
 Risau, W., 5822
 Risinger, J. I., 5100
 Risteli, J., 5028
 Risteli, L., 5028
 Ritch, P. S., 5176
 Ritke, M. K., 3547
 Ritland, S. R., 2393, 4456
 Ritter, J. H., 2947
 Rivenson, A., 2502, 2758, 3493, 3719, 3914
 Rivers, E. N., 1916
 Riviere, J. E., 101
 Rizos, S., 2374
 Ro, J. Y., 1676, 2874
 Roa, R. A., 4477
 Robaszkiewicz, M., 5745
 Robbins, P. F., 2154
 Robert, C., 1625
 Robér, K.-H., 4376
 Robert, N. J., 3509
 Roberts, A. I., 1608
 Roberts, W. G., 153
 Robertson, M., 5581
 Robinow, C. F., 1877
 Robinson, J. C., 3869
 Rochefort, H., 2901
 Rockwell, S., 5127
 Rodbourn, L., 1529
 Roebuck, B. D., 46, 3499, 3925
 Rofstad, E. K., 3308
 Rogler, C. E., 2020
 Rognum, T. O., 5849
 Rom, W. N., 2858
 Roman, S. D., 5940
 Romanakis, K., 4035
 Roncucci, G., 2457
 Roncucci, L., 3726
 Rong, S., 5355
 Rønne, E., 1911
 Roop, D. R., 5071
 Roos, E., 3611
 Roos, J. C., 5413
 Root, M., 577
 Roots, I., 1004
 Rorke, E. A., 4511
 Rosati, R., 5523
 Rose, D. P., 4686
 Rose, E., 2803
 Rosen, S. T., 3877
 Rosenberg, M., 4938
 Rosenberg, S. A., 5, 3561
 Rosenblum, M., 3930
 Rosenblum, M. L., 2386
 Rosenquist, C., 2513
 Rosner, A., 2147
 Ross, D. A., 1348
 Ross, H., 1273
 Ross, R. A., 4978
 Ross, R. K., 1162
 Roth, J. A., 1676, 1743, 4129, 4362, 5361
 Rothberg, J., 2118
 Rothnagel, J. A., 5071
 Roths, J. B., 1665
 Rotstein, S., 3707, 4356
 Rouanet, P., 2901
 Rougier, P., 1550
 Rousseau, F., 1037
 Rouyer, N., 165
 Rowinsky, E. K., 1794
 Rowlands, C., 1802
 Roy, D., 2256
 Roza, L., 609

- Rozengurt, E., 5208
 Ruan, S., 5395
 Rubin, A. S., 1565
 Rubin, J., 5654
 Rubinstein, D. B., 3139
 Rubio, M-P., 3465
 Rudoll, T. L., 3765
 Rudy, W., 1262, 1516
 Rugghetti, A., 2457
 Rugstad, H. E., 4874
 Ruitter, D. J., 6061
 Ruka, W., 5012
 Ruppert, J. M., 4477, 5093, 5620
 Rusch, V. W., 2379
 Rushfeldt, C., 658
 Russell, C., 4555
 Russell, E. K., 4169
 Russell, M., 3386
 Russo, A., 5908
 Rustagi, P., 2810
 Rustan, T. D., 509
 Rustum, Y. M., 1560
 Rutka, J. T., 3624
 Rutz, H-P., 957
 Ruven, H. J. T., 1642
 Ryan, A. J., 2012
 Ryberg, D., 5853
- S
- Saba, V., 5429
 Sabzevari, H., 4933
 Safe, S., 1802
 Sagae, S., 1702, 3382
 Sage, R. E., 3455
 Sager, R., 5004
 Saijo, N., 3302
 Saiki, R. K., 2472
 Saisho, H., 2472
 Saishoji, T., 464
 Saito, H., 2676
 Saito, H., 3382
 Saito, H., 4466
 Saito, H., 5624
 Saito, J., 3382
 Saito, S., 3382
 Saito, S., 5528
 Saka, M., 147
 Sakai, A., 1982
 Sakai, K., 1043
 Sakai, T., 1328
 Sakakura, C., 687
 Sakamoto, H., 1136
 Sakamoto, M., 2005
 Sakr, W., 2723
 Saksela, E., 5600
 Saksena, N. K., 6067
 Salavati, R., 1511
 Saldanha, J., 851
 Saleh, M. N., 4555
 Salgaller, M. L., 2154
 Salghetti, S. E., 985
 Salour, M., 833
 Salvatore, M., 3198
 Samejima, K., 3948
 Samet, J. M., 4817
 Samid, D., 4890
 Samlowski, W. E., 5507
 Sampson, K. E., 1354
 Samuel, J., 1484
 Sanchez, R., 937
 Sandberg-Nordqvist, A-C., 2475
 Sanderson, N. D., 1719
 Sandlund, J. T., 127
 Sandvig, K., 1755
 Santelli, G., 5523
 Santen, R. J., 6042
 Santodonato, L., 1107
 Santos, O., 1091
 Santostefano, M., 1802
 Sara, V., 2475
 Sarasin, A., 1625
 Sarkaria, J. N., 4413
 Sartorelli, A. C., 4907, 5127, 5487
 Sartorius, S. E., 1794
 Sasaki, H., 1136
 Sasaki, H., 1906
 Sasaki, K., 1982
 Sasaki, S., 687
 Sasaki, T., 1397
 Sasaki, Y., 3632
 Sato, H., 1397
 Sato, K., 851
 Sato, M., 2538
 Sato, M., 2944
 Sato, N., 1702, 3078
 Sato, S., 1085
 Satoh, M., 1829, 4767
 Satomi, Y., 1328
 Satomura, S., 5419
 Sattler, G. L., 3145
 Saucier, J-M., 5987
 Sausville, E. A., 2081
 Sauter, G., 2199
 Sauveur, C., 3536
 Savarese, D. M. F., 2587
 Sawada, H., 772
 Sawada, M., 5559
 Sawai, K., 687
 Sawaya, R., 2208, 4143
 Scambia, G., 1297, 2457
 Scamps, C., 3655
 Scanlon, M., 891, 5784
 Scardino, P. T., 4461
 Schaafsma, H. E., 3241
 Schaefer, D. I., 4946
 Schäfer, R., 4670
 Schalken, J. A., 1995, 3241, 5512
 Schally, A. V., 5439
 Schantz, S. P., 2189
 Scheck, A. C., 5605
 Schecter, R. L., 4900
 Scheffer, G. L., 1475
 Schelling, M. E., 4075
 Schendel, D. J., 4020
 Schenker, T., 2840
 Scheper, R. J., 456, 1475
 Scheppach, W., 3283
 Scheumann, G., 4987
 Schibler, M. J., 4701
 Schiff, P. B., 1388
 Schildberg, F. W., 1690
 Schiller, J. H., 1286
 Schilsky, R. L., 1293, 2304
 Schinkel, A., 310
 Schlabach, L., 2810
 Schlager, J. J., 1338
 Schlaifer, D., 4850
 Schleicher, R., 3968
 Schlessinger, J., 3118, 4424
 Schlichtholz, B., 5872
 Schlom, J., 600, 2154, 3355, 3776, 4555
 Schlumberger, M., 5872
 Schlussel, R. N., 4971
 Schmid, F. A., 587
 Schmidt, H., 3283
 Schmidt, E. E., 2736
 Schmidt, H., 5143
 Schmidt, L., 861
 Schmidt, W., 799
 Schmits, R., 4367
 Schmitt, E., 4134
 Schmock, B. J., 271
 Schneiderman, M. H., 6017
 Schneller, H. E., 127
 Schofield, P. C., 3405
 Schomacker, K. T., 5954
 Schornagel, J. H., 5669
 Schreiber, G. J., 2560
 Schreiber, H., 840, 1978
 Schrijvers, A. H. G. J., 4383
 Schroeder, M. E., 968
 Schubiger, P. A., 5727
 Schuh, A. C., 615
 Schuhmann, A., 4189
 Schüller, H. M., 2498
 Schultz-Hector, S., 1444
 Schulz, K-D., 5439
 Schulze-Osthoff, K., 2623
 Schumaker, L. M., 3712
 Schuster, J. M., 2338
 Schuur, E., 4148
 Schwab, M., 3327
 Schwade, J. G., 1091
 Schwander, J., 4680
 Schwartz, C. E., 2553
 Schwartz, D. R., 1461
 Schwartz, E. L., 1142, 3509
 Schwartz, M., 663, 668
 Schwartz, M. A., 1503
 Schwartz-Albiez, R., 1262
 Schwechheimer, K., 2386
 Schwonzen, M., 4367
 Schy, W. E., 4582
 Scott, D. P., 1338
 Scott, L., 737
 Scott, R. E., 1338
 Sebers, S., 2081
 Sedlmayer, A., 1788
 Sedwick, W. D., 997
 Seed, T. M., 4518
 Seelen, C. M. J., 1642
 Seftor, E. A., 3411
 Seftor, R. E. B., 3411
 Segarini, P., 3386
 Seiki, M., 1397
 Seitz, G., 4035
 Sekhavat, M., 3139
 Sekido, Y., 1709
 Sekiguchi, K., 2005
 Sekiya, C., 5419
 Sela, M., 5251
 Seligman, P., 3968
 Sellers, T. A., 4230
 Selstam, G., 2309
 Selzer, M. G., 4493
 Senger, D. R., 2912, 4727
 Senter, P. D., 2123
 Seppo, A., 5600
 Séré, E., 5121
 Sergeev, I. N., 3935
 Serre, C-M., 4695
 Seruca, R., 5853
 Servidei, T., 304
 Seslar, S. P., 1233
 Setanoians, A., 523
 Sethi, T., 5208
 Setlow, R. B., 2249
 Setser, A., 4828
 Seung, S., 840
 Sexton, C. J., 5328
 Seyama, T., 2940
 Seynaeve, C. M., 2081
 Sgagias, M. K., 1538
 Shabahang, M., 3712
 Shaffer, D. W., 5929
 Shah, G., 38
 Shah, S. A., 1360
 Shani, A., 5962
 Shao, Z-M., 3226
 Shapiro, D. N., 5108, 5535
 Sharkey, F., 3369
 Sharkey, S. M., 4994
 Sharma, A., 5877
 Sharma, M., 2771
 Sharp, R., 4329
 Shaw, G. L., 5181
 Shaw, M. E., 1230
 Shay, J. W., 4772
 Shé, M. N., 944
 Shearer, M. H., 5734
 Sheehan, J., 4082
 Sheikh, M. S., 3226
 Shen, X., 968
 Shepherd, T. A., 3956
 Sher, E., 5566
 Sherman, J., 2410
 Sherman, M. P., 6067
 Sherr, C. J., 1986, 5535
 Sheth, A. R., 4855
 Sheu, J-C., 1653
 Shewach, D. S., 5219
 Shi, D., 5784
 Shi, F., 3986
 Shi, Y. E., 1409
 Shibagaki, I., 846
 Shields, P. G., 3486
 Shiku, H., 5395
 Shillitoe, E. J., 2189, 2330
 Shimada, H., 6051
 Shimada, S., 600
 Shimada, Y., 846
 Shimamoto, Y., 4004
 Shimazu, H., 1281
 Shimokata, K., 1, 1709
 Shimokawa, K., 5350
 Shimosato, Y., 5903
 Shimotsuma, M., 687
 Shin, D. M., 2874
 Shin, K-H., 4811
 Shiomi, T., 495
 Shiozaki, H., 1696, 3421
 Shipp, N. G., 550
 Shirahata, A., 3948
 Shiraishi, Y., 3427
 Shirakawa, F., 4643
 Shirasaka, T., 4004
 Shirasawa, H., 3179
 Shirasu, M., 687
 Shirasuna, K., 147
 Shively, J. E., 1612

* For title of article and coauthors, see listing in Contents of Volume 53 beginning on page i at the end of this index issue.

- Shoup, T. M., 5867
 Shpitz, B., 271
 Shu, S., 1043, 4315
 Shu, W.-P., 4971
 Shubik, P., 6075
 Shultz, K. L., 1059, 3741
 Shultz, L. D., 3741
 Sica, D., 1380
 Siciliano, M., 3603
 Siddik, Z. H., 4567
 Siddiki, B., 884
 Sidman, C. L., 1665
 Sidransky, D., 2231, 4477, 5093, 5620
 Siegal, G. P., 1906
 Siegall, C. B., 334
 Siegfried, J. M., 4349
 Siemens, H. J., 4268
 Siems, W. G., 5143
 Silber, J. R., 3416
 Silber, R., 5908
 Simi, B., 4182
 Simizu, B., 3179
 Simmons, A., 67
 Simons, J. W. I. M., 4797
 Singer, S., 810
 Singer, S., 5808
 Singh, G., 4994, 5452
 Sioussat, T. M., 2912
 Siracusa, L. D., 1498
 Sirica, A. E., 254
 Siriwardana, G., 3968
 Sirotak, F. M., 587
 Sizemore, N., 4511
 Siziopikou, K. P., 3362
 Skinner, D. G., 4066
 Sklar, J., 4676
 Skoog, L., 3707, 4356
 Skrincosky, D. M., 2667
 Skroch-Angel, P., 4197
 Skunca, M., 2618
 Slamon, D. J., 4960
 Slaper, H., 53
 Slate, D. L., 4658
 Slawin, K., 4461
 Slayter, M. V., 1480
 Slebos, R. J., 4164
 Slichenmyer, W. J., 4164
 Sliwkowski, M., 4960
 Slovak, M. L., 1475, 3221, 4866
 Sluiter, W., 2548
 Sly, L., 2287
 Smaaland, R., 3129
 Smedsrød, B., 658
 Smit, J. J. M., 1747
 Smith, A., 5727
 Smith, A. J., 1747
 Smith, C. D., 1343
 Smith, C. G., 4010
 Smith, G. J., 500
 Smith, G. K., 810
 Smith, I. E., 266
 Smith, J. A., 4627
 Smith, J. C., 5507
 Smith, J. M., 1480
 Smith, J. W., II, 2204
 Smith, K. J., 2728
 Smith, K. S., 1354
 Smith, L. S., 5929
 Smith, M. T., 1023
 Smith, S., 2231
 Smith, S. A., 1218
 Smith, S. G., 5697
 Smith, S. L., 3624
 Smith, T. J., 3276
 Smithers, D. A., 266
 Sninsky, J. J., 2472
 Snow, G. B., 3524, 4383
 Snyder, S. W., 766
 Snyderman, C., 5654
 Sobel, E., 3943
 Sobrero, A., 3677
 Sobrinho-Simoes, M., 5494
 Soini, Y., 4817
 Solere, P., 3536
 Soloway, A. H., 3308
 Soma, H., 3427
 Somerville, J. E., 2123
 Sondak, V. K., 1043
 Sondag, P. M., 1286
 Song, C. W., 324, 1431, 1599, 2076
 Sonnier, M., 235
 Soong, S.-J., 2816
 Sorensen, J. M., 4828
 Sothorn, R. B., 3129
 Sotnik-Barkai, I., 1838, 5962
 Soule, H. D., 3394
 Soussi, T., 5872
 Soutter, A. D., 5297
 Sparano, J. A., 3509
 Sparkes, R. S., 212, 5083
 Sparks, R. L., 1770
 Spate, V., 795
 Speicher, D., 1450
 Spelsberg, F., 1590
 Spence, A., 5663
 Spengler, B. A., 4978
 Spicer, T. P., 6067
 Spillare, E. A., 1684
 Spirio, L., 5581
 Spitz, M. R., 2189
 Sporn, M. B., 1480, 4461
 Springer, B., 5439
 Spruck, C. H., III, 1162, 4066, 5620
 Spyrtos, F., 5076
 Squartini, F., 2846
 Squires, S., 2012
 Sredni, B., 1838, 5962
 Srinivasan, R., 5361
 Srivastava, S., 1889, 4452
 Stables, J. N., 5328
 Stacewicz-Sapuntzakis, M., 3723
 Stack, M. S., 1998
 Stackhouse, T., 861
 Stafford, W. F., III, 4026
 Stahel, R. A., 2840
 Ståhlbom, P.-A., 2475
 Staib, L., 1113
 Stanbridge, E. J., 6011
 Stancovski, I., 5251
 Staniunas, R. J., 4048
 Stanley, J., 5613
 Stanners, C. P., 3817
 Stanton, P., 4161
 Stapleton, P., 2313
 Star, W. M., 2548
 Starling, J. J., 3956
 Starnes, H. F., Jr., 4010
 Stass, S. A., 4449
 Stastny, J. J., 5740
 Staubus, A. E., 3308
 Stearns, M. E., 878, 3073
 Steck, P. A., 2208, 5043
 Steeg, P. S., 1971
 Steele, C., 2330
 Steele, G. D., Jr., 1916, 4048
 Stefanski, S. A., 410
 Stegeman, J. J., 3700
 Stein, C. A., 2239
 Stein, G. S., 2399
 Stein, J. L., 2399
 Steinbach, G., 2745
 Steinberg, B. M., 910
 Steinberg, S. M., 67, 600, 4828, 5181
 Steinbrueck, T., 2947
 Steiner, M. G., 681
 Steinmetz, K. A., 536, 4230
 Stelmack, G. L., 3530
 Stendahl, U., 2309
 Sterenborg, H. J. C. M., 53
 Sterling-Levis, K., 1222
 Stern, H. S., 271
 Stern, R., 5251
 Stetler-Stevenson, M., 2081
 Stetler-Stevenson, W. G., 2208, 3159, 3411
 Steven, K., 1162, 5620
 Stevens, J. K., 5148
 Stevens, J. L., 4542
 Stevenson, D. K., 2700
 Stewart, A. J., 4156
 Stewart, B. W., 4287
 Stieglitz, K., 310
 Stöhrer, G., 4107
 Stolfi, R. L., 3518
 Stone, M. J., 1392
 Stoner, G., 1620
 Stoppacciaro, A., 5067
 Stoppelli, M. P., 3198
 Storer, B., 1286
 Straubinger, R. M., 5877
 Strauss, E. E., 1770
 Streilein, J. W., 728
 Strife, A., 401
 Strutt, H. L., 2012
 Stuart, N. S. A., 5649
 Stubblefield, E., 5043
 Sturmans, F., 75, 4860
 Su, B., 1751
 Su, J. Q., 4456
 Su, L.-K., 2728
 Su, S. L., 3327
 Su, Z.-Z., 1929
 Suarez, H., 1625
 Subbarao, V., 2790
 Suberville, A. M., 235
 Sublett, J. E., 5108
 Subrahmanyam, V. V., 1023
 Subramanian, R., 2368
 Subramanyam, B., 766
 Suchard, S. J., 378
 Suda, H., 490
 Sudo, K., 4262, 5233
 Suematsu, M., 2676
 Sugahara, H., 675
 Sugano, H., 953
 Suganuma, M., 239, 992, 1012, 1982, 3462
 Sugawara, S., 6001
 Sugimachi, K., 1706, 2884, 5000
 Sugimoto, Y., 2538
 Sugimura, T., 1136, 2786
 Sugio, K., 5000
 Sugiyama, M., 2484
 Sugiyama, T., 147
 Sugiyama, H., 5589
 Sugiyama, T., 3795
 Sugiyama, T., 3899
 Suit, H. D., 5012, 5018
 Sulfaro, S., 5775
 Sumizawa, T., 5680
 Summerhayes, I. C., 5620
 Sundareshan, P., 3217
 Sundqvist, K.-G., 4376
 Sung, C., 2092, 3752
 Supko, J. G., 3062, 4843
 Surh, Y.-J., 1017
 Sussenbach, J. S., 5754
 Susumu, N., 3643
 Sutherland, R. L., 5940
 Sutherland, R. M., 2700
 Suttle, D. P., 1373
 Sutton, F., 2803
 Suyama, K., 5452
 Suyama, M., 1
 Suzui, M., 3908
 Suzuki, H., 1709
 Suzuki, M., 5528
 Svennerholm, L., 120
 Svensson, H. P., 2123
 Swenberg, J. A., 3895
 Switzer, B. R., 2750
 Symann, M. L., 3139
 Szallasi, Z., 2507
 Sze, L., 5244
 Szepesi, A., 3968
 Szinai, I., 1098
 Szwegold, B. S., 1751

T

- Tada, A., 1906
 Tada, M., 2472
 Tada, S., 2676
 Taetle, R., 3386
 Taffe, B. G., 5377
 Taga, H., 5419
 Taga, S., 5314
 Taghian, A., 5012, 5018
 Taguchi, T., 4349
 Tahara, E., 4102
 Tahara, H., 1696, 3421
 Tai, M.-S., 4026
 Tai, T., 5395
 Tainaka, K., 2326
 Takada, A., 354
 Takada, K., 4238
 Takagi, H., 4329
 Takagi, K., 1555
 Takahashi, H., 1612
 Takahashi, H., 1906
 Takahashi, H., 3179
 Takahashi, H., 5079
 Takahashi, M., 1709
 Takahashi, M., 2786
 Takahashi, M., 2830
 Takahashi, R., 3795
 Takahashi, S., 32
 Takahashi, S., 1702
 Takahashi, T., 1, 1709
 Takahashi, T., 1, 1709
 Takahashi, T., 687

* For title of article and coauthors, see listing in Contents of Volume 53 beginning on page i at the end of this index issue.

- Takahashi, Y., 5350
 Takano, S., 464
 Takao, S., 1281
 Takashima, A., 4014
 Takatsuka, Y., 1696
 Takayama, H., 4329
 Takayama, S., 4701
 Takebe, H., 2944
 Takeda, K., 6001
 Takeda, R., 4218
 Takeda, Y., 3302
 Takeichi, M., 1696, 3421
 Takemoto, K., 4153
 Takeshima, Y., 4817
 Taketa, K., 2970, 5419
 Taketo, M., 5589
 Takeuchi, A., 1871
 Takeuchi, Y., 4218
 Takimoto, H., 106
 Takizawa, H., 4175
 Talpaz, M., 2118, 3289
 Tamai, S., 5038
 Tamargo, R. J., 329
 Tamatani, T., 1871
 Tamimi, Y., 5512
 Tamura, M., 2566
 Tanabe, M., 3179
 Tanaka, H., 32
 Tanaka, J., 5638
 Tanaka, K., 2566
 Tanaka, K., 5079
 Tanaka, S., 2884
 Tanaka, S., 4701, 4978
 Tanaka, T., 772, 2775, 3903, 3908, 5350
 Tanda, S., 5528
 Tang, D. C., 4059
 Tang, H.-Y., 5219
 Taniguchi, H., 687
 Taniguchi, N., 3207, 3899
 Tanikawa, K., 5419
 Tanimura, H., 1085
 Tanizawa, A., 4251
 Tanizawa, O., 1883
 Tannenbaum, S. R., 1017
 Taraboletti, G., 3812
 Tarone, R., 3694
 Tasimowicz-Alpini, A., 4652
 Taskinen, P. J., 4486
 Tataka, R. J., 4303
 Tateishi, M., 5000
 Taub, R., 3789
 Taupin, J.-L., 5610
 Taylor, A. M. R., 438
 Taylor, C. R., 3233
 Taylor, D. J., 5649
 Taylor, M. W., 3555
 Taylor, P. A., 4273
 Tedeschi, M., 544
 Teelmann, K., 2319
 Teh, S. J., 3700
 Teneriello, M. G., 3103
 Tennenbaum, T., 4803
 Tennent, B. J., 1059, 3741
 Tepper, R. I., 3125
 Terada, M., 1136
 Terada, N., 3968
 Terao, N., 4823
 Terasawa, M., 2051
 Terashima, Y., 1906
 Terheggen, P. M. A. B., 5669
 Termont, D. S. M. L., 248
 Tesch, H., 4310
 Testa, J. R., 3217, 4349, 4761
 Testa, U., 569, 1297
 Testi, A. M., 3800
 Tetenes, E., 1727
 Thakkar, N. S., 2057
 Thetler, O., 1027
 Theuer, C. P., 340
 Thiele, C. J., 926
 Thiessen, J. J., 4837
 Thijssen, J. H. H., 4563
 Thilly, W. G., 5808
 Thomas, D., 5365
 Thomas, D. C., 3270
 Thomas, P. E., 3276
 Thompson, A. M., 2947
 Thompson, C. H., 5649
 Thompson, E. A., 5447
 Thompson, E. W., 1416, 3229
 Thompson, T. C., 4461
 Thompson, W. D., 212, 5083
 Thomson, D., 3468
 Thorens, B., 4204
 Thorgeirsson, S. S., 1719
 Thorlacius, S., 1637
 Thorpe, P. E., 3000
 Thun, M. J., 1322
 Thusu, K., 5104
 Tibbels, S., 4619
 Tikhonov, Y. V., 5143
 Timmer, A., 5707
 Timmer-Bosscha, H., 5707
 Tishler, R. B., 2212
 Titani, K., 2005
 Titlestad, I., 5920
 Tiu, S. N., 170
 Tius, M. A., 3462
 Tjandra, N., 5386
 Tkeshelashvili, L. K., 4172
 Tlsty, T. D., 3098, 4946
 Tobe, T., 846
 Tobias, V., 1222
 Tobler, A., 921
 Toge, T., 5815
 Tognazzi, K., 4727
 Toguchida, J., 368, 846, 3795
 Toh, Y., 2884
 Tokino, K., 5093, 5620
 Tokino, T., 2231
 Tolleson, W. H., 905
 Tomassetti, A., 5791
 Tomasz, M., 5127
 Tomlinson, G., 4757
 Tomoda, Y., 2051
 Tong, A. W., 1392
 Tong, W. P., 3730
 Tong, Y., 1889
 Tong, Y. A., 4452
 Toniolo, A., 2957
 Toniolo, P., 460
 Topalian, S. L., 5
 Topham, J., 3919
 Torri, J. A., 873, 1409
 Torrisi, R., 4769
 Torti, F. M., 4010, 4658
 Torti, S. V., 4658
 Tortora, G., 868
 Tory, K., 861, 3118
 Toso, J. F., 1461
 Tosto, L. M., 6011
 Tounekti, O., 5462
 Toussaint, C., 3541, 4608
 Towle, M. J., 2553
 Tracey, P. A., 3771
 Trachtenberg, J., 1304
 Traganos, F., 3186, 4613, 5096
 Trail, P. A., 334
 Travis, W. D., 4817
 Traystman, R. J., 1833
 Trédaniel, J., 5872
 Triadafilopoulos, G., 2374
 Trickett, A. E., 1222
 Triebel, F., 3569
 Tritarelli, E., 569
 Tritton, T. R., 5237
 Trogadis, J., 5148
 Troll, W., 4528
 Trucco, M., 4745
 Trump, B. F., 4817
 Trunet, P. F., 266
 Tsai, C.-M., 1079
 Tsai, Y. C., 1162, 4066, 5620
 Tsao, S.-W., 1489
 Tsao, Y.-P., 5908
 Tsarfaty, I., 5355
 Tseng, H.-J., 4691
 Tsiftoglou, A. S., 1072
 Tsioulas, G. J., 2374
 Tsongalis, G. J., 3865
 Tsuboi, C., 5382
 Tsuchida, Y., 5284
 Tsuchiya, M., 851
 Tsuchiya, M., 2676
 Tsuchiya, Y., 1397
 Tsujimoto, H., 687
 Tsujisaki, M., 4927
 Tsujiuchi, T., 5038
 Tsukada, Y., 4238
 Tsukaguchi, T., 2319
 Tsukahara, S., 2538
 Tsukamoto, T., 1709
 Tsukita, S., 3585
 Tsukui, T., 3257
 Tsuruo, T., 2538, 5022, 5475, 5802
 Tsutsui, J.-i., 1281
 Tsutsumi, M., 5038
 Tsuyama, N., 2940
 Tsuyouka, K., 354
 Tu, C.-P. D., 231
 Tuason, L., 1380
 Tubbs, R. R., 1380, 5613
 Tudor, E. G., 5954
 Tung, Y., 2796
 Turbide, C., 4938
 Turc-Carel, C., 3655
 Turchi, V., 2457
 Tursz, T., 5314
 Tuttle, T. M., 833
 Tweardy, D. J., 3579
 Tyrrell, R. M., 4505
 U
 Überla, K., 714
 Uchida, E., 5289
 Uchiyama, T., 1085
 Uchiyama, A., 949
 Uckun, F. M., 447, 1431
 Udove, J. A., 4960
 Ueda, R., 1, 1709
 Uemura, D., 490
 Ueno, M., 3046
 Uhlenbruck, G., 4367
 Ullmann, C. D., 600
 Ullrich, A., 4424, 5822
 Umbas, R., 3241, 5512
 Umezawa, K., 4896
 Untawale, S., 1630
 Unteregger, G., 4035
 Upadhyaya, P., 3719
 Upeslacijs, J., 3336
 Urba, W. J., 2204
 Urban, J. L., 840
 Urmacher, C., 279
 Uytterlinde, A. M., 4383
 V
 Vacca, A., 5067
 Vaden, S. L., 101
 Vähäkangas, K. H., 4817
 Vainio, H., 5643
 Valenti, M., 2581
 Valentine, M., 5535
 Valinski, H., 3172
 Valleria, D. A., 4273
 Valteau-Couanet, D., 1534
 Valve, E. M., 5199
 Vambutas, A., 910
 van Acker, S. A. B. E., 4603
 Van Beneden, R. J., 2976
 Van Cong, N., 2888
 van de Loosdrecht, A. A., 4399
 van de Merbel-de Wit, L. E. A., 2548
 van den Berg, F. M., 4754
 van den Brandt, P. A., 75, 4860
 van den Broek, M., 2614
 van den Ent, F. M. I., 2399
 van der Leun, J. C., 53, 4212
 Van der Meer, R., 248, 784
 van der Poel, H. G., 5512
 van der Riet, P., 4477
 van der Valk, P., 1475
 Van Der Ven, L. T. M., 5754
 van der Vijgh, W. J. F., 4603
 van der Wall, E., 4563
 Vande Woude, G. F., 5355
 van Dongen, G. A. M. S., 3524, 4383
 Vanhaesebroeck, B., 2623
 Vanhamme, L., 615, 622
 van Heijningen, T. H. M., 1475
 van Kalken, C. K., 1475
 van Krieken, J. H. J. M., 4148
 Vánky, F., 2416
 van Laar, J. A. M., 1560
 Van Meir, E. G., 957, 5345
 van Muijen, G. N. P., 6061
 Van Rensburg, C. E. J., 318
 Van Roy, F., 2623
 van Solinge, W. W., 1823
 Van Staden, A. M., 318
 van Tellingen, O., 2061
 van't Veer, P., 75, 4860
 van Walsum, M., 3524, 4383
 van Weelden, H., 53
 van Wijnen, A. J., 2399
 van Zeeland, A. A., 1149, 1642
 Varban, M. L., 3172
 Varesco, L., 5581
 Varticovski, L., 3028
 Varvayanis, S., 3085

- Vassal, G., 1534
 Vaughan, A. T. M., 2300
 Vaysse, N., 1182
 Vecchio, G., 5523
 Végh, Z., 2416
 Veigl, M. L., 997
 Veissière, D., 2762
 Velasco, J. A., 4474
 Velicescu, M., 4138
 Vellucci, V. F., 899
 Vercellotti, G. M., 5308
 Vergely, C., 4595
 Vermorken, J. B., 456, 5413
 Verna, J.-M. G., 4715
 Veronesi, U., 6036
 Versantvoort, C. H. M., 1747
 Versnel, M. A., 388
 Vertino, P. M., 1684
 Vicentini, L. M., 5566
 Vichi, P. J., 5237
 Vidali, G., 741
 Viel, S., 3569
 Vierbuchen, M., 4367
 Vigneri, R., 3736
 Vihko, P., 1051
 Vile, R. G., 962, 3860
 Vincek, V., 728
 Vinci, J. M., 348
 Vindivich, D., 744
 Vinters, H. V., 170
 Vionnet, J. A., 242, 3694
 Vishwanatha, J. K., 6017
 Visser, G. W. M., 3524
 Vitetta, E. S., 1392
 Vitolo, D., 5654
 Vivier, E., 5610
 Vlamis, V., 3730
 Vlock, D. R., 5654
 Voest, E. E., 4603
 Vogan, K., 5269
 Vogel, C.-W., 592, 2368
 Vogelstein, B., 1986, 2231, 2728
 Vogelzang, N. J., 1293, 2304
 Vogt, P. K., 615
 Vokes, E., 3667
 Volant, A., 5745
 Vollmers, H. P., 4197
 Volovics, A., 75
 von Deimling, A., 3465
 von Eschenbach, A. C., 2852
 von Flidner, V., 4310
 Von Hoff, D. D., 5929
 von Holst, H., 2475
 Voravud, N., 2874
 Vore, M., 5382
 Vreman, H. J., 2700
 Vrieling, H., 1149
 Vuillequez, J. J., 393
 Vukanovic, J., 1833
 Vukosavljevic, T., 5775
- W**
- Waalkes, M. P., 922
 Waber, P. G., 6028
 Wachter, H., 260
 Wacker, J., 1450
 Waddick, K., 1431
 Wadler, S., 3509
 Wagata, T., 846
 Wagner, B. A., 711
 Wagner, T., 4268
- Waibel, R., 2840
 Wakeling, A. E., 3229
 Wakusawa, S., 1555
 Walbridge, S., 83, 3752
 Waldman, F., 2199
 Waldmann, T. A., 5683
 Walensky, L. D., 4720
 Walker, B. E., 1546
 Walker, S., 4837
 Wallace, D. M. A., 2300
 Wallace, L., 1727
 Wallace, M., 2947
 Wallace, P. K., 2358
 Wallace, R., 3336
 Walsh, J. H., 5208
 Walsh, P. C., 3869
 Walsh, T. E., 5181
 Walton, M. I., 1853
 Walz, T. M., 191
 Wan, M., 4138
 Wands, J. R., 3823
 Wang, B., 2272
 Wang, F.-S., 3677
 Wang, H. H., 2912
 Wang, J., 6006
 Wang, J. C., 3591, 4343
 Wang, J. M., 564
 Wang, L., 717
 Wang, L.-D., 1783
 Wang, M., 878, 3073
 Wang, P., 2416
 Wang, Q.-c., 4588
 Wang, R. C., 3314
 Wang, R. R. C., 4041
 Wang, S., 4452
 Wang, X., 1802
 Wang, Y., 1213
 Wang, Y., 1620
 Wang, Y., 1620
 Wang, Y., 2227
 Wang, Y., 5244
 Wang, Z., 2740
 Wang, Z., 3349, 4303
 Ward, J. M., 4329
 Wardlaw, S. A., 2965
 Warmoth, M. R., 1373
 Warren, R. C., 2937
 Wary, K. K., 1498
 Wasan, H., 5365
 Wasserman, R. A., 3591
 Wasteson, A., 191
 Watabe, H., 5475
 Watanabe, H., 5297
 Watanabe, M., 1204, 3070
 Watanabe, T., 5244
 Waters, K., 810
 Waters, R., 1522
 Watson, G. J., 3000
 Watson, P., 5100
 Wattenberg, L. W., 5890
 Watts, P., 94
 Waugh, A. P. W., 609
 Waxman, D. J., 2490, 5629
 Waxman, J., 5365
 Waxman, S., 4109
 Wazer, D. E., 1952
 Weber, B. L., 627
 Weber, E., 2840
 Weber, G., 5982
 Weber, G. F., 5629
 Webster, L., 5004
- Webster, M. K., 1808, 1816
 Wei, H., 1255
 Wei, M. X., 3125
 Wei, S.-J. C., 3294
 Wei, W., 1867
 Weichselbaum, R. R., 1978, 3667, 5542
 Weidmann, E., 4745
 Weigel, R. J., 3472
 Weinberg, J., 4224
 Weinberg, J. B., 1939
 Weiner, A. K., 4803
 Weiner, L. M., 94, 3217, 4026
 Weisburger, J. H., 2422
 Weiss, C., 4268
 Weiss, G., 260
 Weiss, G. R., 5929
 Weiss, N. S., 2313
 Weiss, R., 5581
 Weitzman, S. A., 2644
 Weksler, B., 5483
 Welch, D. R., 5802
 Welch, W. R., 1489
 Wells, S. A., Jr., 2947
 Wellstein, A., 1409
 Welsch, C. W., 2272
 Welsh, J. A., 4817
 Wen, D., 5251
 Weng, C.-N., 4443
 Wennerberg, J., 2140
 Werelius, B., 4356
 Wernicke, D., 1102
 Wesley, O., 1286
 Westendorf, J. J., 5320
 Weston, A., 3486
 Westrick, L., 5176
 Weterman, M. A. J., 6061
 Whartenby, K. A., 5274
 Wheeler, R. H., 4555
 Whetton, A. D., 1735
 Whipple, J. A., 1761
 Whitaker, R. S., 1939
 Whitbread, J. A., 1142
 White, A. E., 3098, 4946
 White, E., 2313
 White, L., 1222
 White, R., 5581
 White, T., 5494
 Whiteside, T. L., 1461, 4745, 5654, 5828
 Whitfield, D. M., 2906
 Whitlow, M., 3776
 Whitmore, W., 2987
 Whorton, A. R., 3765
 Whysong, D., 1853
 Wicke, D., 2762
 Wickstrom, E., 577
 Wiedemann, G. J., 4268
 Wielenga, V. J. M., 4754
 Wiels, J., 5314
 Wiener, J. R., 1939
 Wientjes, M. G., 3314
 Wiestler, O. D., 3465
 Wijnands, Y., 3611
 Wijnen, J., 2614
 Wikstrand, C. J., 120
 Wilander, E., 4550
 Wilbanks, G., 3362
 Wilder, R. B., 3022
 Wildrick, D. M., 1630
 Wilkinson, D. A., 4224
- Willard, T. B., 1777
 Willemse, P. H. B., 5915
 Willey, J. C., 985
 Williams, A. T., 5328
 Williams, B. R. G., 2712
 Williams, D. E., 1565
 Williams, G., 5365
 Williams, G. M., 4534
 Williams, K. J., 2895
 Williams, S. S., 3964
 Williamson, M., 133
 Willis, S. M., 3723
 Willson, J. K. V., 1986
 Wilson, B. C., 4994
 Wilson, H. R., 810
 Wilson, P., 523
 Wilson, T., 3405
 Wiltrout, R. H., 5613
 Winawer, S. J., 279
 Winick, N. J., 2954
 Wink, D. A., 5845
 Winokur, T. S., 1480
 Winqvist, R., 4486
 Winter, S. F., 3257
 Wiseman, R. W., 1218
 Wisniewski, D., 401
 Witt, P. L., 5176
 Witte, O. N., 485
 Wojcik, S. J., 3405
 Wolf, C., 165, 4096
 Wolf, G. T., 5113
 Wolf, J. K., 891
 Wolf, R. F., 5483
 Wolff, E. A., 2560
 Wong, A. J., 3217
 Wong, C.-Q., 3294
 Wong, G. Y., 2830
 Wong, J. M., 1916
 Wong, P. T., 762
 Wong, R. K. H., 3723
 Woo, A., 4900
 Wood, J. F., 3776
 Woodhouse, L. F., 5090
 Woodruff, L. S., 127
 Woods, V. L., Jr., 4890
 Woodworth, T., 3930
 Worland, P. J., 2081
 Wössmann, W., 4268
 Wright, M. A., 6006
 Wright, S. E., 4920
 Wu, C.-W., 2865
 Wu, G., 1724
 Wu, H.-C., 2852, 5300
 Wu, N. Z., 3765
 Wu, R., 2527
 Wu, S., 1939
 Wu, S., 5597
 Wu, S. V., 5208
 Wu, T.-C., 4720
 Wullich, B., 4035
 Wunsch, P. H., 5797
 Wyatt, J. I., 5090
 Wyllie, R., 3758
 Wynder, E. L., 2758
 Wynn, D. M., 5802
- X**
- Xie, Y., 2906
 Xing, P.-X., 4082
 Xu, F., 1304

* For title of article and coauthors, see listing in Contents of Volume 53 beginning on page i at the end of this index issue.

- Xu, G-w., 1317
 Xu, Y-Y., 3823
- Y
- Yabkowitz, R., 378
 Yagi, H., 1273, 3294
 Yagi, T., 2944
 Yagita, M., 5600
 Yago, K., 5559
 Yagura, H., 675
 Yakushiji, M., 5225
 Yalovich, J. C., 3547
 Yamada, A., 490
 Yamada, H., 3795
 Yamada, K., 4238
 Yamada, M., 5284
 Yamada, T., 5759
 Yamada, Y., 1085
 Yamada, Y., 3459
 Yamagishi, M., 3046
 Yamaguchi, K., 2538
 Yamakawa, K., 1
 Yamamoto, K., 3427
 Yamamoto, K., 5284
 Yamamoto, M., 5172
 Yamamoto, S., 4218
 Yamamoto, T., 4262, 5233
 Yamamura, K., 423, 3459
 Yamanaka, Y., 2704, 4741, 5289
 Yamaoka, M., 4262, 5233
 Yamashiro, S., 5395
 Yamashita, J-i., 464
 Yamashita, K., 2970
 Yamashita, N., 2786
 Yamashita, N., 4175
 Yamashita, S-i., 464
 Yamashita, U., 4102
 Yan, P. S., 641
 Yanagihara, K., 5815
 Yanagihara, R., 6067
 Yanagisawa, A., 953, 5087
 Yanase, T., 2566
 Yandell, D. W., 368, 846, 3465
 Yane, K., 4408
 Yang, A. S., 1162
 Yang, C. S., 1783, 3276
 Yang, D., 2020
 Yang, H., 112
 Yang, H-K., 3165
 Yang, J. C., 2358
 Yang, J-L., 2865
 Yang, L. Y., 1583
- Yang, M. B., 329
 Yang, P., 4449
 Yang, S. Y., 4303
 Yang, Y-C., 3000
 Yanuck, M., 3257
 Yao, K-s., 3662
 Yao, M., 861
 Yarden, Y., 5251
 Yasui, A., 495
 Yasui, W., 4102
 Yasumura, S., 1461, 4745
 Yatsunami, J., 239, 992, 1012, 1982
 Yazawa, K., 2786
 Ye, B. H., 2732
 Ye, J., 1255
 Ye, Y., 2712
 Yeh, G. C., 5977
 Yeh, Y., 3159
 Yen, A., 3085
 Yen, N., 1743
 Yeo, K-T., 2912
 Yeo, T-K., 2912
 Yeoh, G. C. T., 515
 Yeoman, L. C., 1630
 Yieh, L., 1409
 Yim, C-Y., 5507
 Yin, J., 1889
 Yokota, T., 3776
 Yokozaki, H., 868
 Yokozaki, H., 4102
 Yoneda, T., 354
 Yoneda, T., 737
 Yonehara, S., 2591
 Yonei, Y., 2676
 Yoo, J., 744
 Yoon, W-H., 1437
 Yorke, E. D., 2987
 Yoshida, E., 490
 Yoshida, M., 1328
 Yoshida, O., 3795
 Yoshii, A., 3349, 4927
 Yoshikai, Y., 106
 Yoshikawa, T., 2326
 Yoshimi, N., 2775
 Yoshinari, T., 490
 Yoshioka, H., 147
 Yoshizawa, H., 1043
 Yoshizawa, S., 1012
 You, M., 1620
 You, W-c., 1317
 Youle, R. J., 2092, 3752
- Young, C. W., 1226, 4109
 Young, M. R. I., 6006
 Yow, H., 1916
 Yu, C., 1332
 Yu, D., 891, 5784
 Yu, F., 5554
 Yu, J. S., 3125
 Yu, L., 4627
 Yu, M., 528
 Yu, M., 6031
 Yu, M. C., 1162, 4138
 Yu, M-W., 790
 Yu, Y. B., 6051
 Yuan, M., 884
 Yuan, S., 1304
 Yule, S. M., 3758
 Yun, C-H., 2028
 Yun, K., 5166
 Yung, W. K. A., 5043
 Yuspa, S. H., 992, 4803
 Yuzuki, D. H., 949
- Z
- Zadunaisky, J. A., 1255
 Zafferani, M., 3747
 Zaidi, S. I. A., 5897
 Zajchowski, D. A., 5004
 Zakut, R., 5
 Zalcman, G., 5872
 Zaman, G. J. R., 1747
 Zaman, M., 2379
 Zang, K. D., 4035
 Zangemeister-Wittke, U., 2840
 Zarrabi, M. H., 140
 Zasloff, M., 3052
 Zauli, G., 4481
 Zawadzki, V., 1516
 Zbar, B., 861, 3118
 Zea, A. H., 5613
 Zeff, R. A., 4303
 Zeiner, M., 3513
 Zeller, K-P., 5135
 Zelnick, C. R., 5251
 Zeng, X-r., 1317
 Zenita, K., 5559
 Zetter, B. R., 1971, 2661
 Zghal, M., 2944
 Zhai, Y-F., 2272
 Zhang, B-Q., 1392
 Zhang, H., 5714
 Zhang, H. B., 1128
 Zhang, K., 2950
- Zhang, L., 1023
 Zhang, L., 1317
 Zhang, M. H., 5714
 Zhang, Q-H., 5528
 Zhang, Q-X., 5882
 Zhang, R., 2816, 5433
 Zhang, W., 4772
 Zhang, Y., 1743
 Zhang, Y., 2858
 Zhao, L., 1317
 Zhao, S., 1493
 Zhao, X-l., 2712
 Zhao, Y., 2901
 Zhao, Z., 1550
 Zhou, H. E., 5300
 Zhen, W., 2344
 Zheng, J., 4138
 Zheng, W., 795
 Zhitkovich, A., 460
 Zhou, H., 3817
 Zhou, W., 3925
 Zhou, X-J., 5121
 Zhou, Y., 2912
 Zhou, Z-l., 899
 Zhou-Pan, X-R., 5121
 Zhu, G-G., 5028
 Zia, F., 5214
 Zietman, A., 5012, 5018
 Zijlstra, J. G., 1064
 Zimbalist, E., 279
 Zimmer, S. G., 1516, 1929
 Zimmermann, A., 921
 Zimmermann, R., 3058
 Zimniski, S. J., 2937
 Zindy, F., 235
 Zipf, T. F., 3289
 Zlotecki, R. A., 2466
 Zöller, M., 1262, 1516
 Zorbas, M. A., 1630
 Zordan-Nudo, T., 5994
 Zou, X., 3462
 Zou, Y., 3046
 Zou, Z-Q., 1889
 Zsebo, K. M., 1709
 Zucker, S., 140, 1195, 3154
 Zvibel, I., 652
 Zweizig, S., 4138
 Zwellling, L. A., 1373
 Zwergel, T., 4035
 Zwiebel, J., 2168
 Zygmunt, A. I., 1770

SUBJECT INDEX

Volume 53

A

- Abrin**
entry of protein toxins
polarized epithelial cells, 1755
- A121 cells**
galaptin-mediated adhesion
detection, cellular galaptin-binding
glycoproteins, 2667
- A431 cells**
xenografts
anti-epidermal growth factor receptor
monoclonal antibody, cisplatin,
4637
- Acetamide**
alkylamides as inducers
human leukemia cell differentiation,
structure-activity relationship, 766
- 2-Acetylaminofluorene**
glucuronidation of carcinogen metabo-
lites
complementary DNA-expressed uri-
dine 5'-diphosphate glucuronosyl-
transferases, 1529
-induced lung and liver tumors
ras mutations, 1620
- Acetylator**
metabolic activation of *N*-hydroxy-2-
aminofluorene
colon cytosols, Syrian hamsters con-
genic at *NAT2* locus, 509
phenotype
amonafile dosing, Phase I study, 2304
- Acetyldinaline**
differential activity
leukemic cells and normal stem cells,
rat leukemia, 3008
- β 1,4-*N*-Acetylgalactosaminyltransferase**
genetic and enzymatic basis
GM2 and *GD2* differential expression,
human cancer cell lines, 5395
- N*-Acetylglucosaminyltransferase**
III and V mRNA levels
hepatocarcinogenesis, LEC rats, 3899
- N*-Acetyltransferase**
metabolic activation of *N*-hydroxy-2-
aminofluorene
colon cytosols, Syrian hamsters con-
genic at *NAT2* locus, 509
- Acidification**
intracellular
etoposide-induced apoptosis, HL-60
cells, 2349
- Aclarubicin**
aberrant functions
teniposide-resistant CEM cells, 5946
- Acquired immunodeficiency syndrome**
systemic expression of HIV-1 *tat* gene
endothelial proliferation, tumors of
different histotypes, 5569
- 4'-(9-Acridinylamino)methanesulfon-*m*-ani-
side**
topoisomerase II as a target
atypical multidrug resistance, small
cell lung carcinoma cells, 1064
- Acridonecarboxamide**
derivative GF120918
reversal of multidrug resistance, 4595
- Acrolein**
modulation of rat hepatic cytochrome
P450 2C11
- cyclophosphamide, messenger RNA
levels, 2490
- Actin**
E-cadherin-dependent cell-cell adhesion
blockage of, stimulation of urokinase-
type plasminogen activator expres-
sion, 3618
- Adenocarcinoma**
colonic
induction of TGF- α promoter activity
and TGF- α secretion, TGF- β 1, 4041
local hyperthermia and SR 4233, en-
hanced radioimmunotherapy, 3022
neopterin and prognosis, 260
reduction of interstitial fluid pressure,
dexamethasone, 4764
colonic and colorectal
gastrin gene expression, 2919
endometrial
p53 alterations, c-*K-ras* activation,
1883
gastric
poorly differentiated type, genetic in-
stability in pancreatic cancer, 5087
gastrointestinal
5-fluorouracil and calcium leucovorin,
N-(phosphonacetyl)-L-aspartate
combination, 4828
vascular permeability factor, its recep-
tors, 4727
"intestinal-type"
furan treatment, right/caudate liver
lobes, 254
mammary
glucocorticoids, suppression of
growth, 1808
isoglobotetraosylceramide, marker for
highly metastatic cells, 2906
protective and curative potential of
vaccination, IL-2 gene-transfected
cells, 5067
spontaneous metastasis, serum and
plasma *M*, 92,000 progelatinase lev-
els, 5802
ovarian
improved prediction of survival, im-
munocytochemistry and estrogen re-
ceptor, 5188
pancreatic
aberrant expression, type I fibroblast
growth factor receptor, 4741
detection of *ras* gene mutations, pan-
creatic juice and peripheral blood,
2472
prostatic
metastatic potential, cell motility and
glyceraldehyde-3-phosphate dehy-
drogenase expression, 1995
suppression of tumor growth, inhibin,
4855
- Adenoma**
chromosome 12 breakpoints
benign and malignant lipogenic tu-
mors, 1670
rapid screening method
nonsense and frame-shift mutations,
disease-causing *APC* alleles, 5581
sporadic
HLA class I antigens, histologically
normal mucosa of colon, 2374
- Adenomatous polyposis**
familial
wild type and mutant *APC* gene prod-
ucts, 2728
- Adenomatous polyps**
frequency of
strength of family history, epithelial
cell proliferative compartment, 279
- Adenosine monophosphate, cyclic**
-dependent protein kinase
antisense oligodeoxynucleotide, deple-
tion of RI α subunit, 868
growth factor-like properties
parathyroid hormone-related peptide,
transfected rodent cell lines, 2980
- Adenosine triphosphatase**
Ca²⁺-transporting ATPase isoform 2
gene
cloning, von Hippel-Lindau syndrome,
861
- Adenosine triphosphate**
inhibition of doxorubicin-induced apop-
tosis
2-deoxy-D-glucose, 2057
protein interaction of pRb110
M, 73,000 heat shock cognate protein,
1702
single-strand conformational polymor-
phism
M, 170,000 isozyme, DNA topoiso-
merase II, 1373
- S-Adenosylhomocysteine hydrolase**
inhibitor Z-4',5'-didehydro-5'-deoxy-5'-
fluoroadenosine
suppression of proliferation, keratino-
cytes and squamous carcinoma cell
lines, 6058
- Adenovirus**
E1A
counteraction of tumor suppression,
neu-encoded oncoproteins, 5784
suppression of severe malignancy, c-
erbB/neu in ovarian cancer cells,
891
wild-type type 5 transforming genes
transdominant suppressors of onco-
genesis, transformed rat embryo fi-
broblast cells, 1929
- Adhesion**
E-cadherin expression and invasiveness
esophageal cancer cell line, 3421
CEA-mediated
specificity, anti-CEA monoclonal anti-
bodies, 3817
cell surface molecules
suppression of T-lymphoma cell apop-
tosis, monoclonal antibodies, 5022
galaptin-mediated
detection, cellular galaptin-binding
glycoproteins, 2667
hepatocytes
integrin $\alpha_6\beta_4$, TA3/Ha mammary car-
cinoma cells, 3611
laminin peptides
malignant properties, melanoma, 423
- Adhesion molecules**
CD54/CD11a and CD58/CD2
differential expression, human mela-
noma cells, 3343
cellular recognition mechanisms, 2192
gap junction function and cancer, 3475
- Adjuvants**

- carriers of immunogenicity in xenogeneic hosts
 - mouse anti-idiotypic monoclonal antibody MK2-23, 112
 - vaccinations with genetically engineered tumor cells
 - production of different cytokines, 714
- Adozelesin**
 - DNA alkylation
 - induction of CC-1065, *in vivo* mutagenesis, 5690
 - V79 cell resistance
 - multidrug resistance, 1354
- Adrenal cortex**
 - suramin
 - multiple potential mechanisms of action, 2239
- Adriamycin**
 - circumvention of multidrug resistance
 - direct binding to P-glycoprotein, thalidomide, 2544
 - enhanced activity
 - W-77, human ovarian carcinoma cells, 2051
 - pharmacokinetic and pharmacodynamic advantages
 - pirarubicin, VX2 tumor model, 1550
 - protection from cytotoxicity
 - brefeldin A, L1210 cells, 5237
 - resistant human tumor cells
 - M, 85,000 protein, complementary DNA, 2538
 - resistant P388 leukemia
 - DNA topoisomerase II α gene rearrangement, 5885
 - temperature-sensitive liposomal
 - hepatic artery, liver W256 carcinosarcoma, 3046
- Aerodigestive tract**
 - head and neck cancers and discordant *p53* gene mutations, 1676
 - neoplasms
 - chemoprevention strategies, 1469
- Aflatoxin B₁**
 - DNA adducts
 - detection in human placenta and cord blood, 1278
 - induced hepatic tumorigenesis
 - transient intervention, oltipraz, 3499
 - induced rat hepatic hyperplastic nodules
 - no site-specific mutation, *p53* gene, 9
 - resistance
 - expression of aldo-keto reductase, 3887
- Agaricus bisporus**
 - lectin
 - reversible inhibition of proliferation, epithelial cell lines, 4627
- Aging**
 - formation of small-cell colonies
 - cultures, primary rat hepatocytes, 3145
- AGM-1470: see** TNP-470
- AgSK1**
 - carcinoma-associated antigen, 1122
- Aldehyde reductase**
 - expression of aldo-keto reductase
 - resistance to aflatoxin B₁, catalytic activity, 3887
- Alkaline phosphatase**
 - mechanism of protective effect
 - supplemental dietary calcium, cytolytic activity of fecal water, 248
- Alkylamides**
 - inducers of human leukemia cell differentiation
 - structure-activity relationship, 766
- Alkylating agents**
 - damage increased by folate deficiency
 - γ -irradiation, Chinese hamster ovary cells, 5401
 - DNA damage induced by *N*-methyl-*N*-nitrosourea
 - fluorescence postlabeling assay, 2771
 - O*⁶-Alkylguanine-DNA alkyltransferase
 - expression by transformed Chinese hamster ovary cell line
 - specificity, bischloroethylnitrosourea-induced mutation, 997
 - single amino acid change
 - inactivation by *O*⁶-benzylguanine, 4750
- Alkyltransferase**
 - repair of *O*⁶-methylguanine and *O*⁴-methylthymidine
 - 1,2-dimethylhydrazine and *O*⁶-benzylguanine, rat liver, 3895
- Allele**
 - deletions in renal tumors
 - histopathological correlations, 5780
 - disease-causing *APC*
 - rapid screening method, nonsense and frame-shift mutations, 5581
 - Fv-1*^b
 - lymphomagenesis, congenic mice, 3433
 - loss of heterozygosity
 - invasive low-grade and high-grade epithelial ovarian carcinoma, 4456
 - 17p
 - loss in neural tumors, DNA hypermethylation, 2715
- Allografts**
 - renal
 - malignant transformation of cutaneous lesions, human papillomavirus, 5328
- American Cancer Society**
 - funding mechanisms for research, 2436s
- American Cancer Society Research Workshop**
 - cancer and nutrition, 2431s, 2432s
- Group A report**
 - cancer and nutrition, panel on human studies, 2449s
- Group B report**
 - cancer and nutrition, 2452s
- Group C report**
 - cancer and nutrition, cell and organ culture studies, 2455s
- Amines**
 - heterocyclic
 - cooked foods, possible human carcinogens, 2422
- 2-Amino-3,8-dimethylimidazo[4,5-*f*]quinoxaline**
 - intra- and interindividual variability
 - systemic exposure, cooked beef, 6075, 6076
- Amino acids**
 - glycine 363 change to cysteine
 - DNA topoisomerase I, camptothecin resistance, 4343
 - major CD44 proteins
 - different splice variants, metastatic rat tumor cell line, 1262
- position 95
 - allelic variation in dihydrofolate reductase gene, antifolate resistance, 6031
 - single change
 - O*⁶-alkylguanine-DNA alkyltransferase, inactivation by *O*⁶-benzylguanine, 4750
- 3-Amino-6-chloro-5-(1-homopiperidyl)-*N*-(diaminomethylene)-pyrazinecarboxamide**
 - lowering of intracellular pH
 - increased thermosensitivity, tumor cells, 1599
- 3-Amino-1-hydroxypropylidene-1,1-bisphosphonate**
 - treated rats
 - increased growth rate and tumor burden, Walker 256 cells, 5452
- 2-Amino-3-methylimidazo[4,5-*f*]quinoline**
 - inhibitory effect of *Bifidobacterium longum*
 - colon/mammary/liver carcinogenesis, 3914
- 2-Amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine**
 - intra- and interindividual variability
 - systemic exposure, cooked beef, 6075, 6076
- 6-Aminonicotinamide**
 - N*-(phosphonacetyl)-L-aspartate and 6-methylmercaptapurine
 - potentiation, radiation, 3518
- Aminopeptidase N**
 - biochemical and functional characterization
 - human melanoma cells, 1450
- Aminosugars**
 - immunosuppressive
 - deacetylase activity, human tumor cells, 5600
- Ammonia**
 - intermediate biomarker of carcinogenesis
 - proliferation, human colonic mucosa, 3283
- Ammonium trichloro(dioxyethylene-*O*-*O'*)tellurate: see** AS101
- Amonafide**
 - dosing based on acetylator phenotype
 - Phase I study, 2304
- Amphiregulin**
 - epidermal growth factor receptor
 - estrogen receptor expression and, primary breast cancer, 3597
- Amphotericin B**
 - modulation of cisplatin sensitivity
 - lung cancer cell lines, 3302
- Amsacrine**
 - drug resistance
 - temperature-sensitive topoisomerase II allele, 89
- Androgen**
 - induction of ovarian granulosa cell tumorigenesis
 - genetic susceptibility, SWXJ strains of mice, 1059
 - inhibition of cell proliferation
 - androgen receptor complementary DNA, PC-3 cells, 1304
 - ovaries from tumor-susceptible donors
 - granulosa cell tumorigenesis, genetically hypogonadal-immunodeficient

- mice, 3741
 receptor status of neuroendocrine cells
 benign and malignant prostatic tissue,
 1967
 -responsive Shionogi carcinoma cells
 growth, steroid hormones and opioid
 peptides, 4224
- Androstenedione**
 inhibition of *in vivo* conversion to es-
 trone
 vorozole, healthy postmenopausal
 women, 4563
 steroid production
 different parts, malignant and benign
 ovarian tumors, 2309
- Anemia**
 aplastic
 chronic radiation-induced alteration,
 hematopoietic repair, 4518
- Angiogenesis**
 antiangiogenic effects
 quinoline-3-carboxamide linomide,
 1833
 inhibition by antiestrogens, 533
 inhibitors
 heparin-steroid conjugates, antitumor
 activity, 3000
 inhibitor TNP-470
 inhibition of tumor growth, hormone-
 independent breast and prostate car-
 cinoma, 5233
 inhibition of tumor growth and metas-
 tasis, rodent tumors, 4262
 tumor growth and metastasis, human
 cell lines, 2566
 rat glioma model
 up-regulation of vascular endothelial
 growth factor, cognate receptors,
 5822
 relationship of endothelial cell prolifera-
 tion
 tumor vascularity, human breast can-
 cer, 4161
- Angiotensin II**
 induced hypertension
 tumor blood flow, interstitial fluid
 pressure, 2466
 mechanisms of change in tumor blood
 flow
 morphometry, 5528
- Anion channels**
 volume-regulated
 inwardly rectifying potassium chan-
 nels, small cell lung cancer cells,
 4156
- Annamycin**
in vitro cytotoxicity
 cellular pharmacology, DNA lesions,
 1583
- Annexin II**
 expression
 regulation during mammalian cell
 cycle, 6017
- Anthracycline**
 apoptosis induced by antibiotics
 P388 parent and multidrug-resistant
 cells, 1845
- Antibiotics**
 anthracycline
 induction of apoptosis, P388 parent
 and multidrug-resistant cells, 1845
 antitumor
- calicheamicins, monoclonal antibody
 conjugates, 3336
- Antibodies**
 bispecific
 cytolysis of leukemic B-cells, T-cells,
 4310
 delivery of saporin,
 targeting via CD22 in B-cell lym-
 phoma, 3015
 - β -lactamase conjugates
 site-specific prodrug activation, colon
 carcinoma xenograft models, 3956
- Antibody-dependent cell-mediated cytotoxic-
 ity**
 human carcinoma cells engineered with
 mAb genes
 self-reactive antibody expression, 3355
- Anticancer drugs**
 prevention of carcinogenicity
 metallothionein induction, 4767
 study of
 use of yeast, targeting of DNA topo-
 isomerases, 3591
- Antiestrogens**
 inhibition of angiogenesis, 533
 steroidal
 sensitivity to ICI 182,780, MCF7/
 LCC2 cells, 3229
- Antifolates**
 acquisition of resistance
 enhanced γ -glutamyl hydrolase activ-
 ity, 2227
 inhibitors
 thymidylate and purine synthesis,
 WiDr colonic carcinoma cells, 5697
- Antileukemic drugs**
 biochemical consequences
 resistance to tiazofurin, K562 cells,
 2344
- Antineoplastic drugs**
 mechanism of action
 anticancer drug-sensitive murine eryth-
 roleukemia clone, 1877
- Antioxidants**
 oxy radicals and
 cancer, 3207
 selenium status
 risk of lung cancer, 4860
- Antisense oligodeoxynucleotide**
 depletion of R1 α subunit
 cyclic AMP-dependent protein kinase,
 growth inhibition in cancer cells,
 868
- Antisense oligonucleotides**
 human papillomavirus type 18-specific
 transformed phenotype, human carci-
 noma cell lines, 2330
- Antitumor agents**
 induction of apoptosis
 susceptibility of HL-60 cells, cell cycle
 differences, 3186
- Aorta**
 endothelium-dependent relaxation
 photodynamic therapy, 2548
- Apoptosis**
 antiproliferative effects of isoflavones
 gastrointestinal tract, human cancer
 cell lines, 5815
 chemotherapy-induced
 specific proteolytic cleavage,
 poly(ADP-ribose) polymerase, 3976
 DNA strand breaks
- terminal deoxynucleotidyl transferase,
 nick translation assays, 1945
- doxorubicin-induced
 inhibition by 2-deoxy-D-glucose, 2057
 effects of cisplatin on induction
 proliferating hepatoma cells, nonproli-
 ferating immature thymocytes, 2133
- etoposide-induced
 inhibition by bcl-2 protein, topoiso-
 merase II-induced DNA strand
 breaks and their repair, 4251
- etoposide-induced cytotoxicity
 T-cell leukemic lines, 4287
 growth and
 transforming growth factor β 1, acute
 myelogenous leukemia, 3386
 induction by anthracycline antibiotics
 P388 parent and multidrug-resistant
 cells, 1845
 induction by anticancer drugs
 modulation by bcl-2, resistance to thy-
 midylate stress, 3321
 induction by N-(4-hydroxy-
 phenyl)retinamide
 malignant hemopoietic cell lines, no
 response to retinoic acid, 6036
 induction by nitrogen mustard and
 camptothecin
 modulation by bcl-2, 1853
 induction in Burkitt's lymphoma cells
 Gb3/CD77 glycolipid antigen, 5314
 insight on biology of neuroectodermal
 tumors, 926
 loss of p53-associated G1 checkpoint
 cell survival after DNA damage, 4164
 -mimetic drug
 bleomycin, two types of cell death,
 5462
 phospholipase activation
 photosensitized mouse lymphoma
 cells, 5897
 prevention by caffeine
 camptothecin or topotecan, HL-60
 cells, 4613
 protection
 HIV-1 Tat protein, 4481
 retroviral wild-type p53 expression vec-
 tor
 penetration of human lung cancer
 spheroids, 4129
 suppression in hemopoietic cells
 activation, Abelson tyrosine kinase ac-
 tivity, 1735
 suppression of GRP78 induction
 elimination of resistance, cell-mediated
 cytotoxicity, 6001
 susceptibility of HL-60 cells
 cell cycle differences, induction by var-
 ious antitumor agents, 3186
 T-lymphoma cell
 suppression, monoclonal antibodies
 against cell surface adhesion mole-
 cules, 5022
- 1- β -D-Arabinofuranosylcytosine**
 prolongation of drug exposure
 encapsulation into DepoFoam, cere-
 brospinal fluid, 1596
- Arachidonic acid**
 growth signal
 murine P815 mastocytoma cells, 3405
 modulation of metabolism
 sensitivity of tumoricidal function,

- macrophages, 3362
- Arginine vasopressin**
atrial natriuretic factor production and serum sodium, lung cancer cell lines, 67
- Aromatase**
inhibition of androstenedione conversion to estrone
vorozole, healthy postmenopausal women, 4563
inhibitor CGS 20267
Phase I study, postmenopausal advanced breast cancer, 266
- Arotinoid**
Ro 40-8757
all-*trans*- and 13-*cis*-retinoic acids, breast cancer, 2319
- Aryl hydrocarbon**
responsiveness
aryl hydrocarbon receptor and, human ovarian carcinoma cell lines, 1802
- AS101**
protective role
combined with several cytotoxic drugs, mechanisms of action, 5962
protection of bone marrow stromal cells
toxic effects of cyclophosphamide, ASTA-Z 7557 and etoposide, 1838
- A2780/S**
cellular pharmacology
liposomal *cis*-bis-neodecanoato-*trans*-*R,R*-1,2-diaminocyclohexane-platinum(II), 4913
- Ascites**
malignant
pathogenesis of formation, 2631
mice bearing human ovarian carcinoma xenografts
synthetic matrix metalloproteinase inhibitor, 2087
tumor and inflammatory effusions
vascular permeability factor, guinea pig and human, 2912
- Ascorbate**
free radicals
increased generation, L1210 cells exposed to edelfosine, 711
- Ascorbic acid**
oxy radicals and antioxidative responses in cancer, 3207
- Aspirin**
use
risk of fatal cancer, 1322, 6074
- Assays**
colorimetric *in situ* messenger RNA hybridization
epidermal growth factor receptor, colon carcinoma surgical specimens, 937
CYFRA 21-1
serum fragment of cytokeratin subunit 19, marker of lung cancer, 61
fluorescence postlabeling
DNA damage induced by *N*-methyl-*N*-nitrosourea, 2771
gel electrophoresis
quantification of hypoxic fraction, human breast cancer, 733
high-performance liquid chromatography
plasma pharmacokinetics, vinblastine and *N*-(deacetyl-*O*-4-vinblastoyl-23)-*L*-ethyl isoleucinate, 2061
- histoculture drug-response
"patient-like" treatment model, pancreatic cancer, 3070
measurement in serum
polyclonal and monoclonal anti-taxol antibodies, 1388
presence of transforming genes
gonadal tumors, bivalve mollusk species, 2976
terminal deoxynucleotidyl transferase and nick translation
detection of DNA strand breaks, individual apoptotic cells, 1945
- ASTA-Z 7557**
toxic effects
protection of stromal cells, AS101, 1838
- Astrocytoma**
human
accumulation, wild type p53 protein, 3465
oligodendrocyte-associated genes
glioma and neuroblastoma, 170
transfection with glial fibrillary acidic protein complementary DNA
expression, proliferation and tumorigenicity, 3624
- Ataxia-telangiectasia**
Fifth International Workshop, 438
gene in 64 families
premenopausal bilateral breast cancer, linkage analysis of *DRD2*, 5083
- Atomic bomb survivors**
in vitro irradiation
RET oncogene rearrangement, 2940
- Atrial natriuretic factor**
arginine vasopressin production and serum sodium, lung cancer cell lines, 67
- Atrial natriuretic peptide**
expression of functional receptors
human small cell lung cancer cell lines, 3165
- Autoradiography**
quantitative
spatial distribution of immunotoxins, solid tumors, 2092
urokinase receptor concentration, malignant and benign breast tumors, 3198
- Azaserine**
-induced preneoplastic lesions
cholecystokinin-A receptors, pancreas, 3925
- Azoxymethane**
carcinogenesis
chemopreventive effects of oltipraz, 2502
colon carcinogenesis
chemoprevention, organosulfur compounds, 3493
-induced biochemical changes
inhibitory effect, caffeic acid esters, 4182
- B**
- B669**
inhibition of cancer cell line proliferation
phospholipase A₂-mediated mechanisms, 318
- Bacillus Calmette-Guérin**
vaccine
delayed-type hypersensitivity reactions, tumor-associated antigens, 456
- Baculovirus**
recombinants
expression, human carcinoembryonic antigen gene, 2154
- BALB/3T3 cells**
transformation
tumor necrosis factor as tumor promoter, 1982
- Basement membrane**
biochemical and functional characterization
aminopeptidase N, 1450
expression of thrombospondin and its receptors
normal, hyperplastic and neoplastic breast, 1421
- BB-94**
synthetic matrix metalloproteinase inhibitor
decreased tumor burden, mice bearing human ovarian carcinoma xenografts, 2087
- B-cells**
cancer-defined epitopes
analysis of p53 antibodies, exposure on protein surface, 5872
control of HLA-DR antigen expression
 γ -interferons, thyroid cells, 3943
immune response
polymorphic epithelial mucin, 2457
leukemic
cytolysis by T-cells, bispecific antibodies, 4310
Ly-1⁺ and IgH rearrangements
"normal" spleens and lymphomas, AKR/J and AKR Fv-1^b mice, 2147
production of growth-promoting factor
wide target cell spectrum, THP-1 cells, 1871
- bcl-2**
modulation of apoptosis
induction by anticancer drugs, resistance to thymidylate stress, 3321
- BCL-2 protein**
enhanced survival of mouse fibrosarcoma cells
tumor necrosis factor-mediated cytotoxicity, 1456
inhibition of etoposide-induced apoptosis
topoisomerase II-induced DNA strand breaks, repair, 4251
- Beef, cooked**
intra- and interindividual variability
systemic exposure, carcinogens, 6075, 6076
- Benzene**
phenolic metabolites and
oxidative DNA damage, HL-60 cells and bone marrow, 1023
- Benzo(a)pyrene**
glucuronidation of carcinogen metabolites
complementary DNA-expressed uridine 5'-diphosphate glucuronosyltransferases, 1529
- Benzo(a)pyrene diol-epoxide**
DNA adduct in hepatocytes
inactivation, plasmid reporter gene expression, 2279
- Benzo[b]thiophene-2-carboxamides**

- 4-substituted
inhibition of urokinase, 2553
- Benzo[c]phenanthrene dihydrodiol epoxides**
stereoisomeric
sequence specificity, interaction with *supF* gene, 1273
- Benzophenoxazine**
analogues
phototoxicity and pharmacokinetics, EMT-6 cells, 2571
- Benzoquinazoline**
inhibitor 1843U89
biochemical and cellular pharmacology, 810
- O⁶-Benzylguanine**
1,2-dimethylhydrazine and repair of O⁶-methylguanine and O⁴-methylthymidine, rat liver, 3895
inactivation
single amino acid change, O⁶-alkylguanine-DNA alkyltransferase, 4750
with or without streptozotocin
1,3-bis(2-chloroethyl)-1-nitrosourea sensitivity, depletion of O⁶-methylguanine DNA methyltransferase activity, 4281
- BIBW 22**
bifunctional modulator on tumor cells
P-glycoprotein and nucleoside transport, 1974
- Bifidobacterium longum**
inhibitory effect
induction by a food mutagen, colon/mammary/liver carcinogenesis, 3914
- Bile**
glycoprotein
CEA-related gene, down-regulation in malignant mouse tissues, 4938
differential regulation of carcinoembryonic antigen, γ -interferon, 1612
- Biochanin A**
antiproliferative effects of isoflavones
gastrointestinal tract, human cancer cell lines, 5815
- Biochemistry**
derivation of etiology from human-based studies, 2437s
- 2,2'-Bipyridyl-6-carbothioamide**
ferrous complex and
antitumor activity, inhibition of ribonucleotide reductase R2 subunit, 19
- Bis-aceto-ammine-dichloro-cyclohexylamine platinum(IV)**
preclinical antitumor evaluation, 2581
- Bischloroethylnitrosourea**
-induced mutation in Chinese hamster ovary cells
O⁶-alkylguanine-DNA alkyltransferase expression, 997
- 1,3-Bis(2-chloroethyl)-1-nitrosourea**
resistance
contribution of glutathione transferase M3-3, non-small cell lung cancer cell line, 4257
sensitivity
depletion of O⁶-methylguanine DNA methyltransferase activity, O⁶-benzylguanine with or without streptozotocin, 4281
- Bis-diol-epoxide**
metabolic activation of dibenz[a,h]anthracene
- DNA-binding species, mouse skin, 944
- 1,19-Bis-(ethylamino)-5,10,15-triazanonecane**
interaction with DNA and effect on growth
human brain tumor cell lines, 3948
- N¹,N¹-Bis(ethyl)norspermine**
antitumor activity
human melanoma xenografts, possible correlates of drug action, 581
- N¹,N¹²-Bis(ethyl)spermine**
growth inhibition
hormone-responsive and -resistant human breast cancer, 2071
- Bismuth**
-DOTA-conjugated anti-Tac antibody α -emitter therapy, 5683
- cis-Bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II)**
liposomal
cellular pharmacology, A2780/S and A2780/PDD cells, 4913
- Bisphosphonate**
-treated rats
increased growth rate and tumor burden, Walker 256 cells, 5452
- Bladder**
human
penetration of mitomycin C, 3314
urothelial cells
influence on cellular processes, altered extracellular matrices, 4971
- Bladder neoplasms**
distinct pattern of p53 mutations
relationship to tobacco usage, 1162
heterogeneity
erbB-2 gene amplification, 2199
infrequency of H-ras mutation, 133
microsatellite instability, 5620
modulation of cisplatin nephrotoxicity and drug resistance
control of metallothionein synthesis, 1829
poor survival
decreased E-cadherin immunoreactivity, 3241
preliminary mapping
deleted region of chromosome 9, 1230
role of chromosome 9, 4066
suppressor loci
human chromosome 9, 5093
tumor grade and invasion
levels of matrix metalloproteases, 5365
- Blasts**
primary clonogenic
radiation damage repair capacity, acute lymphoblastic leukemia, 1431
- Bleomycin**
apoptosis-mimetic drug
two types of cell death, number of molecules internalized, 5462
iododeoxyuridine and
Phase I clinical and pharmacological study, advanced cancer, 1293
- Blood**
cord
detection, aflatoxin B₁-DNA adducts, 1278
- Blood flow**
heat-induced changes
influence of vascular thermotolerance, cell survival in tumors, 2076
- reduction in tumors
high-energy shock waves, 1590
- tumor
microvascular mechanisms, morphometry, 5528
- Blood group A antigen**
incompatible histobiosynthetic basis, gastric cancer tissue of type O individuals, 5494
- Bloom's syndrome**
elevated production of active oxygen, 5104
malignantly transformed cells
mucinous ovarian cancer antigen, 3427
- Bone**
biological response
1,25-dihydroxyvitamin D₃ and two analogues, 3935
metastasis
parathyroid hormone-like protein gene expression, breast cancer, 5076
- Bone marrow**
chronic myelogenous leukemia
lineage-negative blast subpopulations, c-kit ligand, 401
detection of AML1/ETO fusion transcript
t(8;21) masked translocation, acute myelogenous leukemia, 4449
eradication of small cell lung cancer cells
immunotoxins, 3784
irradiated human
effect of stem cell factor, 3857
micrometastasis
immunocytological detection, operable non-small cell lung cancer, 1027
oxidative DNA damage
benzene and phenolic metabolites, 1023
protection of stromal cells from toxic effects
AS101, 1838
removal of breast cancer cells
in vitro purging, ether lipids and cryopreservation, 3747
sequential impact on enzymic program
tiazofurin and ribavarin, 5982
transplantation
acceleration of granulocyte recovery, G-CSF and metastatic breast cancer, 5424
transplantation and Phase I trial
carboplatin/etoposide/cyclophosphamide, refractory germ cell tumors, 3730
- Boron neutron capture theory**
intracerebral melanoma
boronophenylalanine as a capture agent, 3308
- Bovine serum albumin**
-doxorubicin conjugate
multidrug resistance, rat hepatoma, 4238
- Brain**
drug delivery
controlled release polymers, interstitial chemotherapy, 329
elevated levels
M_r 92,000 type IV collagenases, 2208
experimental cerebral metastases

- murine melanoma B16, protection with active immunization, 1113
- fetal rat cells
- migratory pattern, human glioma cells in adult rat brain, 5158
- metastases
- metastasis-related CD44 expression, not in glioblastomas, 5345
- NCr/Sed-nu/nu nude and scid mice
- transplantability, human and murine tumors, 5018
- Brain neoplasms**
- associated cyst fluids
- immunodetection, endogenous opioid peptides, 4715
- characterization of insulin-like growth factor 1, 2475
- disseminated tumor growth
- quantitative analysis, *lacZ* reporter gene, 176
- interaction of polyamine analogue and DNA, 3948
- O*⁶-methylguanine-DNA methyltransferase activity, 3416
- pediatric
- efficacy, transferrin receptor-targeted immunotoxins, 1348
- retroviral-mediated gene transfer, 83
- Breast**
- epithelial cells
- protein tyrosine phosphatases, *neu* transformation, 2272
- fibroadenoma and phyllodes tumor clonal analysis, 4071
- normal/hyperplastic/neoplastic expression, thrombospondin and its receptor, 1421
- Breast neoplasms**
- advanced
- cyclophosphamide/doxorubicin/5-fluorouracil, plus interferon- α 2b, 3509
- postmenopausal patients, Phase I study of CGS 20267, 266
- associated mucin fusion protein
- Escherichia coli*, tumor-specific epitope, 4920
- breast/ovarian cancer locus
- deletion unit on chromosome 17q, epithelial ovarian tumors, 1218
- chemotherapy and bone marrow transplantation
- acceleration of granulocyte recovery, granulocyte colony-stimulating factor, 5424
- detailed deletion mapping
- chromosome 17q, 3382
- ductal carcinoma *in situ*
- allelic loss, chromosome 17, 2947
- estradiol induction
- retinoic acid receptors, 5841
- estrogen-negative cell line
- constitutively active estrogen receptor variant, 5934
- estrogen receptor expression
- amphiregulin, epidermal growth factor receptor, 3597
- estrogen-responsive
- estrogen receptor variant messenger RNA lacking exon 4, 741
- exon 5 deletion variant of estrogen receptor
- coexpression, wild-type estrogen receptor, 5882
- expression of E-cadherin cell adhesion molecules
- relationship to metastasis, 1696
- favorable prognosis
- cell surface antigen LEA.135, 3233
- growth and drug resistance
- small heat shock protein hsp27, 4443
- growth and lung metastasis
- diets containing different linoleic acid levels, 4686
- growth suppression of MCF-7 cells
- 2,3,7,8-tetrachlorodibenzo-*p*-dioxin, 3149
- high proliferative capacity
- c-myc* amplification, 1956
- hormone-dependent
- matrix-degrading enzyme protease, 1409
- hormone-responsive and -resistant
- growth inhibition, *N*¹,*N*¹²-bis(ethyl)spermine, 2071
- human primary
- distinct regions, 1p deletion, 1990
- increase in *M*, 92,000 type IV collagenase
- plasma, 140
- induction of *jun* gene family members
- not 17 β -estradiol, 291
- inhibition of estrone sulfatase activity
- estrone-3-methylthiophosphonate, 298
- lowering of plasma insulin-like growth factor I levels
- fenretinide, 4769
- low risk
- insulin-like growth factor-I, 3736
- malignant and benign
- urokinase receptor concentration, quantitative autoradiography, 3198
- MCF7/LCC2 cells
- sensitivity to ICI 182,780, 3229
- multidrug-resistant
- flavonol-stimulated efflux, 7,12-dimethylbenzanthracene, 5977
- node-negative
- HER-2/*neu* expression, 4960
- normal cells and
- nuclear matrix proteins, 3394
- normal luminal mammary epithelial cells and
- differential isolation, primary and metastatic sites, 627
- parathyroid hormone-like protein gene expression
- PCR analysis, 5076
- peritumoral tissues and
- main drug-metabolizing enzyme systems, 3541
- postmenopausal
- risk of, dietary fat, 75
- premenopausal bilateral
- linkage analysis of *DRD2*, ataxia-telangiectasia gene, 5083
- linkage analysis of D17S74, thirty-five families, 212
- production of immunoreactive endothelin 1
- stimulation by interleukin 6, 464
- putative tumor marker, 1751
- quantification of hypoxic fraction
- gel electrophoresis, individual cells, 733
- refinement of regional loss of heterozygosity
- chromosome 11p15.5, 4486
- relationship of endothelial cell proliferation
- tumor vascularity, 4161
- removal of cells from bone marrow
- in vitro* purging, ether lipids and cryopreservation, 3747
- role of cathepsin D in invasiveness, 873
- suramin
- multiple potential mechanisms of action, 2239
- therapeutic effects
- Ro 40-8757, all-*trans*- and 13-*cis*-retinoic acids, 2319
- Brefeldin A**
- protection from Adriamycin cytotoxicity
- L1210 cells, 5237
- Bromodeoxyuridine**
- labeling and flow cytometry
- tamoxifen-induced increase in doubling time, MCF-7 xenografts, 4413
- Bronchial epithelial cells**
- altered chromosomal methylation patterns
- oncogene-induced transformation, 1684
- immortalized human
- biological consequences of overexpression, *c-erbB-2* gene, 2035
- simian virus 40-immortalized
- development of tumorigenicity, 985
- Bronchial neoplasia**
- early
- p53 protein accumulation, 4817
- BR96 sFV-PE40**
- selective killing of carcinoma cells, 334
- Bryostatins**
- 1
- in vivo* administration
- platelet and neutrophil activation, modulation of protein kinase C activity, 2810
- T-cell-induced tumor regression
- γ -interferon, 833
- Buccal cells**
- cancer patients
- carboplatin and cisplatin chemotherapy, drug-induced DNA modification, 5669
- Busulfan**
- high-dose
- chronopharmacology, children, 1534
- Butanol**
- extraction and nuclease P1 versions of ³²P postlabeling
- tobacco smoking, DNA adducts in human oral tissue, 1522
- Buthionine sulfoximine**
- variable baseline γ -glutamylcysteine synthetase mRNA expression
- peripheral mononuclear cells, 3662
- L-Buthionine sulfoximine**
- glutathione depletion
- antagonism, taxol cytotoxicity, 2066
- Butylated hydroxyanisole**
- 3-methoxycatechol or
- sodium nitrite and catechol, rat multiorgan carcinogenesis model, 32
- styrene 7,8-oxide and
- induction of cell proliferation, fore-

- stomach, 3505
- Butyrate**
intermediate marker of carcinogenesis
proliferation, human colonic mucosa,
3283
- BW12C79**
left-shifting agent
mitomycin C and, skeletal muscle me-
tabolism and magnetic resonance
spectroscopy, 5649
- Bystander effect**
tumor regression
fraction of tumor mass genetically
modified, 5274
- C**
- CA 19-9**
urokinase-type plasminogen activator an-
tigen
clinical value of determination, colo-
rectal cancer, 1788
- Caco-2 cells**
insertion of human Ha-ras or polyoma
virus middle T oncogenes
increased protein kinase C α expres-
sion, 2762
- E-Cadherin**
cell adhesion molecules
expression in breast cancer tissues, re-
lationship to metastasis, 1696
correlation of expression with invasive-
ness
esophageal cancer cell line, 3421
decreased immunoreactivity
poor survival, bladder tumors, 3241
-dependent cell-cell adhesion
blockage of, stimulation of urokinase-
type plasminogen activator expres-
sion, 3618
differentiation marker
thyroid malignancies, 4987
expression in primary and metastatic
gastric cancer
down-regulation, cellular dedifferentia-
tion, 1690
reduction of levels
deletion of α -catenin gene, prostate
cancer cells, 3585
- Caffeic acid esters**
inhibitory effect
azoxymethane-induced biochemical
changes, aberrant crypt foci, 4182
- Caffeic acid phenethyl ester**
inhibition of tumor promoter-mediated
processes
mouse skin, bovine lens, 1255
- Caffeine**
induction by hyperthermia and hot mate
infusion
mutagenicity, *Saccharomyces cerevis-
iae*, 5750
prevention of apoptosis and cell cycle ef-
fects
camptothecin or topotecan, HL-60
cells, 4613
release of radiation-induced S and G₂
phase arrest
histone messenger RNA levels, V79
cells, 1507
- Calcitriol**
TPA-induced tumorigenic transforma-
tion
- osteopontin expression, mouse JB6
epidermal cells, 2217
- Calcium**
control of HLA-DR antigen expression
 γ -interferons, thyroid cells, 3943
dietary
antiproliferative effect, colonic epithe-
lium, 784
mechanism of protective effect, cytol-
ytic activity of fecal water, 248
inhibition of multidrug resistance by
NA-382, 1555
intermediate biomarker of carcinogenesis
proliferation, human colonic mucosa,
3283
mobilization and clonal growth
CCK_A and CCK_B, small cell lung can-
cer lines, 5208
reversal of hypercalcemia
neutralizing antibodies to interleukin
6, human squamous carcinoma, 737
-transporting ATPase isoform 2 gene
cloning, von Hippel-Lindau syndrome,
861
- Calcium leucovorin**
5-fluorouracil and
N-(phosphonacetyl)-L-aspartate combi-
nation, metastatic gastrointestinal
adenocarcinoma, 4828
- Calceylin**
expression in melanocytic lesions, 6061
- Calicheamicins**
preparation and characterization
monoclonal antibody conjugates, 3336
- Calmodulin**
control of HLA-DR antigen expression
 γ -interferons, thyroid cells, 3943
- Camptothecin**
9-amino and 10,11-methylenedioxy de-
rivatives
pharmacokinetics, mice, 3062
hypersensitivity of Cockayne's cells
double strand breaks, nascent DNA,
2012
induction of apoptosis and cell cycle ef-
fects
caffeine, HL-60 cells, 4613
modulation by *bcl-2*, 1853
resistance from a single mutation
glycine in DNA topoisomerase I to
cysteine, 4343
- Cancer**
-associated mucin epitope
clinical evaluation, M43, 2803
derivation of etiology from human-based
studies, 2437s
diet and nutrition
development of hypotheses, evaluation
in animal studies, 2442s
elevated expression
human mitochondrial hinge protein
gene, 2460
nutrition and
American Cancer Society Research
Workshop, 2431s, 2432s
cell and organ culture studies, Ameri-
can Cancer Society Research Work-
shop, 2455s
panel on animal studies, American
Cancer Society Research Workshop,
2452s
panel on human studies, American
Cancer Society Research Workshop,
2449s
problem
prevention, therapy and basic science,
5890
- Canventol**
inhibition of tumor promotion in CD-1
mouse skin
inhibition of tumor necrosis factor α
release, protein isoprenylation, 3462
- Carbohydrate**
diet restrictions
inhibition, skin tumor promotion, 27
incompatible histo-blood group A anti-
gen expression
biosynthetic basis, gastric cancer tissue
of type O individuals, 5494
- Carbohydrate antigens**
blood group Le^b
subcellular localization, endometrial
cancer cells, 3643
sialyl Lewis A and X
adhesion of human cancer cells, vascu-
lar epithelium, 354
- Carbonic anhydrase**
-like domain of *Ptpng* gene
homozygous deletion, murine L-cells,
1498
- Carboplatin**
cisplatin and
drug-induced DNA modification, buc-
cal cells of cancer patients, 5669
etoposide and cyclophosphamide
Phase I trial with autologous bone
marrow transplantation, refractory
germ cell tumors, 3730
- 1-Carboxymethyl-2-iminoimidazolidine**
inhibition of growth
broad spectrum of cancer cells, solid
tumors, 3172
- Carcinoembryonic antigen**
biliary glycoprotein and
differential regulation, γ -interferon,
1612
gene expression
baculovirus recombinants, 2154
improved radioimmunotherapeutic effi-
cacy
¹³¹I-CC49 and γ -interferon, 600
monoclonal antibodies
specificity, CEA-mediated adhesion,
3817
-related gene
biliary glycoprotein, down-regulation
in malignant mouse tissues, 4938
site-specific prodrug activation
antibody- β -lactamase conjugates, co-
lon carcinoma xenograft models,
3956
urokinase-type plasminogen activator an-
tigen
clinical value of determination, colo-
rectal cancer, 1788
- Carcinogenesis**
accumulation of p53 protein
human esophageal precancerous le-
sions, 1783
colonic
chemoprevention, organosulfur com-
pounds, 3493
chemoprevention, protocatechuic acid,
3908

- colon/mammary/liver
inhibitory effect of *Bifidobacterium longum*, food mutagen, 3914
- 7,12-dimethylbenzanthracene
flavonol-stimulated efflux, multidrug-resistant breast cancer cells, 5977
- early markers in head and neck cancer
transforming growth factor α , epidermal growth factor receptor messenger RNA, 3579
- environmental
prevention of, head and neck cancer, 2189
- expression of sulfated glycoprotein 2
induction by *N*-nitroso-*N*-methylurea, prostate and seminal vesicle, 1480
- familial breast/ovarian cancer locus
deletion unit on chromosome 17q, epithelial ovarian tumors, 1218
- fidelity of DNA replication
extracts, normal and malignantly transformed human cells, 3270
- genetic predisposition
transplacentally induced renal cell carcinoma, Eker rat, 5856
- induction by azoxymethane
chemopreventive effects of oltipraz, 2502
- liver
chromosome mapping, murine susceptibility loci, 209
- modification of
identification and characterization of agents, cell and organ cultures, 2446s
- mutated p53
tumor-distant epithelia, squamous cell carcinoma, 4189
- nickel
induction of signature mutation, oxygen free radical damage, 4172
- oral
chemoprevention with DL- α -difluoromethylornithine, tongue neoplasms, 772
- HPV-16, *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine, 4811
- oxy radicals and antioxidant responses in cancer, 3207
- pancreatic
caloric restriction and intervention, 46
- possible roles of metallothionein, 922
- proliferation of human colonic mucosa
intermediate biomarker, 3283
- rat multiorgan model
sodium nitrite and catechol, 3-methoxycatechol or butylated hydroxyanisole, 32
- reduction in formation and growth
1,2-dimethylhydrazine-induced aberrant crypt foci, 2786
- skin
malignant progression, suprabasal expression of $\alpha 6 \beta 4$ integrin, 4803
- studying clonal heterogeneity in human cancers, 921
- tamoxifen
Alderley Park Wistar-derived rats, 3919
- tobacco
dietary fat, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, 2758
- UV-sensitive Chinese hamster ovary mutant cell line
identification of cellular defect, 495
- Carcinogenicity**
induction of renal carcinoma by phenacetin
hydronephrosis-bearing rats of SD/cShi strain, 4218
- 4-nitroquinoline-*N*-oxide
potent intracellular oxidative stress, 3250
- prevention
anticancer drugs, metallothionein induction, 4767
- transplacental
cisplatin, SENCAR mice, 3874
- Carcinogens**
chemical
different susceptibilities, cell lines from *gpc* congenic rat strains, 4089
- chemointervention strategies
A/J mouse lung as a model, 410
- chromatophoromas and chromatophore hyperplasia
Pacific rockfish, 1761
- clarification
scientific evidence and speculation, 4107
- clonal analysis of multiple transformed phenotypes
tumorigenicity, 10T $\frac{1}{2}$ cells, 500
- cooked beef
intra- and interindividual variability, systemic exposure, 6075, 6076
- glucuronidation of metabolites
complementary DNA-expressed uridine 5'-diphosphate glucuronosyltransferases, 1529
- heterocyclic amines in cooked foods, 2422
- initiation of pancreatic cancer
DNA damage, repair and cell proliferation, 2790
- metabolizing enzyme systems
non-small cell lung cancer, peritumoral tissues, 4608
- 6-nitrochrysene
induction of mammary cancer, 3719
- phenobarbital/3-methylcholanthrene/dithiolethiones
glutathione *S*-transferase class α transcripts, hepatocytes, 231
- potentiation of genetic damage
folate deficiency, Chinese hamster ovary cells, 5401
- transformation of Syrian hamster embryo fibroblasts
amplification potential, 3098
- Carcinoid neoplasms**
pulmonary
infrequent mutations, p53 gene, 5797
- Carcinoma**
adenoid cystic cells
extracellular matrix production and degradation, plasminogen activator, 147
- associated antigen AgSK1, 1122
- inhibition of skin tumor promotion
restriction, fat and carbohydrate calories, 27
- motility
response to thrombospondin, met-
- astatic potential, 378
- neuroendocrine
stable expression of peripherin, 1175
- rapid screening method
nonsense and frame-shift mutations, disease-causing APC alleles, 5581
- selective cell killing
BR96 sFV-PE40, 334
- Wilms' tumor and
heparin-binding growth/differentiation factors, 1281
- Carcinoma, breast**
antibody response
c-erbB-2 oncoprotein, 5864
- antitumor effect of 22-oxa-calcitriol
synergism with tamoxifen, 2534
- cell cycle arrest and growth inhibition
UCN-01, 2081
- cytosolic extracts
urokinase-type plasminogen activator, PAI-1, 2513
- differential expression
p53-binding protein MDM2 gene, 3226
- ductal
receptor for urokinase, tumor-associated macrophages, 1911
- estrogen receptor-negative
transcriptional control, estrogen receptor, 3472
- expression of thrombospondin and its receptors, 1421
- familial
deletions in chromosome 16, development of distant metastases, 3707
- loss of heterozygosity, 4356
- favorable prognosis
cell surface antigen LEA.135, 3233
- hormone-independent
inhibition of tumor growth, angiogenesis, 5233
- human chromosome 14q32 expression
interferon- α -inducible gene, 4096
- inhibition of cellular growth
O-phospho-L-tyrosine, activation of protein tyrosine phosphatases, 557
- invasive
p53 mutations, histological type, 4665
- metastatic
allelotyping and clonal analysis, limited genetic heterogeneity, 3804
- primary
frequent deletion, three regions on chromosome 17q, 5617
- regression
9-nitrocarnitocin-treated immunodeficient mice, 1577
- regulation of fibroblast hepatocyte growth factor/scatter factor
peptide growth factors, 1233
- somatic p53 mutations
Icelandic population, 1637
- urokinase receptor concentration
quantitative autoradiography, 3198
- Carcinoma, colonic**
antitumor activity
5-fluoro-2'-deoxyuridine \pm N-phosphonoacetyl-L-aspartate, 1560
- associated increase
mucin-bound sialyl-Lewis^x expression, altered glycosylation of MUC-1 protein core, 4082

- associated mucins
 - epitope on α 3/4-monofucosylated polylactosaminoglycans, monoclonal antibody FW6, 4367
- cell line differentiation and growth inhibition
 - 1,25-dihydroxyvitamin D₃ receptor as a marker, 3712
- discrimination of MUC1 mucins
 - other sialyl-Le^x-carrying glycoproteins, monoclonal antibody, 755
- locus of interaction
 - 5-fluorouracil, leucovorin and interferon- α 2a, 4243
- neopterin and prognosis, 260
- paraffin-embedded surgical specimens
 - colorimetric *in situ* messenger RNA hybridization, epidermal growth factor receptor, 937
- sensitivity of human cells
 - mild hyperthermia, 2740
- WiDr cells
 - cytotoxicity of antifolate inhibitors, thymidylate and purine synthesis, 5697
- xenograft models
 - site-specific prodrug activation, antibody- β -lactamase conjugates, 3956
- Carcinoma, colorectal**
 - antitumor activity of 5-fluorocytosine expression of cytosine deaminase, 4619
 - cyclin gene amplification, 1986
 - early growth response gene
 - ubiquitin-ribosomal protein S27a gene, 1916
 - growth inhibition by interleukin 1
 - enhanced expression, γ -interferon receptors, 636
 - hereditary non-polyposis syndrome
 - microsatellite instability, 5853
 - increased expression
 - sialyl Lewis^x antigen, poor survival, 3632
 - signal-transducing ζ chains
 - tumor-infiltrating T-cells and NK cells, 5610
 - specific targeting and killing activities
 - anti-P-glycoprotein monoclonal antibody MRK16, 5475
 - suspected
 - tumor detection, ¹³¹I-labeled monoclonal antibody COU-1, 5920
 - TGF- α production and autoinduction
 - epidermal growth factor receptor gene, 1630
 - two tumor suppressor genes
 - chromosome 8p, 1172
- Carcinoma, embryonal**
 - cis*-diamminedichloroplatinum(II)
 - resistance *in vitro* and *in vivo*, 5707
- Carcinoma, endometrial**
 - genetic instability of microsatellites, 5100
 - mutation of Ki-ras protooncogene, 1906
- Carcinoma, epidermoid**
 - xenografts
 - preclinical evaluation, ¹¹¹In-labeled B3 monoclonal antibody, 2834
- Carcinoma, esophageal**
 - altered messenger RNA
 - mutational profiles, p53 and Rb, 1889
- Carcinoma, gastric**
 - autocrine growth stimulator
 - interleukin 1 α , 4102
 - genetic changes at p53
 - base transitions, 2614
 - hepatocellular carcinoma and
 - ribosomal protein mRNAs, colonic carcinoma, 4048
 - intestinal and diffuse-type
 - differential expression, CD44 splice variants, 4197
 - Signet ring cell
 - T-cell receptor V region gene usage, CTL and TIL, 3078
- Carcinoma, gastrointestinal**
 - immunoelectron microscopic localization
 - transforming growth factor- β 1, binding protein, 183
- Carcinoma, hepatocellular**
 - aflatoxin B₁-induced hepatic hyperplastic nodules
 - no site-specific mutation, p53 gene, 9
 - carcinogenicity study
 - Alderley Park Wistar-derived rats, 3919
 - early detection
 - lectin-reactive α -fetoproteins, 5419
 - frequent multiplication
 - long arm of chromosome 8, 857
 - gastric carcinoma and
 - ribosomal protein mRNAs, colonic carcinoma, 4048
 - p53 expression
 - tumor growth, invasiveness, 4691
 - rejection of
 - immune reactions, hepatitis B viral antigens, 4648
 - risk of
 - elevated serum testosterone levels, 790
 - role and mutational heterogeneity
 - p53 gene, 368
 - splicing mutations of p53 gene, 1653
 - sugar chains
 - human cord serum α -fetoprotein, 2970
 - tumor progression
 - mediation by p53 mutation, 2884
- Carcinoma, lung**
 - marker for susceptibility
 - glutathione S-transferase μ polymorphism, 2313
 - sensitivity of human cells
 - mild hyperthermia, 2740
 - stimulation of proliferation
 - insulin-like growth factor-I, lung fibroblast-derived IGF-I, 3399
- Carcinoma, mammary**
 - alkylator-induced toxicity
 - glutathione S-transferase cDNA, 4900
 - suppressor gene *Mcs*
 - cloning of overexpressed genes, 5766
 - TA3/Ha cells
 - integrin $\alpha_6\beta_4$, adhesion to hepatocytes, 3611
- Carcinoma, non-small cell lung**
 - DT-diaphorase gene expression
 - cigarette smoking as determinant, 5458
 - mutated epidermal growth factor receptor, 3217
- Carcinoma, ovarian**
 - aryl hydrocarbon receptor
 - aryl hydrocarbon responsiveness, 1802
- enhanced Adriamycin activity
 - bifunctional inhibitor W-77, 2051
- galaptin-mediated adhesion
 - cellular galaptin-binding glycoproteins, 2667
- high-grade
 - adjacency of benign or low-grade malignancies, molecular characteristics, 4138
- invasive low-grade and high-grade epithelial
 - comparison, loss of heterozygosity, 4456
- kinetics and tissue distribution
 - radiolabeled chimeric monoclonal antibody MOv18 IgG, F(ab')₂ fragments, 5413
- p53 mutation
 - common genetic event, 2128
- progressive
 - synthesis of types I and III procollagens, tumor tissue and peritoneal cavity, 5028
- xenografts
 - decreased tumor burden, synthetic matrix metalloproteinase inhibitor, 2087
 - fenretinide effectiveness, potentiation of cisplatin activity, 5374
- Carcinoma, prostatic**
 - genotypic characterization, 4035
 - growth factor regulation of gene expression, 1051
 - hormone-independent
 - inhibition of tumor growth, angiogenesis, 5233
 - loss of expression and heterozygosity
 - suppressor gene *DCC*, 2723
- Carcinoma, renal cell**
 - chromosome 17p deletions
 - p53 mutations, 3092
 - estrogen-induced
 - increase, insulin-like growth factor 1 receptors, 2256
 - familial
 - genetic and physical map of chromosome 3p, translocation, 3118
 - glycolipid sulfoltransferase activity levels
 - regulation, involvement of protein kinase C, 2484
 - infiltration of T-cells
 - production, interleukin 2 and receptors, 5828
 - inhibition of cellular growth
 - O-phospho-L-tyrosine, activation of protein tyrosine phosphatases, 557
 - loss of T-cell receptor ζ chain
 - p56^{lck}, 5613
 - metastasis
 - oligoclonal T-cell response, vaccination with autologous tumor cells, 4745
 - pelvic
 - induction by phenacetin, hydronephrosis-bearing rats of SD/cShi strain, 4218
 - regulation of activity levels
 - glycolipid sulfoltransferases, transforming growth factor α , 5638
 - T-cell infiltration
 - poor proliferative response, 1380
 - transplacentally induced

- genetic predisposition, Eker rat, 5856
tumor-specific lysis
tumor-infiltrating lymphocytes, 4020
- Carcinoma, skin**
basal cell
distinct infrared spectroscopic patterns, 762
- Carcinoma, small cell lung**
compensatory occurrence of IV²Fuα, II³NeuAcα-Gg₄Cer
human fetal antigen Lc₄Cer, small cell lung carcinoma, 5903
stimulation of serotonergic autocrine loop
nicotine, 5566
topoisomerase II as a drug target
atypical multidrug resistance, 1064
- Carcinoma, squamous cell**
adult
infrequency of MDM2 gene amplification, pediatric solid tumors, 6028
chromosome changes
in vitro response to radiation, 5542
- esophageal**
loss of 17p, *p53* gene mutation and *p53* protein overexpression, 846
TP53 gene mutation, 5745
β-fibroblast growth factor expression
regional endothelial cell proliferation, 1444
- head and neck**
culture conditions, chromosome abnormalities, 2140
E48 and IgG-mediated therapy, xenografts, 3524
environmental carcinogenesis and its prevention, 2189
immunotargeting, monoclonal antibody U36, 4383
incidence, *p53* mutations, 4477
local invasiveness, increased stromelysin 3 gene expression, 165
peritumoral IL-2 injections, local and systemic activation of immune cells, 5654
pharynx preservation, cancer chemoprevention, 5113
p53 mutation, lack of correlation with radiosensitivity, 3667
restricted specificity, human cytotoxic T-cell lines, 1461
three discrete regions of deletion, 3p, 5775
transforming growth factor α, epidermal growth factor receptor messenger RNA, 3579
- interaction between UVA and UVB**
hairless mice, 4212
- lung**
serum fragment of cytokeratin subunit 19, CYFRA 21-1, 61
multicellular tumor spheroids
enhancement, heme oxygenase expression, 2700
protection against malignant conversion of benign papillomas
polyphenolic fraction, green tea, 5409
reversal of hypercalcemia
neutralizing antibodies to human interleukin 6, 737
suppression of proliferation
Z-4',5'-didehydro-5'-deoxy-5'-fluoro-adenosine, 6058
tumor-distant epithelia
mutated *p53*, 4189
- Carcinoma, transitional cell**
bladder
local control, differences in DNA supercoiling, 2300
epidermal growth factor receptor
autocrine and paracrine stimulation, 5300
urinary bladder
high-risk human papillomavirus infections, *p53* overexpression, 4823
- Carcinoma cells**
human papillomavirus type 18-specific antisense oligonucleotides
transformed phenotype, 2330
role of carrier ligand
platinum resistance, 799
self-reactive antibody
monoclonal antibody genes, 3355
Shionogi
growth, steroid hormones and opioid peptides, 4224
- Carcinoma, liver**
W256
temperature-sensitive liposomal Adriamycin, hepatic artery, 3046
- Cardiotoxicity**
mitoxantrone
inhibition by ICRF-187, neonatal rat heart cells, 550
- β-Carotene**
chemoprevention strategies
lung and upper aerodigestive tract cancer, 1469
inhibition of rectal mucosal ornithine decarboxylase
colon cancer, 3723
selenium status
risk of lung cancer, 4860
- Carotenoids**
serum micronutrients
subsequent risk, oral and pharyngeal cancer, 795
vegetables and fruit
lung cancer, Iowa Women's Health Study, 536
- Casein**
cloning of overexpressed genes
mammary carcinoma suppressor gene, 5766
- Cataract**
bovine lens and mouse skin
inhibition of tumor promoter-mediated processes, caffeic acid phenethyl ester, 1255
- Catechol**
sodium nitrite and
3-methoxycatechol or butylated hydroxyanisole, rat multiorgan carcinogenesis model, 32
- α-Catenin**
deletion of gene
reduction of E-cadherin levels, prostate cancer cells, 3585
- Cathepsin D**
mannose-6-phosphate/IGFIII receptor and
benign and malignant mammary tumors, 2901
role in invasiveness
human breast cancer cells, 873
- Cathepsin G**
mechanism of neutrophil-mediated lysis
human neuroblastoma cells, 362
- CC-1065**
induction of *in vivo* mutagenesis
adozelesin DNA alkylation, 5690
- CD4**
autoreactive and heat shock protein 60
antitumor activity, syngeneic fibrosarcoma, 106
-dependent mechanism
development of tumor-reactive cytotoxic cells, interleukin 3, 2112
- CD8**
peptide-induced
target, mutant *p53* tumor suppressor protein, 3257
- CD11a**
binding of intestinal intraepithelial cells
colon cancer cells, 1608
- CD16**
c-erbB-2 and
bispecific monoclonal antibody targeting, human tumor xenograft, 94
- CD34**
effect of stem cell factor
irradiated human bone marrow, 3857
- CD36**
expression of thrombospondin and its receptors
normal, hyperplastic and neoplastic breast, 1421
M, 85,000 protein
complementary DNA, Adriamycin-resistant human tumor cells, 2538
- CD44**
differential expression of splice variants
intestinal- and diffuse-type gastric carcinoma, normal gastric mucosa, 4197
major proteins from different splice variants
metastatic rat tumor cell lines, 1262
metastasis-related
expression in human brain metastases, not in glioblastomas, 5345
promoter activity
link, *ras* and metastatic behavior of tumor cells, 1516
variant proteins
tumor progression, human colorectal cancer, 4754
- CD44H**
mediation
binding of ovarian cancer cells, peritoneal mesothelium, 3830
- CD51**
expression of thrombospondin and its receptors
normal, hyperplastic and neoplastic breast, 1421
- CD54/CD11a**
CD58/CD2 and
differential expression, human melanoma cells, 3343
- CD59**
complement inhibitors
messenger RNA expression, human tissues and tumors, 348
- Cell culture**
differential isolation

- normal luminal mammary epithelial cells, breast cancer cells, 627
- identification and characterization of agents
- modification, carcinogenesis, 2446s
- physiological
- normal and malignant mammary epithelial cells, discrimination of cell type, 2644
- report of Group C
- American Cancer Society Research Workshop, 2455s
- Cell cycle**
- arrest and growth inhibition
- UCN-01, human breast carcinoma cells, 2081
- arrest and role of *p53*
- radiosensitivity, Burkitt's lymphoma cell lines, 4776
- association of origins of replication
- nuclear matrix, normal human fibroblasts, 3865
- cell-free SV40 DNA replication system
- interaction between replication forks, topoisomerase I-DNA cleavable complexes, 5908
- chromosomes 8/12/17 copy number
- DNA ploidy, Astler-Coller stage C colon cancer, 681
- circadian stage of cell sampling
- DNA synthesis and ploidy, non-Hodgkin's lymphoma, 3129
- cyclin A expression
- cell proliferation marker, hematological malignancies, 235
- cyclin A and cyclin B
- differential effect of ionizing radiation, HeLa cells, 1128
- cyclin A and cyclin E
- candidates for restriction point protein, 1493
- differences in susceptibility of HL-60 cells
- apoptosis, induction by various antitumor agents, 3186
- effect of stem cell factor
- irradiated human bone marrow, 3857
- glutathione depletion
- L-buthionine sulfoximine, antagonism of taxol cytotoxicity, 2066
- G₁ or late S phase
- cisplatin at 41.5°C, cell killing and chromosomal aberrations, 1239
- G₂-M
- arrest of progression, genistein, 1328
- growth inhibition by deferrioxamine
- neuroblastoma sensitivity, 3968
- hyperphosphorylation
- retinoblastoma protein and *p53*, okadaic acid, 239
- interactions and DNA repair
- radiation sensitization, etoposide, 2105
- kinetics
- different DNA ploidy levels, DNA content and cyclin B, 5096
- loss of *p53*-associated G₁ checkpoint
- cell survival after DNA damage, 4164
- mammalian
- regulation, annexin II expression, 6017
- methionine dependence
- biochemical defect, fresh patient tumors in primary histoculture, 2479
- normal and neoplastic growth and development, 929
- overexpression of DNA binding activity
- distal CCAAT box, thymidine kinase promoter, 3253
- quiescent state of yeast cells, 1867
- radiation and oncogenic transformation
- taxol, 1368
- radiation induced S and G₂ phase arrest
- caffeine release, histone messenger RNA levels, 1507
- specific effects of tumor necrosis factor α
- monocyte-mediated leukemic cell death, role of β_2 -integrins, 4399
- therapeutic tumor-specific block
- methionine starvation, 5676
- Cell motility**
- glyceraldehyde-3-phosphate dehydrogenase expression
- prostatic adenocarcinoma, 1995
- inhibition
- nm23* transfection, human and murine tumor cells, 1971
- CEM cells**
- teniposide-resistant
- non-complex-stabilizing inhibitors of enzyme, aberrant functions, 5946
- CEM-C7 cells**
- cloning and expression
- mutant glucocorticoid receptors, 4059
- Central nervous system neoplasms**
- characterization of thread proteins
- neuroectodermal tumors, 3823
- lactotetraose series ganglioside 3',6'-isoL_D
- tumors of other systems, 120
- plasma and cerebrospinal fluid pharmacokinetic study
- nonhuman primates, 725
- c-erbB-2**
- CD16 and
- bispecific monoclonal antibody targeting, human tumor xenograft, 94
- c-myc** amplification
- high proliferative capacity, breast cancer, 1956
- transfected gene
- biological consequences of overexpression, immortalized human bronchial epithelial cells, 2035
- c-erbB-2/neu**
- enhanced expression
- severe malignancy, ovarian cancer cells, 891
- Cerebrospinal fluid**
- pharmacokinetics and toxicology of immunotoxins
- administration into the subarachnoid space, nonhuman primates and rodents, 3752
- pharmacokinetic study of topotecan
- nonhuman primates, 725
- prolongation of drug exposure
- encapsulation into DepoFoam, 1596
- Cervical cells**
- human papillomavirus-transfected
- genetic analysis, *in vitro* progression, 1167
- Cervix**
- epithelium
- retinoid status, appearance of reserve cells and keratin expression, 2287
- c-fos**
- mechanism of induction by ultraviolet B
- mouse JB6 epidermal cells, 38
- CGS 20267**
- Phase I study
- postmenopausal patients, advanced breast cancer, 266
- Chains**
- signal-transducing ζ
- tumor-infiltrating T-cells and NK cells, colorectal carcinoma, 5610
- single
- anti-carcinoma antibody fused to β -lactamase, genetic construction, 2123
- Chemoimmunotherapy**
- protective role of AS101
- combined with several cytotoxic drugs, mechanisms of action, 5962
- Chemointervention strategies**
- A/J mouse lung as a model, 410
- Chemoprevention**
- agents
- inhibition of oxidative stress, HeLa cells, 4528
- caffeic acid phenethyl ester
- inhibition of tumor promoter-mediated processes, mouse skin and bovine lens, 1255
- colon carcinogenesis
- organosulfur compounds, 3493
- protocatechuic acid, 3908
- dietary DL- α -difluoromethylornithine
- initiation and postinitiation stages, hepatocarcinogenesis, 3903
- diethylnitrosamine-induced hepatocarcinogenesis
- protocatechuic acid, 2775
- environmental carcinogenesis and its prevention
- head and neck cancer, 2189
- head and neck multistage tumorigenesis
- increased polysomies, chromosomes 7 and 17, 2874
- inhibition of tumor promotion by canventol
- inhibition of tumor necrosis factor α release, CD-1 mouse skin, 3462
- oltipraz
- carcinogenesis induced by azoxymethane, 2502
- oral carcinogenesis
- DL- α -difluoromethylornithine, tongue neoplasms, 772
- p53* protein accumulation
- early bronchial neoplasia, 4817
- strategies
- lung and upper aerodigestive tract cancer, 1469
- therapy and basic science
- resolution of cancer problem, 5890
- Chemotaxis**
- chemokinesis and
- prostate stromal cell secretory proteins, prostate tumor cell lines, 1416
- haptotaxis and
- autocrine motility factor-like substance, human malignant mesothelioma cells, 4376

- mediation by stem cell factor
c-kit, small cell lung cancer, 1709
- Chemotherapy**
 acceleration of granulocyte recovery
 granulocyte colony-stimulating factor,
 metastatic breast cancer, 5424
 amphibolic drug combinations
 multienzyme systems, 3998
 BIBW 22 as bifunctional modulator
 P-glycoprotein and nucleoside trans-
 port, 1974
 biological properties and growth in
 SCID mice
 cell line KBM-5, 3603
 circadian-dependent toxicity
 5-fluorouracil, pyrimidine enzymes,
 2816
 circadian stage of cell sampling
 DNA synthesis and ploidy, non-Hodg-
 kin's lymphoma, 3129
 differences in activities and substrate
 specificity
 pyrimidine nucleoside phosphorylases,
 3687
 DNA damaging agents and
 sequence-specific DNA binding, p53,
 2212
 evaluation of drug disposition
 perfused tumor and skin preparation,
 101
 evasion by cancer cells, 747
 5-fluorouracil
 dihydropyrimidine dehydrogenase ac-
 tivity, human peripheral blood
 mononuclear cells and liver, 5433
 high-dose regimen for refractory lym-
 phomas
 plasma and cellular pharmacokinetics,
 mitoxantrone, 4850
 Hoechst 33342
 cytotoxicity and drug resistance, hu-
 man cell cultures, 1332
 individualized
 neuroendocrine markers and drug sen-
 sitivity testing, non-small cell lung
 cancer, 5181
 -induced apoptosis
 specific proteolytic cleavage,
 poly(ADP-ribose) polymerase, 3976
 interstitial
 controlled release polymers, drug de-
 livery in brain, 329
 main drug-metabolizing enzyme systems
 human breast tumors, peritumoral tis-
 sues, 3541
 methylthioadenosine phosphorylase defi-
 ciency
 non-small cell lung cancers, 1098
 modeling of development of metastases
 primary and locally recurrent tumors,
 clinical data base for prostatic can-
 cer, 2987
 modulation of cisplatin nephrotoxicity
 and drug resistance
 control of metallothionein synthesis,
 bladder synthesis, 1829
 pharmacokinetics and metabolism of
 ifosfamide
 continuous infusion, children, 3758
 pharmacokinetics of recombinant human
 interleukin 3
 ovarian cancer, 5915
- quiescent state of yeast cells
 cell cycle, 1867
 roles of metallothionein in carcinogene-
 sis, 922
 synergy of anti-Fas antibody
 overcoming tumor necrosis factor and
 drug resistance, 2591
 three drug
 potentiation of regimen, radiation,
 3518
 tumor cell heme uptake
 induction of ferritin synthesis, altered
 oxidant sensitivity, 5308
- Chinese hamster cells**
 allelic variation in dihydrofolate reduc-
 tase gene
 amino acid position 95, antifolate re-
 sistance, 6031
- Chinese hamster ovary cells**
 transformed to express human *O*⁶-alkyl-
 guanine-DNA alkyltransferase
 specificity, bischloroethylnitrosourea-
 induced mutation, 997
 cell killing and chromosomal aberrations
 cisplatin at 41.5°C, G₁ or late S phase,
 1239
 increased genetic damage
 alkylating agents and γ -irradiation,
 folate deficiency, 5401
 radiation yield of interphase chromo-
 some breaks
 mitosis-promoting factor activity, in-
 ducer mitotic cells, 5592
 sensitivity to *ERCC-1* overexpression
 DNA damaging agents, 3237
 transfection with interleukin 10
 prevention, tumor growth and macro-
 phage infiltration, 4134
 UV-sensitive mutant cell line
 identification of cellular defect, UVS1,
 495
- O*-(Chloroacetyl-carbamoyl)fumagillol: see
 TNP-470
- 8-Chloroadenosine**
 mediation of 8-chloro-cyclic AMP-in-
 duced down-regulation
 cAMP-dependent protein kinase, neo-
 plastic mouse lung epithelial cells,
 393
- Cholestasis**
 17 β -estradiol glucuronide as inducer
 multidrug resistance transporter, 5382
- Cholic acid**
 prediction of colonic tumor incidence
 aberrant crypt foci, 4499
- Choriocarcinoma**
 cell line development
 evaluation, drug disposition, 101
 genesis of
 successive activation, platelet-derived
 growth factor β receptor and growth
 factor B genes, 2927
- c-H-ras**
 mRNA and nucleoside diphosphate ki-
 nase/*nm23*
 lung metastasis, rat-transplantable os-
 teosarcoma, 5038
- Chromatin**
 modification of DNA bases
 intact target human cells, activated
 polymorphonuclear leukocytes, 1269
 regional DNA hypermethylation at
- D17S5
 progression of renal tumors, 2718
- Chromatophoromas**
 chromatophore hyperplasia and
 Pacific rockfish, 1761
- Chromosome 1p**
 deletion
 distinct regions, human primary breast
 cancer, 1990
- Chromosome 1p36**
 deletion as primary aberration
 intestinal tumorigenesis, 1895
- Chromosome 3p**
 deletions and p53 mutations
 prognostic significance, primary re-
 sect non-small cell lung cancer, 1
 detailed genetic and physical map
 familial renal cell carcinoma transloca-
 tion, 3118
 three discrete regions of deletion
 head and neck cancers, 5775
- Chromosome 6**
 human epithelial ovarian cancer allelo-
 type, 2393
- Chromosome 7**
 17 and
 increased polysomies, head and neck
 multistage tumorigenesis, 2874
- Chromosome 8**
 complementation of radiosensitive phe-
 notype
 SCID mice, 6011
 frequent multiplication of long arm
 hepatocellular carcinoma, 857
- Chromosome 8p**
 two tumor suppressor genes
 colorectal carcinoma, 1172
- Chromosome 8p22**
 homozygous deletion and frequent allelic
 loss of loci
 human prostate cancer, 3869
- Chromosome 9**
 bladder cancer suppressor loci, 5093
 preliminary mapping of deleted region
 bladder cancer, 1230
 role in human bladder cancer, 4066
- Chromosome 9p**
 critical region deleted in lung cancer
 homozygous loss, interferon genes,
 2410
 localization of homozygous deletions
 continuous linkage group, glioma cell
 lines, 3674
- Chromosome 10**
 loss in human glioblastoma
 functional role, 5043
 loss of heterozygosity for loci
 morphologically malignant menin-
 gioma progression, 2386
- Chromosome 11**
 disruption of *ALL-1* gene
 epipodophyllotoxin-related secondary
 AML, 2954
- Chromosome 11p15.5**
 refinement of regional loss of heterozy-
 gosity
 human breast tumors, 4486
- Chromosome 11q23**
 Southern blot analysis of *ALL-1* re-
 arrangements
 acute leukemia, 3800
- Chromosome 12**

- breakpoints
benign and malignant lipogenic tumors, 1670
- Chromosome 14q32**
interferon- α -inducible gene
expression in breast carcinoma, 4096
- Chromosome 16**
deletions in familial breast carcinoma
development, distant metastases, 3707
- Chromosome 17**
7 and
increased polysomies, head and neck
multistage tumorigenesis, 2874
allelic loss
ductal carcinoma *in situ*, breast, 2947
- Chromosome 17p**
allelic loss in neural tumors
DNA hypermethylation, 2715
deletions and *p53* mutations
renal cell carcinoma, 3092
loss
p53 gene mutation and protein overexpression, esophageal squamous cell carcinoma, 846
- Chromosome 17q**
deletion unit
epithelial ovarian tumors, 1218
detailed deletion mapping
ovarian and breast cancers, 3382
frequent deletion of three regions
primary human breast carcinomas, 5617
linkage analysis of D17S74
thirty-five families, premenopausal bilateral breast cancer, 212
- Chromosomes**
aberrations and cell killing
cisplatin at 41.5°C, Chinese hamster ovary cells, 1239
abnormalities and karyotypic patterns
culture conditions, head and neck squamous cell carcinoma, 2140
altered methylation patterns
oncogene-induced transformation, bronchial epithelial cells, 1684
changes characterizing *in vitro* response
radiation, human squamous cell carcinoma lines, 5542
8/12/17 copy number
proliferative activity and DNA ploidy, Astler-Coller stage C colon cancer, 681
homozygous deletions within 9p21-p22
critical region of chromosome loss, malignant mesothelioma, 4761
loss of heterozygosity
invasive low-grade and high-grade epithelial ovarian carcinoma, 4456
mapping of murine susceptibility loci
liver carcinogenesis, 209
proliferating cell nuclear antigen and *myc*
ultrastructural localization, synchronized neuroblastoma cells, 1899
radiation yield of interphase chromosome breaks
mitosis-promoting factor activity, inducer mitotic cells, 5592
recurrent deletions of specific sites
1p/3p/6q/9p, human malignant mesothelioma, 4349
sequential genetic alterations
- allele analysis of skin tumors, polymorphic microsatellites, 6022
translocations affecting band 3q27
cloning of *bcl-6*, B-cell lymphoma, 2732
t(6;11) translocation
cloning of *ALL-1* fusion partner, *AF-6* gene, 5624
t(9;11) translocation
topoisomerase II DNA-binding sites, acute myeloid leukemia, 4489
- Chromosome X**
inactivation
formalin-fixed paraffin-embedded tissue, 4676
- Chronopharmacology**
high-dose busulfan in children, 1534
- Chronotherapy**
circadian stage of cell sampling
DNA synthesis and ploidy, non-Hodgkin's lymphoma, 3129
- Cigarette smoking**
detection of DNA adducts
human oral tissue, 1522
determinant of DT-diaphorase gene expression
non-small cell lung carcinoma, 5458
dose and susceptibility to lung cancer polymorphisms, *CYP1A1* and glutathione *S*-transferase, 2994
glutathione *S*-transferase μ polymorphism
marker for susceptibility, lung carcinoma, 2313
incidence of *p53* mutations
progression, head and neck cancer, 4477
metabolites of tobacco-specific nitrosamine
smokers' urine, 721
schistosomiasis and
p53 gene mutation, urothelial cancer, 3795
- Circadian rhythm**
-dependent toxicity of 5-fluorodeoxyuridine
pyrimidine enzymes, relevance to chemotherapy, 2816
stage of cell sampling
DNA synthesis and ploidy, non-Hodgkin's lymphoma, 3129
- Cirrhosis**
early detection of hepatocellular carcinoma
lectin-reactive α -fetoproteins, 5419
- Cisplatin: see also cis-Diamminedichloroplatinum(II)**
anti-epidermal growth factor receptor monoclonal antibody and
antitumor effect, A431 cell xenografts, 4637
carboplatin and
drug-induced DNA modification, buccal cells of cancer patients, 5669
41.5°C during G₁ or late S phase
cell killing and chromosomal aberrations, Chinese hamster ovary cells, 1239
-induced DNA cross-links
topoisomerase II inhibition, glioblastoma, 5663
-induced neurotoxicity
- protection with reduced glutathione, rats, 544
induction of apoptosis
proliferating hepatoma cells, nonproliferating immature thymocytes, 2133
modulation of sensitivity
accumulation by amphotericin B, lung cancer cell lines, 3302
nephrotoxicity and drug resistance
metallothionein synthesis, bladder tumor, 1829
potentiation of activity
fenretinide effectiveness, ovarian carcinoma xenograft, 5374
primary resistance
cross-resistance to diverse drugs, ovarian cancer cell lines, 5225
-resistant ovarian cancer cells
ormaplatin sensitivity/resistance, 242
sensitivity
tamoxifen modulation, malignant melanoma cells, 1571
transformation, rat ovarian epithelial and Rat-1 fibroblast cell lines, 3771
tirapazamine and
tumor-dependent schedule-dependent interaction, 4633
transplacental carcinogenicity
SENCAR mice, 3874
- c-kit**
lineage-negative blast subpopulations
chronic myelogenous leukemia, 401
- Clofazimine**
inhibition of cancer cell line proliferation
phospholipase A₂-mediated mechanisms, 318
- c-myc**
amplification
high proliferative capacity, breast cancer, 1956
correlation with suppression of *c-kit* expression
small cell lung cancer cell lines, 4337
deregulation
theophylline-induced differentiation, Burkitt's lymphoma, 127
drug-induced changes in gene expression
synthesis of *M*, 72,000 constitutive heat shock protein, HL-60 cell differentiation, 3034
E μ -myc transgenic mice
multiple mechanisms, tumorigenesis, 1665
nuclear oncogenes and growth factors
tumorigenesis, transgenic mouse model, 1719
- Cockayne's cells**
hypersensitivity to camptothecin
double strand breaks, nascent DNA, 2012
- Codon 248**
p53 mutation and tumor suppressor function
enhancement of tumor growth, antisense *p53*, 4362
- Collagen**
type IV
chemotaxis and haptotaxis, human malignant mesothelioma cells, 4376
- Collagenase**
M, 72,000 matrix metalloproteinase
binding and localization, cell surface

- invadopodia, 3159
- tumor cell-derived stimulatory factor
- expression of interstitial collagenase, stromelysin and *M*, 72,000 gelatinase, 3154
- type IV
 - benign and malignant prostate, 878
- type IV *M*, 72,000
 - differential integrin expression, melanoma cell invasion, 3411
- type IV *M*, 92,000
 - elevated levels, human brain tumors, 2208
 - increase in plasma, colon and breast cancers, 140
- Colon**
 - aberrant crypt foci
 - azoxymethane-induced biochemical changes, inhibitory effect of caffeic acid esters, 4182
 - aberrant crypts
 - cell kinetic evaluation, 3726
 - carcinogenesis
 - chemoprevention, organosulfur compounds, 3493
 - chemoprevention, protocatechuic acid, 3908
 - inhibitory effect of *Bifidobacterium longum*, food mutagen, 3914
 - 1,2-dimethylhydrazine aberrant crypt foci
 - reduction in formation, docosahexaenoic acid, 2786
 - epithelial cell proliferation
 - caloric restriction, dietary fat, 2745
 - histologically normal mucosa
 - HLA class I antigens, 2374
- Colonic mucosa**
 - proliferation as intermediate biomarker carcinogenesis, effects of various agents, 3283
- Colonic neoplasms**
 - antiproliferative effect of dietary calcium colonic epithelium, 784
 - Astler-Coller stage C
 - proliferative activity and DNA ploidy, chromosomes 8/12/17 copy number, 681
 - binding of intestinal intraepithelial cells HML-1 and CD11a, 1608
 - cytolytic activity of fecal water
 - mechanism of protective effect, supplemental dietary calcium, 248
 - increase in *M*, 92,000 type IV collagenase
 - plasma, 140
 - inhibition of rectal mucosal ornithine decarboxylase activity
 - β -carotene, 3723
 - permanently labeled by lectin-mediated endocytosis
 - trap label, distribution of, 658
 - prediction of tumor incidence
 - aberrant crypt foci, cholic acid, 4499
 - proliferation of human colonic mucosa
 - intermediate biomarker of carcinogenesis, 3283
 - putative tumor marker, 1751
 - quantitative differential effects
 - magnetic resonance spectroscopy, 5808
 - reduced risk
 - high intake of vitamin E, 4230
 - risk of fatal cancer
 - aspirin use, 1322
- Colony-stimulating factor**
 - granulocyte
 - acceleration of granulocyte recovery after chemotherapy and bone marrow transplantation, metastatic breast cancer, 5424
 - pharmacokinetics of piroxantrone, Phase I trial, 2587
 - granulocyte-macrophage
 - block of lung tumor production, 1 α , 25-dihydroxyvitamin D₃ plus γ -interferon, 6006
 - controlled release, biodegradable cytokine depots, 5841
 - description of genes and lack of proliferation, nonhematopoietic human malignant cell lines, 3139
 - high efficiency gene transfer, primary human tumor explants, 2221
 - inhibition of binding to receptors, dimethyl sulfoxide, 1142
 - Phase I trial of chronic oral etoposide, advanced malignancies, 5929
 - macrophage
 - cytokine regulation, human monocyte differentiation, 2603
 - interleukin 2 and, protection from T-cell leukemia/lymphoma EL4, 4273
- Colorectal neoplasms**
 - CD44 variant proteins
 - tumor progression, 4754
 - clinical value of determination
 - urokinase-type plasminogen activator antigen, plasma, 1788
 - comparative dual label study
 - first and second generation TAG-72, 271
 - cytokinetic effects of interferon
 - design of interferon/5-fluorouracil combinations, 5429
 - genomic instability
 - clinicopathological variables, family history, 5849
 - metabolic activation of *N*-hydroxy-2-aminofluorene
 - colon cytosols, Syrian hamsters congenic at *NAT2* locus, 509
 - metastasis
 - mutation in *nm23* gene, 717
 - strength of family history
 - frequency of adenomatous polyps, epithelial cell proliferative compartment, 279
- Comedocarcinoma**
 - expression of thrombospondin and its receptors
 - normal, hyperplastic and neoplastic breast, 1421
- Complements**
 - C3b
 - paracrine migration-stimulating factor, hepatic sinusoidal endothelial cells, 4418
 - inhibitors
 - messenger RNA expression, human tissues and tumors, 348
 - resistance
 - molecular basis, melanoma cells exposed to C3-cleaving membrane protease p65, 592
- Cortisol**
 - heparin conjugates
 - antitumor activity, 3000
- Corynebacterium parvum***
 - cytokine production
 - vaccinations, cytokine production by genetically engineered tumor cells, 714
- Cryopreservation**
 - ether lipids and
 - in vitro* purging, removal of breast cancer cells from bone marrow, 3747
- Crypts**
 - aberrant
 - cell kinetic evaluation, 3726
 - aberrant foci
 - prediction of colonic tumor incidence, cholic acid, 4499
- Cu,Zn-superoxide dismutase**
 - oxy radicals and antioxidant responses in cancer, 3207
- 3',5'-Cyclic nucleotide phosphodiesterase**
 - potential target for tumor growth inhibition
 - tumor cells, 3058
- Cyclin**
 - gene amplification
 - colorectal carcinoma, 1986
- Cyclin A**
 - cyclin B and
 - differential effect of ionizing radiation, HeLa cells, 1128
 - expression in human hematological malignancies
 - marker of cell proliferation, 235
- Cyclin B**
 - DNA content and
 - different ploidy levels, cell cycle kinetics, 5096
- Cyclin D1**
 - rearrangements of gene
 - breakpoints within *BCL-1* locus, B-cell lymphoma, 4148
- Cyclin E**
 - cyclin A and
 - candidates for restriction point protein, 1493
- Cyclobutane pyrimidine dimers**
 - ultraviolet-induced
 - selective removal from epidermis, hairless mouse, 1642
- Cyclocreatine**
 - inhibition of growth
 - broad spectrum of cancer cells, solid tumors, 3172
- Cyclopenta[*c*,*d*]pyrene**
 - metabolites
 - sulfotransferase-mediated activation, 1017
- Cyclopentenylcytosine**
 - resistance in murine leukemia L1210 cells, 5714
- Cyclophosphamide**
 - carboplatin and etoposide
 - Phase I trial with autologous bone marrow transplantation, refractory germ cell tumors, 3730
 - doxorubicin and 5-fluorouracil
 - plus interferon- α 2b, advanced breast cancer, 3509
 - ifosfamide and

- differential activation by cytochromes P-450 2B and 3A, liver microsomes, 5629
- induced myelosuppression
protection, combined interleukin 1 β /interleukin 2 treatment, 569
- modulation of rat hepatic cytochrome P450 2C11
steroid 5 α -reductase activity and messenger RNA, acrolein and phosphoramidate mustard, 2490
- protective role of AS101
combination with several cytotoxic drugs, mechanisms of action, 5962
- Cyclosporin A**
doxorubicin and
Phase I pharmacokinetic study, 4837
- CYFRA 21-1**
immunoradiometric assay
serum fragment of cytokeratin subunit 19, marker of lung cancer, 61
- Cystadenoma**
benign or low-grade malignancies
adjacency to high-grade ovarian carcinoma, molecular characteristics, 4138
- Cytochrome *b₅***
reductive activation of mitomycin C, 4907
- Cytochrome *c* oxidase**
mitochondrial
target site for daunomycin, K562 cells and heart tissue, 1072
- Cytochrome P450**
hepatic and pulmonary enzymes
metabolism of 6-nitrochrysene, 2028
- induced cytotoxicity of mitoxantrone
formation, electrophilic intermediates, 5135
- oxidative catabolism of all-*trans*-retinoic acid
lipid peroxides, human microsomes, 1226
- Cytochrome P450 1A1**
hepatic cellular distribution
immunohistochemistry, rainbow trout, 3700
- P450 EF and
reversal of expression, MCA-C3H/10T $\frac{1}{2}$ cell-derived tumors, 968
- Cytochrome P450 3A**
2B and
cyclophosphamide and ifosfamide, liver microsomes, 5629
- liver
vinblastine metabolism, drug interactions, 5121
- Cytochrome P450 2C11**
modulation by cyclophosphamide
messenger RNA levels, acrolein and phosphoramidate mustard, 2490
- Cytogenetics**
genotypic characterization
prostatic carcinoma, 4035
- Cytokeratins**
hyperphosphorylation
okadaic acid class tumor promoters, primary keratinocytes, 992
- subunit 19
serum fragment measured by CYFRA 21-1 assay, marker for lung cancer, 61
- Cytokines**
autologous stem cell transplantation
sequential production, granulocyte recovery, 1297
- constitutive expression patterns
footprinting, individual tumors and their variants, 1978
- controlled release, biodegradable depots
cancer vaccine design, 5841
- engineered interleukin 4-secreting cells
glioma treatment, 3125
- interleukin 1 α and interleukin 6
inhibition of growth, MCF-7 cells, 1538
- interleukin 2 and interferon- γ
immunological and clinical effects, 1286
- oncostatin M-induced growth inhibition
increased resistance, melanoma cell lines derived from advanced-stage lesions, 2708
- production by genetically engineered tumor cells
vaccinations, 714
- regulation
human monocyte differentiation, 2603
- secondary secretion
human interleukin 2 analogues, immunotherapy, 2597
- Cytolysin**
cytotoxic protein purification
characterization, transformed fibroblasts, 1195
- Cytoplasm**
elk-1 proteins
phosphoproteins and activators, mitogen-activated protein kinase, 3449
- Cytosine deaminase**
antitumor activity of 5-fluorocytosine
colorectal carcinoma cells, 4619
- Cytosol**
colonic
metabolic activation of *N*-hydroxy-2-aminofluorene, Syrian hamsters
congenic at *NAT2* locus, 509
- extracts of breast carcinoma
urokinase-type plasminogen activator, PAI-1, 2513
- glutathione *S*-transferase
chemical selectivity, drug-resistant L5178Y murine lymphoblasts, 3530
- Cytostasis**
proliferation of A375 melanoma cells
inhibition by nitric oxide/nucleophile complexes, 564
- Cytotoxic cells**
tumor-reactive
interleukin 3-enhanced development, CD4-dependent mechanism, 2112
- Cytotoxic T-lymphocytes**
autoreactive and heat shock protein 60
antitumor activity, syngeneic fibrosarcoma, 106
- DNA sequence analysis
T-cell receptor genes, oligoclonal T-cell response, 840
- human B-cell immune response
polymorphic epithelial mucin, 2457
- in situ* amplification
antitumor activity, human regressive melanoma, 3569
- peptide-induced CD8⁺
target, mutant *p53* tumor suppressor protein, 3257
- restricted specificity
squamous cell carcinoma, head and neck, 1461
- selective loss of HLA class I allospecificities
staining of melanoma cells, monoclonal antibodies, 3349
- suppression of growth
spontaneous melanoma metastases, SCID/hu mice, 4933
- suppression of stress protein GRP78 induction
elimination of resistance, cell-mediated cytotoxicity, 6001
- T-cell receptor V region gene usage
autologous gastric Signet ring cell carcinoma, 3078
- D**
- DAB₄₈₆IL-2**
Phase I trial of 90-min infusion
hematological cancers, 3930
- Daunomycin**
-antibody immunoconjugates
management, soft tissue sarcomas, 5740
- mitochondrial cytochrome *c* oxidase as a target site
K562 cells and heart tissue, 1072
- Deacetylase**
activity of human tumor cells
production, immunosuppressive aminoglycosides, 5600
- N*-(Deacetyl-*O*-4-vinblastoyl-23)-L-ethyl isoleucinate
plasma pharmacokinetics of vinblastine and
high-performance liquid chromatography, 2061
- Decay-accelerating factor**
complement inhibitors
messenger RNA expression, human tissues and tumors, 348
- Deferrioxamine**
growth inhibition
neuroblastoma sensitivity, 3968
- Deoxycholate**
intermediate biomarker of carcinogenesis
proliferation, human colonic mucosa, 3283
- 2-Deoxy-D-glucose**
inhibition of doxorubicin-induced apoptosis, 2057
- 12-Deoxyphorbol 13-esters**
inhibition
phorbol 12-myristate 13-acetate induced tumor promotion, CD-1 mouse skin, 2507
- Deoxyuridine triphosphatase**
elevation of activity
failure to accumulate deoxyuridine triphosphate, fluorodeoxyuridine-induced DNA damage, 5219
- DopoFoam**
prolongation of drug exposure
cerebrospinal fluid, 1596
- Dermis**
reticular
calcylin expression, melanocytic lesions, 6061

- Desmoid neoplasms**
familial adenomatous polyposis
somatic and germ-line mutations, *APC*
gene, 5079
- Desmoplasia**
expression of thrombospondin and its receptors
normal, hyperplastic and neoplastic
breast, 1421
- Detergents**
nonionic
P-glycoprotein drug binding, reversal
of multidrug resistance, 5994
- Dexamethasone**
reduction of interstitial fluid pressure
human colon adenocarcinoma xenograft, 4764
- 1,2-Diaminocyclohexane platinum(IV) complexes**
modulation of cytotoxicity
cellular pharmacology, axial and equatorial ligands, 4567
- cis-Diamminedichloroplatinum(II): see also Cisplatin**
5-fluorouracil and
with and without leucovorin, non-small cell lung cancer cell lines, 1079
interleukin 1 and
synergistic antitumor activity, solid tumors, 1091
resistance *in vitro* and *in vivo*
human embryonal carcinoma cells, 5707
- Dibenz[*a,h*]anthracene**
metabolic activation
bis-diol-epoxide involvement, DNA-binding species in mouse skin, 944
- Dicumarol**
hypoxia and
adducts of mitomycin C and DNA, EMT6 mouse mammary tumor cells, 5127
reductive activation of mitomycin C
NADH:cytochrome *b₅* reductase, 4907
- Z-4',5'-Didehydro-5'-deoxy-5'-fluoroadenosine**
suppression of proliferation
keratinocytes, squamous carcinoma cell lines, 6058
- Diet**
calcium
antiproliferative effect, colonic epithelium, 784
caloric restriction and dietary fat
epithelial cell proliferation, rat colon, 2745
pancreatic carcinogenesis, rat, 46
calories/parity/prolactin
mammary tumor risk, epithelial kinetics and differentiation, 1188
derivation of etiology from human-based studies, 2437s
different levels of linoleic acid
breast cancer growth, lung metastasis, 4686
fenretinide
decreased tumor incidence, mouse prostate reconstitution model system, 4461
flavonol-stimulated efflux
7,12-dimethylbenzanthracene, multi-drug resistance, 5977
- food mutagen**
inhibitory effect of *Bifidobacterium longum*, colon/mammary/liver carcinogenesis, 3914
intermediate biomarker of carcinogenesis
proliferation, human colonic mucosa, 3283
nutrition and cancer
development of hypotheses, evaluation in animal studies, 2442s
restriction-induced inhibition
mononuclear cell leukemia, insulin-like growth factor 1 axis, 2750
restriction of fat and carbohydrate calories
inhibition, skin tumor promotion, 27
vegetables and fruit
lung cancer, Iowa Women's Health Study, 536
- Dietary fat**
antiproliferative effect of dietary calcium
colonic epithelium, 784
caloric restriction and
epithelial cell proliferation, rat colon, 2745
risk of postmenopausal breast cancer, 75
tobacco carcinogenesis
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, 2758
- Diethylnitrosamine**
-induced hepatocarcinogenesis
chemoprevention, protocatechuic acid, 2775
chemopreventive effects, dietary DL- α -difluoromethylornithine, 3903
- Diethylstilbestrol**
prenatal exposure
pituitary tumors, 1546
- Differentiation factors**
heparin-binding growth-
new family of, Wilms' tumor and other human carcinomas, 1281
- Differentiation therapy**
cancer
laboratory and clinical investigations, 4109
- 2',2'-Difluorodeoxycytidine**
template-located
kinetics and fidelity of base insertion, Klenow fragment, 4582
- α -Difluoromethylornithine**
development of resistance to hydroxyurea
treatment of K562 cells, 5262
- DL- α -Difluoromethylornithine**
chemoprevention of oral carcinogenesis
tongue neoplasms, rats, 772
chemopreventive effects
initiation and postinitiation stages, hepatocarcinogenesis, 3903
- Digestive tract neoplasms**
risk of fatal cancer
aspirin use, 1322
- Dihydrofolate reductase**
delivery of radionuclides
pretargeted monoclonal antibodies, affinity system, 2368
- Dihydropyrimidine dehydrogenase**
activity
human peripheral blood mononuclear cells, liver, 5433
- Dihydrotestosterone**
hormone regulation of human prostate organ culture, 5199
- 3,4-Dihydroxy-3,4-dihydrocyclopenta[*c,d*]pyrene**
sulfotransferase-mediated activation, 1017
- 7R,8S-Dihydroxy-9S,10R-epoxy-7,8,9,10-tetrahydrobenzo[*a*]pyrene**
dose-dependent differences in profile of mutations
coding region of hypoxanthine phosphoribosyltransferase gene, Chinese hamster V-79 cells, 3294
- 1 α ,25-Dihydroxyvitamin D₃**
 γ -interferon and
block of lung tumor production, GM-CSF and induction of immunosuppressor cells, 6006
receptor as marker
human colon carcinoma cell line differentiation and growth inhibition, 3712
TPA-induced tumorigenic transformation
osteopontin expression, mouse JB6 epidermal cells, 2217
two analogues and
biological response, target organs, 3935
- Dilantin: see Phenytoin**
- 7,12-Dimethylbenzanthracene**
flavonol-stimulated efflux
7,12-dimethylbenzanthracene, multi-drug-resistant breast cancer cells, 5977
- 1,2-Dimethylhydrazine**
-induced aberrant crypt foci in colon
reduction in formation, docosahexanoic acid, 2786
- Dimethyl sulfoxide**
inhibition of binding of GM-CSF and insulin to receptors
human leukemia cells, 1142
- Diphtheria toxin**
fusion toxin DAB₄₈IL-2
Phase I trial of 90-min infusion, hematological cancers, 3930
- Dipyridamole**
analogue BIBW 22
P-glycoprotein and nucleoside transport, 1974
- Dithiolethiones**
glutathione S-transferase class α transcripts
hepatocytes, 231
- DNA**
adduct formation and hepatocarcinogenicity
toremifene and tamoxifen, 4534
alkylation
in vivo mutagenesis, induction by CC-1065 and adozelesin, 5690
antisense
inhibition of tumor growth, induction by c-Ha-ras, 577
association of origins of replication
nuclear matrix, normal human fibroblasts, 3865
binding activity
distal CCAAT box, human thymidine kinase promoter in human tumor

- cell lines, 3253
- binding by p53
 - chemotherapy and DNA damaging agents, 2212
- binding species in mouse skin
 - bis-diol-epoxide involvement, metabolic activation of dibenz[*a,h*]anthracene, 944
- bulk damage
 - teniposide antiproliferative activity, MCF-7 cells, 3547
- complementation of radiosensitive phenotype
 - chromosome 8, SCID mice, 6011
- damage
 - cell survival, loss of p53-associated G1 checkpoint, 4164
- damaging agents
 - sensitivity to *ERCC-1* overexpression, Chinese hamster ovary cells, 3237
- different ploidy levels and cell cycle kinetics
 - DNA content, cyclin B, 5096
- digestion
 - bleomycin, apoptosis-mimetic drug, 5462
- double strand break repair defect
 - scid mice, 1244
- drug-induced modification
 - buccal cells of cancer patients, carboplatin and cisplatin chemotherapy, 5669
- elk-1* variant
 - differential splicing, encoding of activators and repressors, 215
- fidelity of replication
 - extracts, normal and malignant transformed human cells, 3270
- fragmentation
 - etoposide-induced cytotoxicity, T-cell leukemia lines, 4287
- frequent multiplication
 - long arm of chromosome 8, hepatocellular carcinoma, 857
- hypermethylation
 - D17S5, progression of renal tumors, 2719
- 17p allelic loss, neural tumors, 2715
- in situ* hybridization
 - genotypic characterization, prostatic carcinoma, 4035
- interaction of a polyamine analogue
 - human brain tumor cell lines, 3948
- intracellular acidification
 - etoposide-induced apoptosis, HL-60 cells, 2349
- intratumoral injection
 - inhibition of melanoma growth, herpes simplex virus thymidine kinase gene, 3860
- introplicine and topoisomerase II
 - molecular and cellular interactions, surface-enhanced Raman scattering spectroscopy, 4784
- lesions produced by anamycin
 - in vitro* cytotoxicity, cellular pharmacology, 1583
- melfalan-damaged
 - binding, poly(ADP-ribose) polymerase, 5370
- modification of bases in chromatin
 - intact target human cells, activated polymorphonuclear leukocytes, 1269
- mutagenicity in *Saccharomyces cerevisiae*
 - induction by hyperthermia, hot mate infusion and hot caffeine, 5750
- nascent
 - double strand breaks, Cockayne's syndrome cells and camptothecin hypersensitivity, 2012
- no detectable amplifications
 - acquisition of hormone-independent growth, MSF-7 cells, 283
- nuclear
 - oxidative damage in liver, rats exposed to psychological stress, 4153
- p53 abnormalities
 - different subtypes, human sarcomas, 468
- ploidy and proliferative activity
 - chromosomes 8/12/17 copy number, Astler-Coller stage C colon cancer, 681
- ploidy and synthesis
 - circadian stage of cell sampling, non-Hodgkin's lymphoma, 3129
- presence of point mutations
 - N-ras* gene, radiation-transformed rat embryo cells, 1511
- presence of transforming genes
 - gonadal tumors, bivalve mollusk species, 2976
- protein complexes
 - induction in HeLa S3 cells, KW-2149, 4466
- protein cross-links
 - molecular implications, welders, 460
- sequence analysis of T-cell receptor genes
 - oligoclonal T-cell response, tumor with multiple target antigens, 840
- sequence-specific binding
 - redox modulation, p53 conformation, 4469
- sequence-specific interaction
 - conformational domain, p53, 5361
- strand bias
 - repair of p53 gene, normal and xeroderma pigmentosum group C fibroblasts, 5377
- strand breaks in individual apoptotic cells
 - terminal deoxynucleotidyl transferase, nick translation assays, 1945
- studying clonal heterogeneity in human cancers, 921
- supercoiling
 - local control, T2/3 transitional cell carcinoma of the bladder, 2300
- synthesis
 - chronic radiation-induced alteration, aplastic anemia, 4518
- topoisomerase I-mediated cleavage
 - induction by ED-110, 490
- DNA, complementary
 - basic fibroblast growth factor tumor necrosis, H-ras-transformed cells, 158
- expressed uridine 5'-diphosphate glucuronosyltransferase
 - glucuronidation, carcinogen metabolites, 1529
- glutathione *S*-transferase
 - alkylator-induced toxicity, rat mammary carcinoma cells, 4900
- interleukin 2
 - tumor-specific lysis by tumor-infiltrating lymphocytes, renal cell carcinoma, 4020
- kidney
 - down-expression in Wilms' tumor, subtractive hybridization approach, 2888
- molecular cloning
 - prostate-specific membrane antigen, 227
- molecular cloning and characterization
 - M, 85,000 protein, overexpression in Adriamycin-resistant human tumor cells, 2538
- mouse heparin-binding growth factor receptor
 - use of kinase insert sequence, 1136
- DNA adducts
 - aflatoxin B₁
 - detection in human placenta and cord blood, 1278
 - benzo(a)pyrene diol-epoxide
 - inactivation of plasmid reporter gene expression, hepatocytes, 2279
 - detection in human oral tissue
 - tobacco smoking, ³²P postlabeling, 1522
- hemoglobin
 - 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, red blood cells, 777
- mitomycin C and
 - hypoxia and dicumarol, EMT6 mouse mammary tumor cells, 5127
- 2-nitroimidazole
 - detection of hypoxic cells, monoclonal antibody, 5721
- platinum resistance
 - role of carrier ligand, human carcinoma cell lines, 799
- polycyclic aromatic hydrocarbons
 - cancer susceptibility genes, human lung, 3486
- pyridyloxobutyl
 - inhibition of repair, *O*⁶-methylguanine, 2780
- DNA damage
 - distinct pattern of p53 mutations
 - bladder cancer, relationship to tobacco usage, 1162
 - fluorodeoxyuridine-induced
 - elevation of deoxyuridine triphosphatase, failure to accumulate deoxyuridine triphosphate, 5219
 - N*-methyl-*N*-nitrosourea
 - fluorescence postlabeling assay, 2771
 - oxidative
 - benzene and phenolic metabolites, HL-60 cells and bone marrow, 1023
 - oxy radicals and antioxidant responses in cancer, 3207
 - repair and cell proliferation
 - carcinogen treatment, initiation of pancreatic cancer, 2790
 - ultraviolet radiation-induced
 - photorepair in skin, platyfish *Xiphophorus*, 2249
- DNA footprinting
 - individual tumors and their variants
 - constitutive cytokine expression patterns, 1978

- DNA polymerase α**
 interruption of progression of DNA synthesis
 codons 12 and 13, *H-ras*, 2895
- DNA repair**
 cell cycle interactions and
 radiation sensitization, topoisomerase II poison etoposide, 2105
 -deficient xeroderma pigmentosum patients
 high mutation frequency, *ras* genes, 1625
 identification of cellular defect
 UV-sensitive Chinese hamster ovary mutant cell line, 495
 role of carrier ligand
 platinum resistance, human carcinoma cell lines, 799
- DNA synthesis**
 persistent inhibition
H-ras and *v-myc* expression, rat embryo fibroblasts, 1213
 ploidy and
 circadian stage of cell sampling, non-Hodgkin's lymphoma, 3129
- DNA topoisomerase I**
 -DNA cleavable complexes
 interaction between replication forks, cell-free SV40 DNA replication system, 5908
 glycine 363 change to cysteine
 camptothecin resistance, 4343
 inhibitor
 therapeutic efficacy, human tumor xenografts, 2823
 mammalian poison Hoechst 33342
 cytotoxicity and drug resistance, human cell cultures, 1332
 -mediated DNA cleavage
 induction by ED-110, 490
 topoisomerase II activities and
 inhibition by intropicline, 5987
- DNA topoisomerase II**
 DNA-binding sites at breakpoints
 t(9;11) chromosome translocation, acute myeloid leukemia, 4489
 enhanced gene expression
 response to heat shock stress, KB cells, 1085
 etoposide
 radiation sensitization, DNA repair and cell cycle interactions, 2105
 -induced DNA strand breaks and their repair
 etoposide-induced apoptosis, inhibition by bcl-2 protein, 4251
 inhibition and altered kinetics
 nitrosourea and cisplatin-induced DNA cross-links, glioblastoma, 5663
 inhibitors
 aberrant functions, teniposide-resistant CEM cells, 5946
 intropicline and DNA
 molecular and cellular interactions, surface-enhanced Raman scattering spectroscopy, 4784
 protection from Adriamycin cytotoxicity
 brefeldin A, L1210 cells, 5237
 single-strand conformational polymorphism
M, 170,000 isozyme, human tumor cells, 1373
 target of VM-26 and 4'-(9-acridinylamino)methanesulfon-*m*-aniside
 atypical multidrug resistance, small cell lung carcinoma cells, 1064
 temperature-sensitive allele
 drug resistance, amsacrine and etoposide, 89
- DNA topoisomerase II α**
 drug-resistant small cell lung cancer cell line
 VP-16, 4866
 gene rearrangement
 fusion mRNA transcript, Adriamycin-resistant P388 leukemia, 5885
 targeting
 study of anticancer drugs, use of yeast, 3591
- Docosa-hexanoic acid**
 1,2-dimethylhydrazine aberrant crypt foci
 reduction in formation, colon, 2786
- Doxorubicin**
 antibody-targeted delivery
 entrapment in liposomes, eradication of lung cancer, 1484
 -bovine serum albumin conjugate
 multidrug resistance, rat hepatoma, 4238
 cardiotoxicity
 effect of verapamil, altered muscle gene expression, 4658
 combined with liposome-encapsulated muramyl tripeptide
 canine monocyte activation, 3986
 cyclophosphamide and 5-fluorouracil plus interferon- α 2b, advanced breast cancer, 3509
 cyclosporin A and
 Phase I pharmacokinetic study, 4837
 encapsulated in liposomes
 initial clinical trial, 2796
 growth and drug resistance
 small heat shock protein hsp27, breast cancer cell lines, 4443
 -induced apoptosis
 inhibition by 2-deoxy-D-glucose, 2057
 -pretreated BALB/c mice
 cardioprotective properties, *O*-(β -hydroxyethyl)-rutosides, 4603
 resistance
 modulatory effects, tamoxifen and recombinant human α -interferon, 3040
 sterically stabilized liposomes
 arrest of growth, human lung tumor xenograft, 3964
 -treated normal and tumor-bearing mice
 protective effects, interleukin 1 α , 1565
 treatment of sarcoma-bearing rats
 preservation of lean body mass, growth hormone, 5483
- Drug delivery**
 controlled release polymers
 interstitial chemotherapy, 329
- Drug resistance**
 alternatively spliced glucocorticoid receptor mRNAs
 human multiple myeloma cells, 3877
 cross-resistance to diverse drugs
 primary cisplatin resistance, ovarian cancer cell lines, 5225
- growth and
 small heat shock protein hsp27, breast cancer cell lines, 4443
 L5178Y murine lymphoblasts
 chemical sensitivity, cytosolic glutathione *S*-transferases, 3530
 mammalian DNA topoisomerase I poison
 Hoechst 33342, human cell cultures, 1332
 nephrotoxicity and
 cisplatin and metallothionein synthesis, bladder tumor, 1829
 temperature-sensitive topoisomerase II allele
 amsacrine and etoposide, 89
- Drug screening**
 amphibolic drug combinations
 multienzyme systems, 3998
- D17S74**
 linkage analysis in thirty-five families
 premenopausal bilateral breast cancer, 212
- DT-diaphorase**
 density-dependent growth inhibition
 normal but not transformed cells, 1338
 gene expression
 cigarette smoking as determinant, non-small cell lung carcinoma, 5458
- DU-145 cells**
 invasive potential
 metalloproteinase matrilysin, 417
- E**
- ED-110**
 induction
 topoisomerase I-mediated DNA cleavage, 490
- Edatrexate**
 compared to methotrexate
 leucovorin rescue, metastatic murine solid tumors, 587
- Edelfosine**
 exposure of L1210 cells
 increased generation, lipid-derived and ascorbate free radicals, 711
- Effector cells**
 anti-CD3/IL-2
 cross-reactivity, lymph nodes draining heterologous clones of a murine tumor, 4315
- Effusions**
 tumor and inflammatory
 vascular permeability factor, guinea pig and human, 2912
- Ehrlich ascites**
 tumor-bearing mice
 purine nucleotide levels, host tissues, 5143
- Eicosanoids**
 modulation of arachidonic acid metabolism
 sensitivity of tumoricidal function, macrophages from different sites, 3362
- ELAM-1**
 adhesion of human cancer cells
 carbohydrate antigens, vascular endothelium, 354
- Electron paramagnetic resonance**
 membrane lipid free radicals

- photofrin photosensitization, L1210 murine leukemia cells, 3670
- Electrophilic intermediates**
formation of
cytochrome P-450-induced cytotoxicity, mitoxantrone, 5135
- Elk-1 proteins**
phosphoproteins
activators, mitogen-activated protein kinase, 3449
- Elongation factor 2**
phosphorylation
normal and malignant rat glial cells, 2260
- Embryo cells**
radiation-transformed rat
presence of point mutations, *N-ras* gene, 1511
rat fibroblast
wild-type adenovirus type 5 transforming genes, transdominant suppressors of oncogenesis, 1929
- Syrian hamster**
immortalization, 4797
induction of neoplastic progression, protein phosphatase inhibitors, 1777
- EMT6 cells**
adducts of mitomycin C and DNA
hypoxia and dicumarol, 5127
phototoxicity and pharmacokinetics
benzophenoxazine analogues, 2571
- Endometrial neoplasms**
subcellular localization
blood group Le^b carbohydrate antigen, 3643
- Endometrium**
hyperplasia and carcinoma
mutation, *Ki-ras* protooncogene, 1906
uterine
p53 alterations, *c-K-ras-2* activation, 1883
- Endoplasmic reticulum**
subcellular distribution
bcl-2 oncoprotein, 4701
- Endothelial cells**
antiangiogenic effects
quinoline-3-carboxamide linomide, 1833
migration and invasiveness
induction by soluble factor, polyoma virus-transformed middle T oncogene, 3812
platelet-derived growth
sensitivity of KB cells, pyrimidine antimetabolites, 5680
proliferation
relationship to tumor vascularity, human breast cancer, 4161
regional proliferation
 β -fibroblast growth factor expression, squamous cell carcinoma, 1444
- Endothelial growth factor**
vascular
photosensitizer uptake, 153
- Endothelin 1**
stimulation of production by interleukin 6
human breast cancer cells, 464
- Endothelioma**
soluble factor
induction of endothelial cell migration and invasiveness, polyoma virus
middle T oncogene, 3812
- Endothelium**
-dependent relaxation
photodynamic therapy, rat aorta, 2548
proliferation
tumors of different histotypes, systemic expression of HIV-1 *tat* gene, 5569
- Enzymes**
drug- and carcinogen-metabolizing
non-small cell lung cancer, peritumoral tissues, 4608
main drug-metabolizing systems
human breast tumors, peritumoral tissues, 3541
multienzyme systems
amphibolic drug combinations, 3998
sequential impact of tiafufurin and ribavarin
bone marrow, 5982
- 1,6-Epi-cyclophellitol**
inhibition of metastasis, 4896
- Epidemiology**
derivation of etiology from human-based studies, 2437s
- Epidermal growth factor**
blockade of receptor function
bivalent and monovalent fragments, monoclonal antibodies, 4322
inhibition of laryngeal papilloma differentiation
epidermal growth factor receptor, 910
-like growth factor secretion
inhibition by vitamin A, tracheobronchial epithelial cells, 2527
-mediated receptor-dependent events
inhibitory effects, α -interferon, 5148
receptor-mediated autocrine and paracrine stimulation
transitional cell carcinoma, 5300
regulation of fibroblast hepatocyte growth factor/scatter factor
breast carcinoma cell lines, 1233
- Epidermis**
mouse dendritic T-cells
killing, skin-derived tumor cells, 4014
transgenic
cooperation between *v-fos* and *v-ras*
Ha, papillomas, 5071
ultraviolet-induced cyclobutane pyrimidine dimers
hairless mouse, 1642
- Epinephrine**
mechanisms of change in tumor blood flow
morphometry, 5528
- Epipodophyllotoxin**
-related secondary AML
disruption, common region of *ALL-1* gene, 2954
- Epithelial cells**
ectocervical
immortalization, human papillomavirus, 4511
mammary
estrogen receptor-negative, inhibition of growth by estrogen, 5004
mechanism of protective effect
supplemental dietary calcium, cytolytic activity of fecal water, 248
polarized
entry of protein toxins, 1755
proliferation in rat colon
caloric restriction, dietary fat, 2745
proliferative compartment
frequency of adenomatous polyps, strength of family history, 279
rat kidney
HPV16 transformation, glucocorticoid requirement for growth, 4432
reversible inhibition of proliferation
Agaricus bisporus lectin, 4627
- Epithelial neoplasms**
mucin synthesis and secretion
MUC-1 mucin gene, 1437
- Epithelium**
cervical
retinoid status, appearance of reserve cells and keratin expression, 2287
colonic
antiproliferative effect, dietary calcium, 784
small intestinal
inhibition of doxorubicin-induced apoptosis, 2-deoxy-D-glucose, 2057
tumor-distant
mutated p53, head and neck cancer, 4189
vascular
adhesion of human cancer cells, carbohydrate antigens, 354
- Epitopes**
cancer-defined B-cell
analysis of p53 antibodies, exposure on protein surface, 5872
cross-reactivity of anti-CD3/IL-2 activated effector cells
lymph nodes draining heterologous clones, murine tumor, 4315
tumor-specific
Escherichia coli, breast tumor-associated mucin fusion protein, 4920
- erbB-2**
gene amplification
heterogeneity, bladder cancer, 2199
overexpressing rat thyroid cells
loss of thyrotropin regulation, TGF- β -induced growth arrest, 5548
overexpression in breast tumors
high-level of expression, ribosomal protein L19, 1403
- Erythroleukemia**
anticancer drug-sensitive clone
mechanism of antineoplastic drugs, 1877
induced differentiation
differential modulation, protein kinase C isoforms, 5554
- Esophageal neoplasms**
correlation
E-cadherin expression, invasiveness, 3421
risk of fatal cancer
aspirin use, 1322
- Esophagus**
normal/dysplastic/squamous cell carcinoma
expression of sialyl-Tn antigens, 1706
precancerous lesions
accumulation of p53 protein, carcinogenesis, 1783
squamous cell carcinoma
TP53 gene mutation, 5745
- Estradiol**

- hormone regulation of human prostate organ culture, 5199
- induced renal tumors
- localization of estrogen receptors, interstitial cells, 5447
- induction of retinoic acid receptors human breast cancer cells, 5940
- 17 β -Estradiol**
- induction of *jun* gene family members breast cancer cells, 291
- 17 β -Estradiol glucuronide**
- inducer of cholestasis
- physiological substrate, multidrug resistance transporter, 5382
- Estramustine**
- depolymerization of microtubules binding to tubulin, 4573
- Estrogen**
- antiestrogen modulation and insulin-like growth factor-binding proteins, MCF-7 cells, 5193
- antiestrogens
- inhibition of angiogenesis, 533
- induced kidney tumors
- increase, insulin-like growth factor 1 receptors, 2256
- inhibition of estrone sulfatase activity estrone-3-methylthiophosphonate, breast cancer, 298
- inhibition of growth
- estrogen receptor-negative mammary epithelial cells, 5004
- localization of receptors in interstitial cells
- estradiol-induced renal tumors, interstitial cells, 5447
- receptor
- exon 5 deletion variant, wild-type estrogen receptor in breast cancer, 5882
- receptor-negative BT-20 breast cancer cell line
- constitutively active estrogen receptor variant, 5934
- receptor-positive transplantable rat thyroid tumor cell lines
- establishment of, 4408
- regulated genes
- acquisition of hormone-independent growth, MCF-7 cells, 283
- responsive breast cancer cell lines
- estrogen receptor variant messenger RNA lacking exon 4, 741
- type II binding sites
- dysplastic dorsolateral prostate, Noble rat, 528
- Estrone**
- inhibition of *in vivo* conversion of androstenedione
- vorozole, healthy postmenopausal women, 4563
- Estrone sulfatase**
- inhibition by estrone-3-methylthiophosphonate
- breast cancer therapy, 298
- Ethanol**
- transplacental induction
- pancreas tumors in hamsters, 2498
- Ether lipid analogues**
- inhibition of phosphatidylinositol-3-kinase, 4297
- cryopreservation and
- in vitro* purging, removal of breast cancer cells from bone marrow, 3747
- edelfosine
- lipid-derived and ascorbate free radicals, L1210 cells, 711
- N*-Ethyl-*N'*-nitro-*N*-nitrosoguanidine
- mutagenic processing of ethylation damage
- mammalian cells, 1149
- 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxy-camptothecin**
- therapeutic efficacy
- human tumor xenografts, 2823
- Etiology**
- derivation from human-based studies, 2437s
- ET-18-OCH₃**
- inhibition of phosphatidylinositol-3-kinase, 4297
- Etoposide**
- carboplatin and cyclophosphamide
- Phase I trial with autologous bone marrow transplantation, refractory germ cell tumors, 3730
- drug resistance
- temperature-sensitive topoisomerase II allele, 89
- induced apoptosis
- inhibition by bcl-2 protein, topoisomerase II-induced DNA strand breaks and their repair, 4251
- induced apoptosis in HL-60 cells
- intracellular acidification, 2349
- induced cytotoxicity
- human T-cell leukemia lines, 4287
- pharmacokinetics in children
- dosing equation, 4881
- radiation sensitization
- DNA repair and cell cycle interactions, 2105
- randomized Phase I trial
- granulocyte-macrophage colony-stimulating factor, advanced malignancies, 5929
- reversal of resistance by novobiocin
- non-P-glycoprotein expressing multidrug-resistant tumor cell lines, 5487
- toxic effects
- protection of stromal cells, AS101, 1838
- Ewing's tumor**
- chimeric EWS-FL11 transcript
- complex t(11;22;14) translocation, 3655
- EWS/Flt-1**
- chimeric protein
- transcriptional activator, 5859
- Exon 7**
- lack of
- APC* gene messenger RNA, novel isoforms, 5589
- Extracellular matrix**
- altered
- influence on cellular processes, bladder urothelial cells, 4971
- M*, 72,000 matrix metalloproteinase
- binding and localization, cell surface invadopodia, 3159
- melanoma-mediated dissolution
- proteolytic pathways, 693
- metalloproteases
- tumor grade and invasion, bladder cancer, 5365
- production and degradation
- plasminogen activator, adenoid cystic carcinoma cells, 147
- reorganization
- radiation-induced transforming growth factor β , murine mammary gland, 3880
- type II transforming growth factor β receptor
- enhanced expression, human pancreatic cancer cells, 2704
- F**
- F(ab')₂ fragments**
- ⁶⁷Cu-labeled intact and fragmented anti-colon carcinoma monoclonal antibody MAb35
- preclinical evaluation, 5727
- radiolabeled chimeric monoclonal antibody MOv18 IgG and
- kinetics and tissue distribution, ovarian carcinoma, 5413
- Farallon Island Radioactive Waste Dump**
- chromatophoromas and chromatophore hyperplasia
- Pacific rockfish, 1761
- Fas antigen**
- antibody and drugs or toxins
- overcoming tumor necrosis factor and drug resistance, 2591
- Fenretinide**
- dietary
- decreased tumor incidence, mouse prostate reconstitution model system, 4461
- effectiveness against human ovarian carcinoma xenograft
- potentiation, cisplatin activity, 5374
- lowering of plasma insulin-like growth factor I levels
- breast cancer, 4769
- treatment of prostate cancer, 224
- Ferritin**
- induction of synthesis
- tumor cell heme uptake, altered oxidant sensitivity, 5308
- FET cells**
- induction of TGF- α promoter activity
- TGF- α secretion, colon adenocarcinoma, 4041
- α -Fetoprotein**
- human cord serum
- sugar chains, human liver and hepatocellular carcinoma, 2970
- lectin-reactive
- early detection, hepatocellular carcinoma, 5419
- Fetus**
- prenatal exposure to diethylstilbestrol
- pituitary tumors, 1546
- rat brain cells
- migratory pattern, human glioma cells in adult rat brain, 5158
- Fibroadenoma**
- phyllodes tumor and
- clonal analysis, breast, 4071
- Fibroblast growth factor**
- β -
- regional endothelial cell proliferation, squamous cell carcinoma, 1444

- acidic and basic
overexpression, advanced stage pancreatic cancer, 5289
- basic
overexpression of complementary DNA, *H-ras*-transformed cells, 158
secretion by an animal tumor, detection in urine, 5297
unscheduled expression, pancreatic acinar cancer cell line, 1182
differential growth factor production high and low metastatic variants, B16BL6 melanoma, 4075
type I receptor
aberrant expression, pancreatic adenocarcinoma, 4741
- Fibroblast growth factor 4**
LacZ and
cotransfection of MCF-7 cells, spontaneous metastasis, 2178
transfection of MCF-7 cells
tumorigenicity, tamoxifen-treated athymic nude mice, 2168
- Fibroblasts**
activation protein
regulation and heteromeric structure, cells of mesenchymal and neuroectodermal origin, 3327
amphiregulin and epidermal growth factor receptor
estrogen receptor expression, human primary breast cancer, 3597
diploid human
factors that stimulate production of hyaluron
human mesothelioma cells, 388
- H-ras*-transformed
spontaneous revertants, up-regulation of lysyl oxidase, 4670
- human diploid
production of morphological transformants, transforming growth factor- α , 2162
- hypersensitivity of human lymphocytes
UV-B and solar irradiation, 609
- lung
insulin-like growth factor-I, lung carcinoma cells, 3399
neoplastic transformation and tumorigenic conversion
 $\alpha 6$ integrin, 2950
normal and group C
DNA strand bias, repair of *p53* gene, 5377
normal human
association of origins of replication, nuclear matrix, 3865
preneoplastic and neoplastic Syrian hamster embryo
transformation by carcinogens, amplification potential, 3098
presence of transforming genes
gonadal tumors, bivalve mollusk species, 2976
production of growth-promoting factor wide target cell spectrum, THP-1 cells, 1871
rat embryo cells
inhibition of DNA synthesis, *H-ras* and *v-myc*, 1213
wild-type adenovirus type 5 transforming genes, transdominant suppressors of oncogenesis, 1929
regulation of hepatocyte growth factor/scatter factor expression
peptide growth factors, breast carcinoma cell lines, 1233
SV40-infected precursors
multiple mechanisms, *N*-(phosphonacetyl)-L-aspartate drug resistance, 4946
transformed
purification and characterization, cytotoxic protein, 1195
- Fibronectin**
adhesion of metastatic *ras*-transformed NIH 3T3 cells, 701
chemotaxis and haptotaxis
autocrine motility factor-like substance, human malignant mesothelioma cells, 4376
pre-messenger RNA alternative splicing coordinate oncogene developmental modulation, liver tumor, 2005
- Fibrosarcoma**
enhanced survival
BCL-2 protein expression, tumor necrosis factor-mediated cytotoxicity, 1456
- Fibrosarcoma**
syngeneic
autoreactive and heat shock protein 60, antitumor activity, 106
- Flavonoids**
arrest of cell cycle progression
G₂-M, genistein, 1328
- Flavonol**
-stimulated efflux
7,12-dimethylbenzanthracene, multidrug-resistant breast cancer cells, 5977
- Fli-1 protein**
EWS/Fli-1 chimeric protein
transcriptional activator, 5859
- Flow cytometry**
bromodeoxyuridine labeling and tamoxifen-induced increase in doubling time, MCF-7 xenografts, 4413
genotypic characterization
prostatic carcinoma, 4035
- Fluid**
accumulation
pathogenesis, malignant ascites formation, 2631
interstitial
pressure and tumor blood flow, angiotensin II-induced hypertension, 2466
- Fluorescence**
laser-induced
pharmacokinetics, fluorescent drug, 5954
- 5-Fluorocytosine**
antitumor activity
colorectal carcinoma cells, cytosine deaminase expression, 4619
- Fluorodeoxyuridine**
-induced DNA damage and cytotoxicity
elevation of deoxyuridine triphosphatase, failure to accumulate deoxyuridine triphosphate, 5219
- 5-Fluorodeoxyuridine**
circadian-dependent toxicity
pyrimidine enzymes, relevance to chemotherapy, 2816
- 5-Fluoro-2'-deoxyuridine**
 \pm *N*-phosphonacetyl-L-aspartate
antitumor activity, colon carcinoma 26, 1560
- 5-Fluoropyrimidines**
differences in activities and substrate specificity
pyrimidine nucleoside phosphorylases, chemotherapy, 3687
- 5-Fluorouracil**
calcium leucovorin and
N-(phosphonacetyl)-L-aspartate combination, metastatic gastrointestinal adenocarcinoma, 4828
chemotherapy-induced myocardial ischemia
protein kinase C-mediated vasoconstriction, vascular smooth muscle, 3028
clinical implication for chemotherapy
dihydropyrimidine dehydrogenase activity, human peripheral blood mononuclear cells and liver, 5433
cyclophosphamide and doxorubicin plus interferon- $\alpha 2b$, advanced breast cancer, 3509
cis-diamminedichloroplatinum(II) and with and without leucovorin, non-small cell lung cancer cell lines, 1079
inhibition of gastrointestinal toxicity
oxonic acid, no loss of antitumor activity, 4004
-interferon combinations
cytokinetic effects of interferon, colorectal cancer, 5429
leucovorin and interferon- $\alpha 2a$
locus of interaction, colon carcinoma cells, 4243
novel mechanism of resistance
decreased folylpolyglutamate synthetase expression, 3677
protective role of AS101
combination with several cytotoxic drugs, mechanisms of action, 5962
- FO-1 cells**
induction and antigenic profile
HLA-A and -B antigens, β_2 -microglobulin, 4303
- Folate**
deficiency
damage by alkylating agents and γ -irradiation, Chinese hamster ovary cells, 5401
- Folate binding protein**
gene transfection and expression
NIH/3T3 cells, 5791
- Folylpolyglutamate synthetase**
decreased expression
novel mechanism, fluorouracil resistance, 3677
- Forestomach**
induction of cell proliferation
styrene 7,8-oxide, butylated hydroxyanisole, 3505
- Formalin**
-fixed paraffin-embedded tissue
X chromosome inactivation, 4676
- Fostriecin**
aberrant functions
teniposide-resistant CEM cells, 5946
- Fourier transform infrared spectroscopy**

- ultrastructural appraisal
 - multidrug resistance, K562 and LR73 cell lines, 3681
- Free radicals
 - membrane lipid
 - photofrin photosensitization, L1210 murine leukemia cells, 3670
- Friend erythroleukemia
 - anticancer drug-sensitive murine clone
 - mechanism of action, antineoplastic drugs, 1877
- Friend leukemia cells
 - metastatic
 - α_1 -interferon gene transfer, abrogation of tumorigenicity, 1107
- Fruit
 - vegetables and
 - lung cancer, Iowa Women's Health Study, 536
- α -1,3-Fucosyltransferases
 - synthesis of sialyl Le^x and sialyl Le^a
 - human malignant cell lines, 5559
- Funding
 - mechanisms
 - research through the American Cancer Society, 2436s
 - research through the National Cancer Institute, 2434s
- Furan
 - preferential induction in right/caudate liver lobes
 - "intestinal-type" adenocarcinoma, 254
- Fusion proteins
 - breast tumor-associated
 - Escherichia coli*, tumor-specific epitope, 4920
 - BR96 sFV-PE40
 - selective killing, carcinoma cells, 334
 - single chain anti-carcinoma antibody fused to β -lactamase
 - genetic construction, expression and characterization, 2123
- Fusion toxins
 - DAB₄₈₆IL-2
 - Phase I trial, hematological cancers, 3930
- Fv molecules
 - 741F8 anti-*c-erbB-2* single-chain Fv
 - monovalent and divalent forms, *in vivo* tumor targeting, 4026
- G**
- Galactoside
 - binding lectin
 - regulation of expression, monocytic differentiation, 5033
- Galactin
 - mediated adhesion
 - A121 cells, detection of cellular galactin-binding glycoproteins, 2667
- Gallium nitrate
 - inhibition of protein tyrosine phosphatase, 1862
- Gangliosides
 - G_{M2} and G_{D2}
 - genetic and enzymatic basis, human cancer cell lines, 5395
 - G_{M3}
 - molecular cloning of monoclonal antibody, human cancers, 5244
 - lactotetraose series
 - 3',6'-isoL_{D1}, tumors of central nervous system, 120
- Gap junction
 - function and cancer, 3475
- Gastric neoplasms
 - base transitions
 - genetic changes at p53, 2614
 - high affinity binding sites
 - gastrin-releasing peptide, Ménétrier's mucosa, 5090
 - human cell line in chick embryo
 - TIMP-1, negative regulator of metastatic ability, 1397
 - monoclonal antibody 2B5
 - truncated mucin glycan, 4791
 - poorly differentiated type
 - genetic instability, pancreatic cancer, 5087
 - primary and metastatic
 - E-cadherin expression, 1690
 - tissue of type O individuals
 - biosynthetic basis, incompatible histoblood group A antigen, 5494
- Gastrin
 - expression and processing of progastrin
 - ovarian cancer, 1823
 - gene expression
 - normal human colon and colorectal adenocarcinoma, 2919
- Gastrin-releasing peptide
 - high affinity binding sites
 - human gastric cancer, Ménétrier's mucosa, 5090
- Gastritis
 - precancerous gastric lesions
 - high risk population, stomach cancer, 1317
- Gastrointestinal neoplasms
 - Phase I clinical trial
 - monoclonal antibody D612, metastatic gastrointestinal cancer, 4555
- Gastrointestinal tract
 - adenocarcinoma
 - vascular permeability factor, its receptors, 4727
 - human cancer cell lines
 - antiproliferative effects, isoflavones, 5815
 - inhibition of oxonic acid
 - 5-fluorouracil, no loss of antitumor activity, 4004
- Gelatinase
 - 72-kDa
 - interstitial collagenase and stromelysin, tumor cell-derived collagenase-stimulatory factor, 3154
- Gel electrophoresis
 - individual cells
 - quantification of hypoxic fraction, human breast cancers, 733
- Gene
 - AF-6
 - cloning of *ALL-1* fusion partner, acute myeloid leukemia, 5624
 - ALL-1
 - disruption in common region, epipodophyllotoxin-related secondary AML, 2954
 - rearrangements analyzed by Southern blot, chromosome 11q23 in acute leukemia, 3800
 - altered expression
 - oxy radicals and antioxidant responses, cancer, 3207
- AML1/ETO* fusion transcript
 - t(8;21) masked translocation, acute myelogenous leukemia, 4449
- analysis of *in vitro* progression
 - human papillomavirus-transfected cervical cells, 1167
- APC
 - messenger RNA, novel isoforms that lack exon 7, 5589
 - somatic and germ-line mutations, desmoid tumors, 5079
 - wild type and mutant gene products, 2728
- ataxia-telangiectasia
 - Fifth International Workshop, 438
- bcl-2*
 - modulation, nitrogen mustard and camptothecin induced apoptosis, 1853
 - regulation of oncoprotein, human neuroblastoma cells, 4978
 - tumor necrosis factor-mediated cytotoxicity, survival of mouse fibrosarcoma cells, 1456
- BCL-ABL*
 - role in human leukemia, 485
- bcl-2* oncoprotein
 - subcellular distribution, 4701
- bulk damage to DNA
 - teniposide antiproliferative activity, MCF-7 cells, 3547
- E-cadherin
 - differentiation marker, thyroid malignancies, 4987
- cancer susceptibility
 - polycyclic aromatic hydrocarbon-DNA adducts, human lung, 3486
- carcinoembryonic antigen
 - baculovirus recombinants, 2154
- α -catenin
 - reduction of E-cadherin levels, prostate cancer cells, 3585
- Ca²⁺-transporting ATPase isoform
 - cloning, von Hippel-Lindau syndrome, 861
- CDK4*
 - coamplification with *MDM2* and *GLI*, human sarcomas, 5535
- CEA-related
 - biliary glycoprotein, down-regulation in malignant mouse tissues, 4938
- cell density inhibition of proliferation
 - multiple histone promoter factors, osteosarcoma cells, 2399
- chimeric EWS-FL11 transcript
 - Ewing cell line, complex t(11;22;14) translocation, 3655
- chromosome mapping of murine susceptibility loci
 - liver carcinogenesis, 209
- complementary DNA
 - heparin-binding growth factor receptor, use of kinase insert sequence, 1136
- cyclin
 - amplification, colorectal carcinoma, 1986
- cyclin D1
 - breakpoints within *BCL-1* locus, B-cell lymphoma, 4148
- CYP1A1* and glutathione *S*-transferase

- polymorphisms, lung cancer susceptibility and cigarette dose, 2994
- DCC**
expression in human gliomas, 5606
loss of expression and heterozygosity, prostatic carcinoma, 2723
deleted region of chromosome 9
preliminary mapping, bladder cancer, 1230
detection and intervention
early ovarian cancer, 3839
dihydrofolate reductase
allelic variation at amino acid position 95, antifolate resistance in Chinese hamster cells, 6031
disease-causing *APC* alleles
rapid screening method, nonsense and frame-shift mutations, 5581
DNA topoisomerase II
response to heat shock stress, KB cells, 1085
DT-diaphorase
cigarette smoking as determinant, non-small cell lung carcinoma, 5458
elk-1 variant
differential splicing, encoding of activators and repressors, 215
epidermal growth factor receptor
TGF- α production and autoinduction, colorectal carcinoma cell line, 1630
erbB-2: see *erbB2*
ERCC-1
sensitivity of Chinese hamster ovary cells, DNA damaging agents, 3237
erythropoietin
down-modulation, induced megakaryocytic maturation, 1156
estrogen receptor
transcriptional control, estrogen receptor-negative breast carcinoma, 3472
EWS/*Fli-1* chimeric protein
transcriptional activator, 5859
expression and cell proliferation in liver 2,3,7,8-tetrachlorodibenzo-*p*-dioxin exposure, 2265
familial breast/ovarian cancer locus
deletion unit on chromosome 17q, epithelial ovarian tumors, 1218
fibronectin pre-mRNA alternative splicing
coordinate oncogene developmental modulation, liver tumor, 2005
fusion of *PAX3*
transcription factors, alveolar rhabdomyosarcoma, 5108
gastrin
expression, normal human colon and colorectal adenocarcinoma, 2919
genetic and enzymatic basis
G_{M2} and G_{D2} differential expression, human cancer cell lines, 5395
genetic modification of fraction of tumor mass
bystander effect, tumor regression, 5274
glutathione *S*-transferase μ polymorphism
marker for susceptibility, lung carcinoma, 2313
grc congenic strains of rats
different susceptibilities, chemical carcinogens, 4089
- growth factor B
platelet-derived growth factor β receptor and, genesis of choriocarcinoma, 2927
growth factor dependency
preneoplastic mouse mammary epithelial cells, 668
growth factor regulation of expression
human prostatic carcinoma cell line, 1051
heme oxygenase
singlet oxygen, UVA/near-visible light, 4505
heterogeneity in MLL/AF-4 fusion mRNA
polymerase chain reaction, t(4;11) acute leukemia, 3853
high efficiency transfer
primary human tumor explants, no cell selection, 2221
high mobility group protein I(Y)
increased expression, high grade prostatic cancer, 5512
progressive transformation, mouse mammary epithelial cells, 2655
- hinge**
human mitochondria, elevated expression in cancer, 2460
HIV-1 *tat*
endothelial proliferation, tumors of different histotypes, 5569
HNPPC
genetic instability of microsatellites, endometrial carcinoma, 5100
homeobox *HB24*
ability to form tumors in nude mice, human T-cell line, 373
- hprt**
profile of mutations, 7R,8S-dihydroxy-9S,10R-epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene, 3294
IGF2
maintenance of genomic imprinting, locus in hepatoblastoma, 4781
instability
clinicopathological variables and family history, colorectal cancer, 5849
instability in pancreatic cancer
poorly differentiated type, gastric cancer, 5087
insulin-like growth factor II
*Ava*II restriction fragment length polymorphism, occurrence of smooth muscle tumors, 5754
inhibition of expression, tamoxifen, 1727
- int-2**
growth-stimulating activity of IL-6, mammary epithelial cells, 2957
interferon
homozygous loss, critical region on 9p deleted in lung cancer, 2410
 α -interferon-inducible
human chromosome 14q32 expression, breast carcinoma, 4096
 α_1 -interferon transfer
metastatic Friend leukemia cells, abrogation of tumorigenicity, 1107
 γ -interferon
enhanced HLA molecule expression, human tumor infiltrating lymphocytes, 3561
- interleukin 2
protective and curative potential of vaccination, mouse mammary adenocarcinoma, 5067
transfection into melanoma cells, cellular immune response, 949
in vitro and *in vivo* targeting of expression
melanoma cells, 962
Ki-ras expression
production of transgenic mice, thyroglobulin promoter, 5523
- LacZ**
cotransfection of MCF-7 cells with fibroblast growth factor 4, spontaneous metastasis, 2178
lacZ reporter
quantitative analysis, disseminated tumor growth within brain, 176
limited molecular heterogeneity
allelotyping and clonal analysis, metastatic breast carcinoma, 3804
linkage analysis of *DRD2*
ataxia-telangiectasia gene, premenopausal bilateral breast cancer, 5083
loss of heterozygosity
invasive low-grade and high-grade epithelial ovarian carcinoma, 4456
M, 170,000 isozyme
single-strand conformational polymorphism, DNA topoisomerase II, 1373
MAGE-1/MAGE-2/MAGE-3
messenger RNA expression, transformed and normal human cell lines, 5
- MDM2**
amplification, metastatic osteosarcoma, 16
amplification and overexpression, glioma without *p53* mutation, 2736
amplification in pediatric solid tumors, lack of association with *p53* in adult squamous cell carcinoma, 6028
MDM2 amplification
p53 mutation, human soft tissue sarcoma, 2231
- mdr1**
P-glycoprotein external epitope, monoclonal antibody, 310
- mdr3**
transcriptional activation, multidrug-resistant P388 tumor cells, 1657
mechanisms of drug-induced changes
heat shock proteins, differentiation, 3034
monoclonal antibody
self-reactive antibody expression, human carcinoma cells, 3355
monomorphic *NAT1* and polymorphic *NAT2*
metabolic activation of *N*-hydroxy-2-aminofluorene, colon cytosols, 509
- MRP**
non-P-glycoprotein multidrug resistance, 190-kDa membrane bound glycoprotein, 3658
transmembrane drug transporter, multidrug-resistance lung cancer cell lines, 1747
- MUC-1**
mucin synthesis and secretion, epithelial cancer cell lines, 1437

- mucin
heterogeneity of expression, normal and neoplastic tissues, 641
multidrug resistance-associated localization, HT1080/DR4 and H69AR human tumor cell lines, 3221
mutated *WT1*
altered *trans*-activational properties, WAGR-associated Wilms' tumor, 4757
nm23
mutation associated with metastasis, colorectal cancer, 717
transfection and inhibition of cell motility, human and murine tumor cells, 1971
N-ras
presence of point mutations, radiation-transformed rat embryo cells, 1511
oligodendrocyte-associated human glioma and neuroblastoma cell lines, 170
ornithine decarboxylase and ribonucleotide reductase R2 subunit resistance to hydroxyurea, K562 cells, 5262
overexpressed
cloning, mammary carcinoma suppressor, 5766
parathyroid hormone-related protein PCR analysis, breast cancer and bone metastases, 5076
p53-binding protein *MDM2*
differential expression, human breast carcinoma, 3226
plasmid reporter
inactivation of expression, one benzo(a)pyrene diol-epoxide DNA adduct in hepatocytes, 2279
predisposition
transplacentally induced renal cell carcinoma, Eker rat, 5856
progastrin
ovarian cancer, 1823
prostatic nerve growth factor inducible A binding of novel element, retinoblastoma gene promoter, 5597
Ptprg
carbonic anhydrase-like domain, homozygous deletion in L-cells, 1498
ras mutations
detection in pancreatic juice and peripheral blood, pancreatic adenocarcinoma, 2472
rearrangement in Adriamycin-resistant P388 leukemia
DNA topoisomerase II α , 5885
retroviral-mediated transfer
treatment of brain tumors, rats, 83
scid
complementation of radiosensitive phenotype, chromosome 8, 6011
stromelysin 3
local invasiveness, head and neck squamous cell carcinoma, 165
supF
sequence specificity, stereoisomeric benzo(c)phenanthrene dihydrodiol epoxides, 1273
susceptibility in SWXJ strains of mice
C19 androgen induction, ovarian granulosa cell tumorigenesis, 1059
T-cell receptor
DNA sequence analysis, oligoclonal T-cell response, 840
therapy
cytokine-modified renal carcinoma cells, 4020
three regions on chromosome 17q frequent deletion, primary human breast carcinomas, 5617
thymidine kinase
herpes simplex virus, inhibition of melanoma growth by intratumoral DNA injection, 3860
TP53 mutations
esophageal squamous cell carcinoma, 5745
transcriptional activity
inactive *p53* mutants, wild-type *p53*, 4772
selective removal from epidermis, ultraviolet-induced cyclobutane pyrimidine dimers, 1642
transfection and expression
folate binding protein, NIH/3T3 cells, 5791
transforming
presence in gonadal tumors, bivalve mollusk species, 2976
ubiquitin-ribosomal protein S27a early growth response gene, human colorectal carcinoma, 1916
WT1
granulosa cell and other sex cord-stromal tumors, 2712
Genistein
antiproliferative effects of isoflavones gastrointestinal tract, human cancer cell lines, 5815
arrest of cell cycle progression
G₂-M, 1328
Genomic imprinting
maintenance of
IGF2 locus, hepatoblastoma, 4781
Genotoxicity
benzene and phenolic metabolites oxidative DNA damage, HL-60 cells and bone marrow, 1023
DNA-protein cross-links
molecular implications, welders, 460
induction of cell proliferation in forestomach
styrene 7,8-oxide, butylated hydroxyanisole, 3505
Germ cell neoplasms
Phase I trial with autologous bone marrow transplantation
carboplatin, etoposide and cyclophosphamide, 3730
GF120918
reversal of multidrug resistance, 4595
Glial cells
normal and malignant
phosphorylation of elongation factor 2, 2260
Glial fibrillary acidic protein
transfection of human astrocytoma cells
expression, proliferation and tumorigenicity, 3624
Glioblastoma
chromosome 10 loss
functional role, 5043
elevated levels
M, 92,000 type IV collagenases, brain, 2208
human brain metastases
metastasis-related CD44 expression, 5345
modulation of *in vitro* invasion
urokinase-type plasminogen activator receptor antibody, 4143
retroviral-mediated gene transfer
brain tumors in rats, 83
topoisomerase II inhibition and altered kinetics
nitrosourea and cisplatin-induced DNA cross-links, cytotoxicity, 5663
Glioma
elevated levels
M, 92,000 type IV collagenases, brain, 2208
expression of tumor suppressor gene
DCC, 5605
human cells in adult rat brain
migratory pattern, fetal rat brain cells, 5158
localization of chromosome 9p homozygous deletions
continuous linkage group, 3674
model of tumor angiogenesis
up-regulation of vascular endothelial growth factor, cognate receptors, 5822
oligodendrocyte-associated genes, 170
sensitivity of human cells
mild hyperthermia, 2740
treatment by engineered interleukin 4-secreting cells, 3125
Turcot's syndrome
absence of germ line mutations, *p53* gene, 957
without *p53* mutation
amplification and overexpression, *MDM2* gene, 2736
xenografts
intraarterial therapy, 4-hydroperoxycyclophosphamide, 2338
Glucocorticoids
alternatively spliced glucocorticoid receptor mRNAs
human multiple myeloma cells, 3877
disruption of transforming growth factor α autocrine loop
suppression of growth, rat mammary adenocarcinoma cells, 1808
-mediated suppression of mammary tumor growth
overexpression, transforming growth factor α , 1816
requirement for growth
HPV16-transformed rat kidney epithelial cells, 4432
-sensitive and -resistant leukemic cells
cloning and expression, mutant glucocorticoid receptors, 4059
Glucose
transporter protein GLUT 2
reduction in expression, preneoplastic and neoplastic hepatic lesions, 4204
 α -Glucosidase
inhibition of metastasis
1,6-epi-cyclophellitol, 4896
 γ -Glutamylcysteine synthetase

- variable messenger RNA expression
 - peripheral mononuclear cells, buthionine sulfoximine treatment, 3662
- γ -Glutamyl hydrolase
 - enhanced activity
 - acquisition of resistance to antifolates, 2227
- Glutathione
 - depletion by L-buthionine sulfoximine antagonism, taxol cytotoxicity, 2066
 - oxy radicals and antioxidative responses in cancer, 3207
 - reduced
 - cisplatin-induced neurotoxicity, rats, 544
- Glutathione *S*-reductase
 - expression of aldo-keto reductase resistance to aflatoxin B₁, catalytic activity, 3887
- Glutathione *S*-transferase
 - bifunctional inhibitor W-77
 - enhanced Adriamycin activity, human ovarian carcinoma, 2051
 - class α transcripts
 - carcinogen exposure, hepatocytes, 231
 - complementary DNA
 - alkylator-induced toxicity, rat mammary carcinoma cells, 4900
 - cytosolic
 - chemical sensitivity, drug-resistant L5178Y murine lymphoblasts, 3530
 - immunohistochemical localization
 - human lung, 5643
 - polymorphisms
 - lung cancer susceptibility, cigarette dose, 2994
- Glutathione *S*-transferase μ
 - cancer susceptibility genes
 - polycyclic aromatic hydrocarbon-DNA adducts, human lung, 3486
 - isoenzymes
 - genotype and phenotype, lung cancer, 1004
 - polymorphism
 - marker for susceptibility, lung carcinoma, 2313
- Glutathione transferase M3-3
 - 1,3-bis(2-chloroethyl)-1-nitrosourea resistance
 - non-small cell lung cancer cell line, 4257
- Glycan
 - truncated mucin
 - monoclonal antibody 2B5, gastric and duodenal glands, 4791
- Glyceraldehyde-3-phosphate dehydrogenase
 - association with cell motility
 - metastatic potential, prostatic adenocarcinoma, 1995
- Glycolipid sulfotransferase
 - involvement of protein kinase C
 - activity levels, renal cell carcinoma cells, 2484
 - regulation of activity levels
 - transforming growth factor α , renal cell carcinoma cells, 5638
- Glycolipids
 - Gb3/CD77 antigen
 - induction of apoptosis, Burkitt's lymphoma, 5314
- Glycoprotein 2
 - sulfated
 - carcinogenesis induced by *N*-nitroso-*N*-methylurea, prostate and seminal vesicle, 1480
- Glycoproteins
 - biliary
 - CEA-related gene, down-regulation in malignant mouse tissues, 4938
 - differential regulation of carcinoembryonic antigen, γ -interferon, 1612
 - IIB/IIIA binding to fibrinogen
 - inhibition, tumor cell membrane proteins, 221
 - M*_r 190,000 membrane bound
 - MRP* gene, non-P-glycoprotein multidrug resistance, 3658
 - platelet membrane Ib/IX and IIb/IIIa
 - platelet α -granule proteins, aggregation induced by osteosarcoma cells, 4695
 - sialyl-Le^x-carrying
 - discrimination of MUC1 mucins, colon carcinoma, 755
- Glycosaminoglycan
 - suramin
 - multiple potential mechanisms of action, 2239
- Glycosphingolipids
 - compensatory occurrence of IV²Fuca, II³NeuAc α -G₂Cer
 - human fetal antigen Lc₄Cer and, small cell lung carcinoma, 5903
- Glycosyltransferases
 - blood group Le^x carbohydrate antigen
 - subcellular localization, endometrial cancer cells, 3643
- G nucleotides
 - incidence of *p53* mutations
 - progression, head and neck cancer, 4477
- Golgi apparatus
 - blood group Le^x carbohydrate antigen
 - subcellular localization, endometrial cancer cells, 3643
- Gonadal neoplasms
 - presence of transforming genes
 - bivalve mollusk species, 2976
- gp46
 - immunogenic and neutralizing domain
 - sequence analysis, HTLV-I, 6067
- gp110
 - tumor rejection antigen
 - BALB/c Meth A sarcoma, 1602
- Grants
 - trends in program project grant funding
 - National Cancer Institute, 477
- Granulocytes
 - differentiating HL-60 cells
 - transforming growth factor- α protooncogene, 191
 - recovery
 - sequential production, autologous stem cell transplantation, 1297
- Granulosa cell neoplasms
 - WT1* analysis, 2712
- Granulosa cells
 - ovarian
 - tumorigenesis, androgen induction and genetic susceptibility, 1059
 - tumorigenesis
 - genetically hypogonadal-immunodeficient mice grafted with ovaries from tumor-susceptible donors, 3741
- Growth factors
 - dependency and gene expression
 - preneoplastic mouse mammary epithelial cells, 668
 - differential production
 - high and low metastatic variants, B16BL6 melanoma, 4075
 - diverse chemical carcinogens and
 - hepatocarcinogenesis, TGF- α transgenic mice, 4329
 - epidermal growth factor-like
 - inhibition of secretion by vitamin A, tracheobronchial epithelial cells, 2527
 - heparin-binding growth/differentiation factors
 - new family of, Wilms' tumor and other human carcinomas, 1281
 - lack of latent transforming growth factor β binding protein
 - malignant prostatic tissue, 3193
 - like properties
 - parathyroid hormone-related peptide, transfected rodent cell lines, 2980
 - nuclear oncogenes and
 - tumorigenesis, transgenic mouse model, 1719
 - peptide
 - regulation of fibroblast growth factor/scatter factor, breast carcinoma cell lines, 1233
 - platelet-derived
 - prognostic significance, epithelial ovarian neoplasms, 4550
 - regulation of gene expression
 - human prostatic carcinoma cell line, 1051
 - suramin
 - multiple potential mechanisms of action, 2239
- Growth hormone
 - insulin-like growth factor 1 axis
 - diet restriction-induced inhibition, mononuclear cell leukemia, 2750
 - preservation of lean body mass
 - doxorubicin treatment, sarcoma-bearing rats, 5483
- GRP78
 - suppression of induction in B/C10ME tumor
 - elimination of resistance, cell-mediated cytotoxicity, 6001
- H
- Haptotaxis
 - chemotaxis and
 - autocrine motility factor-like substance, human malignant mesothelioma cells, 4376
- H69AR cells
 - localization
 - multidrug resistance-associated gene, 3221
- H-2 complex
 - H-2D^b
 - radiation-enhanced expression, B16 melanoma cells, 1952
- Head and neck cancer
 - discordant *p53* gene mutations, 1676
 - multistage tumorigenesis
 - increased polysomies, chromosomes 7 and 17, 2874

- pharynx preservation
cancer chemoprevention, 5113
- Heart**
cardioprotective properties
 O-(β -hydroxyethyl)-rutosides, doxorubicin-pretreated BALB/c mice, 4603
mitochondrial cytochrome *c* oxidase target site for daunomycin, 1072
neonatal rat cells
 mitoxantrone cardiotoxicity, protection with ICRF-187, 550
- Heat**
-induced changes in blood flow and cell survival
 influence, vascular thermotolerance, 2076
- Heat shock proteins**
failure to increase levels
 oxidative injury, activation of heat shock transcription factor, 12
hsp27
 growth and drug resistance, breast cancer cell lines, 4443
hsp60
 recognition of CD4⁺ T-cells, syngeneic fibrosarcoma, 106
 mechanisms of drug-induced changes
 gene expression, HL-60 cell differentiation, 3034
 M, 73,000
 protein interaction, retinoblastoma gene product pRB110, 1702
- Heat shock stress**
enhanced expression of DNA topoisomerase II gene
 KB cells, 1085
- HeLa cells**
differential effect of ionizing radiation
 cyclin A and cyclin B, 1128
 extracts from normal and malignantly transformed human cells
 fidelity, DNA replication, 3270
 inhibition of oxidative stress
 chemopreventive agents, 4528
 radiation yield of interphase chromosome breaks
 mitosis-promoting factor activity, inducer mitotic cells, 5592
- HeLa S3 cells**
induction of protein-DNA complexes
 KW-2149, 4466
- Hematological neoplasms**
cell proliferation marker
 cyclin A expression, 235
 Phase I trial of 90-minute infusion
 fusion toxin DAB₄₈₆IL-2, 3930
- Hematopoiesis**
autologous stem cell transplantation
 sequential production, granulocyte recovery, 1297
 differentiating HL-60 cells
 transforming growth factor- α protooncogene, 191
 normal and neoplastic growth and development, 929
- Hematopoietic cells**
malignant cell lines unresponsive to retinoic acid
 N-(4-hydroxyphenyl)retinamide, induction of apoptosis, 6036
 suppression of apoptosis
 activation, Abelson tyrosine kinase activity, 1735
- Hematopoietic growth factor**
induced megakaryocytic maturation
 down-modulation, erythropoietin gene expression, 1156
- Hematopoietic progenitors**
heterogeneity of lineage derivation
 Philadelphia-positive acute lymphoblastic leukemia, 3289
- Heme**
tumor cell uptake
 induction of ferritin synthesis, altered oxidant sensitivity, 5308
- Heme oxygenase**
enhancement of expression and activity
 A431 squamous carcinoma multicellular tumor spheroids, 2700
 gene induction
 singlet oxygen, UVA/near-visible light, 4505
- Hemoglobin**
4-(methylnitrosamino)-1-(pyridyl)-1-butanone adducts
 red blood cells, 777
- Hemostasis**
platelet glycoprotein IIB/IIIA binding to fibrinogen
 inhibition, tumor cell membrane proteins, 221
- Heparin**
-binding growth/differentiation factors
 new family of, Wilms' tumor and other human carcinomas, 1281
-binding growth factor receptor
 complementary DNA, use of kinase insert sequence, 1136
-steroid conjugates
 angiogenesis inhibitors, antitumor activity, 3000
suramin
 multiple potential mechanisms of action, 2239
- Hepatitis**
early detection of hepatocellular carcinoma
 lectin-reactive α -fetoproteins, 5419
- Hepatitis B**
viral antigens
 immune reactions, rejection of hepatocellular carcinoma, 4648
- Hepatitis virus, woodchuck**
precancerous altered hepatic foci
 N-myc 2 and insulin-like growth factor II, 2020
- Hepatoblastoma**
IGF2 locus
 maintenance, genomic imprinting, 4781
- Hepatocarcinogenesis**
N-acetylglucosaminyltransferase III and V
 LEC rats, 3899
 diethylnitrosamine-induced
 chemoprevention, protocatechuic acid, 2775
 growth factors and diverse chemical carcinogens
 TGF- α transgenic mice, 4329
 initiation and postinitiation stages
 chemopreventive effects, dietary DL- α -difluoromethylornithine, 3903
- reduction in expression
 glucose transporter protein GLUT 2, reexpression of GLUT 1, 4204
- Hepatocarcinogenicity**
DNA adduct formation and
 toremifene and tamoxifen, 4534
- Hepatocyte growth factor**
-scatter factor regulation
 peptide growth factors, breast carcinoma cell lines, 1233
- Hepatocytes**
adhesion
 integrin $\alpha_6\beta_4$, TA3/Ha mammary carcinoma cells, 3611
fetal rat
 transformation-induced alterations, tyrosine aminotransferase expression, 515
 glutathione *S*-transferase class α transcripts
 carcinogen exposure, 231
human cord serum α -fetoprotein
 sugar chains, hepatocellular carcinoma, 2970
inactivation of plasmid reporter gene expression
 one benzo(*a*)pyrene diol-epoxide DNA adduct, 2279
primary rat cell cultures
 effect of age, formation of small-cell colonies, 3145
- Hepatoma**
multidrug resistance
 bovine serum albumin-doxorubicin conjugate, 4238
- Hepatoma cells**
Kupffer cell-induced reduction of mitochondrial energization
 mediation by nitric oxide, 2676
proliferating
 effects of cisplatin, induction of apoptosis, 2133
- Hepatotoxicity**
4-ipomeanol
 Phase I and pharmacological study, lung cancer, 1794
- HepG2 cells**
insulin-like growth factor II expression
 promotion by suramin, inhibition of growth, 652
- Heregulin**
induction of ICAM-1
 implications, mammary tumors, 5251
- Her-2/*neu***
expression in node-negative breast cancer, 4960
- Herpes simplex virus**
thymidine kinase gene
 inhibition of murine melanoma growth, intratumoral injection of DNA, 3860
- Heterotransplantation**
solubilized attachment matrix
 early B-lineage acute lymphoblastic leukemia, 1222
- Hexamethylene bisacetamide**
differential modulation
 protein kinase C isoforms, erythroleukemia during induced differentiation, 5554
- Hexosamines**
production of immunosuppressive ami-

- nosugars
deacetylase activity, human tumor cells, 5600
- High mobility group protein I(Y)**
elevated gene expression
progressive transformation, mammary epithelial cells, 2655
increased expression
high grade prostatic cancer, 5512
- Histone**
messenger RNA levels and p34^{cdc2} activation
caffeine release, radiation-induced S and G₂ phase arrest, 1507
promoter factors
cell density inhibition of proliferation, osteosarcoma cells, 2399
- Histopathology**
correlations
allelic deletions, renal tumors, 5780
- HLA complex**
-A and -B antigens
induction and antigenic profile, differential effect of β_2 -microglobulin in FO-1 melanoma cells, 4303
class I
sporadic adenomas, histologically normal mucosa of colon, 2374
differential expression of *MAGE-1*/*MAGE-2*/*MAGE-3*
messenger RNA, transformed and normal human cell lines, 5
DR antigen expression
signal transduction, malignant and nonmalignant human thyroid cells, 3943
enhanced expression of molecules
stimulation of tumor infiltrating lymphocytes, transduction of melanoma cells, 3561
human epithelial ovarian cancer allelotype, 2393
loss of class I allospecificities
staining of melanoma cells, melanoma cells, 3349
- HL-60 cells**
differentiation
drug-induced changes in gene expression, constitutive heat shock protein, 3034
transforming growth factor- α protooncogene expression, 191
etoposide-induced apoptosis
intracellular acidification, 2349
induction of apoptosis and cell cycle effects
prevention by caffeine, camptothecin or topotecan, 4613
oxidative DNA damage
benzene and phenolic metabolites, 1023
susceptibility to apoptosis
cell cycle differences, induction by various antitumor agents, 3186
- HML-1**
binding of intestinal intraepithelial cells
colon cancer cells, 1608
- Hodgkin's disease**
advanced
serum interleukin 6 levels, correlation with survival, 2118
- Hoechst 33342**
- mammalian DNA topoisomerase I poison
cytotoxicity and drug resistance, human cell cultures, 1332
- Hormones**
regulation of human prostate organ culture, 5199
- H-ras**
codons 12 and 13
DNA synthesis interruption, DNA polymerase α , 2895
infrequency of mutation
bladder cancer, 133
insertion in human colonic Caco-2 cells
increased protein kinase C α expression, 2762
-transformed cells
basic fibroblast growth factor complementary DNA, 158
- HT1080 cells**
inhibition of invasion
recombinant plasminogen activator inhibitor, 6051
- HT1080/DR4 cells**
localization
multidrug resistance-associated gene, 3221
- HTLV-I**
sequence analysis
immunogenic and neutralizing domain, gp46 surface membrane protein, 6067
- Human immunodeficiency virus-1**
systemic expression of *tat* gene
endothelial proliferation, tumors of different histotypes, 5569
Tat protein
protection from apoptosis, 4481
- Human papillomavirus**
high-risk infections
overexpression of p53 protein, transitional cell carcinoma of the urinary bladder, 4823
malignant transformation of cutaneous lesions
renal allografts, 5328
-transfected human cervical cells
genetic analysis, *in vitro* progression, 1167
type 16
immortalization, normal human ectocervical epithelial cells, 4511
N-methyl-*N'*-nitro-*N*-nitrosoguanidine, oral carcinogenesis, 4811
retinoic acid inhibition, transformation of keratinocytes, 905
type 16 transformed rat kidney epithelial cells
glucocorticoid requirement for growth, 4432
type 18-specific antisense oligonucleotides
transformed phenotype, human carcinoma cell lines, 2330
- Hyaluron**
factors to stimulate production
human mesothelioma cells, fibroblasts, 388
- Hydrocarbons, aromatic**
major metabolites of cyclopenta[*c,d*]pyrene
sulfoltransferase-mediated activation, 1017
- Hydrocarbons, polycyclic aromatic**
-DNA adducts
cancer susceptibility genes, human lung, 3486
hepatic cellular distribution
cytochrome P-450 IA1, rainbow trout, 3700
- Hydrolyzed benzoquinone mustard**
chemical sensitivity
cytosolic glutathione *S*-transferases, drug-resistant L5178Y murine lymphoblasts, 3530
- Hydronephrosis**
-bearing rats of SD/cShi strain
induction of renal pelvic carcinoma, phenacetin, 4218
- Hydroperoxides**
lipid
oxidative catabolism of all-*trans*-retinoic acid, human microsomes, 1226
- 4-Hydroperoxycyclophosphamide**
intraarterial therapy
human glioma xenografts, 2338
-purged marrow in women with metastatic breast cancer
acceleration of granulocyte recovery, granulocyte colony-stimulating factor, 5424
- 4-Hydroxy-3,4-dihydrocyclopenta[*c,d*]pyrene**
sulfoltransferase-mediated activation, 1017
- N*-Hydroxy-2-acetylaminofluorene**
metabolic activation by NAT1 and NAT2
colon cytosols, Syrian hamsters congenic at *NAT2* locus, 509
- O*-(β -Hydroxyethyl)-rutosides**
cardioprotective properties
doxorubicin-pretreated BALB/c mice, 4603
- N*-(4-Hydroxyphenyl)retinamide**
induction of apoptosis
malignant hematopoietic cell lines, no response to retinoic acid, 6036
- Hydroxyurea**
development of resistance
 α -difluoromethylornithine, treatment of K562 cells, 5262
- Hypercalcemia**
reversal of
neutralizing antibodies to interleukin 6, human squamous carcinoma, 737
- Hypersensitivity, delayed-type**
reactions to tumor-associated antigens
autologous tumor cell/*Bacillus Calmette-Guérin* vaccine, colon carcinoma, 456
- Hypertension**
angiotensin II-induced
tumor blood flow, interstitial fluid pressure, 2466
- Hyperthermia**
antitumor effects
role of active oxygen species, lipid peroxidation, 2326
cisplatin at 41.5°C during G₁ or late S phase
cell killing and chromosomal aberrations, Chinese hamster ovary cells, 1239
effects of temperature

- therapeutic efficacy, ifosfamide pharmacokinetics, 4268
- induction of resistance to UVB primary and immortalized epidermal keratinocytes, 4952
- influence of vascular thermotolerance heat-induced changes, cell survival in tumors, 2076
- interleukin 1 α and antitumor effect, 324
- mild sensitivity of human cells, 2740
- SR 4233 and antitumor effects of radioimmunotherapy, nude mice with human colonic adenocarcinoma xenografts, 3022
- Hypothalamus**
prenatal exposure to diethylstilbestrol pituitary tumors, 1546
- Hypoxanthine phosphoribosyltransferase gene in V-79 cells**
profile of mutations, 7R,8S-dihydroxy-9S,10R-epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene, 3294
- Hypoxia**
dicumarol and adducts of mitomycin C and DNA, EMT6 mouse mammary tumor cells, 5127
- mammalian cell radiosensitization nitric oxide, 5845
- quantification of hypoxic fraction gel electrophoresis of individual cells, human breast cancer, 733
- unusual oxygen concentration toxicity of SR-4233, 3992
- Hypoxic cells**
detection by monoclonal antibody recognition, 2-nitroimidazole adducts, 5721
- I**
- IA-1**
marker for neuroendocrine differentiation human lung cancer cell lines, 4169
- ICAM-1**
clinical relevance of expression primary lesions, serum of patients with malignant melanoma, 4927
- induction by heregulin implications, mammary tumors, 5251
- γ -interferon-induced bifunctional antibody-mediated lysis, LFA-1-dependent mechanism, 4652
- transduction of retinoic acid and γ -interferon human tumor cell lines, 826
- Iceland**
somatic p53 mutations human breast carcinoma, 1637
- ICI 182,780**
inhibition insulin-like growth factor I gene expression, stimulation by tamoxifen, 5585
- sensitivity of MCF7/LCC2 cells, 3229
- ICRF-187**
protection from mitoxantrone cardiotoxicity neonatal rat heart cells, 550
- Ifosfamide**
cyclophosphamide and differential activation by cytochromes P-450 2B and 3A, liver microsomes, 5629
- pharmacokinetics effects of temperature, therapeutic efficacy, 4268
- pharmacokinetics and metabolism continuous infusion, children, 3758
- Image analysis**
computerized HER-2/*neu* expression, node-negative breast cancer, 4960
- Imiquimod**
oral immunomodulator and interferon inducer Phase I trial, 5176
- Immortalization**
Syrian hamster embryo cells, 4797
- Immune cells**
local and systemic activation peritumoral IL-2 injections, advanced squamous cell carcinoma of the head and neck, 5654
- Immune response**
humoral tumor immunity, recombinant SV40 large tumor antigen and monoclonal anti-idiotypic, 5734
- Immunization**
active protection, cerebral metastases of melanoma B16, 1113
- Immunoassays**
radio- and enzyme monoclonal antibody, pharmacokinetics of S 12363, 3536
- Immunobead-polymerase chain reaction**
detection of circulating tumor cells, 3455
- Immunochemotherapy**
site-specific prodrug activation antibody- β -lactamase conjugates, colon carcinoma xenograft models, 3956
- Immunoconjugates**
daunomycin-antibody management, soft tissue sarcomas, 5740
- Immunocytochemistry**
estrogen receptor levels and improved prediction of survival, advanced ovarian adenocarcinoma, 5188
- Immunoelectron microscopy**
localization of transforming growth factor- β 1 TGF- β 1 binding protein, gastrointestinal carcinoma, 183
- Immunogen**
immunotargeting of head and neck cancer monoclonal antibody U36, 4383
- Immunoglobulin G**
-mediated therapy ¹⁸⁶Re-labeled E48, human head and neck squamous cell carcinoma xenografts, 3524
- monoclonal antibody homodimers enhanced antitumor activity, nude mice, 2560
- Immunoglobulin H**
rearrangements and Ly-1⁺ "normal" spleens and lymphomas, AKR/J and AKR Fv-1^b mice, 2147
- Immunoglobulins**
clonal gene rearrangement coexistence of aneuploid subclones, 5320
- DNA double strand break repair defect acid mice, 1244
- theophylline-induced differentiation deregulation of c-myc, Burkitt's lymphoma, 127
- Immunohistochemistry**
hepatic cellular distribution cytochrome P-450 1A1, rainbow trout, 3700
- HER-2/*neu* expression node-negative breast cancer, 4960
- localization parathyroid hormone-related protein, human prostate cancer, 1724
- localization of glutathione S-transferases human lung, 5643
- Immunomodulator**
oral interferon inducer and, Phase I trial, 5176
- Immunoscintigraphy**
¹³¹I-labeled monoclonal antibody COU-1 suspected colorectal carcinoma, 5920
- Immunosuppression**
enhanced activity metastatic lymphoma cells, 1921
- Immunotherapy**
adoptive tracking of tumor-infiltrating lymphocytes, LAK cells, 2358
- vaccine-primed T-cells, secondary sensitization to tumor, 1043
- differential expression of *MAGE-1*/*MAGE-3* messenger RNA, transformed and normal human cell lines, 5
- human carcinoma cells engineered with mAb genes self-reactive antibody expression, 3355
- human interleukin 2 analogues reduced secondary cytokine secretion, 2597
- imaging of activated natural killer cells positron emission tomography, preferential uptake in tumors, 5867
- mouse anti-idiotypic monoclonal antibody MK2-23 modulation by adjuvants, carriers of immunogenicity, 112
- quantitative analysis of *lacZ* reporter gene disseminated tumor growth within brain, 176
- src*-specific immune regression Rous sarcoma virus-induced tumors, 915
- target for peptide-induced CD8⁺ cytotoxic T-cells mutant p53 tumor suppressor protein, 3257
- Immunotoxins**
anti-B4-blocked ricin therapeutic efficacy, different SCID mouse tumor models, 1360
- BR96 sFV-PE40 selective killing, carcinoma cells, 334

- entry of protein toxins
 polarized epithelial cells, 1755
 eradication of small cell lung cancer cells
 bone marrow, 3784
 no proteolysis required for activity
 recombinant form, *Pseudomonas* exo-
 toxin A, 340
 pharmacokinetics and toxicology
 administration into the subarachnoid
 space, nonhuman primates and ro-
 dents, 3752
Pseudomonas exotoxin-based
 antibody LL2 or LL2-Fab', regression
 of B-cell lymphoma, 819
 spatial distribution in solid tumors
 quantitative autoradiography, 2092
 transferrin receptor-targeted
 efficacy, pediatric brain tumors, 1348
- Inflammation**
 lipopolysaccharide-induced
 rat urinary bladder tumorigenesis,
 5172
- Infrared spectroscopy**
 distinct patterns
 human basal cell carcinoma, skin, 762
- Inhibin**
 prostatic
 suppression of tumor growth, Dunning
 R3327G rat tumor, 4855
- Insulin**
 inhibition of binding to receptors
 dimethyl sulfoxide, human leukemia
 cells, 1142
- Insulin-like growth factor**
 -binding protein-2
 regulation of insulin-like growth factor
 action, lung tumors, 4680
 -binding proteins
 estrogen and antiestrogen modulation,
 MCF7 cells, 5193
 receptor inhibition
 human melanoma, athymic mice, 2522
- Insulin-like growth factor I**
 axis
 diet restriction-induced inhibition,
 mononuclear cell leukemia, 2750
 gene expression in uterus
 stimulation by tamoxifen, inhibition
 by ICI 182780, 5585
 human lung fibroblast-derived IGF-I and
 stimulation of proliferation, lung car-
 cinoma cells, 3399
 human primary brain tumors, 2475
 inhibition of gene expression
 tamoxifen, 1727
 normal human mesothelial cells
 mesothelial cell lines, 2858
 peptide analogues
 inhibition of growth, prostatic cancer
 cell lines, 1102
 plasma
 lowering of level by fenretinide, breast
 cancer, 4769
 receptor increase
 estrogen-induced kidney tumors, 2256
 receptor overexpression
 low risk, human breast cancer, 3736
- Insulin-like growth factor II**
 gene
*Ava*II restriction fragment length poly-
 morphism, occurrence of smooth
 muscle tumors, 5754
- N-myc-2** and
 precancerous altered hepatic foci,
 woodchuck hepatitis virus carriers,
 2020
 promotion of expression by suramin
 inhibition of growth, HepG2 cells, 652
 WT1 transcript localization and
 human fetal kidney, Wilms' tumor,
 5166
- Integrins**
 α_6
 neoplastic transformation and tumori-
 genic conversion, fibroblasts, 2950
 regulation by laminin, tumor cell
 chemotaxis receptor, 2661
 $\alpha_6\beta_4$
 suprabasal expression, malignant pro-
 gression in skin carcinogenesis,
 4803
 TA3/Ha mammary carcinoma cells,
 adhesion to hepatocytes, 3611
 $\alpha_4\beta_3$ and $\alpha_5\beta_1$
 72 kDa type IV collagenase, mela-
 noma cell invasion, 3411
 β_2
 monocyte-mediated leukemic cell
 death, tumor necrosis factor α , 4399
 gap junction function and cancer, 3475
 signaling
 implications for tumorigenesis, 1503
- Interferon**
 cytokinetic effects
 colorectal cancer, 5429
 genes
 homozygous loss, critical region on 9p
 deleted in lung cancer, 2410
 inducer
 oral immunomodulator, Phase I trial,
 5176
 α -Interferon
 -inducible gene on chromosome 14q32
 expression in breast carcinoma, 4096
 inhibitory effects
 epidermal growth factor-mediated re-
 ceptor-dependent events, 5148
 localization of chromosome 9p homozy-
 gous deletions
 continuous linkage group, glioma cell
 lines, 3674
 tamoxifen and
 modulatory effects, doxorubicin resist-
 ance, 3040
 tumor-specific lysis by tumor-infiltrating
 lymphocytes
 renal cell carcinoma, 4020
 with and without
 immunological and clinical effects, in-
 terleukin 2, 1286
 $\alpha 1$ -Interferon
 gene transfer into Friend leukemia cells
 abrogation of tumorigenicity, immuno-
 competent mice, 1107
 $\alpha 2a$ -Interferon
 5-fluorouracil and leucovorin
 locus of interaction, colon carcinoma
 cells, 4243
 $\alpha 2b$ -Interferon
 cyclophosphamide/doxorubicin/5-fluo-
 rouracil
 Phase I trial, advanced breast cancer,
 3509
 γ -Interferon
- cytokine regulation
 human monocyte differentiation, 2603
 differential regulation
 carcinoembryonic antigen, biliary gly-
 coprotein, 1612
 $1\alpha,25$ -dihydroxyvitamin D₃ and
 block of lung tumor production, GM-
 CSF and induction of immunosup-
 pressor cells, 6006
- gene
 enhanced HLA molecule expression,
 human tumor infiltrating lympho-
 cytes, 3561
¹³¹I-CC49 and
 improved radioimmunotherapeutic ef-
 ficacy, 600
 -induced ICAM-1
 bifunctional antibody-mediated lysis,
 LFA-1-dependent mechanism, 4652
 retinoic acid and
 ICAM-1 expression, human tumor cell
 lines, 826
 role in T-cell-induced tumor regression,
 833
- Interleukin 1**
 cis-diamminedichloroplatinum(II) and
 synergistic antitumor activity, solid tu-
 mors, 1091
 growth inhibition by interleukin 1
 enhanced expression, γ -interferon re-
 ceptors, 636
 receptor antagonist
 inhibition of metastasis augmentation,
 melanoma-nude mouse system, 5051
- Interleukin 1 α**
 autocrine growth stimulator
 human gastric carcinoma cells, 4102
 hyperthermia and
 antitumor effect, 324
 interleukin 6 and
 inhibition of growth, MCF-7 cells,
 1538
 protective effects
 doxorubicin-treated normal and tu-
 mor-bearing mice, 1565
 tumor necrosis factor- α and
 induction of anchorage independence,
v-jun transgenic murine cells, 615
- Interleukin 1 β**
 induction of interleukin 1 receptor an-
 tagonist
 tumor necrosis factor binding protein,
 humans, 4010
 interleukin 2 treatment and
 protection, cyclophosphamide-induced
 myelosuppression, 569
- Interleukin 2**
 analogues
 reduced secondary cytokine secretion,
 2597
 complementary DNA
 tumor-specific lysis by tumor-infiltrat-
 ing lymphocytes, renal cell carci-
 noma, 4020
 development of tumor-reactive cytotoxic
 cells
 CD4-dependent mechanism, interlu-
 kin 3, 2112
 functional expression of receptor
 human factor-dependent megakaryo-
 blastic leukemia cell line, 675
 gene-transfected cells

- vaccination, mouse mammary adenocarcinoma, 5067
- gene transfection
- cellular immune response augmentation, melanoma cells, 949
- immunological and clinical effects
- with and without interferon- α , 1286
- interleukin 1 β treatment and protection, cyclophosphamide-induced myelosuppression, 569
- macrophage-colony stimulating factor and
- antitumor protection, T-cell leukemia/lymphoma EL4, 4273
- peritumoral injections
- local and systemic activation of immune cells, advanced squamous cell carcinoma of the head and neck, 5654
- poor proliferative response
- infiltration of renal cell carcinoma, T-cells, 1380
- protection of hairy leukemic cells
- LAK-mediated cytotoxicity, 3555
- receptors and
- T-cells infiltrating renal cell carcinoma, 5828
- Interleukin 3**
- description of genes
 - lack of proliferation, nonhematopoietic human malignant cell lines, 3139
 - development of tumor-reactive cytotoxic cells
 - CD4-dependent mechanism, 2112
- pharmacokinetics
- after chemotherapy for ovarian cancer, 5915
- Interleukin 4**
- inhibitory effect on production of IL-6
 - adult T-cell leukemia cells, 4643
 - secreting engineered cells
 - glioma treatment, 3125
- Interleukin 6**
- dependent tumor cell growth
 - inhibition, reshaping of human antibody, 851
 - description of genes
 - lack of proliferation, nonhematopoietic human malignant cell lines, 3139
 - growth inhibition
 - human lung cancer cell lines, 4175
 - growth-stimulating activity
 - transfection with *int-2* gene, mammary epithelial cells, 2957
 - inhibitory effect of IL-4
 - adult T-cell leukemia cells, 4643
 - interleukin 1 α and
 - inhibition of growth, MCF-7 cells, 1538
 - neutralizing antibodies
 - reversal of hypercalcemia, human squamous carcinoma, 737
 - oncostatin M-induced growth inhibition
 - increased resistance, melanoma cell lines derived from advanced-stage lesions, 2708
 - production of immunoreactive endothelin 1
 - human breast cancer cells, 464
 - serum levels
 - lymphoma patients, survival in advanced Hodgkin's disease, 2118
- Interleukin 10**
- transfection into CHO cells
 - prevention, tumor growth and macrophage infiltration, 4134
- Interstitial cells**
- localization of estrogen receptors
 - kidney, estradiol-induced renal tumors, 5447
- Interstitial fluid**
- pressure
 - reduction by dexamethasone, human colon adenocarcinoma xenograft, 4764
- Intestine**
- biological response
 - 1,25-dihydroxyvitamin D $_3$ and two analogues, 3935
 - intraepithelial lymphocytes
 - binding to colon cancer cells, HML-1 and CD11a, 1608
 - pharmacological retinoids
 - vitamin A-metabolizing enzymes, 2965
 - tumorigenesis
 - deletion of 1p36, primary chromosomal aberration, 1895
- Intestine, small**
- epithelium
 - inhibition of doxorubicin-induced apoptosis, 2-deoxy-D-glucose, 2057
- Introplicine**
- DNA and topoisomerase II
 - molecular and cellular interactions, surface-enhanced Raman scattering spectroscopy, 4784
 - inhibition of both topoisomerase I and II activities, 5987
- Invadopodia**
- cell surface
 - binding and localization, *M*, 72,000
 - matrix metalloproteinase, 3159
- Invasion**
- metalloproteinase matrilysin
 - DU-145 cells, 417
- m-Iodobenzylguanidine**
- uptake and storage
 - frequent neuronal functions, neuroblastoma cell lines, 304
- Iododeoxyuridine**
- bleomycin and
 - Phase I clinical and pharmacological study, advanced cancer, 1293
- Iowa Women's Health Study**
- lung cancer
 - vegetables and fruit, 536
- 4-Isopomeanol**
- Phase I and pharmacological study
 - lung cancer, 1794
- Iron**
- 2,2'-bipyridyl-6-carboxithioamide and its ferrous complex
 - antitumor activity, inhibition of ribonucleotide reductase R2 subunit, 19
- Irradiation**
- differences in DNA supercoiling
 - local control, T2/3 transitional cell carcinoma of the bladder, 2300
 - in vitro*
 - RET oncogene rearrangement, 2940
 - solar
 - UVB and, hypersensitivity of human lymphocytes, 609
- γ -Irradiation**
- alkylating agents and
 - folate deficiency, genetic damage in Chinese hamster ovary cells, 5401
- Isoflavones**
- antiproliferative effects
 - gastrointestinal tract, human cancer cell lines, 5815
- Isoglobotetraosylceramide**
- marker for highly metastatic cells
 - rat mammary adenocarcinoma, 2906
- J**
- JB6 cells**
- mechanism of induction of *c-fos*
 - ultraviolet B, 38
- jun**
- induction by transforming growth factor- α
 - not 17 β -estradiol, breast cancer cells, 291
- JunB**
- promoter-specific *trans*-activation and inhibition, 3789
- Jurkat cells**
- protection from apoptosis
 - HIV-1 Tat protein, 4481
- K**
- KB cells**
- enhanced expression of DNA topoisomerase II gene
 - response to heat shock stress, 1085
 - expression of platelet-derived endothelial cell growth factor
 - sensitivity, pyrimidine antimetabolites, 5680
- KBM-5 cells**
- biological properties and growth
 - SCID mice, 3603
- K562 cells**
- biochemical consequences
 - resistance to tiazofurin, 2344
 - development of resistance to hydroxyurea
 - α -difluoromethylornithine, 5262
 - merocyanine 540-mediated phototherapy
 - enhancement by salicylate, 806
 - mitochondrial cytochrome *c* oxidase
 - target site for daunomycin, 1072
 - ultrastructural appraisal
 - multidrug resistance, Fourier transform infrared spectroscopy, 3681
- Keratin**
- expression in mouse cervical epithelium
 - retinoid status, 2287
- Keratinocytes**
- human papillomavirus type 16-mediated transformation
 - inhibition by retinoic acid, 905
 - hyperphosphorylation of cytokeratins
 - okadaic acid class tumor promoters, 992
 - oral carcinogenesis
 - HPV-16, *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine, 4811
 - primary and immortalized
 - induction of resistance to UVB, hyperthermia, 4952
 - resistance to transforming growth factor- β_1

- mutant *p53*, 899
suppression of proliferation
Z-4',5'-didehydro-5'-deoxy-5'-fluoro-adenosine, 6058
- Kidney**
allograft
malignant transformation of cutaneous lesions, human papillomavirus, 5328
biological response
1,25-dihydroxyvitamin D₃ and two analogues, 3935
complementary DNAs down-expressed in Wilms' tumor
subtractive hybridization approach, 2888
⁶⁷Cu-labeled intact and fragmented anti-colon carcinoma monoclonal antibody MAb35
preclinical evaluation, 5727
epithelial cells
HPV16 transformation, glucocorticoid requirement for growth, 4432
genetic predisposition
transplacentally induced renal cell carcinoma, Eker rat, 5856
human fetal
Wilms' tumor and, insulin-like growth factor II and WT1 transcript, 5166
localization of estrogen receptors
interstitial cells, 5447
progression of neoplasms
regional DNA hypermethylation, D17S5, 2719
regeneration
regulation, protein kinase C isozymes, 4542
- Kinase**
role of *BCR-ABL* oncogene
human leukemia, 485
- Klenow fragment**
kinetics and fidelity of base insertion
template-located 2',2'-difluorodeoxycytidine, 4582
- K1000 neoplasms**
secretion by an animal tumor
detection of basic fibroblast growth factor, urine, 5297
- K-ras**
antisense retroviral construct
intratracheal instillation, prevention of orthotopic lung cancer growth, 1743
p53 gene mutations and
epithelial ovarian neoplasms, 3103
- Kupffer cells**
-induced reduction of mitochondrial energization
nitric oxide, hepatoma cells, 2676
- KW-2149**
induction of protein-DNA complexes
HeLa S3 cells, 4466
- L**
- β -Lactamase**
-antibody conjugates
site-specific prodrug activation, colon carcinoma xenograft models, 3956
fusion with single chain anti-carcinoma antibody
genetic construction, expression and characterization, 2123
- Lactone ring**
9-amino and 10,11-methylene derivatives
camptothecin, pharmacokinetics in mice, 3062
- Lactotetraose series**
ganglioside 3',6'-isoL_{D1}
tumors of central nervous system, other systems, 120
- LAK cells**
mechanisms of adoptive immunotherapy
tracking of tumor-infiltrating lymphocytes, 2358
-mediated cytotoxicity
protection by interleukin 2, hairy leukemic cells, 3555
- Laminin**
A chain
plasminogen activator production, B16F10 melanoma, 1998
adhesion of metastatic *ras*-transformed NIH 3T3 cells, 701
chemotaxis and haptotaxis
autocrine motility factor-like substance, human malignant mesothelioma cells, 4376
peptides
adhesion and malignant properties, melanoma, 423
regulation
tumor cell chemotaxis receptor, laminin-binding integrin subunit α_6 , 2661
- Laser**
-induced fluorescence
pharmacokinetics, fluorescent drug, 5954
- Lc₄Cer**
human fetal antigen
compensatory occurrence of IV²Fu α , II³NeuAc α -G α Cer, small cell lung carcinoma, 5903
- L-cells**
homozygous deletion
carbonic anhydrase-like domain, *Ptprg* gene, 1498
- L1210 cells**
exposure to edelfosine
increased generation, lipid-derived and ascorbate free radicals, 711
membrane lipid free radicals
photofrin photosensitization, electron paramagnetic resonance spin trapping, 3670
protection from Adriamycin cytotoxicity
brefeldin A, 5237
resistance to cyclopentenylcytosine, 5714
- LEA.135**
identification of cell surface antigen
favorable prognosis, human breast cancer, 3233
- Lectin**
Agaricus bisporus
reversible inhibition of proliferation, epithelial cell lines, 4627
galactoside-binding
regulation of expression, monocytic differentiation, 5033
-mediated endocytosis of a trap label
permanently labeled colon cancer cells, distribution of, 658
-reactive α -fetoproteins
early detection, hepatocellular carcinoma, 5419
- Leiomyoma**
chromosome 12 breakpoints
benign and malignant lipogenic tumors, 1670
- Lens**
inhibition of tumor promoter-mediated processes
caffeic acid phenethyl ester, 1255
- Leucovorin**
cis-diamminedichloroplatinum(II) and 5-fluorouracil
non-small cell lung cancer cell lines, 1079
5-fluorouracil and
N-(phosphonacetyl)-L-aspartate combination, metastatic gastrointestinal adenocarcinoma, 4828
5-fluorouracil and α 2a-interferon
locus of interaction, colon carcinoma cells, 4243
rescue
edatrexate compared to methotrexate, metastatic murine solid tumors, 587
- Leukemia**
ability to form tumors in nude mice
homeobox gene *HB24*, human T-cell line, 373
benzene and phenolic metabolites
oxidative DNA damage, HL-60 cells and bone marrow, 1023
cell differentiation
alkylamides as inducers, structure-activity relationship, 766
human factor-dependent megakaryoblastic
functional expression, interleukin 2 receptor, 675
inhibition of binding of GM-CSF and insulin to receptors
dimethyl sulfoxide, 1142
monocyte-mediated leukemic cell death
role of β_2 -integrins, cell cycle-specific effects of TNF- α , 4399
mononuclear cell
diet restriction-induced inhibition, insulin-like growth factor 1 axis, 2750
role of *BCR-ABL* oncogene, 485
t(4;11) acute
heterogeneity in MLL/AF-4 fusion mRNA, polymerase chain reaction, 3853
- Leukemia, acute**
Southern blot analysis
ALL-1 rearrangements, chromosome 11q23, 3800
- Leukemia, lymphoblastic**
acute
primary clonogenic blasts, radiation damage repair capacity, 1431
early B-lineage acute
heterotransplantation, solubilized attachment matrix, 1222
Philadelphia-positive acute
heterogeneity, lineage derivation, 3289
- Leukemia, lymphocytic**
chronic
binding of melphalan-damaged DNA, poly(ADP-ribose) polymerase, 5370
- Leukemia, myeloblastic**
acute
modulation, p145^{c-kit} function in cells, 4424
- Leukemia, myelocytic**

- acute
 - differential activity of acetyldinaline, rat, 3008
- Leukemia, myelogenous**
 - acute
 - growth and apoptosis, transforming growth factor $\beta 1$, 3386
 - t(8;21) masked translocation, *AML1/ETO* fusion transcript, 4449
 - blasts
 - transforming growth factor- $\beta 1$ and stem cell factor, *c-kit*, 3638
 - chronic
 - derivation of cell line KBM-5, biological properties and growth in *SCID* mice, 3603
 - lineage-negative blast subpopulations, *c-kit* ligand responsiveness, 401
- Leukemia, myeloid**
 - acute
 - cloning of *ALL-1* fusion partner, *AF-6* gene, 5624
 - epipodophyllotoxin, disruption of *ALL-1* gene, 2954
 - topoisomerase II DNA-binding sites, t(9;11) chromosome translocation, 4489
 - induction of differentiation
 - liposomal all-*trans*-retinoic acid, 2100
- Leukemia, P388**
 - Adriamycin-resistant
 - DNA topoisomerase II α gene rearrangement, 5885
 - milky spots as implantation site for malignant cells
 - peritoneal dissemination, mice, 687
- Leukemia, promyelocytic**
 - acute
 - induction of differentiation, liposomal all-*trans*-retinoic acid, 2100
- Leukemia, T-cell**
 - adult
 - HTLV-I-associated myelopathy, sequence analysis of an immunogenic and neutralizing domain, 6067
 - inhibitory effect of IL-4, production of IL-6, 4643
 - etoposide-induced cytotoxicity, 4287
 - lymphoma EL4
 - antitumor protection, macrophage-colony stimulating factor and interleukin 2, 4273
- Leukemia cells**
 - differential activity of acetyldinaline rat leukemia, 3008
 - glucocorticoid-sensitive and -resistant cloning and expression, mutant glucocorticoid receptors, 4059
 - hairly
 - protection by interleukin 2, LAK-mediated cytotoxicity, 3555
 - induced megakaryocytic maturation
 - down-modulation, erythropoietin gene expression, 1156
 - megakaryocytic differentiation
 - TPA and staurosporine, retinoblastoma tumor suppressor gene expression, 3085
 - promyelocytic
 - differentiation, glucocorticoid receptors, 3513
- Leukemia virus**
- bovine
 - lymphosarcoma, phenotype and ontogeny of cells carrying tumor-associated antigen, 429
- Leukocytes**
 - activated polymorphonuclear
 - modification of DNA bases in chromatin, intact target human cells, 1269
 - DNA
 - platinum-DNA adduct, different types of malignancies, 3694
- Lewis antigens**
 - sialyl Le^x and sialyl Le^a
 - α -(1,3)-fucosyltransferases, human malignant cell lines, 5559
- LFA-1**
 - dependent mechanism
 - bifunctional antibody-mediated lysis, interferon- γ -induced ICAM-1, 4652
- Liarozole**
 - 13-*cis*-retinoic acid and
 - anti-prostatic tumor activity, 3073
- Li-Fraumeni syndrome**
 - malignant tumors and family history of cancer
 - screening, germ line *p53* mutations, 452
- Ligands**
 - axial and equatorial
 - modulation of cytotoxicity and cellular pharmacology, 1,2-diaminocyclohexane platinum(IV) complexes, 4567
 - cis*-diammine and 1,2-diaminocyclohexane
 - platinum resistance, human carcinoma cell lines, 799
- Light**
 - near-visible/UVA
 - singlet oxygen, induction of heme oxygenase gene, 4505
- Linoleic acid**
 - diets containing different levels
 - breast cancer growth, lung metastasis, 4686
- Linomide**
 - antiangiogenic effects, 1833
- Lipid peroxidation**
 - active oxygen species and
 - antitumor effects, hyperthermia, 2326
- Lipids**
 - derived and ascorbate free radicals
 - L1210 cells exposed to edelfosine, 711
 - effects of nonionic detergents
 - P-glycoprotein drug binding, multi-drug resistance, 5994
 - ether lipid analogues
 - inhibition of phosphatidylinositol-3-kinase, 4297
 - free radicals
 - photoirradiation photosensitization, L1210 murine leukemia cells, 3670
 - hydroperoxides
 - oxidative catabolism of all-*trans*-retinoic acid, human microsomes, 1226
 - in vitro* cytotoxicity
 - cellular pharmacology, annamycin, 1583
- Lipogenic neoplasms**
 - benign and malignant
 - chromosome 12 breakpoints, 1670
- Lipopolysaccharide**
- induced inflammation
 - rat urinary bladder tumorigenesis, 5172
- Liposomes**
 - Adriamycin
 - hepatic artery, liver W256 carcinosarcoma, 3046
 - all-*trans*-retinoic acid
 - induction of differentiation, myeloid leukemia cell lines, acute promyelocytic leukemia cells, 2100
 - cis*-bis-neodecanoato-*trans*-*R,R*-1,2-diaminocyclohexaneplatinum(II)
 - cellular pharmacology, A2780/S and A2780/PDD cells, 4913
 - DepoFoam
 - prolongation of drug exposure, cerebrospinal fluid, 1596
 - encapsulated doxorubicin
 - eradication of lung cancer, 1484
 - initial clinical trial, 2796
 - encapsulated muramyl tripeptide
 - doxorubicin and, canine monocyte activation, 3986
 - Stealth
 - preferential accumulation in tumor tissue, increased microvascular permeability, 3765
 - sterically stabilized
 - doxorubicin, arrest of growth in human lung tumor xenograft, 3964
 - taxol-containing
 - antitumor effect, taxol-resistant murine tumor model, 5877
- Liver**
 - aflatoxin B₁-induced hepatic hyperplastic nodules
 - no site-specific mutation, *p53* gene, 9
 - carcinogenesis
 - chromosome mapping, murine susceptibility loci, 209
 - inhibitory effect of *Bifidobacterium longum*, food mutagen, 3914
 - cellular distribution of cytochrome P-450
 - 1A1
 - immunohistochemistry, rainbow trout, 3700
 - cytochrome P450 3A
 - vinblastine metabolism, drug interactions, 5121
 - cytochrome P450 enzymes
 - metabolism of 6-nitrochrysene, 2028
 - gene expression and cell proliferation
 - 2,3,7,8-tetrachlorodibenzo-*p*-dioxin exposure, 2265
 - metastases
 - clinical relevance of ICAM-1 expression, serum of patients with malignant melanoma, 4927
 - mouse sinusoidal endothelial cells
 - paracrine migration-stimulating factor, metastatic tumor cells, 4418
 - oxidative damage of nuclear DNA
 - rats exposed to psychological stress, 4153
 - peripheral blood mononuclear cells and dihydropyrimidine dehydrogenase activity, 5433
 - pharmacological retinoids
 - vitamin A-metabolizing enzymes, 2965
 - Phase I and pharmacological study
 - 4-ipomeanol, lung cancer, 1794

- precancerous altered hepatic foci
N-myc 2 and insulin-like growth factor II, woodchuck hepatitis virus carriers, 2020
 promoter-specific *trans*-activation and inhibition
JunB, 3789
 rats treated with 1,2-dimethylhydrazine and *O*⁶-benzylguanine
 repair, *O*⁶-methylguanine and *O*⁶-methylthymidine, 3895
 right/caudate lobes
 furan treatment, "intestinal-type" adenocarcinoma, 254
- Liver microsomes**
 differential activation of cyclophosphamide and ifosfamide
 cytochromes P-450 2B and 3A, 5629
- Liver neoplasms**
 2-acetylaminofluorene-induced *ras* mutations, 1620
 aflatoxin-induced tumorigenesis
 transient intervention, oltipraz, 3499
 coordinate oncogene developmental modulation
 fibronectin pre-mRNA alternative splicing, 2005
 W256 carcinosarcoma
 temperature-sensitive liposomal Adriamycin, hepatic artery, 3046
- LNCaP cells**
 autocrine regulation
 prostate-specific antigen gene expression, 2852
- Locus**
 bladder cancer suppressor
 chromosome 9, 5093
- L19 protein**
 high-level of expression
erbB-2 overexpression, breast tumors, 1403
- LR73 cells**
 ultrastructural appraisal
 multidrug resistance, Fourier transform infrared spectroscopy, 3681
- Lung**
A/J mouse
 model, chemointervention strategies, 410
 cancer susceptibility genes
 polycyclic aromatic hydrocarbon-DNA adducts, 3486
 carcinoid tumors
 infrequent mutations, *p53* gene, 5797
 cytochrome P450 enzymes
 metabolism of 6-nitrochrysene, 2028
 fibroblast-derived IGF-I and insulin-like growth factor-I
 stimulation of proliferation, lung carcinoma cells, 3399
 immunohistochemical localization
 glutathione *S*-transferases, 5643
 metastasis and breast cancer growth
 diets containing different linoleic acid levels, 4686
 metastasis from rat-transplantable osteosarcoma
 nucleoside diphosphate kinase/*nm23* and *c-Ha-ras* mRNA, 5038
- Lung epithelial cells**
 mediation of 8-chloro-cyclic AMP-induced down-regulation
 cyclic AMP-dependent protein kinase, 393
- Lung neoplasms**
 2-acetylaminofluorene-induced *ras* mutations, 1620
 antibody-targeted delivery
 doxorubicin entrapped in liposomes, 1484
 atrial natriuretic factor
 arginine vasopressin production, serum sodium, 67
 block of production of GM-CSF
 1 α ,25-dihydroxyvitamin D₃ plus γ -interferon, 6006
 chemoprevention strategies, 1469
 critical region of 9p
 homozygous loss, interferon genes, 2410
 genotype and phenotype
 glutathione *S*-transferase class μ isoenzymes, 1004
 growth inhibition by IL-6
 autocrine mechanism, 4175
 human xenograft
 arrest of growth, doxorubicin encapsulated in sterically stabilized liposomes, 3964
 marker for neuroendocrine differentiation
 IA-1, 4169
 modulation of cisplatin sensitivity
 accumulation of amphotericin B, 3302
 non-small cell
 cisplatin and 5-fluorouracil, with and without leucovorin, 1079
 down-regulation of growth, thymosin α 1, 5214
 immunocytological detection, bone marrow micrometastasis, 1027
 individualized chemotherapy, neuroendocrine markers and drug sensitivity testing, 5181
 main drug- and carcinogen-metabolizing enzyme systems, peritumoral tissues, 4608
 methylthioadenosine phosphorylase deficiency, 1098
p53 alterations, metastatic involvement, 2846
 prognostic significance, *p53* mutations and 3p deletions, 1
 penetration of spheroids
 retroviral wild-type *p53* expression vector, induction of apoptosis, 4129
 Phase I and pharmacological study
 4-ipomeanol, 1794
 prevention of growth
 intratracheal instillation, retroviral antisense *K-ras* construct, 1743
 primary non-small cell
 preferential expression, epidermal growth factor receptor, 2379
 regulation of insulin-like growth factor action
 membrane and secreted insulin-like growth factor-binding protein-2, 4680
 selenium status and, 4860
 serum fragment of cytokeratin subunit 19
 CYFRA 21-1 immunoradiometric assay, 61
- small cell
 altered topoisomerase II α , VP-16, 4866
 CCK_A and CCK_B receptors, Ca²⁺ mobilization, 5208
c-myc expression, correlation with *c-kit* expression, 4337
 eradication of cells from bone marrow, immunotoxins, 3784
 expression, functional atrial natriuretic peptide receptors, 3165
 inwardly rectifying K⁺ channels, volume-regulated anion channels, 4156
 mediation of chemotaxis by stem cell factor, *c-kit*, 1709
 monoclonal antibody SEN7, epitope on NCAM, 2840
 surgically treated patients
 proliferating cell nuclear antigen, argyrophilic nucleolar organizer regions, 5000
 susceptibility and cigarette dose
 polymorphisms, *CYP1A1* and glutathione *S*-transferase, 2994
 vegetables and fruit
 Iowa Women's Health Study, 536
 Luteinizing hormone releasing hormone analogues in ovarian cancer cell lines
 high affinity binding, antiproliferative effects, 5439
- Ly-1**
 B cell populations and IgH rearrangements
 "normal" spleens and lymphomas, AKR/J and AKR Fv-1^b mice, 2147
- Lymph node**
 hilar and mediastinal
 metastasis and *p53* alterations, non-small cell lung cancer, 2846
 micrometastatic prostate cancer cells
 reverse transcriptase-polymerase chain reaction, 5350
 tumor-draining
 T-cell-induced tumor regression, γ -interferon, 833
- Lymphoblasts**
 drug-resistant L5178Y murine
 chemical sensitivity, glutathione *S*-transferase, 3530
- Lymphocytes**
 DNA double strand break repair defect
 scid mice, 1244
 hypersensitivity to UVB and solar irradiation, 609
 intestinal intraepithelial
 binding to colon cancer cells, HML-1 and CD11a, 1608
in vitro-sensitized vaccine-draining lymph node
 oligoclonal T-cell response, metastasis of renal cell carcinoma, 4745
 tumor-infiltrating
 adoptive immunotherapy and improved tracking, LAK cells, 2358
 enhanced HLA molecule expression, transduction of melanoma cells, 3561
 poor proliferative response, renal cell carcinoma, 1380
 T-cell receptor V region gene usage, autologous gastric Signet ring cell carcinoma, 3078

- tumor-specific lysis, renal cell carcinoma, 4020
- Lymphohematopoietic precursors**
role of tyrosine phosphorylation
activation of *c-jun*, 447
- Lymphoma**
Burkitt's
deregulation of *c-myc*, theophylline-induced differentiation, 127
induction of apoptosis, Gb3/CD77 glycolipid antigen, 5314
radiosensitivity, role of *p53* in cell cycle arrest, 4776
interstitial pressure of subcutaneous nodules
changes during treatment, 2204
metastatic
enhanced immunosuppressive activity, 1921
non-Hodgkin's
agricultural risk factors, 2421
circadian stage of cell sampling, DNA synthesis and ploidy, 3129
photosensitized mouse cells
phospholipase activation, apoptosis, 5897
refractory
high-dose regimen, mitoxantrone, 4850
serum interleukin 6 levels
survival, advanced Hodgkin's disease with B symptoms, 2118
suramin
multiple potential mechanisms of action, 2239
T-cell
suppression of apoptosis, monoclonal antibodies against cell surface adhesion molecules, 5022
-T-cell leukemia
antitumor protection, macrophage-colony stimulating factor and interleukin 2, 4273
- Lymphoma, B-cell**
cloning of *bcl-6*
chromosome translocations, 2732
delivery of saporin using bispecific antibody
targeting via CD22, 3015
multiple breakpoints within *BCL-1* locus
rearrangements, cyclin D1 gene, 4148
regression
Pseudomonas exotoxin-based immunotoxins, antibody LL2 or LL2-Fab', 819
- Lymphomagenesis**
AKR.Fv-*J^h* congenic mice, 3433
- Lymphosarcoma**
bovine leukemia virus
phenotype and ontogeny, cells carrying tumor-associated antigen, 429
- Lysophospholipid**
phospholipase A₂-mediated mechanisms
inhibition of cancer cell line proliferation, riminophenazine agents, 318
- Lysyl oxidase**
up-regulation
spontaneous revertants, H-*ras*-transformed fibroblasts, 4670
- M
- M43
- clinical evaluation, 2803
- Macrophages**
control of HLA-DR antigen expression
 γ -interferons, thyroid cells, 3943
differentiation of human promyeloid leukemia cells
glucocorticoid receptor expression, 3513
infiltration
prevention of tumor growth, IL-10 transfected into CHO cells, 4134
nitric oxide synthesis
delay of progression, UV light-induced skin cancers, 5507
sensitivity of tumoricidal function
modulation of arachidonic acid metabolism, different anatomical sites, 3362
tumor-associated
receptor for urokinase, ductal breast carcinoma, 1911
- Magainin2**
analogue peptides and anticancer efficacy, 3052
- Magnetic resonance spectroscopy**
quantitative differential effects
rhodamine 123, normal and human colon cancer cells, 5808
skeletal muscle metabolism
left-shifting agent BW12C79, mitomycin C, 5649
- Major histocompatibility complex**
cell lines from *gpc* congenic strains of rats
different susceptibilities, chemical carcinogens, 4089
class I alleles
selectively down-regulated expression, human solid tumors, 2416
class I antigen H-2D^f
radiation-enhanced expression, B16 melanoma cells, 1952
- Malignancy**
advanced
chronic oral etoposide, granulocyte-macrophage colony-stimulating factor, 5929
antitumor effect
anti-epidermal growth factor receptor monoclonal antibody, cisplatin, 4637
ascites formation
pathogenesis, 2631
benign and low-grade
adjacency to high-grade ovarian carcinoma, molecular characteristics, 4138
borderline
mutation of K-*ras* protooncogene, ovarian epithelial tumors, 1489
carcinoma-associated antigen AgSK1, 1122
different types
platinum-DNA adduct, leukocyte DNA, 3694
environmental carcinogenesis and its prevention
head and neck cancer, 2189
expression of α -(1,3)-fucosyltransferases
synthesis, sialyl Le^x and sialyl Le^a, 5559
expression of tumor suppressor gene
- DCC**
human gliomas, 5605
family history of cancer and screening, germ line *p53* mutations, 452
hematological
cell proliferation marker, cyclin A expression, 235
hemopoietic cell lines
N-(4-hydroxyphenyl)retinamide, induction of apoptosis, 6036
high mobility group protein I(Y)
increased expression, high grade prostatic cancer, 5512
human basal cell carcinoma of skin
distinct infrared spectroscopic patterns, 762
increased polysomes
chromosomes 7 and 17, head and neck multistage tumorigenesis, 2874
increased sialyl Lewis^x antigen expression
poor survival, colorectal carcinoma, 3632
individual tumors and their variants
footprinting, constitutive cytokine expression patterns, 1978
milky spots as implantation site for malignant cells
peritoneal dissemination, mice, 687
morphologically malignant meningioma progression
loss of heterozygosity, loci on chromosome 10, 2386
mouse tissues
biliary glycoprotein, CEA-related gene, 4938
multiple mechanisms of tumorigenesis
Eu-myc transgenic mice, 1665
nonhematopoietic human cell lines
lack of proliferation, GM-CSF/IL-3/IL-6 receptors, 3139
normal and malignant mammary epithelial cells
physiological culture, discrimination of cell type, 2644
normal human mesothelial cells and cell lines
insulin-like growth factor I, 2858
ovarian cancer cells
enhanced *c-erbB/neu* expression, 891
pediatric brain tumors
efficacy, transferrin receptor-targeted immunotoxins, 1348
progression in oral carcinogenesis
HPV-16, *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine, 4811
progression of skin carcinogenesis
suprabasal expression, $\alpha 6\beta 4$ integrin, 4803
prostate
benign tissue and, type IV collagenase, 878
rat glial cells
phosphorylation of elongation factor 2, 2260
risk of fatal cancer
aspirin use, 6074
suppression by antisense oligonucleotide, 868
therapeutic efficacy
anti-B4-blocked ricin immunotoxin,

- different SCID mouse tumor models, 1360
- thyroid
 - differentiation marker, E-cadherin, 4987
- Malignant potential**
 - p53* and *Ki-ras* gene mutations epithelial ovarian neoplasms, 3103
- Malignant transformation**
 - early markers of carcinogenesis in head and neck cancer
 - transforming growth factor α , epidermal growth factor receptor messenger RNA, 3579
- Mammalian cells**
 - hypoxic
 - radiosensitization by nitric oxide, 5845
 - mitogenic processing of ethylation damage
 - methoxyamine, site-directed mutagenesis, 1149
- Mammary cells**
 - formation of hyperplastic outgrowths *p53* mutations, 1646
- Mammary epithelial cells**
 - growth-stimulating activity of IL-6 transfection with *int-2* gene, 2957
 - kinetics and differentiation
 - calories, parity and prolactin, 1188
 - normal and malignant
 - physiological culture, discrimination of cell type, 2644
 - normal luminal cell and breast cancer
 - differential isolation, primary and metastatic sites, 627
 - preneoplastic
 - growth factor dependency, gene expression, 668
 - progressive transformation
 - elevated high mobility group-I(Y) gene expression, 2655
 - TM preneoplastic outgrowths
 - morphological and functional properties, 663
- Mammary gland**
 - carcinogenesis
 - inhibitory effect of *Bifidobacterium longum*, food mutagen, 3914
 - radiation-induced transforming growth factor β
 - extracellular matrix reorganization, 3880
- Mammary neoplasms**
 - benign and malignant
 - in situ* hybridization, mannose-6-phosphate/IGFIII receptor and cathepsin D, 2901
 - development
 - preneoplastic stage, *p53* mutations, 3374
 - glucocorticoid-mediated suppression of growth
 - overexpression, transforming growth factor α , 1816
 - induction
 - tamoxifen dependency, 2937
 - induction by 6-nitrochrysene (rats), 3719
 - induction of ICAM-1
 - neu differentiation factor, 5251
 - monoterpene-induced regression
 - mannose 6-phosphate/insulin-like growth factor receptor II, transform-
 - ing growth factor- β levels, 3849
 - ovary-independent
 - systematic H-*ras* amplification, progressively anaplastic phenotypes, 5339
 - risk of
 - calories/parity/prolactin, epithelial kinetics and differentiation, 1188
- Mannose-6-phosphate**
 - IGFII receptor and cathepsin D RNA levels
 - in situ* hybridization, benign and malignant mammary tumors, 2901
 - IGFII receptor
 - transforming growth factor- β , monoterpene-induced regression of mammary tumors, 3849
- Mastocytoma**
 - arachidonic acid as growth signal, 3405
 - production of growth-promoting factor wide target cell spectrum, THP-1 cells, 1871
- Mathematical model**
 - development of metastases
 - primary and locally recurrent tumors, clinical data base for prostatic cancer, 2987
- Matrigel**
 - heterotransplantation
 - early B-lineage acute lymphoblastic leukemia, 1222
- Matrix**
 - degrading enzyme protease
 - hormone-dependent breast cancer cells, 1409
 - invasion
 - overexpression of urokinase receptor, cell migration in osteosarcoma cell line, 3109
- Matrix metalloproteinase**
 - increase in *M*, 92,000 type IV collagenase
 - plasma, colon and breast cancers, 140
 - inhibitor
 - decreased tumor burden, mice bearing human ovarian carcinoma xenografts, 2087
 - secretion by human prostate
 - explant cultures, inhibitors, 4493
 - TIMP-1 as negative regulator
 - human gastric cancer cell line, chick embryo, 1397
- MCA-C3H/10T $\frac{1}{2}$ cells**
 - reversal of cytochrome P-4501A1 and P-450-EF expression, 968
- MCF-7 cells**
 - acquisition of hormone-independent growth
 - estrogen-regulated genes, no detectable DNA amplifications, 283
 - cotransfection with fibroblast growth factor 4
 - LacZ*, spontaneous metastasis, 2178
 - 3',5'-cyclic nucleotide phosphodiesterase potential target, tumor growth inhibition, 3058
 - dissociation
 - bulk damage to DNA, teniposide antiproliferative activity, 3547
 - estrogen and antiestrogen modulation
 - insulin-like growth factor-binding proteins, 5193
- growth suppression
 - 2,3,7,8-tetrachlorodibenzo-*p*-dioxin, 3149
- inhibition of growth
 - interleukin 1 α and interleukin 6, 1538
- transfection
 - fibroblast growth factor 4, tumorigenicity, 2168
- xenografts
 - tamoxifen-induced increase in doubling time, bromodeoxyuridine labeling and flow cytometry, 4413
- MCF-10 cells**
 - nuclear matrix proteins, 3394
- MCF7/LCC2 cells**
 - sensitivity to ICI 182,780, 3229
- MDL 28,842**
 - suppression of proliferation
 - keratinocytes and squamous carcinoma cell lines, 6058
- Megakaryocytes**
 - induced maturation of leukemia cell line UT-7
 - down-modulation, erythropoietin gene expression, 1156
- Melanocytic neoplasms**
 - calcyclin expression, 6061
- Melanoma**
 - adhesion to laminin peptides
 - differences, malignant properties, 423
 - associated antigen expression
 - high molecular weight, primary acral lentiginous lesions with poor prognosis, 2830
 - biochemical and functional characterization
 - aminopeptidase N, 1450
 - blood flow reduction in tumors
 - high-energy shock waves, 1590
 - cell invasion
 - 72 kDa type IV collagenase, differential integrin expression, 3411
 - cell lines derived from advanced-stage lesions
 - increased resistance, oncostatin M-induced growth inhibition, 2708
 - cells exposed to C3-cleaving membrane protease *p65*
 - molecular basis, complement resistance, 592
 - differential expression of *MAGE-1*/*MAGE-2*/*MAGE-3*
 - messenger RNA, transformed and normal human cell lines, 5
 - differential expression
 - CD54/CD11a and CD58/CD2, 3343
 - environmental skin cancer
 - mechanisms, models and human relevance, 3439
 - human culture
 - insulin-like growth factor receptor inhibition, 2522
 - human xenografts
 - antitumor activity, *N*¹,*N*¹-bis(ethyl)norspermine, 581
 - induction and antigenic profile
 - HLA-A and -B antigens, β_2 -microglobulin, 4303
 - inhibition of growth by intratumoral DNA injection
 - herpes simplex virus thymidine kinase gene, 3860

- insight on biology of neuroectodermal tumors, 926
- interstitial pressure of subcutaneous nodules
- changes during treatment, 2204
- intracerebral
- boron neutron capture theory, 3308
- malignant
- clinical relevance of ICAM-1 expression, primary lesions, 4927
- development of, p53 overexpression as late event, 2235
- mediated dissolution of extracellular matrix
- proteolytic pathways, 693
- molecular cloning of monoclonal antibody
- reactivity to ganglioside G_{M3}, human cancers, 5244
- mouse anti-idiotypic monoclonal antibody MK2-23
- modulation by adjuvants, carriers of immunogenicity, 112
- nude mouse system
- interleukin 1 receptor antagonist, inhibition of metastasis augmentation, 5051
- production of growth-promoting factor
- wide target cell spectrum, THP-1 cells, 1871
- proliferation of A375 cells
- inhibition by nitric oxide/nucleophile complexes, 564
- regressive
- antitumor activity, *in situ* amplification of cytotoxic T-lymphocytes, 3569
- replicative senescence and melanogenesis
- specific tyrosinases, 2469
- spontaneous metastases
- suppression of growth by CTL, SCID/hu mice, 4933
- staining with monoclonal antibodies
- selective loss, HLA class I allospecificities, 3349
- tamoxifen modulation
- cisplatin sensitivity (humans), 1571
- targeting of gene expression, 962
- transduction
- enhanced HLA molecule expression, human tumor infiltrating lymphocytes, 3561
- transfection of interleukin 2 gene
- augmentation, cellular immune response, 949
- Melanoma, B16**
- cerebral metastases
- protection, active immunization, 1113
- 3',5'-cyclic nucleotide phosphodiesterase
- potential target, tumor growth inhibition, 3058
- radiation-enhanced expression
- MHC class I antigen H-2D^b, 1952
- Melanoma, B16BL6**
- high and low metastatic variants
- differential growth factor production, secretion, 4075
- Melanoma, B16F10**
- plasminogen activator production
- modulation by synthetic peptide, laminin A chain, 1998
- Melphalan**
- damaged DNA
- binding, poly(ADP-ribose) polymerase, 5370
- DNA damaging agents
- sensitivity to *ERCC-1* overexpression, Chinese hamster ovary cells, 3237
- Membrane**
- permeability
- etoposide-induced cytotoxicity, T-cell leukemic lines, 4287
- Ménétrier's mucosa**
- high affinity binding sites
- gastrin-releasing peptide, gastric cancer, 5090
- Meningioma**
- morphologically malignant
- progression of, loss of heterozygosity for loci on chromosome 10, 2386
- progesterone receptor expression, 1312
- Merbarone**
- aberrant functions
- teniposide-resistant CEM cells, 5946
- Merocyanine 540**
- mediated phototherapy
- enhancement by salicylate, 806
- Mesenchyme**
- regulation and heteromeric structure
- fibroblast activation protein, 3327
- Mesothelial cells**
- normal human cells and cell lines
- insulin-like growth factor I, associated molecules, 2858
- Mesothelioma**
- factors that stimulate production of hyaluron
- mesothelial cells, fibroblasts, 388
- human malignant
- chemotaxis and haptotaxis, autocrine motility factor-like substance, 4376
- recurrent deletions of specific chromosomal sites, 1p/3p/6q/9p, 4349
- malignant
- critical region of chromosome loss, 9p21-p22, 4761
- Mesothelium**
- peritoneal
- binding of ovarian cancer cells, mediation by CD44H, 3830
- Metal ions**
- structural role
- "wild-type" conformation, p53, 1739
- Metalloproteases**
- matrix
- tumor grade and invasion, bladder cancer, 5365
- Metalloproteinase**
- dependent proteolytic pathways
- melanoma-mediated dissolution, extracellular matrix, 693
- elevated levels
- M, 92,000 type IV collagenases, brain, 2208
- M, 72,000
- binding and localization, cell surface invadopodia, 3159
- matrilysin
- invasive potential, expression in DU-145 cells, 417
- Metallothionein**
- control of synthesis
- modulation of cisplatin nephrotoxicity and drug resistance, bladder tumor, 1829
- induction**
- prevention of carcinogenicity, anticancer drugs, 4767
- possible roles in carcinogenesis, 922
- resistance *in vitro* to tumor necrosis factor, 4874
- Metastasis**
- adhesion to hepatocytes
- integrin $\alpha_6\beta_4$, TA3/Ha mammary carcinoma cells, 3611
- amphiregulin and epidermal growth factor receptor
- estrogen receptor expression, human primary breast cancer, 3597
- augmentation induced by IL-1 or LPS
- interleukin 1 receptor antagonist, human melanoma/nude mouse system, 5051
- behavior of tumor cells
- ras, CD44 promoter activity, 1516
- bone
- parathyroid hormone-like protein gene expression, breast cancer, 5076
- breast cancer
- acceleration of granulocyte recovery, granulocyte colony-stimulating factor, 5424
- allelotyping and clonal analysis, limited genetic heterogeneity, 3804
- E-cadherin cell adhesion molecule expression
- breast cancer, 1696
- cerebral
- murine melanoma B16, protection with active immunization, 1113
- colorectal cancer
- mutation in *nm23* gene, 717
- distant
- development in primary familial breast carcinoma, deletions on chromosome 16, 3707
- distribution of permanently labeled colon cancer cells
- lectin-mediated endocytosis, trap label, 658
- fibroblast growth factor 4 transfection
- MCF-7 cells, tumorigenicity, 2168
- Friend leukemia cells
- α_1 -interferon gene transfer, abrogation of tumorigenicity, 1107
- gastric cancer
- E-cadherin expression, 1690
- high and low metastatic variants
- B16BL6 melanoma, differential growth factor production, 4075
- inhibition by 1,6-epi-cyclophellitol, 4896
- inhibition of tumor growth and multimeric forms, Tyr-Ile-Gly-Ser-Arg peptide, 3459
- inhibition of tumor growth
- O-(chloroacetyl-carbamoyl)fumagillol, 4262
- isoglobotetraosylceramide as marker
- rat mammary adenocarcinoma, 2906
- lung
- breast cancer growth, dietary linoleic acid, 4686
- nucleoside diphosphate kinase/*nm23* and c-Ha-ras mRNA, rat-transplantable osteosarcoma, 5038
- lymphoma cells

- enhanced immunosuppressive activity, 1921
- melanoma
 - suppression of growth by CTL, SCID/hu mice, 4933
- milky spots as implantation site for malignant cells
 - peritoneal dissemination, mice, 687
- modeling of development
 - primary and locally recurrent tumors, clinical data base for prostatic cancer, 2987
- nude mouse models
 - human stomach cancer, 1204
- osteosarcoma
 - MDM2* gene amplification, 16
- p53* alterations
 - non-small cell lung cancer, 2846
- paracrine migration-stimulating factor
 - mouse hepatic sinusoidal endothelial cells, 4418
- rat tumor cell lines
 - major CD44 proteins, different splice variants, 1262
- related variant CD44
 - expression in human brain metastases, not in glioblastomas, 5345
- renal cell carcinoma
 - oligoclonal T-cell response, vaccination with autologous tumor cells, 4745
- solid tumors
 - edatrexate compared to methotrexate, leucovorin rescue, 587
- spontaneous
 - cotransfection with fibroblast growth factor 4 and *LacZ*, MCF-7 cells, 2178
 - development of model, human osteosarcoma transplanted orthotopically into bone of athymic mice, 4890
 - serum and plasma *M*, 92,000 progelatinase, 5802
- suppressing function of *E1A*
 - counteraction of tumor suppression, reexpression of *neu*-encoded oncoprotein, 5784
- suramin
 - multiple potential mechanisms of action, 2239
- TIMP-1 as negative regulator
 - human gastric cancer cell line, chick embryo, 1397
- tumor growth and
 - inhibitory effect of TNP-470, human cell lines, 2566
- Metastatic potential
 - cell motility and glyceraldehyde-3-phosphate dehydrogenase expression
 - prostatic adenocarcinoma, 1995
 - motility of human carcinoma cells
 - response to thrombospondin, 378
- Methionine
 - dependence
 - biochemical defect, fresh patient tumors in primary histoculture, 2479
 - starvation
 - therapeutic tumor-specific cell cycle block, 5676
- Methotrexate
 - compared to edatrexate
 - leucovorin rescue, metastatic murine solid tumors, 587
- delivery of radionuclides
 - pretargeted monoclonal antibodies, affinity system, 2368
- Methoxamine
 - mechanisms of change in tumor blood flow
 - morphometry, 5528
- Methoxyamine
 - mutagenic processing of ethylation damage
 - mammalian cells, 1149
- 3-Methoxycatechol
 - butylated hydroxyanisole or sodium nitrite and catechol, rat multigene carcinogenesis model, 32
- 3-Methylcholanthrene
 - glutathione *S*-transferase class α transcripts
 - hepatocytes, 231
- N*-Methylformamide
 - induced changes
 - synthesis of *M*, 72,000 constitutive heat shock protein, HL-60 cell differentiation, 3034
- O*⁶-Methylguanine
 - inhibition of repair
 - pyridyloxobutyl DNA adducts, 2780
 - O*⁶-methylthymidine and repair of, rats treated with 1,2-dimethylhydrazine and *O*⁶-benzylguanine, 3895
- O*⁶-Methylguanine-DNA methyltransferase
 - activity
 - brain tumors and adjacent normal brain, 3416
 - prolonged depletion of activity
 - O*⁶-benzylguanine with or without streptozotocin, 1,3-bis(2-chloroethyl)-1-nitrosourea sensitivity, 4281
 - ribozyme-mediated modulation, 1731
- 6-Methylmercaptopurine
 - N*-(phosphonacetyl)-L-aspartate and 6-aminonicotinamide
 - potentiation, radiation, 3518
- 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone
 - bioactivation
 - mechanisms of inhibition, dietary phenethyl isothiocyanate, 3276
 - hemoglobin adducts
 - red blood cells, 777
 - metabolites in smokers' urine, 721
 - tobacco carcinogenesis
 - dietary fat, 2758
 - transplacental induction
 - pancreas tumors in hamsters, 2498
- N*-Methyl-*N'*-nitro-*N*-nitrosoguanidine
 - hprt* gene
 - mutagenicity, mutational spectrum, 2865
 - HPV-16 and
 - oral carcinogenesis, 4811
- Methylthioadenosine phosphorylase
 - deficiency in human non-small cell lung cancers, 1098
- Microautoradiography
 - normal organ distribution
 - radioiodinated single-chain Fv and other immunoglobulin forms, 3776
- Microcirculation
 - blood flow reduction in tumors
- high-energy shock waves, 1590
- Microfilament
 - depolarizing agents
 - scytophycins, circumvention of P-glycoprotein-mediated multidrug resistance, 1343
- β_2 -Microglobulin
 - induction and antigenic profile of HLA-A and -B antigens
 - FO-1 melanoma cells, 4303
- Micrometastasis
 - bone marrow
 - immunocytological detection, operable non-small cell lung cancer, 1027
- Microsatellite
 - genetic instability
 - endometrial carcinoma, 5100
 - genomic instability in colorectal cancer
 - clinicopathological variables, family history, 5849
 - instability
 - bladder cancer, 5620
 - hereditary non-polyposis colorectal carcinoma syndrome, 5853
 - polymorphic
 - allele analysis of skin tumors, chromosome alterations, 6022
- Microsomes
 - oxidative catabolism of all-*trans*-retinoic acid
 - lipid peroxides, 1226
- Microtubules
 - depolymerization of estramustine
 - binding to tubulin, 4573
- Microvasculature
 - increased permeability
 - preferential accumulation of Stealth liposomes, tumor tissue, 3765
 - mechanisms of change in tumor blood flow
 - morphometry, 5528
- Migration-stimulating factor
 - paracrine
 - metastatic tumor cells, mouse hepatic sinusoidal endothelial cells, 4418
- Milky spots
 - implantation site for malignant cells
 - peritoneal dissemination, mice, 687
- Misonidazole
 - unusual oxygen concentration
 - toxicity of SR-4233, 3992
- Mitochondria
 - alterations
 - photodynamic therapy-resistant cells, 4994
 - cytochrome *c* oxidase as a target site
 - daunomycin, K562 cells and heart tissue, 1072
 - energization
 - Kupffer cell-induced reduction, mediation by nitric oxide, 2676
 - hinge protein gene
 - elevated expression, cancer, 2460
 - subcellular distribution
 - bcl-2* oncoprotein, 4701
- Mitogen
 - activated protein kinase
 - elk-1 proteins, phosphoproteins and activators, 3449
- Mitomycin C
 - bioactivation by xanthine dehydrogenase
 - kinetics and mechanism, aerobic and

- hypoxic conditions, 5470
- DNA adducts and
hypoxia and dicumarol, EMT6 mouse
mammary tumor cells, 5127
- induction of protein-DNA complexes
KW-2149, HeLa S3 cells, 4466
- left-shifting agent BW12C79 and
skeletal muscle metabolism, magnetic
resonance spectroscopy, 5649
- penetration in human bladder, 3314
- reductive activation
NADH:cytochrome *b₅* reductase, 4907
- Mitosis**
-promoting factor activity
inducer mitotic cells, radiation yield of
interphase chromosome breaks,
5592
- ultrastructural localization
proliferating cell nuclear antigen, myc
oncoproteins, 1899
- Mitoxantrone**
cardiotoxicity
inhibition by ICRF-187, neonatal rat
heart cells, 550
- cytochrome P-450-induced cytotoxicity
formation, electrophilic intermediates,
5135
- plasma and cellular pharmacokinetics
high-dose chemotherapeutic regimen,
refractory lymphomas, 4850
- Molecular biology**
derivation of etiology from human-based
studies, 2437s
- Mollusk**
bivalve species
presence of transforming genes, go-
nadal tumors, 2976
- Monoclonal antibodies**
anti-B4-blocked ricin immunotoxin
therapeutic efficacy, SCID mouse tu-
mor models, 1360
- anti-carcinoembryonic antigen
specificity, CEA-mediated adhesion,
3817
- anti-colon MAb35
⁶⁷Cu labeling, preclinical evaluation,
5727
- anti-idiotypic
SV40 large tumor antigen, tumor im-
munity, 5734
- anti-idiotypic MK2-23
modulation of adjuvants, immunoge-
nicity, 112
- anti-P-glycoprotein MRK16
targeting and killing, colorectal carci-
noma cell lines, 5475
- anti-taxol
measurement in serum, 1388
- 2B5**
truncated mucin glycan, gastric and
duodenal glands, 4791
- based radio- or enzyme immunoassay
pharmacokinetics, S 12363, 3536
- biophysical characterization
tandem repeats, human mucin protein
core, 5386
- bispecific
c-erbB-2 and CD16, human tumor
xenograft model, 94
- bivalent and monovalent
blockade, epidermal growth factor re-
ceptor function, 4322
- cell surface molecules
suppression, T-lymphoma cell apopto-
sis, 5022
- cisplatin and
antitumor effect, anti-epidermal
growth factor receptor monoclonal
antibodies, 4637
- conjugate preparation and characteriza-
tion
calicheamicins, 3336
- CYFRA 21-1 immunoradiometric assay
serum fragment of cytokeratin subunit
19, marker of lung cancer, 61
- D612**
Phase I clinical trial, metastatic gas-
trointestinal cancer, 4555
- discrimination of MUC1 mucins
other sialyl-Le^x-carrying glycoproteins,
colon carcinoma, 755
- expression of sialyl-Tn antigens
esophageal carcinoma, 1706
- external epitope of *mdr1* P-glycoprotein,
310
- 741F8 anti-c-erbB-2 single-chain Fv
monovalent and divalent forms, *in vivo*
tumor targeting, 4026
- first and second generation TAG-72
comparative dual label study, colorec-
tal cancer, 271
- FW6**
epitope on α 3/4-monofucosylated po-
lylactosaminoglycans, fetal and co-
lon carcinoma-associated mucins,
4367
- gene engineering of human carcinoma
cells
self-reactive antibody expression, 3355
- high molecular weight melanoma-associ-
ated antigen
primary acral lentiginous melanoma
lesions, poor prognosis, 2830
- homodimers
enhanced antitumor activity, nude
mice, 2560
- ¹³¹I-CC49
combined with γ -interferon, improved
radioimmunotherapeutic efficacy,
600
- ¹³¹I-labeled COU-1
tumor detection, suspected colorectal
carcinoma, 5920
- immunobead-PCR
detection of circulating tumor cells,
3455
- ¹¹¹In-labeled
preclinical evaluation, nude mice bear-
ing human epidermoid carcinoma
xenografts, 2834
- intracellular and secreted mucins
multiple forms, pancreatic cancer cell
line, 884
- lactotetraose series ganglioside 3',6'-
isoL_{D1}
tumors of central nervous system,
other systems, 120
- M43**
clinical evaluation, 2803
- molecular cloning
reactivity to ganglioside G_{M3} antigen,
human cancers, 5244
- MSN-1-reactive antigen
subcellular localization, endometrial
cancer cells, 3643
- pretargeted
delivery of radionuclides, dihydrofolate
reductase and methotrexate, 2368
- radioiodinated single-chain Fv and other
immunoglobulin forms
microautoradiography, normal organ
distribution, 3776
- radiolabeled chimeric MOv18 IgG and
F(ab')₂ fragments
kinetics and tissue distribution, ovar-
ian carcinoma, 5413
- recognition of 2-nitroimidazole adducts
detection of hypoxic cells, 5721
- ¹⁸⁶Re-labeled E48
IgG-mediated therapy, human head
and neck squamous cell carcinoma
xenografts, 3524
- response against c-erbB-2 oncoprotein
breast carcinoma, 5864
- SEN7**
epitope on neural cell adhesion mole-
cule, small cell lung cancer, 2840
- single chain anti-carcinoma antibody
fused to β -lactamase
genetic construction, expression and
characterization, 2123
- staining of melanoma cells
selective loss, HLA class I allospecific-
ities, 3349
- targeted delivery
doxorubicin entrapped in liposomes,
eradication of lung cancer, 1484
- U36**
immunotargeting, head and neck squa-
mous cell carcinoma, 4383
- Monocytes**
activation
doxorubicin combined with liposome-
encapsulated muramyl tripeptide,
3986
- autocrine and paracrine growth factor
tumor necrosis factor α , ovarian can-
cer, 1939
- control of HLA-DR antigen expression
 γ -interferons, thyroid cells, 3943
- differentiation
cytokine regulation, 2603
- regulation of expression, galactoside-
binding lectin, 5033
- mediated leukemic cell death
role of β_2 -integrins, cell cycle-specific
effects of TNF- α , 4399
- Mononuclear cells**
peripheral blood
liver and, dihydropyrimidine dehy-
drogenase activity, 5433
- variable baseline γ -glutamylcysteine
synthetase mRNA expression, buth-
ionine sulfoximine treatment, 3662
- Monoterpene**
-induced regression of mammary tumors
mannose 6-phosphate/insulin-like
growth factor receptor II, transform-
ing growth factor- β 1 levels, 3849
- Motility factor**
autocrine
chemotaxis and haptotaxis, human
malignant mesothelioma cells, 4376
- MSI-238**
magainin2 and analogue peptides
anticancer efficacy, 3052

- Mucin**
 breast tumor-associated fusion protein
Escherichia coli, tumor-specific epitope, 4920
 cancer-associated epitope
 clinical evaluation, M43, 2803
 gene expression
 heterogeneity, normal and neoplastic tissues, 641
 polymorphic epithelial
 human B-cell immune response, 2457
 synthesis and secretion
 MUC-1 mucin gene expression, epithelial cancer cell lines, 1437
- Mucinous antigen**
 ovarian cancer
 malignant transformed Bloom's syndrome cells, 3427
- Mucin protein core**
 tandem repeats
 biophysical characterization, 5386
- Mucins**
 discrimination of MUC1 with novel monoclonal antibody
 sialyl-Le^x-carrying glycoproteins, colon carcinoma, 755
 fetal and colon carcinoma-associated epitope on α 3/4-monofucosylated polylactosaminoglycans, monoclonal antibody FW6, 4367
 intracellular and secreted
 multiple forms, pancreatic cell line, 884
 truncated glycan defined by monoclonal antibody 2B5
 gastric and duodenal glands, 4791
- Mucosa**
 gastric
 differential expression, CD44 splice variants, 4197
 histologically normal
 HLA class I antigens, colon, 2374
 Ménétrier's
 high affinity binding sites, gastrin-releasing peptide in gastric cancer, 5090
 rectal
 inhibition of ornithine decarboxylase, β -carotene, 3723
- Mucous cells**
 hyperplasia of pancreas with chronic inflammation
 frequent c-Ki-ras activation, 953
- MUC-1 protein**
 altered glycosylation
 colon carcinoma-associated increase, mucin-bound sialyl-Lewis^x expression, 4082
- Multidrug resistance**
 -associated gene
 localization, HT1080/DR4 and H69AR human tumor cell lines, 3221
 atypical
 topoisomerase II as a drug target, small cell lung carcinoma cells, 1064
 bovine serum albumin-doxorubicin conjugate
 rat hepatoma, 4238
 breast cancer cells
 flavonol-stimulated efflux, 7,12-dimethylbenzanthracene, 5977
- circumvention by thaliblastine
 direct binding to P-glycoprotein, 2544
 colorectal carcinoma cell lines
 targeting and killing, anti-P-glycoprotein monoclonal antibody MRK16, 5475
 component of V79 cell resistance
 adozelesin, 1354
 cytostatic
 second international symposium, 2683
 how cancer cells evade chemotherapy, 747
 inhibition by NA-382, 1555
 lung cancer cell lines
 MRP gene, transmembrane drug transporter, 1747
 non-P-glycoprotein
 MRP gene, 190-kDa membrane bound glycoprotein, 3658
 overexpression, M_r 110,000 vesicular protein, 1475
 non-P-glycoprotein expressing tumor cell lines
 reversal of etoposide, novobiocin, 5487
 P388 cells
 induction of apoptosis, anthracycline antibiotics, 1845
 P-glycoprotein
 circumvention by scytophycins, 1343
 functional imaging, organotechnetium complex, 977
 P-glycoprotein and nucleoside transport
 BIBW 22 as bifunctional modulator, 1974
 P-glycoprotein drug binding
 nonionic detergents, 5994
 P388 tumor cells
 transcriptional activation, *mdr3* gene, 1657
 reversal by GF120918, 4595
 small cell lung cancer cells
 inwardly rectifying K⁺ channels, volume-regulated anion channels, 4156
 transporter
 17 β -estradiol glucuronide as inducer, cholestasis, 5382
 tumor cells
 enhancement of vincristine cytotoxicity, phenytoin, 3262
 ultrastructural appraisal
 Fourier transform infrared spectroscopy, K562 and LR73 cell lines, 3681
- Muramyl tripeptide**
 liposome-encapsulated
 doxorubicin and, canine monocyte activation, 3986
- Muscle**
 gene expression
 effect of verapamil, doxorubicin cardiotoxicity, 4658
- Muscle, skeletal**
 metabolism
 BW12C79 and mitomycin C, magnetic resonance spectroscopy, 5649
- Muscle, smooth**
 occurrence of tumors
 insulin-like growth factor II gene, *Ava*II restriction fragment length polymorphism, 5754
 vascular
 5-fluorouracil chemotherapy and myocardial ischemia, protein kinase C-mediated vasoconstriction, 3028
- Mutagenesis**
 induction by CC-1065
 adozelesin DNA alkylation, transgenic mouse model, 5690
 oxy radicals and antioxidant responses in cancer, 3207
 site-directed
 mutagenic processing of ethylation damage, mammalian cells, 1149
- Mutagenicity**
 induction by hyperthermia
 hot mate infusion and hot caffeine, *Saccharomyces cerevisiae*
 modification of DNA bases in chromatin intact target human cells, activated polymorphonuclear leukocytes, 1269
 mutagenicity
 induction by hyperthermia, hot mate infusion and hot caffeine, 5750
 mutational spectrum and
N-methyl-*N'*-nitro-*N*-nitrosoguanidine, *hprt* gene, 2865
- Mutagens**
 potentiation of genetic damage
 folate deficiency, Chinese hamster ovary cells, 5401
- Mutations**
 clonal heterogeneity in human cancers, 921
 interruption of progression of DNA synthesis
 DNA polymerase α , codons 12 and 13 of H-ras, 2895
 nonsense and frame-shift
 rapid screening method, disease-causing *APC* alleles, 5581
 somatic and germ-line
APC gene, desmoid tumors from patients with familial adenomatous polyposis, 5079
 stereospecific benzo[c]phenanthrene dihydrodiol epoxides
 sequence specificity, interaction with *supF* gene, 1273
- myc**
 proliferating cell nuclear antigen and oncoproteins
 ultrastructural localization, synchronized neuroblastoma cells, 1899
- Myeloid cells**
 production of growth-promoting factor
 wide target cell spectrum, THP-1 cells, 1871
- Myeloma**
 coexistence of aneuploid subclones
 clonal immunoglobulin gene rearrangement, 5320
- Myeloma, multiple**
 alternatively spliced glucocorticoid receptor mRNAs, 3877
 disseminated growth
 SCID mice, 1392
 interleukin 6-dependent tumor cell growth
 inhibition, reshaping of antibody, 851
- Myelopathy**
 human T-cell lymphoma/leukemia virus type I
 sequence analysis, immunogenic and neutralizing domain, 6067

Myelopoiesis
 acceleration of granulocyte recovery
 granulocyte colony-stimulating factor,
 metastatic breast cancer, 5424
 human factor-dependent megakaryoblastic leukemia
 functional expression, interleukin 2 receptor, 675
Myeloproliferative disease
 chronic radiation-induced alteration
 aplastic anemia, DNA synthesis, 4518
Myelosuppression
 cyclophosphamide-induced
 protection, combined interleukin 1 β /
 interleukin 2 treatment, 569
Myelotoxicity
 benzene and phenolic metabolites
 oxidative DNA damage, HL-60 cells
 and bone marrow, 1023
Myocardial ischemia
 5-fluorouracil chemotherapy
 protein kinase C-mediated vasoconstriction, vascular smooth muscle, 3028

N

NA-382
 inhibition of multidrug resistance, 1555
NAD
 kinetics and mechanism of mitomycin C
 bioactivation
 aerobic and hypoxic conditions, 5470
NADH:cytochrome *b₅* reductase
 reductive activation of mitomycin C, 4907
NAD(P)H:(quinone-acceptor) oxidoreductase
 density-dependent growth inhibition
 normal but not transformed cells, 1338
National Cancer Institute
 funding mechanisms for research, 2434s
 trends in program project grant funding, 477
Natural killer cells
 activated
 imaging by positron emission tomography, preferential uptake in tumors, 5867
 production of immunosuppressive aminoglycosides
 deacetylase activity, human tumor cells, 5600
 transdominant suppressors of oncogenesis
 wild-type adenovirus type 5 transforming genes, rat embryo fibroblast cells, 1929
 tumor-infiltrating T-cells and signal-transducing ζ chains, colorectal carcinoma, 5610
NCAM
 epitope recognition by monoclonal antibody SEN7
 small cell lung cancer, 2840
Neoplasia
 elevated production of active oxygen
 Bloom's syndrome, 5104
Neoplastic progression
 induction in Syrian hamster embryo cells
 protein phosphatase inhibitors, 1777
 transformation of Syrian hamster embryo fibroblasts

amplification potential, various carcinogens, 3098
Neoplastic transformation
 normal and neoplastic tissues
 heterogeneity, mucin gene expression, 641
 tumorigenic conversion of fibroblasts
 $\alpha 6$ integrin, 2950
Neopterin
 prognosis
 colonic adenocarcinoma, 260
Nephrotoxicity
 drug resistance and
 cisplatin and metallothionein synthesis, bladder tumor, 1829
Nerve growth factor
 -like protein
 chemotaxis and chemokinesis, prostate tumor cell lines, 1416
 prostatic
 inducible A gene, binding of novel element in retinoblastoma gene promoter, 5597
TRK protooncogene messenger RNA
 and
 coexpression in neuroblastoma, favorable prognosis, 2044
Neu differentiation factor
 induction of ICAM-1
 implications, mammary tumors, 5251
Neural neoplasms
 17p allelic loss
 DNA hypermethylation, 2715
Neuroblastoma
 cell differentiation
 regulation, Bcl-2 oncoprotein, 4978
 frequent neuronal functions
 uptake and storage, *m*-iodobenzylguanidine, 304
 mechanism
 neutrophil-mediated lysis, 362
 messenger RNA for *TRK* protooncogene
 low affinity nerve growth factor receptor, favorable prognosis, 2044
 neuronal differentiation
 alternatively spliced *src* mRNAs, 3179
 oligodendrocyte-associated genes, 170
p53 gene
 relationship, *N-myc* amplification, 4053
p53 mutations in Ewing's sarcomas, 5284
 primary
 absence of *p53* mutations, 5269
 sensitivity to growth inhibition
 deferrioxamine, 3968
 ultrastructural localization
 proliferating cell nuclear antigen, myc oncoproteins, 1899
Neuroectodermal neoplasms
 characterization of thread proteins, 3823
 chimeric EWS-FL11 transcript
 Ewing cell line, complex t(11:22:14) translocation, 3655
 insight on biology of, 926
Neuroendocrine cells
 androgen receptor status
 benign and malignant prostatic tissue, 1967
Neuroendocrine markers
 drug sensitivity testing and individualized chemotherapy, individualized chemotherapy, 5181

alized chemotherapy, 5181
Neurofilaments
 oligodendrocyte-associated genes
 glioma and neuroblastoma, 170
Neurotoxicity
 cisplatin-induced
 protection with reduced glutathione, rats, 544
Neutrophils
 activation
in vivo administration, bryostatins 1, 2810
 -mediated lysis
 mechanism, human neuroblastoma cells, 362
Nickel
 induction of signature mutation
 oxygen free radical damage, 4172
Nicotine
 stimulation of serotonergic autocrine loop
 human small cell lung carcinoma, 5566
Nicotinic acid mononucleotide
 aspirin use
 risk of fatal cancer, 6074
NIH/3T3 cells
 folate binding protein
 gene transfection and expression, 5791
 metastatic *ras*-transformed
 adhesion to osteopontin, fibronectin and laminin, 701
 presence of transforming genes
 gonadal tumors, bivalve mollusk species, 2976
 transformation
 ornithine decarboxylase overexpression, 2618
Nitric oxide
 hypoxic mammalian cell radiosensitization, 5845
 macrophage synthesis
 delay of progression, UV light-induced skin cancers, 5507
 mediation of Kupffer cell-induced reduction
 mitochondrial energization, hepatoma cells, 2676
 -nucleophile complexes
 inhibition, proliferation of A375 melanoma cells, 564
 oxy radicals and antioxidant responses in cancer, 3207
9-Nitrocarnitine
 -treated immunodeficient mice
 regression of breast carcinoma tumors, 1577
6-Nitrochrysene
 induction of mammary cancer, 3719
 metabolism
 hepatic and pulmonary cytochrome P450 enzymes, 2028
Nitrogen mustard
 induction of apoptosis
 modulation by *bcl-2*, 1853
Nitroglycerin
 protein kinase C-mediated vasoconstriction
 5-fluorouracil chemotherapy, myocardial ischemia, 3028
4-Nitroquinoline-N-oxide
 potent intracellular oxidative stress,

- 3250
4-Nitroquinoline 1-oxide
 -induced tongue neoplasms in rats
 chemoprevention of oral carcinogenesis, DL- α -difluoromethylornithine, 772
Nitrosamine
 tobacco-specific
 smokers' urine, 721
N-Nitrosodiethylamine
 chronic ingestion and effects on rats, 4107
N-Nitroso-N-methylurea
 induction of carcinogenesis
 expression of sulfated glycoprotein 2, prostate and seminal vesicle, 1480
Nitrosourea
 cisplatin-induced DNA cross-links and topoisomerase II inhibition and altered kinetics, glioblastoma, 5663
N-myc
 amplification
 mutation of *p53* gene, neuroblastoma, 4053
N-myc 2
 insulin-like growth factor II and precancerous altered hepatic foci, woodchuck hepatitis virus carriers, 2020
Nodules
 subcutaneous
 interstitial pressure, melanoma and lymphoma, 2204
Nonidet P-40
 effects of nonionic detergents
 P-glycoprotein drug binding, multidrug resistance, 5994
Nonsteroidal antiinflammatory drugs
 aspirin
 use and risk of fatal cancer, 1322
Novobiocin
 reversal of etoposide resistance
 non-P-glycoprotein expressing multidrug-resistant tumor cell lines, 5487
Nuclear matrix
 association of origins of replication
 normal human fibroblasts, 3865
 differences in DNA supercoiling
 local control, T2/3 transitional cell carcinoma of the bladder, 2300
Nuclear matrix proteins
 normal and breast cancer cells, 3394
 patterns in human benign prostatic hyperplasia
 prostate cancer, 744
Nucleolar organizer
 argyrophilic
 proliferating cell nuclear antigen and, prognosis in lung cancer, 5000
Nucleoside diphosphate kinase
-nm23
 c-Ha-*ras* mRNA and lung metastasis in osteosarcoma, 5038
Nucleosides
 transport and P-glycoprotein
 BIBW 22 as bifunctional modulator, 1974
Nucleotides
 purine
 levels in host tissues, Ehrlich ascites tumor-bearing mice, 5143
Nutrition
 cancer and
 American Cancer Society Research Workshop, 2431s, 2432s
 cell and organ culture studies, American Cancer Society Research Workshop, 2455s
 panel on animal studies, American Cancer Society Research Workshop, 2452s
 panel on human studies, American Cancer Society Research Workshop, 2449s
 diet and cancer
 development of hypotheses, evaluation in animal studies, 2442s

O

Occupational risks
 agricultural
 non-Hodgkin's lymphoma, 2421
 welders
 DNA-protein cross-links, 460
Okadaic acid
 class tumor promoters
 hyperphosphorylation of cytokeratins, primary keratinocytes, 992
 hyperphosphorylation
 retinoblastoma protein and *p53*, 239
 induction of neoplastic progression
 protein phosphatase inhibitors, Syrian hamster embryo cells, 1777
 teleocidin and
 absence of syngeneic effects, tumor promotion in CD-1 mouse skin, 1012
Oligodendrocyte
 -associated genes
 human glioma and neuroblastoma cell lines, 170
Oligonucleotides
 human papillomavirus type 18-specific antisense
 transformed phenotype, human carcinoma cell lines, 2330
Oltipraz
 chemopreventive effect
 carcinogenesis induced by azoxymethane, 2502
 transient intervention
 aflatoxin-induced hepatic tumorigenesis, 3499
Oncogenes
BCR-ABL
 role in human leukemia, 485
c-Ha-ras
 inhibition of tumor growth, antisense DNA, 577
c-Ki-ras
 activation in mucous cell hyperplasias, pancreas, 953
c-myc: see *c-myc*
elk-1 variant
 differential splicing, encoding of activators and repressors, 215
 environmental skin cancer
 mechanisms, models and human relevance, 3439
H-ras
 spontaneous revertants of rat fibroblasts, up-regulation of lysyl oxidase, 4670
H-ras and *v-myc*
 inhibition of DNA synthesis, rat embryo fibroblasts, 1213
 -induced transformation
 altered chromosomal methylation patterns, bronchial epithelial cells, 1684
Ki-ras
 expression by transgenic mice, control of thyroglobulin promoter, 5523
 loss of heterozygosity
 invasive low-grade and high-grade epithelial ovarian carcinoma, 4456
met expression
 sarcoma tumorigenicity, 5355
 middle T
 induction by soluble factor, endothelial cell migration and invasiveness, 3812
neu
 increased protein tyrosine phosphatases, human breast epithelial cells, 2272
 normal and neoplastic growth and development, 929
 nuclear
 transgenic mouse for synergistic effects, tumorigenesis, 1719
ras: see *ras*
 regulation and heteromeric structure
 fibroblast activation protein, 3327
RET
 rearrangement, *in vitro* irradiation, 2940
src-specific immune regression
 Rous sarcoma virus-induced tumors, 915
 systematic *H-ras* amplification
 ovary-independent mammary tumors, progressively anaplastic phenotypes, 5339
 transformation
 radiation, taxol, 1368
v-fos and *v-ras* Ha
 induction of autonomous papillomas, transgenic epidermis, 5071
v-jun transgenic mice
 characterization of sarcoma cell lines, 622
v-jun transgenic murine cells
 induction of anchorage independence, tumor necrosis factor- α and interleukin 1 α , 615
Oncogenesis
 coamplification of *CDK4* gene
MDM2 and *GLI*, human sarcomas, 5535
 functional role
 chromosome 10 loss, human glioblastomas, 5043
 growth inhibition of lung cancer cell lines
 interleukin 6, 4175
 transdominant suppressors
 wild-type adenovirus type 5 transforming genes, transformed rat embryo fibroblast cells, 1929
Oncoproteins
bcl-2
 differentiation, human neuroblastoma cells, 4978
 subcellular distribution, 4701
c-erbB-2
 antibody response, breast carcinoma,

- 5864
neu-encoded
 counteraction of tumor suppression,
E1A, 5784
- Oncostatin M**
 -induced growth inhibition
 increased resistance, melanoma cell
 lines derived from advanced-stage le-
 sions, 2708
- Opioids**
 endogenous peptides
 human brain tumors, associated cyst
 fluids, 4715
 peptides and steroid hormones
 growth, androgen-responsive Shionogi
 carcinoma cells, 4224
- Oral neoplasms**
 subsequent risk
 serum micronutrients, 795
- Oral tissue**
 detection of DNA adducts
 tobacco smoking, ³²P postlabeling,
 1522
- Organ culture**
 hormone regulation of human prostate,
 5199
 identification and characterization of
 agents
 modification, carcinogenesis, 2446s
 report of Group C
 American Cancer Society Research
 Workshop, 2455s
- Organosulfur compounds**
 chemoprevention
 colon carcinogenesis, 3493
- Organotechnetium complex**
 functional imaging
 multidrug-resistant P-glycoprotein,
 977
- Ormaplatin**
 sensitivity/resistance
 cisplatin-resistant ovarian cancer cells,
 242
- Ornithine decarboxylase**
 development of resistance to hydroxyu-
 rea
 α -difluoromethylornithine, K562 cells,
 5262
 inhibition of activity in rectal mucosa
 β -carotene, colon cancer, 3723
 overexpression
 transformation of NIH/3T3 cells,
 2618
- Osteopontin**
 adhesion of metastatic *ras*-transformed
 NIH 3T3 cells, 701
 TPA-induced tumorigenic transforma-
 tion and
 1 α ,25-dihydroxyvitamin D₃, mouse
 JB6 epidermal cells, 2217
- Osteosarcoma**
 cell migration
 overexpression of urokinase receptor,
 matrix invasion, 3109
 metastatic
MDM2 gene amplification, 16
 rat-transplantable
 lung metastasis, nucleoside diphos-
 phate kinase/*nm23* and *c-Ha-ras*
 mRNA, 5038
 transplanted orthotopically into bone of
 athymic mice
 development, spontaneous metastasis
 model, 4890
- Osteosarcoma cells**
 aggregation
 platelet α -granule proteins, platelet
 membrane glycoproteins Ib/IX and
 IIb/IIIa, 4695
 cell density inhibition of proliferation
 concerted control, multiple histone
 promoter factors, 2399
- Ovarian neoplasms**
 anticancer efficacy
 magainin2 and analogue peptides,
 3052
 anti-p53 antibody response, 3468
 autocrine and paracrine growth factor
 tumor necrosis factor α , 1939
 binding to peritoneal mesothelium
 mediation by CD44H, 3930
 cisplatin-resistant
 ormaplatin sensitivity/resistance, 242
 cross-resistance to diverse drugs
 primary cisplatin resistance, 5225
 detailed deletion mapping
 chromosome 17q, 3382
 detection and intervention
 National Cancer Institute Conference,
 investigational strategies, 3839
- epithelial**
 allelotype, 2393
 deletion unit on chromosome 17q,
 1218
 mutation of *K-ras* protooncogene, bor-
 derline malignancy, 1489
p53 and *Ki-ras* gene mutations, 3103
 prognostic significance, platelet-de-
 rived growth factor, 4550
 expression and processing of progastrin,
 1823
 high efficiency gene transfer
 no cell selection, primary human tu-
 mor explants, 2221
 LHRH analogues
 high affinity binding, direct antiprolif-
 erative effects, 5439
 malignant and benign
 steroid production in different parts,
 2309
 mucinous antigen
 malignantly transformed Bloom's syn-
 drome cells, 3427
 pharmacokinetics of recombinant human
 interleukin 3
 chemotherapy, 5915
- Ovary**
 granulosa cell tumorigenesis, 3741
 C19 androgen induction, genetic sus-
 ceptibility, 1059
 -independent mammary tumors
 systematic *H-ras* amplification, pro-
 gressively anaplastic phenotypes,
 5339
 transformation of epithelial cell lines
R4ST24, no influence on cisplatin
 sensitivity, 3771
- 22-Oxa-calcitriol**
 antitumor effect
 synergism with tamoxifen, athymic
 mice implanted with human breast
 carcinoma, 2534
- Oxaliplatin**
 cytotoxicity and protein binding
 red blood cell partitioning, 5970
- Oxidants**
 altered sensitivity
 tumor cell heme uptake, induction of
 ferritin synthesis, 5308
- Oxidative stress**
 intracellular
 4-nitroquinoline-*N*-oxide, 3250
 lipid-derived and ascorbate free radicals
 exposure to edelfosine, L1210 cells,
 711
- Oxonic acid**
 inhibition of gastrointestinal toxicity
 5-fluorouracil, no loss of antitumor ac-
 tivity, 4004
- Oxygen**
 active
 elevated production, Bloom's syn-
 drome, 5104
 active species and lipid peroxidation
 antitumor effects, hyperthermia, 2326
 damage of nuclear DNA
 liver, rats exposed to psychological
 stress, 4153
 fluence rate effects
 photodynamic therapy, multicell tu-
 mor spheroids, 1249
 free radical damage
 nickel, induction of signature muta-
 tion, 4172
 inhibition of oxidative stress
 chemopreventive agents, HeLa cells,
 4528
 oxidative injury
 activation of heat shock transcription
 factor, heat shock protein levels, 12
 singlet
 induction of human heme oxygenase
 gene, UVA/near-visible light, 4505
 unusual concentration
 toxicity of SR-4233, 3992
- Oxy radicals**
 antioxidant responses and
 cancer, 3207

P

- p34^{cdc2}**
 activation
 caffeine release, radiation-induced S
 and G₂ phase arrest, 1507
- p53**
 abnormalities in different subtypes
 human sarcomas, 468
 absence of germ line mutations of exons
 5 to 9
 Turcot's syndrome, glioma and poly-
 posis, 957
 absence of mutations
 primary neuroblastomas, 5269
 accumulation in esophageal precancer-
 ous lesions
 early biomarker for carcinogenesis,
 1783
 accumulation of wild type protein
 human astrocytoma, 3465
 alterations
 metastatic involvement, non-small cell
 lung cancer, 2846
 analysis of antibodies
 cancer-defined B-cell epitopes, expo-
 sure on protein surface, 5872
 anti-p53 antibody response in cancer pa-

- tients, 3468
- antisense
 - codon 248 *p53* mutations, retention of tumor suppressor function, 4362
- base transitions
 - gastric cancer, 2614
- binding protein *MDM2* gene
 - differential expression, human breast carcinoma, 3226
- conformation
 - redox modulation, sequence-specific DNA binding, 4469
- conformational domain
 - sequence-specific interaction, DNA, 5361
- discordant gene mutations
 - primary head and neck cancers, upper aerodigestive tract, 1676
- distinct pattern of mutations
 - bladder cancer, relationship to tobacco usage, 1162
- gene alterations
 - activation of *c-K-ras-2*, uterine endometrium, 1883
- gene expression
 - hepatocellular carcinoma, tumor growth and invasiveness, 4691
- gene mutation and protein overexpression
 - loss of 17p, esophageal squamous cell carcinoma, 846
- gene mutations
 - cigarette smoking and schistosomiasis, urothelial cancer, 3795
 - lack of occurrence, testis cancer, 3574
- germ line mutant
 - dominant negative effect, tumorigenesis, 4452
- germ line mutation screening
 - malignant tumors, family history of cancer, 452
- high frequency of mutations
 - strand bias and tumor heterogeneity, ultraviolet radiation-induced skin tumors, 2961
- inactive mutants
 - transcriptional activity, wild-type *p53*, 4772
- incidence of mutations
 - progression, head and neck cancer, 4477
- induction
 - wavelength specific patterns in skin, exposure to UV radiation, 2697
- infrequent mutations
 - pulmonary carcinoid tumors, 5797
- Ki-ras* gene mutations and
 - epithelial ovarian neoplasms, 3103
- loss of associated G1 checkpoint
 - cell survival after DNA damage, 4164
- mutant
 - resistance to transforming growth factor- β_1 , murine keratinocytes, 899
- mutant suppressor protein
 - target, peptide-induced CD8⁺ cytotoxic T-cells, 3257
- mutation
 - chromosome 17p deletions, renal cell carcinoma, 3092
 - common genetic event, ovarian carcinoma, 2128
 - Ewing's sarcomas but not neuroblastomas, 5284
- formation of hyperplastic outgrowths, mouse mammary cells, 1646
- histological type, invasive breast carcinoma, 4665
- lack of correlation, radiosensitivity in head and neck cancer cell lines, 3667
- MDM2* amplification, human soft tissue sarcoma, 2231
- preneoplastic stage, mouse mammary tumor development, 3374
- profiles, altered mRNA in esophageal carcinoma, 1889
- relationship to *N-myc* amplification, neuroblastoma, 4053
- subset, advanced stage prostate cancer, 3369
- tumor-distant epithelia, head and neck cancer, 4189
- tumor progression, hepatocellular carcinoma, 2884
- mutations and 3p deletions
 - prognostic significance, primary resected non-small cell lung cancer, 1
- mutations in adult squamous cell carcinoma
 - infrequency of *MDM2* gene amplification, pediatric solid tumors, 6028
- no site-specific mutation
 - aflatoxin B₁-induced hepatic hyperplastic nodules, 9
- overexpression
 - high-risk human papillomavirus infections, transitional cell carcinoma of the urinary bladder, 4823
 - late event, development of malignant melanoma, 2235
- protein accumulation
 - early bronchial neoplasia, 4817
- repair and DNA strand bias
 - normal and xeroderma pigmentosum group C fibroblasts, 5377
- retinoblastoma protein and
 - hyperproliferation, okadaic acid, 239
- retroviral wild-type
 - vector penetration of lung cancer spheroids, induction of apoptosis, 4129
- role and mutational heterogeneity
 - hepatocellular carcinoma, 368
- role in cell cycle arrest
 - radiosensitivity, Burkitt's lymphoma cell lines, 4776
- sequence-specific DNA binding
 - chemotherapy and DNA damaging agents, 2212
- somatic mutations
 - breast carcinoma, Icelandic population, 1637
- splicing mutations
 - human hepatocellular carcinoma, 1653
- subset of human malignant gliomas
 - amplification and overexpression, *MDM2* gene, 2736
- ultraviolet-specific mutations in gene
 - skin tumors, xeroderma pigmentosum, 2944
- "wild-type" conformation
 - structural role, metal ions, 1739
- p56^{lck}*
 - loss of T-cell receptor ζ chain
- T-cells, human renal cell carcinoma, 5613
- p65*
 - exposed melanoma cells
 - molecular basis, complement resistance, 592
- p110*
 - overexpression of vesicular protein non-P-glycoprotein-mediated multidrug resistance, 1475
- p145^{cas}*
 - modulation of function in cells
 - acute myeloblastic leukemia, 4424
- P185*
 - neu* transformation
 - protein tyrosine phosphatases, human breast epithelial cells, 2272
- p190^{BCR-ABL}*
 - p210^{BCR-ABL}* or
 - heterogeneity of lineage derivation, Philadelphia-positive acute lymphoblastic leukemia, 3289
- PAI-1*
 - urokinase-type plasminogen activator and
 - cytosolic extracts, breast carcinoma, 2513
- Pancreas**
 - cholecystokinin-A receptors
 - azaserine-induced preneoplastic lesions, 3925
 - juice and peripheral blood
 - detection of *ras* gene mutations, pancreatic adenocarcinoma, 2472
 - mucous cell hyperplasias
 - chronic inflammation, *c-Ki-ras* activation, 953
- Pancreatic neoplasms**
 - acinar cell line
 - unscheduled expression, basic fibroblast growth factors, 1182
- advanced stage
 - overexpression, acidic and basic fibroblast growth factors, 5289
- carcinogenesis
 - caloric restriction and intervention, 46
- carcinogen treatment in initiation
 - DNA damage, repair and cell proliferation, 2790
- enhanced expression
 - type II transforming growth factor β receptor, 2704
- genetic instability
 - poorly differentiated type, gastric cancer, 5087
- high efficiency gene transfer
 - no cell selection, primary human tumor explants, 2221
- multiple forms
 - intracellular and secreted mucins, 884
- "patient-like" treatment model
 - orthotopic transplantation, human tumor tissue in nude mice, 3070
- transplacental induction
 - ethanol, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, 2498
- Papilloma**
 - autonomous
 - cooperation between *v-fos* and *v-ras*
 - Ha, transgenic epidermis, 5071
 - chemically induced benign
 - protection against malignant conversion

- sion, polyphenolic fraction from green tea, 5409
- laryngeal**
epidermal growth factor receptor, decreased epithelial differentiation, 910
- Paraffin**
-embedded colon carcinoma specimens
colorimetric *in situ* messenger RNA hybridization, epidermal growth factor receptor, 937
-embedded tissue
formalin, X chromosome inactivation, 4676
- Parathyroid hormone**
-related peptide
growth factor-like properties, transfected rodent cell lines, 2980
-related protein gene expression
PCR analysis, breast cancer and bone metastases, 5076
-related protein in human prostate cancer
immunohistochemical localization, 1724
- α -Particles**
extremely low doses
induction of sister chromatid exchange, 2188
- PC-3 cells**
inhibition of cell proliferation
androgen receptor complementary DNA, 1304
- PC-12 cells**
protection from apoptosis
HIV-1 Tat protein, 4481
- P388 cells**
induction of apoptosis
anthracycline antibiotics, 1845
- P815 cells**
arachidonic acid as growth signal, 3405
- Pelvis**
induction of renal carcinoma by phenacetin
hydronephrosis-bearing rats of SD/cShi strain, 4218
- Peptides**
endogenous opioid
human brain tumors, associated cyst fluids, 4715
growth factors
fibroblast hepatocyte growth factor/scatter factor, breast carcinoma cell lines, 1233
-induced CD8⁺ cytotoxic T-cells
target, mutant p53 tumor suppressor protein, 3257
magainin2 and analogues
anticancer efficacy, 3052
synthetic
human B-cell immune response, polymorphic epithelial mucin, 2457
laminin A chain, plasminogen activator production of B16F10 melanoma, 1998
Tyr-Ile-Gly-Ser-Arg
multimeric forms, inhibition of tumor growth and metastasis, 3459
- Peripherin**
stable expression by neuroendocrine carcinomas
skin, xenograft on nude mice and primary cultures, 1175
- Peritoneal cavity**
tumor tissue and
progressive ovarian carcinoma, procolagens types I and III, 5028
- Peritoneum**
dissemination
milky spots as implantation site for malignant cells, 687
- Perspectives in Cancer Research**
competing influences
concomitant tumor resistance, 3266
gap junction function and cancer, 3475
signaling by integrins
tumorigenesis, 1502
suramin
multiple potential mechanisms of action, 2239
- Pesticides**
agricultural risk factors
non-Hodgkin's lymphoma, 2421
- P-glycoprotein**
direct binding
circumvention of multidrug resistance, thaliblastine, 2544
drug binding and reversal of multidrug resistance
nonionic detergents, 5994
enhanced Adriamycin activity
bifunctional inhibitor W-77, human ovarian carcinoma, 2051
inhibition of multidrug resistance by NA-382, 1555
- mdr1***
external epitope, monoclonal antibody, 310
-mediated multidrug resistance
circumvention by scytophycins, 1343
monoclonal antibody MRK16
targeting and killing, multidrug-resistant colorectal carcinoma cell lines, 5475
multidrug-resistant
functional imaging, organotechnetium complex, 977
nucleoside transport and
BIBW 22 as bifunctional modulator, 1974
- pH**
intermediate biomarker of carcinogenesis
proliferation, human colonic mucosa, 3283
intracellular
lowering of, thermosensitivity of tumor cells, 1599
intracellular acidification
etoposide-induced apoptosis, HL-60 cells, 2349
- Phagocytosis**
distribution of permanently labeled colon cancer cells
lectin-mediated endocytosis, trap label, 658
- Pharyngeal neoplasms**
subsequent risk
serum micronutrients, 795
- Pharynx**
preservation
cancer chemoprevention, head and neck cancer, 5113
- Phenacetin**
induction of renal pelvic carcinoma
hydronephrosis-bearing rats of SD/cShi strain, 4218
- 1,10-Phenanthroline**
structural role of metal ions
"wild-type" conformation, p53, 1799
- Phenethyl isothiocyanate**
dietary
mechanisms of inhibition, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone bioactivation, 3276
- Phenobarbital**
glutathione S-transferase class α transcripts
hepatocytes, 231
- Phenytion**
enhancement of vincristine cytotoxicity
multidrug-resistant tumor cells, 3262
- Phorbol 12-myristate 13-acetate**
induced tumor promotion in CD-1 mouse skin
inhibition by 12-deoxyphorbol 13-esters, 2507
- 12-Phorbol-13-myristic acid**
retinoic acid and γ -interferon
ICAM-1 expression, human tumor cell lines, 826
- Phosphatidylcholine**
putative tumor marker
breast and colon cancer, 1751
- Phosphatidylinositol-3-kinase**
inhibition by antitumor ether lipid analogues, 4297
- Phospholipase**
activation-triggered apoptosis
photosensitized mouse lymphoma cells, 5897
- Phospholipase A₂**
-mediated oxidative and nonoxidative mechanisms
inhibition of cancer cell line proliferation, riminophenazine agents, 318
- Phospholipase D**
activation
signal transduction pathways, response to γ -radiation, 4474
- N-(Phosphonacetyl)-L-aspartate**
 \pm 5-fluoro-2'-deoxyuridine
antitumor activity, colon carcinoma 26, 1560
- 6-methylmercaptopurine and 6-aminonicotinamide**
potentiation, radiation, 3518
multiple mechanisms of drug resistance
SV40-infected precrisis human fibroblasts, 4946
- Phosphoproteins**
elk-1 proteins
activators, mitogen-activated protein kinase, 3449
M, 32,000
selective expression, competency for self-renewal, 4720
- Phosphoramidate mustard**
modulation of rat hepatic cytochrome P450 2C11
cyclophosphamide, messenger RNA levels, 2490
- O-Phospho-L-tyrosine**
inhibition of cellular growth
activation, protein tyrosine phosphatases, 557
- Photochemotherapeutic agents**

- benzophenoxazine analogues, 2571
- Photochemotherapy**
pharmacokinetics of fluorescent drug
laser-induced fluorescence, 5954
- Photodynamic therapy**
endothelium-dependent relaxation
rat aorta, 2548
fluence rate effects
multicell tumor spheroids, 1249
-resistant cells
mitochondrial alterations, 4994
- Photofrin**
photosensitization
membrane lipid free radicals, L1210
murine leukemia cells, 3670
- Photorepair**
skin
ultraviolet radiation-induced DNA
damage, platyfish *Xiphophorus*,
2249
- Photosensitization**
mouse lymphoma cells
triggering of apoptosis, phospholipase
activation, 5897
- Photosensitizer**
uptake
tumor-secreted vascular permeability
factor/vascular endothelial growth
factor, 153
- Phototherapy**
merocyanine 540-mediated
enhancement by salicylate, 806
- Phylloides neoplasms**
breast
clonal analysis, comparison to fibroad-
enoma, 4071
- Pirarubicin**
pharmacokinetic and pharmacodynamic
advantages over Adriamycin
intraarterial hepatic administration,
VX2 tumor model, 1550
- Piroxanthone**
pharmacokinetics
Phase I trial with granulocyte-colony
stimulating factor, 2587
- Pituitary neoplasms**
prenatal exposure to diethylstilbestrol,
1546
- Placenta**
detection of aflatoxin B₁-DNA adducts,
1278
transplacental carcinogenicity of cispla-
tin
SENCAR mice, 3874
- Plasma**
pharmacokinetics of vinblastine
N-(deacetyl-*O*-4-vinblastoyl-23)-L-ethyl
isoleucinate, high-performance li-
quid chromatography, 2061
pharmacokinetic study of topotecan
nonhuman primates, 725
- Plasma membrane**
cytotoxic protein purification
characterization, transformed fibro-
blasts, 1195
- Plasmid**
reporter gene inactivation
one benzo(a)pyrene diol-epoxide DNA
adduct, hepatocytes, 2279
- Plasminogen activator**
extracellular matrix production and deg-
radation
adenoid cystic carcinoma cells, 147
inhibitor
inhibition, invasion of HT1080 sar-
coma cells, 6051
modulation of production
synthetic peptide from laminin A
chain, B16F10 melanoma, 1998
urokinase-type
receptor antibody, modulation of inva-
sion in human glioblastoma cells,
4143
stimulation, blockage of E-cadherin-
dependent cell-cell adhesion, 3618
urokinase-type and PAI-1
cytosolic extracts, breast carcinoma,
2513
urokinase-type antigen in plasma
clinical value, detection of colorectal
cancer, 1788
- Platelet-derived growth factor**
 β receptor
successive activation, genesis of human
choriocarcinoma, 2927
- Platelets**
activation
in vivo administration, bryostatin 1,
2810
-derived endothelial cell growth
sensitivity of KB cells, pyrimidine anti-
metabolites, 5680
-derived growth factor and its receptor
prognostic significance, epithelial
ovarian neoplasms, 4550
glycoprotein IIb/IIIa binding to fibrino-
gen
inhibition, tumor cell membrane pro-
teins, 221
membrane glycoproteins Ib/IX and IIb/
IIIa
platelet α -granule proteins, aggrega-
tion induced by osteosarcoma cells,
4695
- Platinum**
-DNA adduct in leukocyte DNA
different types of malignancies, 3694
resistance
cytostatic multidrug resistance, second
international symposium, 2683
role of carrier ligand, human carci-
noma cell lines, 799
- Platinum complexes**
bis-aceto-amine-dichloro-cyclohexyl-
amine platinum(IV)
preclinical antitumor evaluation, 2581
- Pleiotropin**
heparin-binding growth/differentiation
factors
midline expression, Wilms' tumor and
other human carcinomas, 1281
- PM-1 antibody**
reshaping of
inhibition, interleukin 6-dependent tu-
mor cell growth, 851
- Poly(ADP-ribose) polymerase**
binding of melphalan-damaged DNA,
5370
specific proteolytic cleavage
early marker, chemotherapy-induced
apoptosis, 3976
- Polyamine analogues**
*N*¹,*N*¹²-bis(ethyl)spermine
growth inhibition, hormone-responsive
and -resistant human breast cancer,
2071
- DNA interaction**
human brain tumor cell lines, 3948
- Polyamines**
antitumor activity of *N*¹,*N*¹²-
bis(ethyl)spermine
human melanoma xenografts, 581
cancer
international symposium, 2689
- Polyclonal antibodies**
anti-taxol
measurement in serum, 1388
- Polyethylene glycol**
-modified chimeric toxin
transforming growth factor α , *Pseudo-*
monas exotoxin, 4588
- Polylectosaminoglycans**
 α 3/4-monofucosylated
monoclonal antibody FW6, fetal and
colon carcinoma-associated mucins,
4367
- Polymerase chain reaction**
heterogeneity in MLL/AF-4 fusion
mRNA
t(4;11) acute leukemia, 3853
immunobead-PCR
detection of circulating tumor cells,
3455
parathyroid hormone-like protein gene
expression
breast cancer, bone metastases, 5076
- Polymer**
controlled release for drug delivery in
brain
interstitial chemotherapy, 329
- Polymorphism**
*Ava*II restriction fragment length
insulin-like growth factor II gene, oc-
currence of smooth muscle tumors,
5754
- Polyoma virus**
middle T oncogene insertion in Caco-2
cells
increased protein kinase C α expres-
sion, 2762
-transformed middle T oncogene
induction by soluble factor, endothelial
cell migration and invasiveness,
3812
- Polyposis**
Turcot's syndrome
absence of germ line mutations, *p53*
gene, 957
- Polyproline**
biophysical characterization of tandem
repeats
human mucin protein core, 5386
- Positron emission tomography**
imaging of activated natural killer cells
preferential uptake in tumors, 5867
- Potassium channel**
inwardly rectifying
volume-regulated anion channels,
small cell lung cancer cells, 4156
- ³²P postlabeling**
detection of DNA adducts in human oral
tissue
tobacco smoking, 1522
- Pregnancy**
transplacental carcinogenicity of cispla-
tin

- SENCAR mice, 3874
- Preneoplasia**
 mouse mammary epithelial cells
 growth factor dependency, gene expression, 668
 TM preneoplastic mammary outgrowths
 morphological and functional properties, 663
- Pressure**
 interstitial
 subcutaneous nodules, melanoma and lymphoma, 2204
- Prevention**
 therapy and basic science
 resolution of cancer problem, 5890
- Proadipocytes**
 3T3 T
 loss of differentiation control, 1770
- Procollagens**
 types I and III
 progressive ovarian carcinoma, tumor tissue and peritoneal cavity, 5028
- Progastrin**
 expression and processing by ovarian cancer, 1823
- Progelatinase**
 serum and plasma M, 92,000
 spontaneous metastasis, mammary adenocarcinoma, 5802
- Progesterone**
 receptor expression in meningiomas, 1312
 steroid production
 different parts, malignant and benign ovarian tumors, 2309
- Program project**
 grant funding trends
 National Cancer Institute, 477
- Prolactin**
 calories and parity
 mammary tumor risk, epithelial kinetics and differentiation, 1188
- Proliferating cell nuclear antigen**
 expression and argyrophilic nucleolar organizer regions
 prognosis, surgically treated lung cancer patients, 5000
 myc oncoproteins and
 ultrastructural localization, synchronized neuroblastoma cells, 1899
- Prostate**
 benign and malignant tissue
 androgen receptor status, neuroendocrine cells, 1967
 dysplastic dorsolateral
 type II estrogen-binding sites, Noble rat, 528
 expression of sulfated glycoprotein 2
 induction of carcinogenesis, N-nitroso-N-methylurea, 1480
 hormone regulation
 organ culture, 5199
 nerve growth factor inducible A gene binding
 novel element, retinoblastoma gene promoter, 5597
 secretion of matrix metalloproteinases inhibitors, explant cultures, 4493
 -specific antigen gene expression
 autocrine regulation, LNCaP cells, 2852
 -specific membrane antigen
 molecular cloning, complementary DNA, 227
- Prostatic neoplasms**
 advanced stage
 subset, p53 mutation, 3369
 anti-prostatic tumor activity
 liarazole and 13-cis-retinoic acid, 3073
 benign prostatic hyperplasia and nuclear matrix protein patterns, 744
 benign tissue and
 type IV collagenase, 878
 clinical data base
 primary and locally recurrent tumors, modeling of metastases development, 2987
- DU-145 cells**
 invasive potential, metalloprotein matrix, 417
 high grade
 increased expression, high mobility group protein I(Y), 5512
 homozygous deletion and frequent allelic loss
 chromosome 8p22 loci, 3869
 inhibition of cell proliferation
 androgen receptor complementary DNA, 1304
 inhibition of growth
 peptide analogues of insulin-like growth factor-1, 1102
 lack of latent transforming growth factor β binding protein, 3193
 micrometastatic
 detection in lymph nodes, reverse transcriptase-polymerase chain reaction, 5350
 parathyroid hormone-related protein immunohistochemical localization, 1724
 prostate stromal cell secretory proteins chemotaxis and chemokinesis, 1416
 reduction of E-cadherin levels
 deletion, α -catenin gene, 3585
 suppression of tumor growth
 inhibin, Dunning R3327G rat tumor, 4855
 suramin
 multiple potential mechanisms of action, 2239
 treatment with synthetic retinoid fenretinide, 224
- Protease**
 matrix-degrading enzyme
 hormone-dependent breast cancer cells, 1409
- Protein kinase**
 cyclic AMP-dependent
 antisense oligodeoxynucleotide, depletion of RI α subunit, 868
 8-chloroadenosine, mediation of 8-chloro-cyclic AMP-induced down-regulation, 393
 mitogen-activated
 elk-1 proteins, phosphoproteins and activators, 3449
- Protein kinase A**
 control of HLA-DR antigen expression
 γ -interferons, thyroid cells, 3943
- Protein kinase C**
 differential modulation of isoforms
 erythroleukemia, induced differentiation, 5554
 -mediated vasoconstriction of vascular smooth muscle
 5-fluorouracil chemotherapy, myocardial ischemia, 3028
 modulation of activity
 in vivo administration, bryostatin 1, 2810
 regulation of glycolipid sulfotransferase activity levels, renal cell carcinoma cells, 2484
 regulation of isozymes
 kidney regeneration, 4542
- Protein kinase C α**
 insertion of human Ha-ras or polyoma virus middle T oncogenes
 human colonic Caco-2 cells, 2762
- Protein tyrosine phosphatase γ**
Ptprg gene in murine L-cells
 carbonic anhydrase-like domain, homozygous deletion in L-cells, 1498
- Protein tyrosine phosphatases**
 activation
 inhibition of cellular growth, O-phospho-L-tyrosine, 557
 increased expression
 neu transformation, human breast epithelial cells, 2272
 inhibition by gallium nitrate, 1862
- Proteolysis**
 not required for activity
 immunotoxins made with recombinant form, *Pseudomonas* exotoxin A, 340
 specific cleavage of poly(ADP-ribose) polymerase
 chemotherapy-induced apoptosis, 3976
 tumor-associated macrophages
 receptor for urokinase, ductal breast carcinoma, 1911
- Protocatechuic acid**
 chemoprevention
 colon carcinogenesis, 3908
 diethylnitrosamine-induced hepatocarcinogenesis, 2775
- Protooncogenes**
bcl-2
 induction of apoptosis, nitrogen mustard and camptothecin, 1853
bcl-6
 cloning of, B-cell lymphoma, 2732
c-fos versus *c-jun*
 preferential induction, early response to γ -rays in pig skin, 3246
c-jun
 tyrosine phosphorylation, lymphohematopoietic precursor cells, 447
c-kit
c-myc expression, small cell lung cancer cell lines, 4337
 mediation of chemotaxis by stem cell factor, small cell lung cancer, 1709
 transforming growth factor- β 1 and stem cell factor, myelogenous leukemia blasts, 3638
c-K-ras-2 activation
 p53 alterations, uterine endometrium, 1883
c-src
 messenger RNAs, neuronal differentiation of neuroblastoma, 3179
 induction of *jun* gene family members

- not 17 β -estradiol, breast cancer cells, 291
- K-ras**
 mutation, endometrial hyperplasia and carcinoma, 1906
 mutation in ovarian epithelial tumors, borderline malignancy, 1489
 transforming growth factor- α
 differentiating HL-60 cells, 191
- TRK**
 nerve growth factor receptor coexpression, coexpression of messenger RNA in neuroblastoma, 2044
- Pseudomonas aeruginosa***
 entry of protein toxins
 polarized epithelial cells, 1755
- Pseudomonas* exotoxin**
 -based immunotoxins
 antibody LL2 or LL2-Fab', regression of B-cell lymphoma, 819
 transforming growth factor α and polyethylene glycol-modified chimeric toxin, 4588
- Pseudomonas* exotoxin A**
 recombinant form
 immunotoxins, no proteolysis required for activity, 340
- Purine**
 nucleotide levels in host tissues
 Ehrlich ascites tumor-bearing mice, different growth phases of tumor, 5143
 thymidylate and
 cytotoxicity of antifolate inhibitors, WiDr colonic carcinoma cells, 5697
- Pyrazine-2-diazohydroxide**
 single bolus intravenous injection
 Phase I study, advanced solid tumors, 4843
- Pyridyloxobutyl**
 DNA adducts
 inhibition of repair, O⁶-methylguanine, 2780
- Pyrimidine**
 antimetabolites
 sensitivity of KB cells, platelet-derived endothelial cell growth, 5680
 enzymes
 circadian-dependent toxicity, 5-fluorouracil, 2816
- Pyrimidine nucleoside phosphorylases**
 differences in activities and substrate specificity
 implications for chemotherapy, 5-fluoropyrimidines, 3687
- Q**
- Quinoline-3-carboxamide**
 linomide
 antiangiogenic effects, 1833
- Quinone reductase**
 colon carcinogenesis
 chemoprevention, organosulfur compounds, 3493
 oxy radicals and antioxidant responses in cancer, 3207
- R**
- Radiation**
 chromosome changes characterizing *in vitro* response
 human squamous cell carcinoma lines, 5542
 damage repair capacity
 primary clonogenic blasts, acute lymphoblastic leukemia, 1431
 -enhanced expression of H-2D^b
 B16 melanoma cells, 1952
 -induced alteration
 hematopoietic repair, preclinical phases of aplastic anemia and myeloproliferative disease, 4518
 -induced S and G₂ phase arrest
 caffeine release, histone messenger RNA levels, 1507
 -induced transforming growth factor β
 extracellular matrix reorganization, murine mammary gland, 3880
- ionizing**
 DNA double strand break repair defect, scid mice, 1244
 expression of cyclin A and cyclin B, HeLa cells, 1128
 inhibition of DNA synthesis in fibroblasts, H-ras and v-myc, 1213
 modeling of development of metastases
 primary and locally recurrent tumors, clinical data base for prostatic cancer, 2987
 oncogenic transformation and taxol, 1368
 potentiation
 three-drug chemotherapy regimen, 3518
 sensitization by etoposide
 DNA repair, cell cycle interactions, 2105
 -transformed rat embryo cells
 presence of point mutations, N-ras gene, 1511
 yield of interphase chromosome breaks
 mitosis-promoting factor activity, inducer mitotic cells, 5592
- γ -Radiation**
 activation of phospholipase D
 signal transduction pathways, 4474
- Radioimmunoassay**
 pharmacokinetics of S 12363, 3536
- Radioimmunotherapy**
 enhanced effects with local hyperthermia and SR 4233
 nude mice with human colonic adenocarcinoma xenografts, 3022
 improved efficacy
¹³¹I-CC49 and γ -interferon, 600
¹⁸⁶Re-labeled E48
 IgG-mediated therapy, human head and neck squamous cell carcinoma xenografts, 3524
- Radionuclides**
 delivery to pretargeted monoclonal antibodies
 dihydrofolate reductase and methotrexate, affinity system, 2368
- Radiosensitivity**
 head and neck cancer cell lines
 lack of correlation, p53 mutation, 3667
 hypoxic mammalian cell
 nitric oxide, 5845
 role of p53 in cell cycle arrest
 Burkitt's lymphoma cell lines, 4776
- Raman scattering spectroscopy**
 surface-enhanced
 introplicine, DNA and topoisomerase II, 4784
- ras**
 gene mutations
 detection in pancreatic juice and peripheral blood, pancreatic adenocarcinoma, 2472
 high mutation frequency
 DNA repair-deficient xeroderma pigmentosum patients, 1625
 metastatic behavior of tumor cells and CD44 promoter activity, 1516
 mutations
 2-acetylaminofluorene-induced lung and liver tumors, 1620
 transformation by RAST24
 ovarian epithelial and Rat-1 fibroblast cell lines, 3771
 -transformed NIH 3T3 cells
 adhesion to osteopontin, fibronectin and laminin, 701
- Rat-1 cells**
 transformation by RAST24
 no influence on cisplatin sensitivity, 3771
- γ -Rays**
 early response in pig skin
 preferential induction, c-fos versus c-jun, 3246
- Receptors**
 Ah
 growth suppression of MCF-7 cells, 2, 3,7,8-tetrachlorodibenzo-p-dioxin, 3149
 androgen
 inhibition of cell proliferation, PC-3 cells, 1304
 status of neuroendocrine cells, benign and malignant prostatic tissue, 1967
 anti-epidermal growth factor
 monoclonal antibodies plus cisplatin, A431 cell xenografts, 4637
 aryl hydrocarbon
 human ovarian carcinoma cell lines, 1802
 atrial natriuretic peptide
 human small cell lung cancer cell lines, 3165
 basic fibroblast growth factor
 unscheduled expression, pancreatic acinar cancer cell line, 1182
 CCK_A and CCK_B
 Ca²⁺ mobilization and clonal growth, small cell lung cancer lines, 5208
 chemotaxis
 regulation by laminin, laminin-binding integrin subunit α_6 , 2661
 cholecystokinin-A
 azaserine-induced preneoplastic lesions, 3925
 cognate
 up-regulation of vascular endothelial growth factor, glioma model of angiogenesis, 5822
 1,25-dihydroxyvitamin D₃
 marker, human colon carcinoma cell line differentiation and growth inhibition, 3712
 1,25-dihydroxyvitamin D₃ and two analogues
 biological response, target organs, 3935

- elk-1 proteins
phosphoproteins and activators, mitogen-activated protein kinase, 3449
- entry of protein toxins
polarized epithelial cells, 1755
- epidermal growth factor
amphiregulin and estrogen receptor expression, primary breast cancer, 3597
autocrine and paracrine stimulation, transitional cell carcinoma, 5300
blockade of function, bivalent and monovalent monoclonal antibodies, 4322
colorimetric *in situ* messenger RNA hybridization, colon carcinoma surgical specimens, 937
decreased epithelial differentiation, laryngeal papilloma, 910
immortalization of normal human ectocervical epithelial cells, human papillomavirus, 4511
inhibitory effects, α -interferon, 5148
messenger RNA and transforming growth factor α , head and neck cancer, 3579
mutation, non-small cell lung carcinoma, 3217
preferential expression, primary non-small cell lung cancers and adjacent benign lung, 2379
TGF- α production and autoinduction, colorectal carcinoma cell line, 1630
- estrogen
amphiregulin and epidermal growth factor receptor, human primary breast cancer, 3597
establishment, transplantable rat thyroid tumor cell lines, 4408
exon 5 deletion variant, wild-type estrogen receptor in breast cancer, 5882
expression of variant, ER-negative breast cancer cell line, 5934
improved prediction of survival, advanced ovarian adenocarcinoma, 5188
inhibition of receptor-negative mammary epithelial cells by estrogen, 5004
interstitial cells, kidney and estradiol-induced renal tumors, 5447
transcriptional control, estrogen receptor-negative breast carcinoma, 3472
variant messenger RNA lacking exon 4, estrogen-responsive breast cancer cell lines, 741
- fibroblast growth factor type I
aberrant expression, pancreatic adenocarcinoma, 4741
- glucocorticoid
differentiation, human promyeloid leukemia cells, 3513
messenger RNA, human multiple myeloma cells, 3877
mutants, human leukemic cells, 4059
- GM-CSF
lack of proliferation, nonhematopoietic human malignant cell lines, 3139
- GM-CSF and insulin
inhibition of binding, dimethyl sulfoxide, 1142
- growth factor
suramin, multiple potential mechanisms of action, 2239
- heparin-binding growth factor
complementary DNA, use of kinase insert sequence, 1136
- insulin-like growth factor 1
estrogen-induced kidney tumors, 2256
inhibition, human melanoma culture and athymic mice, 2522
inhibition of growth by peptide analogues, prostatic cancer cell lines, 1102
low risk, human breast cancer, 3736
- γ -interferon
growth inhibition by interleukin 1, colorectal carcinoma, 636
- interleukin 1
antagonist, inhibition of metastasis augmentation, 5051
antagonist induced by interleukin 1 β , tumor necrosis factor binding protein, 4010
- interleukin 2
human factor-dependent megakaryoblastic leukemia cell line, 675
human interleukin 2 analogues, reduced secondary cytokine secretion, 2597
T-cell infiltration, renal cell carcinoma, 1380
- interleukin 3
lack of proliferation, nonhematopoietic human malignant cell lines, 3139
- interleukin 6
lack of proliferation, nonhematopoietic human malignant cell lines, 3139
- mannose-6-phosphate/IGFII
transforming growth factor- β 1, monoterpenes-induced regression of mammary tumors, 3849
- mannose-6-phosphate/IGFIII
cathepsin D, benign and malignant mammary tumors, 2901
- nerve growth factor
TRK protooncogene coexpression, neuroblastoma, 2044
- platelet-derived growth factor β
successive activation, genesis of choriocarcinoma, 2927
- progesterone
expression in meningiomas, 1312
- retinoic acid
induction by estradiol, human breast cancer cells, 5841
- T-cell
DNA double strand break repair defect, scid mice, 1244
DNA sequence analysis of genes, oligoclonal T-cell response, 840
- T-cell ζ chain
p56^{lck} in T-cells, human renal cell carcinoma, 5613
- T-cell V region
gene usage of CTL and TIL, autologous gastric Signet ring cell carcinoma, 3078
- thrombospondin
normal, hyperplastic and neoplastic breast, 1421
- thymosin α 1
down-regulation of growth, non-small cell lung cancer cells, 5214
- transferrin
efficacy of targeted immunotoxins, brain pediatric neoplasms, 1348
pharmacokinetics and toxicology of immunotoxins, nonhuman primates and rodents, 3752
- transforming growth factor type II
human pancreatic cancer cells, 2704
- tumor necrosis factor α
autocrine and paracrine growth factor, ovarian cancer, 1939
- urokinase
concentration in malignant and benign breast tumors, quantitative autoradiography, 3198
overexpression and matrix invasion, cell migration in osteosarcoma cell line, 3109
tumor-associated macrophages, ductal breast carcinoma, 1911
- urokinase-type plasminogen activator
antibody, modulation of invasion in glioblastoma cells, 4143
- vascular permeability factor
adenocarcinomas, gastrointestinal tract, 4727
- Rectal neoplasms
risk of fatal cancer
aspirin use, 1322
- Red blood cells
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone hemoglobin adducts, 777
partitioning
cytotoxicity and protein binding, oxaliplatin, 5970
- Renal cell neoplasms
allelic deletions
histopathological correlations, 5780
estradiol-induced
localization of estrogen receptors, interstitial cells, 5447
high efficiency gene transfer
no cell selection, primary human tumor explants, 2221
- Reserve cells
appearance in mouse cervical epithelium
retinoid status, 2287
- Restriction point protein
cyclin E and cyclin A, 1493
- Retinoblastoma
gene product pRb110
protein interaction with *M*, 73,000
heat shock cognate protein, 1702
gene promoter
binding of novel element, prostatic nerve growth factor inducible A gene, 5597
mutational profiles of p53 and altered messenger RNA, esophageal carcinoma, 1889
tumor suppressor gene expression
megakaryocytic differentiation of leukemic cells, TPA and staurosporine, 3085
- Retinoblastoma protein
p53 and
hyperphosphorylation, okadaic acid, 239

- Retinoic acid**
 immortalization of normal human ectocervical epithelial cells
 human papillomavirus, 4511
 inhibition of human papillomavirus type 16
 transformation, human keratinocytes, 905
 γ -interferon and
 ICAM-1 expression, human tumor cell lines, 826
 receptor induction by estradiol
 human breast cancer cells, 5841
 unresponsive malignant hemopoietic cell lines
N-(4-hydroxyphenyl)retinamide, induction of apoptosis, 6036
- 13-*cis*-Retinoic acid**
 liarozole and
 anti-prostatic tumor activity, 3073
 Ro 40-8757 and
 breast cancer, 2319
- all-*trans*-Retinoic acid**
 liposomal
 induction of differentiation, myeloid leukemia cell lines, acute promyelocytic leukemia cells, 2100
 Ro 40-8757 and
 breast cancer, 2319
 oxidative catabolism
 lipid hydroperoxides, human microsomes, 1226
 time course of induction of metabolism
 up-regulation, cellular retinoic acid-binding protein, 472
- Retinoic acid-binding protein**
 cellular
 up-regulation, all-*trans*-retinoic acid metabolism, 472
- Retinoids**
 fenretinide effectiveness
 potentiation of cisplatin activity, ovarian carcinoma xenograft, 5374
 pharmacological
 vitamin A-metabolizing enzymes, 2965
 status
 appearance of reserve cells and keratin expression, mouse cervical epithelium, 2287
 synthetic fenretinide
 treatment of prostate cancer, 224
- Retrovirus**
 antisense *K-ras* construct
 intratracheal instillation, prevention of orthotopic lung cancer growth, 1743
 -mediated gene transfer
 treatment of brain tumors, rats, 83
- Reverse transcription-polymerase chain reaction**
 detection in lymph nodes
 micrometastatic prostate cancer cells, 5350
- Rhabdomyosarcoma**
 alveolar
 fusion of *PAX3*, transcription factors, 5108
 refinement of regional loss of heterozygosity
 chromosome 11p15.5, human breast tumors, 4486
- Rhodamine 123**
 quantitative differential effects
 normal cells and colon cancer cells,
 magnetic resonance spectroscopy, 5808
- Ribavarin**
 tiazofurin and
 sequential impact on enzymic program, bone marrow, 5982
- Ribonucleotide reductase**
 inhibition of R2 subunit
 antitumor activity, 2,2'-bipyridyl-6-carbothioamide and its ferrous complex, 19
- Ribosomal protein**
 high-level of L19 expression
 overexpression or *erbB-2*, breast tumors, 1403
- Ribosome**
 protein mRNAs of colonic carcinoma
 gastrointestinal malignancies, 4048
- Ribozyme**
 -mediated modulation
 human *O*⁶-methylguanine-DNA methyltransferase expression, 1731
- Ricin**
 anti-B4-blocked
 therapeutic efficacy, different SCID mouse tumor models, 1360
 entry of protein toxins
 polarized epithelial cells, 1755
- Ricin A chain**
 pharmacokinetics and toxicology of immunotoxins
 administration into the subarachnoid space, nonhuman primates and rodents, 3752
- RIF-8A cells**
 mitochondrial alterations
 photodynamic therapy-resistant cells, 4994
- Riminophenazine agents**
 clofazimine and B669
 inhibition of cancer cell line proliferation, phospholipase A₂-mediated mechanisms, 318
- Risk assessment**
 clarification
 scientific evidence and speculation, 4107
- RNA**
 HPV16-transformed rat kidney epithelial cells
 glucocorticoid requirement for growth, 4432
 human mitochondrial hinge protein gene
 elevated expression, cancer, 2460
- RNA, messenger**
N-acetylglucosaminyltransferase III and V
 hepatocarcinogenesis, LEC rats, 3899
 alteration
 mutational profiles of p53 and Rb, esophageal carcinoma, 1889
 alternatively spliced glucocorticoid receptor
 human multiple myeloma cells, 3877
 alternatively spliced *src*
 neuronal differentiation, human neuroblastoma, 3179
 annexin II expression
 regulation, mammalian cell cycle, 6017
- APC gene**
 novel isoforms that lack exon 7, 5589
 carcinoembryonic antigen and biliary glycoprotein
 differential regulation, γ -interferon, 1612
 characterization of insulin-like growth factor 1, 2475
 colorimetric *in situ* hybridization technique
 epidermal growth factor receptor, colon carcinoma surgical specimens, 937
 complementary DNA
 heparin-binding growth factor receptor, use of kinase insert sequence, 1136
 complement inhibitors
 human tissues and tumors, 348
 epidermal growth factor
 transforming growth factor α and, head and neck cancer, 3579
 estrogen receptor variant
 lack of exon 4, estrogen-responsive breast cancer cell lines, 741
 fibronectin pre-mRNA alternative splicing
 coordinate oncodevelopmental modulation, liver tumor, 2005
 genetic and enzymatic basis
 G_{M2} and G_{D2} differential expression, human cancer cell lines, 5395
 glucocorticoid receptor expression
 differentiation, human promyelocytic leukemia cells, 3513
 glutathione *S*-transferase class α transcripts
 carcinogen exposure, hepatocytes, 231
 high-level of L19 expression
erbB-2 overexpression, breast tumors, 1403
 histone
 caffeine release, radiation induced S and G₂ phase arrest, 1507
MAGE-1/MAGE-2/MAGE-3
 differential gene expression, transformed and normal human cell lines, 5
 MLL-AF-4 fusion
 heterogeneity, polymerase chain reaction in t(4;11) acute leukemia, 3853
 modulation of cytochrome P450 2C11
 by cyclophosphamide
 messenger RNA levels, acrolein and phosphoramidate mustard, 2490
p53 abnormalities
 different subtypes, human sarcomas, 468
 plasmid reporter gene inactivation
 one benzo(a)pyrene diol-epoxide DNA adduct, hepatocytes, 2279
 progesterone receptor expression
 meningioma, 1312
 prostate-specific antigen gene expression
 autocrine regulation, LNCaP cells, 2852
 radiation-enhanced expression
 MHC class I antigen H-2D^b, B16 melanoma cells, 1952
 ribosomal protein
 colonic carcinoma, gastrointestinal carcinoma, 4048
 ribozyme-mediated modulation

- human *O*⁶-methylguanine-DNA methyltransferase expression, 1731
- transcriptional activation
- mouse *mdr3* gene, multidrug-resistant P388 tumor cells, 1657
- TRK* protooncogene and low affinity nerve growth factor receptor coexpression in neuroblastoma, favorable prognosis, 2044
- variable baseline γ -glutamylcysteine synthetase expression
- peripheral mononuclear cells, buthionine sulfoximine treatment, 3662
- Rosenthal Foundation Award**
- how cancer cells evade chemotherapy, 747
- role of *BCR-ABL* oncogene
- human leukemia, 485
- Rous sarcoma virus**
- induced tumors
- src*-specific immune regression, 915
- RP60475**
- inhibition
- topoisomerase I and II activities, 5987
- RP60475F**
- aberrant functions
- teniposide-resistant CEM cells, 5946
- S
- S 12363**
- pharmacokinetics
- monoclonal antibody-based radio- or enzyme immunoassay, 3536
- Salicylate**
- enhancement of merocyanine 540-mediated phototherapy, 806
- Saporin**
- delivery using bispecific antibody
- targeting via CD22, human B-cell lymphoma, 3015
- Sarcoma**
- BALB/c Meth A
- M*, 110,000 tumor rejection antigen, 1602
- bearing rats
- doxorubicin treatment, growth hormone and preservation of lean body mass, 5483
- cell lines from *v-jun* transgenic mice, 622
- coamplification of *CDK4* gene
- MDM2* and *GLI*, 5535
- different subtypes
- p53* abnormalities, 468
- Ewing's
- p53* mutations, not neuroblastomas, 5284
- HT1080 cells
- inhibition of invasion, plasminogen activator inhibitor, 6051
- Kaposi's
- HIV-1 *tat* gene expression, endothelial proliferation and histotypes, 5569
- Meth A
- tumorigenicity and tumor growth, increased TGF- β expression, 4391
- soft tissue
- management of, daunomycin-antibody immunoconjugates, 5740
- p53* mutation, *MDM2* amplification, 2231
- tumorigenicity
- met* expression, 5355
- Scatter factor**
- regulation of fibroblast hepatocyte growth factor
- peptide growth factors, breast carcinoma cell lines, 1233
- Schistosoma mansoni**
- cigarette smoking and
- p53* gene mutations, urothelial cancer, 3795
- Scytophycins**
- circumvention
- P-glycoprotein-mediated multidrug resistance, 1343
- Selenium**
- status and risk of lung cancer, 4860
- Self-renewal**
- competency
- selective expression, *M*, 32,000, 4720
- Seminal vesicle**
- expression of sulfated glycoprotein 2
- induction of carcinogenesis, *N*-nitroso-*N*-methylurea, 1480
- Seric inhibitors**
- concomitant tumor resistance
- competing influences, 3266
- Serotonin**
- autocrine loop
- stimulation by nicotine, small cell lung carcinoma, 5566
- Serum response factor**
- elk-1* variant
- differential splicing, encoding of activators and repressors, 215
- Severe combined immunodeficiency**
- arrest of growth
- human lung tumor xenograft, doxorubicin encapsulated in sterically stabilized liposomes, 3964
- mice
- complementation of radiosensitive phenotype, human chromosome 8, 6011
- disseminated growth, multiple myeloma, 1392
- NCr/Sed-*nu/nu* nude mice and transplantability into s.c. tissue, human and murine tumors, 5012
- Sex cord-stromal neoplasms**
- WT1* analysis, 2712
- Shigella toxin**
- entry of protein toxins
- polarized epithelial cells, 1755
- Shock waves**
- high-energy
- blood flow reduction in tumors, 1590
- Sialyl Lewis^x antigen**
- increased expression with poor survival colorectal carcinoma, 3632
- mucin-bound
- altered glycosylation of MUC-1 protein core, colon carcinoma-associated increase, 4082
- Sialyl-Tn antigens**
- normal squamous epithelium
- dysplasia and squamous cell carcinoma, esophagus, 1706
- Signal transduction**
- glycolipid antigen Gb3/CD77
- induction of apoptosis, Burkitt's lymphoma, 5314
- HLA-DR antigen expression
- γ -interferons, malignant and nonma-
- lignant human thyroid cells, 3943
- retinoic acid and γ -interferon
- ICAM-1 expression, human tumor cell lines, 826
- Simian virus 40**
- DNA replication system
- interaction between replication forks, topoisomerase I-DNA cleavable complexes, 5908
- immortalized human bronchial epithelial cell lines
- development of tumorigenicity, 985
- infected precrisis human fibroblasts
- multiple mechanisms, *N*-(phosphonacetyl)-L-aspartate drug resistance, 4946
- large tumor antigen and monoclonal anti-idiotypic
- humoral immune responses, tumor immunity, 5734
- Sister chromatid exchange**
- induction
- extremely low doses of α -particles, 2188
- Skeleton**
- bisphosphonate-treated rats
- increased growth rate and tumor burden, Walker 256 cells, 5452
- Skin**
- carcinogenesis
- malignant progression, suprabasal expression of $\alpha 6 \beta 4$ integrin, 4803
- derived tumor cells
- killing by mouse dendritic epidermal T-cells, 4014
- DNA-binding species
- bis-diol-epoxide involvement, metabolic activation of dibenz[*a,h*]anthracene, 944
- early response to γ -rays
- preferential induction, *c-fos* versus *c-jun*, 3246
- exposure to UV radiation
- wavelength-specific patterns, *p53* induction, 2697
- inhibition of tumor promoter-mediated processes
- caffeic acid phenethyl ester, 1255
- inhibition of tumor necrosis factor α release, protein isoprenylation, 3462
- neuroendocrine carcinomas
- stable expression of peripherin, 1175
- phorbol 12-myristate 13-acetate induced tumor promotion
- inhibition by 12-deoxyphorbol 13-esters, 2507
- photorepair
- ultraviolet radiation-induced DNA damage, platyfish *Xiphophorus*, 2249
- preparation for evaluation of drug disposition
- development and characterization, 101
- TPA-induced hyperplasia
- transforming growth factor β_1 induction, TGF- β_2 and - β_3 , 5517
- tumor promotion in CD-1 mice
- absence of syngeneic effects, okadaic acid and teleocidin, 1012
- Skin neoplasms**
- allelotypic analysis
- polymorphic microsatellites, chromo-

- some alterations, 6022
- deleterious effects of UVB light on cutaneous immunity
 - tumor necrosis factor- α polymorphism, 728
- DNA repair-deficient xeroderma pigmentosum patients
 - high mutation frequency, *ras* genes, 1625
- environmental
 - mechanisms, models and human relevance, 3439
- hypersensitivity of human lymphocytes
 - UVB and solar irradiation, 609
- induction by ultraviolet irradiation
 - wavelength dependence, albino hairless mice, 53
- inhibition of tumor promotion
 - restriction of fat and carbohydrate calories, 27
- interaction between UVA and UVB
 - hairless mice, 4212
- mechanism of induction of *c-fos*
 - ultraviolet B, mouse JB6 epidermal cells, 38
- transplacental carcinogenicity of cisplatin
 - SENCAR mice, 3874
- ultraviolet radiation-induced
 - strand bias and tumor heterogeneity, *p53* mutations, 2961
- ultraviolet-specific mutations
 - p53* gene, xeroderma pigmentosum, 2944
- UV light-induced
 - delay of progression, macrophage nitric oxide synthesis, 5507
- SN22995**
 - aberrant functions
 - teniposide-resistant CEM cells, 5946
- Sodium**
 - atrial natriuretic factor
 - arginine vasopressin production, lung cancer cell lines, 67
- Sodium nitrite**
 - catechol and
 - 3-methoxycatechol or butylated hydroxyanisole, rat multiorgan carcinogenesis model, 32
- Sodium orthovanadate**
 - induction of neoplastic progression
 - protein phosphatase inhibitors, Syrian hamster embryo cells, 1777
- Sodium-proton exchange**
 - lowering of intracellular pH
 - increased thermosensitivity, tumor cells, 1599
- Spheroids**
 - human lung cancer
 - penetration by retroviral wild-type *p53* expression vector, induction of apoptosis, 4129
 - multicellular tumor
 - fluence rate effects, photodynamic therapy, 1249
 - heme oxygenase expression, squamous carcinoma, 2700
- SR4233**
 - cisplatin and
 - tumor-dependent and schedule-dependent interaction, 4633
 - local hyperthermia and
 - antitumor effects of radioimmunotherapy, nude mice with human colonic adenocarcinoma xenografts, 3022
- toxicity
 - unusual oxygen concentration, 3992
- Statistical analysis**
 - in vivo* tumor growth experiments, 6042
- Staurosporine**
 - derivative NA-382
 - inhibition of multidrug resistance, 1555
 - inhibition of DNA synthesis
 - H-*ras* and v-*myc*, rat embryo fibroblasts, 1213
 - sensitization of tumor cells
 - tumor necrosis factor action, 2623
 - 12-*O*-tetradecanoylphorbol-13-acetate and
 - increased retinoblastoma tumor suppressor gene expression, megakaryocytic differentiation of leukemic cells, 3085
- Stem cell factor**
 - interference with proliferation-inducing activity
 - transforming growth factor- β 1, myelogenous leukemia blasts, 3638
 - irradiated human bone marrow, 3857
 - mediation of chemotaxis
 - c-kit*, small cell lung cancer, 1709
- Stem cells**
 - autologous transplantation
 - sequential production, granulocyte recovery, 1297
 - differential activity of acetyldinaline
 - acute myelocytic leukemia, rat, 3008
 - 3T3 T proadipocytes
 - loss of differentiation control, 1770
- Steroid**
 - heparin conjugates
 - angiogenesis inhibitors, antitumor activity, 3000
 - production
 - different parts, malignant and benign ovarian tumors, 2309
- Steroid hormones**
 - opioid peptides and
 - growth, androgen-responsive Shionogi carcinoma cells, 4224
- Steroid α -reductase**
 - modulation of rat hepatic cytochrome P450 2C11
 - cyclophosphoramide, messenger RNA levels, 2490
- Stomach neoplasms**
 - high risk population
 - precancerous gastric lesions, 1317
 - human
 - nude mouse metastatic models, 1204
 - risk of fatal cancer
 - aspirin use, 1322
- Streptozotocin**
 - O*⁶-benzylguanine
 - depletion of *O*⁶-methylguanine DNA methyltransferase, 1,3-bis(2-chloroethyl)-1-nitrosourea sensitivity, 4281
- Stress**
 - psychological
 - oxidative damage of nuclear DNA, liver of rats, 4153
- Stress protein**
 - suppression of GRP78 induction
 - elimination of resistance, cell-mediated cytotoxicity, 6001
- Stroma**
 - amphiregulin and epidermal growth factor receptor
 - estrogen receptor expression, human primary breast cancer, 3597
- Stromal cells**
 - fibroadenoma and phyllodes tumor
 - clonal analysis, breast, 4071
 - immunoelectron microscopic localization
 - transforming growth factor- β 1 and binding protein, gastrointestinal carcinoma, 183
 - production of growth-promoting factor
 - wide target cell spectrum, THP-1 cells, 1871
 - protection from toxic effects by AS101
 - cyclophosphamide, ASTA-Z 7557 and etoposide, 1838
 - secretory protein
 - chemotaxis and chemokinesis, prostate tumor cell lines, 1416
- Stromelysin**
 - interstitial collagenase and 72-kDa gelatinase
 - tumor cell-derived collagenase-stimulatory factor, 3154
- Stromelysin 3**
 - increased gene expression
 - local invasiveness, head and neck squamous cell carcinoma, 165
- Styrene 7,8-oxide**
 - butylated hydroxyanisole and
 - induction of cell proliferation, forestomach, 3505
- Sugar**
 - chains of human cord serum α -fetoprotein
 - human liver, hepatocellular carcinoma, 2970
- Sulfotransferase**
 - mediated activation
 - cyclopenta[*c,d*]pyrene metabolites, 1017
- Suramin**
 - inhibition of growth
 - promotion of insulin-like growth factor II, HepG2 cells, 652
 - multiple potential mechanisms of action, 2239
- Surgery**
 - modeling of development of metastases
 - primary and locally recurrent tumors, clinical data base for prostatic cancer, 2987
- Syndrome of inappropriate antidiuretic hormone**
 - atrial natriuretic factor
 - arginine vasopressin production, lung cancer cell lines, 67
- T**
- Tac antibody**
 - DOTA-bismuth-conjugated
 - pharmacokinetics, α -emitter therapy, 5683
- TAG-72**
 - comparative dual label study of monoclonal antibodies
 - colorectal cancer, 271
 - improved radioimmunotherapeutic effi-

- cacy
¹³¹I-CC49 and γ -interferon, 600
 site-specific prodrug activation
 antibody- β -lactamase conjugates, colon carcinoma xenograft models, 3956
- Tamoxifen**
 antitumor effect of 22-oxa-calcitriol
 athymic mice implanted with human breast carcinoma, 2534
 carcinogenicity study
 Alderley Park Wistar-derived rats, 3919
 -dependent rat mammary tumors, 2937
 -induced increase
 doubling time of MCF-7 xenografts, bromodeoxyuridine labeling and flow cytometry, 4413
 inhibition
 insulin-like growth factor I gene expression, 1727
 inhibition by ICI 182,780
 insulin-like growth factor I gene expression, 5585
 modulation of cisplatin sensitivity
 malignant melanoma cells, 1571
 recombinant human α -interferon and modulatory effects, doxorubicin resistance, 3040
 sensitivity to ICI 182,780
 MCF7/LCC2 cells, 3229
 toremifene and
 hepatocarcinogenicity, DNA adduct formation, 4534
 -treated athymic nude mice
 fibroblast growth factor 4 production, MCF-7 cells, 2168
- Tat protein**
 HIV-1
 protection from apoptosis, 4481
- Taxol**
 -containing liposomes
 antitumor effect, taxol-resistant murine tumor model, 5877
 cytotoxicity
 glutathione depletion, L-buthionine sulfoximine, 2066
 polyclonal and monoclonal antibodies
 measurement in serum, 1388
 radiation and oncogenic transformation, 1368
- Taxotere**
 Phase I and pharmacokinetic study
 administration as 24-hour infusion, 523
 short intravenous infusion
 Phase I and pharmacokinetic study, 1037
- Tea, green**
 polyphenolic fraction
 protection against malignant conversion, chemically induced benign skin papillomas, 5409
- T-cells**
 ability to form tumors in nude mice
 homeobox gene *HB24*, 373
 cytolysis of leukemic B-cells
 bispecific antibodies, 4310
 cytotoxic T-lymphocytes
in situ amplification, human regressive melanoma, 3569
 -induced tumor regression
- γ -interferon, 833
 infiltration of renal cell carcinoma
 poor proliferative response, 1380
 production, interleukin 2 and receptors, 5828
 loss of T-cell receptor ζ chain
 p56^{lck}, human renal cell carcinoma, 5613
 mouse dendritic epidermal
 killing, skin-derived tumor cells, 4014
 oligoclonal
 metastasis of renal cell carcinoma, vaccination with autologous tumor cells, 4745
 production of growth-promoting factor
 wide target cell spectrum, THP-1 cells, 1871
 receptor V region gene usage
 CTL and TIL, autologous gastric Signet ring cell carcinoma, 3078
 tumor-infiltrating
 signals-transducing ζ chains, colorectal carcinoma, 5610
 vaccine-primed
 adoptive immunotherapy, secondary sensitization to tumor, 1043
- 10T $\frac{1}{2}$ cells**
 clonal analysis
 multiple transformed phenotypes, tumorigenicity, 500
- Teleocidin**
 okadaic acid and
 absence of syngeneic effects, tumor promotion in CD-1 mouse skin, 1012
- Temperature**
 -sensitive liposomal Adriamycin
 hepatic artery, liver W256 carcinosarcoma, 3046
 therapeutic efficacy
 pharmacokinetics of ifosfamide, 4268
- Teniposide**
 antiproliferative activity and bulk damage to DNA
 MCF-7 cells, 3547
 -resistant CEM cells
 non-complex-stabilizing inhibitors of enzyme, aberrant functions, 5946
 topoisomerase II as a target
 atypical multidrug resistance, small cell lung carcinoma cells, 1064
- Testis neoplasms**
 lack of occurrence
 p53 gene mutations, 3574
- Testosterone**
 elevated serum levels
 risk of hepatocellular carcinoma, 790
 type II estrogen-binding sites
 dysplastic dorsolateral prostate, Noble rat, 528
 1,4,7,10-Tetra-azacyclodecane-*N,N',N'',N'''*-tetraacetic acid
 -bismuth-conjugated anti-Tac antibody α -emitter therapy, 5683
 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin
 aryl hydrocarbon receptor
 aryl hydrocarbon responsiveness, human ovarian carcinoma cell lines, 1802
 exposure
 gene expression and cell proliferation, liver, 2265
- growth suppression of MCF-7 cells, 3149
- 12-*O*-Tetradecanoylphorbol 13-acetate**
 -induced skin hyperplasia
 transforming growth factor β_1 induction, TGF- β_2 and - β_3 down-modulation, 5517
 -induced tumorigenic transformation
 osteopontin expression, 1 α ,25-dihydroxyvitamin D₃, 2217
 inhibition of tumor promoter-mediated processes
 caffeic acid phenethyl ether, mouse skin and bovine lens, 1255
 staurosporine and
 increased retinoblastoma tumor suppressor gene expression, megakaryocytic differentiation of leukemic cells, 3085
- Tetraplatin**
 oxaliplatin
 red blood cell partitioning, biotransformation of oxaliplatin, 5970
- Thaliblastine**
 circumvention of multidrug resistance
 direct binding to P-glycoprotein, 2544
- Theophylline**
 -induced differentiation
 deregulation of *c-myc*, Burkitt's lymphoma, 127
- Thermotolerance**
 vascular
 heat-induced changes, blood flow and cell survival, 2076
- THP-1**
 production of growth-promoting factor
 wide target cell spectrum, 1871
- Thread proteins**
 characterization
 expression in neuroectodermal tumors, 3823
- Thrombospondin**
 its receptor and
 normal, hyperplastic and neoplastic human breast, 1421
 motility of human carcinoma cells
 metastatic potential, structural domains, 378
- Thymidine kinase**
 gene
 herpes simplex virus, inhibition of melanoma growth in intratumoral DNA injection, 3860
 promoter
 overexpression of DNA binding activity, distal CCAAT box, 3253
- Thymidylate**
 purine synthesis and
 cytotoxicity of antifolate inhibitors, WiDr colon carcinoma cells, 5697
 stress resistance
 induction to apoptosis, modulation by *bcl-2*, 3321
- Thymidylate synthase**
 benzoquinazoline inhibitor 1843U89
 biochemical and cellular pharmacology, 810
 decreased folylpolyglutamate synthetase
 novel mechanism, fluorouracil resistance, 3677
- Thymocytes**
 nonproliferating immature

- effects of cisplatin, induction of apoptosis, 2133
- Thymosin $\alpha 1$**
down-regulation of growth
human non-small cell lung cancer cells, 5214
- Thyroglobulin**
promoter
Ki-ras expression, production of transgenic mice, 5523
- Thyroid**
establishment of transplantable tumor cell lines
estrogen receptor, 4408
malignancies
differentiation marker, E-cadherin, 4987
malignant and nonmalignant cells
control of HLA-DR antigen expression, γ -interferons, 3943
- Thyroid neoplasms**
in vitro irradiation
RET oncogene rearrangement, 2940
- Thyrotropin**
loss of regulation
transforming growth factor β -induced growth arrest, *erbB-2* overexpressing rat thyroid cells, 5548
- Tiazofurin**
biochemical consequences of resistance
K562 cells, 2344
ribavarin and
sequential impact on enzymic program, bone marrow, 5982
- TIMP-1**
negative regulator of metastatic ability
human gastric cancer cell line, chick embryo, 1397
- Tirapazamine**
cisplatin and
tumor-dependent schedule-dependent interaction, 4633
- TLC D-99**
initial clinical trial, 2796
- TNP-470**
inhibition of tumor growth
hormone-independent breast and prostate carcinoma, 5233
inhibition of tumor growth and metastasis
rodent tumors, 4262
inhibitory effect of angiogenesis
tumor growth and metastasis, human cell lines, 2566
- Tobacco**
carcinogenesis
dietary fat, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, 2758
oral carcinogenesis
HPV-16, *N*-methyl-*N'*-nitro-*N'*-nitro-soguanidine, 4811
smoking
detection of DNA adducts, human oral tissue, 1522
-specific nitrosamine
smokers' urine, 721
usage
distinct pattern of p53 mutations, bladder cancer, 1162
- α -Tocopherols**
serum micronutrients
subsequent risk, oral and pharyngeal cancer, 795
- Tolytoxin**
scytophycins
circumvention, P-glycoprotein-mediated multidrug resistance, 1343
- Tongue neoplasms**
chemoprevention of oral carcinogenesis
DL- α -difluoromethylornithine, 772
- Topotecan**
24-hour continuous infusion
pediatric Phase I trial, pharmacokinetic study, 1032
induction of apoptosis and cell cycle effects
prevention by caffeine, HL-60 cells, 4613
plasma and cerebrospinal fluid pharmacokinetic study
nonhuman primates, 725
- Toremifene**
tamoxifen and
hepatocarcinogenicity, DNA adduct formation, 4534
- Toxins**
delivery of saporin using bispecific antibody
targeting via CD22, human B-cell lymphoma, 3015
protein
entry in polarized epithelial cells, 1755
synergy of anti-Fas antibody
overcoming tumor necrosis factor and drug resistance, 2591
- Tracheobronchial epithelial cells**
inhibition of epidermal growth factor-like growth factor
vitamin A, 2527
- Transcription factors**
fusion of *PAX3*
alveolar rhabdomyosarcoma, 5108
heat shock
oxidative injury, failure to increase levels of heat shock proteins, 12
normal and neoplastic growth and development, 929
- Transferrin**
receptor-targeted immunotoxins
efficacy, pediatric brain tumors, 1348
- Transforming growth factor- α**
disruption of autocrine loop
glucocorticoids, rat mammary adenocarcinoma cells, 1808
epidermal growth factor receptor messenger RNA and
early markers of carcinogenesis, head and neck cancer, 3579
induction of *cjun* gene family members
not 17 β -estradiol, breast cancer cells, 291
nuclear oncogenes and growth factors
tumorigenesis, transgenic mouse model, 1719
overexpression
glucocorticoids, mammary tumor cell growth, 1816
production and autoinduction
epidermal growth factor receptor gene, colorectal carcinoma cell line, 1630
production of morphological transformants
diploid human fibroblasts, 2162
protooncogene expression
differentiating HL-60 cells, 191
- Pseudomonas* exotoxin and polyethylene glycol-modified chimeric toxin, 4588**
regulation of activity levels
glycolipid sulfotransferases, renal cell carcinoma, 5638
regulation of fibroblast hepatocyte growth factor/scatter factor
breast carcinoma cell lines, 1233
transgenic mice
growth factors and diverse chemical carcinogens, hepatocarcinogenesis, 4329
- Transforming growth factor- β**
differential growth factor production
high and low metastatic variants, B16BL6 melanoma, 4075
increased expression
inhibition of cell proliferation *in vitro*, tumor growth in Meth A sarcoma cells, 4391
-induced growth arrest
loss of thyrotropin regulation, *erbB-2* overexpressing rat thyroid cells, 5548
interleukin 1 α and interleukin 6
inhibition of growth, MCF-7 cells, 1538
latent binding protein
lack in malignant prostatic tissue, 3193
radiation-induced
extracellular matrix reorganization, murine mammary gland, 3880
regulation of fibroblast hepatocyte growth factor/scatter factor
breast carcinoma cell lines, 1233
- Transforming growth factor- $\beta 1$**
growth and apoptosis
human acute myelogenous leukemia cells, 3386
immunoelectron microscopic localization
TGF- $\beta 1$ binding protein, gastrointestinal carcinoma, 183
induction of TGF- α promoter activity
TGF- α secretion, human colon adenocarcinoma cell line, 4041
interference with proliferation-inducing activity
stem cell factor, myelogenous leukemia blasts, 3638
mannose-6-phosphate/IGFII receptor
monoterpene-induced regression, mammary tumors, 3849
resistance in murine keratinocytes
mutant p53, 899
TGF- $\beta 2$ and - $\beta 3$ down-regulation
TPA-induced skin hyperplasia, 5517
- Transplantation**
acceleration of granulocyte recovery
granulocyte colony-stimulating factor, metastatic breast cancer, 5424
autologous stem cell
sequential production, granulocyte recovery, 1297
bone marrow
radiation damage repair capacity, acute lymphoblastic leukemia, 1431
brain of NCr/Sed-*nu/nu* nude and scid mice
human and murine tumors, 5018

- orthotopic
 - "patient-like" treatment model, pancreatic cancer, 3070
- s.c. tissue of NCr/Sed-nu/nu nude and scid mice
 - human and murine tumors, 5012
- Triton X-100
 - effects of nonionic detergents
 - P-glycoprotein drug binding, multi-drug resistance, 5994
- 3T3 T cells
 - proadipocytes
 - loss of differentiation control, 1770
- Tubulin
 - binding
 - depolymerization of microtubules, estramustine, 4573
- Tumor-associated antigens
 - delayed-type hypersensitivity reactions
 - autologous tumor cell/*Bacillus Calmette-Guérin* vaccine, colon carcinoma, 456
 - phenotype and ontogeny
 - bovine leukemia virus-induced lymphosarcoma, 429
 - quantitative analysis of *lacZ* reporter gene
 - disseminated tumor growth within brain, 176
- Tumor cells
 - autologous
 - oligoclonal T-cell response, metastasis of renal cell carcinoma, 4745
- Tumor grade
 - invasion and
 - levels of matrix metalloproteases, bladder cancer, 5365
- Tumorigenesis
 - aflatoxin-induced hepatic
 - transient intervention, oltipraz, 3499
 - clonal immunoglobulin gene rearrangement
 - coexistence, aneuploid subclones within a myeloma cell line, 5320
 - dominant negative effect
 - germ-line mutant *p53*, 4452
 - formation of hyperplastic outgrowths
 - p53* mutations, mammary cell lines, 1646
 - granulosa cell
 - genetically hypogonadal-immunodeficient mice grafted with ovaries from tumor-susceptible donors, 3741
 - inhibition of tumor growth by antisense DNA
 - c-Ha-*ras* oncogene, nude mice, 577
 - intestinal
 - deletion of 1p36, primary chromosomal aberration, 1895
 - O*⁶-methylguanine-DNA methyltransferase activity
 - brain tumors, adjacent normal brain, 3416
 - microsatellite instability
 - bladder cancer, 5620
 - multiple mechanisms
 - Eμ-myc* transgenic mice, 1665
 - nuclear oncogenes and growth factors
 - transgenic mouse model, synergistic effects, 1719
 - ovarian granulosa cell
 - C19 androgen induction, genetic susceptibility in mice, 1059
- promoter-specific *trans*-activation and inhibition
 - JunB, 3789
- signaling by integrins, 1503
- ultraviolet-specific mutations in *p53* gene
 - skin tumors, xeroderma pigmentosum, 2944
- urinary bladder
 - lipopolysaccharide-induced inflammation, 5172
- Tumorigenicity
 - abrogation
 - α_1 -interferon gene transfer, metastatic Friend leukemia cells, 1107
 - biological consequences of overexpression
 - transfected c-*erbB*-2 gene, immortalized human bronchial epithelial cells, 2035
 - clonal analysis
 - multiple transformed phenotypes, 10T $\frac{1}{2}$ cells, 500
 - development
 - simian virus 40-immortalized human bronchial epithelial cell lines, 985
 - fibroblast growth factor 4 transfection
 - MCF-7 cells, tumorigenicity, 2168
 - transfection of human astrocytoma cells
 - glial fibrillary acidic protein complementary DNA, 3624
- Tumor necrosis factor
 - binding protein
 - induction by interleukin 1 β , humans, 4010
 - drug resistance and
 - combination treatment, anti-Fas antibody and drugs or toxins, 2591
 - growth inhibition by interleukin 1
 - γ -interferon receptors, colorectal carcinoma, 636
 - mediated cytotoxicity
 - BCL-2 protein expression, survival of mouse fibrosarcoma cells, 1456
 - resistance *in vitro*
 - metallothionein, 4874
 - sensitization of tumor cells
 - staurosporine, 2623
 - tumor promoter in BALB/3T3 cell transformation, 1982
- Tumor necrosis factor- α
 - autocrine and paracrine growth factor
 - ovarian cancer, 1939
 - cell cycle-specific effects
 - monocyte-mediated leukemic cell death, role of β_2 -integrins, 4399
 - inhibition of release and protein isoprenylation
 - inhibition of tumor promotion by canventol, CD-1 mouse skin, 3462
 - interleukin 1 α and
 - induction of anchorage independence, v-*jun* transgenic murine cells, 615
 - polymorphism
 - deleterious effects of UVB, cutaneous immunity, 728
- Tumor progression
 - benign or low-grade malignancies
 - adjacency to high-grade ovarian carcinoma, molecular characteristics, 4138
 - CD44 variant proteins
 - human colorectal cancer, 4754
- development and
 - molecular mechanisms, 5055
- environmental skin cancer
 - mechanisms, models and human relevance, 3439
- expression of tumor suppressor gene
 - DCC
 - human gliomas, 5605
- hepatocarcinogenesis in TGF- α transgenic mice
 - collaboration, growth factors and diverse chemical carcinogens, 4329
- hepatocellular carcinoma
 - mediation by *p53* mutation, 2884
- Ly-1⁺ B-cell populations and IgH rearrangements
 - "normal" spleens and lymphomas, AKR/J and AKR Fv-1^b mice, 2147
- MDM2* gene amplification
 - metastatic osteosarcoma, 16
- neoplastic transformation and conversion of fibroblasts
 - $\alpha 6$ integrin, 2950
- p53* overexpression as late event
 - development of malignant melanoma, 2235
- renal cell carcinoma
 - chromosome 17p deletions, *p53* mutations, 3092
- Tumor promoter
 - mediated processes
 - inhibition by caffeic acid phenethyl ester, mouse skin and bovine lens, 1255
 - okadaic acid
 - hyperphosphorylation of cytokeratins, primary keratinocytes, 992
 - tumor necrosis factor
 - BALB/3T3 cell transformation, 1982
- Tumor resistance
 - concomitant
 - competing influences, 3266
- Tumors
 - in vivo* growth experiments
 - statistical analysis, 6042
 - solid
 - basic fibroblast growth factor complementary DNA, H-*ras*-transformed cells, 158
 - edatrexate compared to methotrexate, leucovorin rescue, 587
 - infrequency of *MDM2* gene amplification, children, 6028
 - inhibition of growth, cyclocreatine, 3172
 - localization, multidrug resistance-associated gene, 3221
 - Phase I study, pyrazine-2-diazohydroxide, 4843
 - selectively down-regulated expression, MHC class I alleles, 2416
 - synergistic antitumor activity, cisplatin and interleukin 1, 1091
 - targeting of gene expression, melanoma cells, 962
- Tumor suppressor genes
 - chromosome 8p
 - colorectal carcinoma, 1172
 - distinct regions involved in 1p deletion
 - human primary breast cancer, 1990
 - morphologically malignant meningioma

progression
loss of heterozygosity, loci on chromosome 10, 2386

Turcot's syndrome
glioma and polyposis
absence of germ line mutations, *p53* gene, 957

Tyr-Ile-Gly-Ser-Arg peptide
multimeric forms
inhibition, tumor growth and metastasis, 3459

Tyrosinases
association with melanoma replicative senescence
melanogenesis, 2469

Tyrosine
phosphorylation
activation of *c-jun*, lymphohematopoietic precursor cells, 447

Tyrosine aminotransferase
regulation of expression
transformation-induced alterations, fetal rat hepatocytes, 515

Tyrosine kinase
Abelson
suppression of apoptosis, hematopoietic cells, 1735

U

1843U89
biochemical and cellular pharmacology, 810

Ubiquitin
-ribosomal protein S27a gene
early growth response gene, human colorectal carcinoma, 1916

U1810 cells
contribution of glutathione transferase M3-3
1,3-bis(2-chloroethyl)-1-nitrosourea resistance, 4257

UCN-01
cell cycle arrest and growth inhibition
human breast carcinoma cells, 2081

UDP-glucuronosyl transferase
colon carcinogenesis
chemoprevention, organosulfur compounds, 3493

Ultraviolet
environmental skin cancer
mechanisms, models and human relevance, 3439
hypersensitivity of Cockayne's cells to camptothecin
double strand breaks, nascent DNA, 2012
-induced cyclobutane pyrimidine dimers
selective removal from epidermis, hairless mouse, 1642
-induced DNA damage
photorepair in skin, platyfish *Xiphophorus*, 2249
-induced skin cancers
delay of progression, macrophage nitric oxide synthesis, 5507
strand bias and tumor heterogeneity, *p53* mutations, 2961
-sensitive mutant cell line
cellular defect in UVS1, 495
-specific mutations in *p53* gene
skin tumors, xeroderma pigmentosum, 2944

wavelength dependence of skin cancer induction
albino hairless mice, 53
wavelength specific patterns of *p53* induction
human skin, 2697

Ultraviolet A
interaction with ultraviolet B
skin cancer induction, hairless mice, 4212
-near-visible light
singlet oxygen, induction of heme oxygenase gene, 4505

Ultraviolet B
deleterious effects on cutaneous immunity
tumor necrosis factor- α polymorphism, 728
induction of resistance by hyperthermia
primary and immortalized epidermal keratinocytes, 4952
mechanism of induction of *c-fos*
mouse JB6 epidermal cells, 38
solar irradiation and
hypersensitivity of human lymphocytes, 609

Uridine 5'-diphosphate glucuronosyltransferase
complementary DNA-expressed
glucuronidation, carcinogen metabolites, 1529

Urinary bladder
transitional cell carcinoma
high-risk human papillomavirus infections, *p53* overexpression, 4823
tumorigenesis
lipopolysaccharide-induced inflammation, 5172

Urine
detection of basic fibroblast growth factor
secretion by an animal tumor, 5297

Urokinase
-dependent proteolytic pathways
melanoma-mediated dissolution, extracellular matrix, 693
inhibition by 4-substituted benzo[b]thiopen-2-carboxamides, 2553
receptor concentration
quantitative autoradiography, malignant and benign breast tumors, 3198
-type plasminogen activator and PAI-1
cytosolic extracts, breast carcinoma, 2513
-type plasminogen activator receptor antibody
modulation *in vitro* invasion, human glioblastoma cells, 4143
plasma, clinical value and detection of colorectal cancer, 1788

Urothelial cells
bladder
influence on cellular processes, altered extracellular matrices, 4971

Urothelial neoplasms
cigarette smc king and schistosomiasis
p53 gene mutations, 3795

Uterus
endometrium
p53 alterations, c-K-ras activation, 1883
insulin-like growth factor I gene expres-

sion
stimulation by tamoxifen, inhibition by ICI 182780, 5585

V

Vaccine
augmentation of cellular immune response
transfection of interleukin 2 gene, melanoma cells, 949
autologous tumor cell/*Bacillus Calmette-Guérin*
delayed-type hypersensitivity reactions, tumor-associated antigens, 456
autologous tumor cells
oligoclonal T-cell response, renal cell carcinoma, 4745
design for cancer
controlled release, biodegradable cytokine depots, 5841
human B-cell immune response
polymorphic epithelial mucin, 2457
-primed T-cells
adoptive immunotherapy, secondary sensitization to tumor, 1043
protective and curative potential
interleukin 2 gene-transfected cells, mouse mammary adenocarcinoma, 5067
tumor cells genetically engineered
production of different cytokines, 714

Vascular endothelial growth factor
up-regulation
cognate receptors, glioma model of angiogenesis, 5822

Vascular permeability factor
its receptors and
adenocarcinomas, gastrointestinal tract, 4727
tumor and inflammatory effusions
guinea pig and human, 2912
tumor-secreted
photosensitizer uptake, 153

Vasculature
influence of thermotolerance
heat-induced changes, cell survival in tumors, 2076
tumor vascularity
relationship of endothelial cell proliferation, human breast cancer, 4161

Vasoconstriction
protein kinase C-mediated
5-fluorouracil chemotherapy, myocardial ischemia, 3028

V79 cells
caffeine release
radiation-induced S and G₂ phase arrest, 1507
coding region of hypoxanthine phosphoribosyltransferase gene
profile of mutations, 7R,8S-dihydroxy-9S,10R-epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene, 3294
resistance to adozelesin
multidrug resistance, 1354

Vegetables
fruit and
lung cancer, Iowa Women's Health Study, 536

Verapamil
doxorubicin cardiotoxicity
altered muscle gene expression, neona-

- tal rat cardiomyocytes, 4658
- Vesicular protein**
M, 110,000
 overexpression, non-P-glycoprotein-mediated multidrug resistance, 1475
- Vinblastine**
 metabolism and drug interactions
 liver cytochrome P450 3A, 5121
 plasma pharmacokinetics
N-(deacetyl-*O*-4-vinblastoyl-23)-*L*-ethyl isoleucinate, high-performance liquid chromatography, 2061
- Vinca alkaloids**
 pharmacokinetics of S 12363
 monoclonal antibody-based radio- or enzyme immunoassay, 3536
- Vincristine**
 selective enhancement of cytotoxicity
 phenytoin, multidrug-resistant tumor cells, 3262
- Vitamin A**
 inhibition of epidermal growth factor-like growth factor
 tracheobronchial epithelial cells, 2527
 -metabolizing enzymes
 pharmacological retinoids, 2965
 synthetic retinoid fenretinide
 treatment of prostate cancer, 224
- Vitamin C**
 selenium status
 risk of lung cancer, 4860
 vegetables and fruit
 lung cancer, Iowa Women's Health Study, 536
- Vitamin D**
 marker
 human colon carcinoma cell line differentiation and growth, 3712
 molecular mechanisms
 tumor development and progression, 5055
- Vitamin E**
 high intake
 reduced risk of colon cancer, 4230
- VM-26: see Teniposide**
- von Hippel-Lindau syndrome**
 positioning of Ca-ATPase gene, 861
- Vorozole**
 inhibition of *in vivo* conversion of androstenedione
 estrone, healthy postmenopausal women, 4563
- VP-16**
 altered topoisomerase II α
 small cell lung cancer cell lines, 4866
- VX2 tumor model**
 pharmacokinetic and pharmacodynamic advantages
 pirarubicin, Adriamycin, 1550
- W**
- W-77**
 bifunctional inhibitor
 enhanced Adriamycin activity, human ovarian carcinoma cells, 2051

- WAGR syndrome**
 -associated Wilms' tumor
 altered *trans*-activational properties, mutated *WT1* gene product, 4757
- Walker 256 cells**
 spontaneously metastatic
 increased growth rate and tumor burden, skeleton of bisphosphonate-treated rats, 5452
- Welders**
 DNA-protein cross-links
 molecular implications, 460
- Wilms' tumor**
 analysis of *WT1*
 granulosa cell and other sex cord-stromal tumors, 2712
 human fetal kidney
 insulin-like growth factor II and *WT1* transcript, 5166
 kidney complementary DNAs
 subtractive hybridization approach, 2888
 new family
 heparin-binding growth/differentiation factors, 1281
 WAGR-associated
 altered *trans*-activational properties, mutated *WT1* gene product, 4757
- Wound healing**
 tumor necrosis factor- α and interleukin 1 α
 induction of anchorage independence, *v-jun* transgenic murine cells, 615

X

- Xanthine dehydrogenase**
 bioactivation of mitomycin C
 kinetics and mechanism, aerobic and hypoxic conditions, 5470
- Xenografts**
 anti-epidermal growth factor receptor monoclonal antibody
 cisplatin and, antitumor effect, 4637
 colon carcinoma models
 site-specific prodrug activation, antibody- β -lactamase conjugates, 3956
 effects of temperature
 therapeutic efficacy, ifosfamide pharmacokinetics, 4268
- glioma**
 intraarterial therapy, 4-hydroperoxycyclophosphamide, 2338
- heterotransplantation**
 Matrigel, early B-lineage acute lymphoblastic leukemia, 1222
 human colon adenocarcinoma
 reduction of interstitial fluid pressure, dexamethasone, 4764
 human and murine tumors
 transplantability into s.c. tissue, NCr/Sed-nu/nu nude and scid mice, 5012
 human colonic adenocarcinoma
 local hyperthermia and SR 4233, enhanced radioimmunotherapy, 3022
 human epidermoid carcinoma

- preclinical evaluation, ¹¹¹In-labeled B3 monoclonal antibody, 2834
 human head and neck squamous cell carcinoma
¹⁸⁶Re-labeled E48, IgG-mediated therapy, 3524
 human lung tumor
 arrest of growth, doxorubicin encapsulated in sterically stabilized liposomes, 3964
 human melanoma
 antitumor activity, *N*¹,*N*¹-bis(ethyl)norspermine, 581
 human tumor
 bispecific monoclonal antibody targeting *c-erbB-2* and CD16, 94
 therapeutic efficacy, 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin, 2823
- MCf-7**
 tamoxifen-induced increase in doubling time, bromodeoxyuridine labeling and flow cytometry, 4413
 mice bearing human ovarian carcinoma
 decreased tumor burden, synthetic matrix metalloproteinase inhibitor, 2087
 nude mouse model
 management of soft tissue sarcomas, daunomycin-antibody immunoconjugates, 5740
 ovarian carcinoma
 fenretinide effectiveness, potentiation of cisplatin activity, 5374
 stable expression of peripherin
 neuroendocrine carcinomas, 1175
- Xeroderma pigmentosum**
 DNA repair deficiency:
 high mutation frequency, *ras* genes, 1625
 group C fibroblasts
 DNA strand bias, repair of *p53* gene, 5377
 ultraviolet-specific mutations
p53 gene, skin tumors, 2944
- X-rays**
 cytostatic multidrug resistance
 second international symposium, 2683
 radion-transformed rat embryo cells
 presence of point mutations, *N-ras* gene, 1511

Y

- Yeast**
 anticancer drugs
 targeting of DNA topoisomerases, 3591
 quiescent state
 cell cycle phase, 1867

Z

- Zinc**
 roles of metallothionein in carcinogenesis, 922
 structural role of metal ions
 "wild-type" conformation, *p53*, 1739

